<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Bipolar Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Bipolar Disord</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1399-5618</journal-id>
<journal-id journal-id-type="publisher-id">BDI</journal-id>
<journal-title-group>
<journal-title>Bipolar Disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">1398-5647</issn>
<issn pub-type="epub">1399-5618</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29536616</article-id>
<article-id pub-id-type="pmc">5947163</article-id>
<article-id pub-id-type="doi">10.1111/bdi.12609</article-id>
<article-id pub-id-type="publisher-id">BDI12609</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group subj-group-type="heading">
<subject>ORIGINAL ARTICLE</subject>
<subj-group subj-group-type="heading">
<subject>Editor's Choice</subject>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Canadian Network for Mood and Anxiety Treatments (<styled-content style="fixed-case">CANMAT</styled-content>) and International Society for Bipolar Disorders (<styled-content style="fixed-case">ISBD</styled-content>) 2018 guidelines for the management of patients with bipolar disorder</article-title>
<alt-title alt-title-type="left-running-head">YATHAM et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="bdi12609-cr-0001">
<name>
<surname>Yatham</surname>
<given-names>Lakshmi N</given-names>
</name>
<address>
<email>yatham@mail.ubc.ca</email>
</address>
<xref ref-type="aff" rid="bdi12609-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0002">
<name>
<surname>Kennedy</surname>
<given-names>Sidney H</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5339-7185</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0003">
<name>
<surname>Parikh</surname>
<given-names>Sagar V</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0004">
<name>
<surname>Schaffer</surname>
<given-names>Ayal</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6220-5042</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0005">
<name>
<surname>Bond</surname>
<given-names>David J</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0006">
<name>
<surname>Frey</surname>
<given-names>Benicio N</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0007">
<name>
<surname>Sharma</surname>
<given-names>Verinder</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0008">
<name>
<surname>Goldstein</surname>
<given-names>Benjamin I</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0340-349X</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0009">
<name>
<surname>Rej</surname>
<given-names>Soham</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3908-9124</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0010">
<name>
<surname>Beaulieu</surname>
<given-names>Serge</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0011">
<name>
<surname>Alda</surname>
<given-names>Martin</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9544-3944</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0008">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0012">
<name>
<surname>MacQueen</surname>
<given-names>Glenda</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3352-6781</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0009">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0013">
<name>
<surname>Milev</surname>
<given-names>Roumen V</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6884-171X</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0010">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0014">
<name>
<surname>Ravindran</surname>
<given-names>Arun</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0015">
<name>
<surname>O'Donovan</surname>
<given-names>Claire</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0008">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0016">
<name>
<surname>McIntosh</surname>
<given-names>Diane</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0017">
<name>
<surname>Lam</surname>
<given-names>Raymond W</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7142-4669</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0018">
<name>
<surname>Vazquez</surname>
<given-names>Gustavo</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0010">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0019">
<name>
<surname>Kapczinski</surname>
<given-names>Flavio</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0020">
<name>
<surname>McIntyre</surname>
<given-names>Roger S</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4733-2523</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0021">
<name>
<surname>Kozicky</surname>
<given-names>Jan</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0697-0342</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0011">
<sup>11</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0022">
<name>
<surname>Kanba</surname>
<given-names>Shigenobu</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0012">
<sup>12</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0023">
<name>
<surname>Lafer</surname>
<given-names>Beny</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6132-9999</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0013">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0024">
<name>
<surname>Suppes</surname>
<given-names>Trisha</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0014">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0025">
<name>
<surname>Calabrese</surname>
<given-names>Joseph R</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0015">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0026">
<name>
<surname>Vieta</surname>
<given-names>Eduard</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0548-0053</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0016">
<sup>16</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0027">
<name>
<surname>Malhi</surname>
<given-names>Gin</given-names>
</name>
<xref ref-type="aff" rid="bdi12609-aff-0017">
<sup>17</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0028">
<name>
<surname>Post</surname>
<given-names>Robert M</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4246-524X</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0018">
<sup>18</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bdi12609-cr-0029">
<name>
<surname>Berk</surname>
<given-names>Michael</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5554-6946</contrib-id>
<xref ref-type="aff" rid="bdi12609-aff-0019">
<sup>19</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bdi12609-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of British Columbia</institution>
<named-content content-type="city">Vancouver</named-content>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Toronto</institution>
<named-content content-type="city">Toronto</named-content>
<named-content content-type="country-part">ON</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Michigan</institution>
<named-content content-type="city">Ann Arbor</named-content>
<named-content content-type="country-part">MI</named-content>
<country country="US">USA</country>
</aff>
<aff id="bdi12609-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Minnesota</institution>
<named-content content-type="city">Minneapolis</named-content>
<named-content content-type="country-part">MN</named-content>
<country country="US">USA</country>
</aff>
<aff id="bdi12609-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry and Behavioural Neurosciences</named-content>
<institution>McMaster University</institution>
<named-content content-type="city">Hamilton</named-content>
<named-content content-type="country-part">ON</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Departments of Psychiatry and Obstetrics &amp; Gynaecology</named-content>
<institution>Western University</institution>
<named-content content-type="city">London</named-content>
<named-content content-type="country-part">ON</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>McGill University</institution>
<named-content content-type="city">Montreal</named-content>
<named-content content-type="country-part">QC</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Dalhousie University</institution>
<named-content content-type="city">Halifax</named-content>
<named-content content-type="country-part">NS</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Calgary</institution>
<named-content content-type="city">Calgary</named-content>
<named-content content-type="country-part">AB</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0010">
<label><sup>10</sup></label>
<named-content content-type="organisation-division">Departments of Psychiatry and Psychology</named-content>
<institution>Queen's University</institution>
<named-content content-type="city">Kingston</named-content>
<named-content content-type="country-part">ON</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">School of Population and Public Health</named-content>
<institution>University of British Columbia</institution>
<named-content content-type="city">Vancouver</named-content>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bdi12609-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Department of Neuropsychiatry</named-content>
<institution>Kyushu University</institution>
<named-content content-type="city">Fukuoka</named-content>
<country country="JP">Japan</country>
</aff>
<aff id="bdi12609-aff-0013">
<label><sup>13</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Sao Paulo</institution>
<named-content content-type="city">Sao Paulo</named-content>
<country country="BR">Brazil</country>
</aff>
<aff id="bdi12609-aff-0014">
<label><sup>14</sup></label>
<named-content content-type="organisation-division">Bipolar and Depression Research Program</named-content>
<named-content content-type="organisation-division">VA Palo Alto</named-content>
<institution>Department of Psychiatry &amp; Behavioral Sciences Stanford University</institution>
<named-content content-type="city">Stanford</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
<aff id="bdi12609-aff-0015">
<label><sup>15</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University Hospitals Case Medical Center</institution>
<institution>Case Western Reserve University</institution>
<named-content content-type="city">Cleveland</named-content>
<named-content content-type="country-part">OH</named-content>
<country country="US">USA</country>
</aff>
<aff id="bdi12609-aff-0016">
<label><sup>16</sup></label>
<named-content content-type="organisation-division">Bipolar Unit</named-content>
<named-content content-type="organisation-division">Institute of Neuroscience</named-content>
<institution>Hospital Clinic</institution>
<institution>University of Barcelona</institution>
<institution>IDIBAPS, CIBERSAM</institution>
<named-content content-type="city">Barcelona</named-content>
<named-content content-type="country-part">Catalonia</named-content>
<country country="ES">Spain</country>
</aff>
<aff id="bdi12609-aff-0017">
<label><sup>17</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Sydney</institution>
<named-content content-type="city">Sydney</named-content>
<named-content content-type="country-part">NSW</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="bdi12609-aff-0018">
<label><sup>18</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>George Washington University</institution>
<named-content content-type="city">Washington</named-content>
<named-content content-type="country-part">DC</named-content>
<country country="US">USA</country>
</aff>
<aff id="bdi12609-aff-0019">
<label><sup>19</sup></label>
<named-content content-type="organisation-division">Deakin Univeristy</named-content>
<named-content content-type="organisation-division">IMPACT Strategic Research Centre</named-content>
<institution>School of Medicine, Barwon Health</institution>
<named-content content-type="city">Geelong</named-content>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Lakshmi N Yatham, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.<break></break>
Email: <email>yatham@mail.ubc.ca</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2018</year>
</pub-date>
<volume>20</volume>
<issue>2</issue>
<issue-id pub-id-type="doi">10.1111/bdi.2018.20.issue-2</issue-id>
<fpage>97</fpage>
<lpage>170</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>12</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>12</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 John Wiley & Sons A/S <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. <italic>Bipolar Disorders</italic> Published by John Wiley &amp; Sons Ltd</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BDI-20-97.pdf" xlink:type="simple"></self-uri>
<abstract id="bdi12609-abs-0001">
<p>The Canadian Network for Mood and Anxiety Treatments (<styled-content style="fixed-case">CANMAT</styled-content>) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (<styled-content style="fixed-case">ISBD</styled-content>). These 2018 <styled-content style="fixed-case">CANMAT</styled-content> and <styled-content style="fixed-case">ISBD</styled-content> Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar <styled-content style="fixed-case">II</styled-content> disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The <styled-content style="fixed-case">CANMAT</styled-content> and <styled-content style="fixed-case">ISBD</styled-content> groups hope that these guidelines become a valuable tool for practitioners across the globe.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>Canadian Network for Mood and Anxiety Treatments</funding-source>
<award-id>N/A</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="9"></fig-count>
<table-count count="24"></table-count>
<page-count count="74"></page-count>
<word-count count="62815"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bdi12609</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>March 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.8.2 mode:remove_FC converted:11.05.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bdi12609-cit-1001" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, et al. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2018</year>;<volume>20</volume>:<fpage>97</fpage>–<lpage>170</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bdi.12609">https://doi.org/10.1111/bdi.12609</ext-link>
<pub-id pub-id-type="pmid">29536616</pub-id></mixed-citation>
</p>
<fn-group id="bdi12609-ntgp-0001">
<fn id="bdi12609-note-5001">
<p>[copyright line and Funder information updated after the first online publication on 21st April 2018].</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<sec id="bdi12609-sec-0001">
<label>1</label>
<title>INTRODUCTION</title>
<p>In the 20 years since the Canadian Network for Mood and Anxiety Treatments (CANMAT) first published guidelines on the management of BD (BD),<xref ref-type="ref" rid="bdi12609-bib-0001">1</xref> there has been an explosion of research on treatment of this illness. During this time period, CANMAT has strived to translate advances in research into international consensus on evidence‐based clinical management; first by publishing 2005 guidelines accompanied by expert commentaries, then by providing updates in 2007,<xref ref-type="ref" rid="bdi12609-bib-0002">2</xref> 2009<xref ref-type="ref" rid="bdi12609-bib-0003">3</xref> and 2013<xref ref-type="ref" rid="bdi12609-bib-0004">4</xref> in collaboration with the International Society for Bipolar Disorders (ISBD). The main objective of these publications was to synthesize the wealth of evidence on the efficacy, safety, and tolerability of the range of interventions available for this complex and varied illness, with the goal of providing clear, easy to use recommendations for clinicians to improve outcomes in their patients.</p>
<p>Given that 13 years have elapsed since the publication of the last full edition in 2005, the objective of these 2018 CANMAT and ISBD Bipolar Disorder Management Guidelines is to provide a comprehensive, up‐to‐date review of research evidence on the treatment of various phases of BD, translated into clinical recommendations for evidence‐based management. Updated principles related to diagnosis and management are also included, in response to significant changes made in the 5<sup>th</sup> edition of the American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders (DSM‐5).<xref ref-type="ref" rid="bdi12609-bib-0005">5</xref> With increased research into various treatments for BD, the evidence ratings have also been modified to increase rigor; for instance, minimum sample sizes are now specified for randomized controlled trials (RCTs) at each level of evidence (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>).</p>
<table-wrap id="bdi12609-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Definitions for level of evidence ratings</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Level</th>
<th align="left" colspan="1" rowspan="1" valign="top">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Meta‐analysis with narrow confidence interval or replicated double‐blind (DB), randomized controlled trial (RCT) that includes a placebo or active control comparison (n ≥ 30 in each active treatment arm)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Meta‐analysis with wide confidence interval or one DB RCT with placebo or active control comparison condition (n ≥ 30 in each active treatment arm)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">At least one DB RCT with placebo or active control comparison condition (n = 10‐29 in each active treatment arm) or health system administrative data</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Uncontrolled trial, anecdotal reports, or expert opinion</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>As with previous editions of CANMAT guidelines, clinical support for efficacy was an important consideration in arriving at the final treatment recommendations (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0002">2</xref>). Major conflicting data are addressed in blue text boxes (figures) to clarify the rationale for arriving at a specific level of evidence for efficacy.</p>
<table-wrap id="bdi12609-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Definitions for line of treatment ratings</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Line</th>
<th align="left" colspan="1" rowspan="1" valign="top">Evidence level</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">First</td>
<td align="left" colspan="1" rowspan="1">Level 1 or level 2 evidence for efficacy plus clinical support for safety/tolerability and no risk of treatment‐emergent switch<xref ref-type="fn" rid="bdi12609-note-0001">a</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Second</td>
<td align="left" colspan="1" rowspan="1">Level 3 or higher evidence for efficacy plus clinical support for safety/tolerability and low risk of treatment‐emergent switch<xref ref-type="fn" rid="bdi12609-note-0001">a</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Third</td>
<td align="left" colspan="1" rowspan="1">Level 4 evidence or higher for efficacy plus clinical support for safety/tolerability</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not recommended</td>
<td align="left" colspan="1" rowspan="1">Level 1 evidence for lack of efficacy, or level 2 evidence for lack of efficacy plus expert opinion</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0001">
<label>a</label>
<p>The text will specifically note when lack of clinical support for safety/tolerability or risk of treatment‐emergent switch has impacted recommendations.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>In the current edition, an additional distinction is made between safety and tolerability, and a consensus rating is assigned to each medication on these two measures when used in both the acute and maintenance phase. Further, a rating is also assigned to each medication for its propensity to switch patients into mania or depression (treatment‐emergent switch). More information on these ratings can be found in the respective treatment sections, as well as in Section 8.</p>
<p>The final grading of recommendations into first, second, or third‐ line considers levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and risk of treatment‐emergent switch. In addition, hierarchical rankings were created and are listed in the tables for first and second line recommendations for acute mania, depression and maintenance treatment in bipolar I disorder (BDI). This hierarchy was created by considering the impact of each treatment across all phases of illness (Figure <xref ref-type="fig" rid="bdi12609-fig-0001">1</xref>). The rationale for the hierarchical approach is that BD is a chronic lifetime condition with recurrent mood episodes and subsyndromal mood symptoms, and most if not all patients will require maintenance treatment. Since treatments that are prescribed for an acute mood episode are usually continued into maintenance treatment, maintenance efficacy should be considered when choosing acute‐phase treatments. Treatments that have demonstrated efficacy across the spectrum of the illness should thus be tried first before treatments that have demonstrated efficacy for only selective phases of the disorder. As an example, if two treatments are shown to be similarly effective in acute mania, and if only one of these treatments has demonstrated efficacy for maintenance treatment, the treatment with evidence for maintenance would be placed higher in the hierarchical ranking.</p>
<fig fig-type="Figure" id="bdi12609-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Hierarchical rankings of treatment recommendations: How were they arrived at? [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="BDI-20-97-g001"></graphic>
</fig>
<p>Of note, when a treatment is listed as a monotherapy, that implies that it may be used on its own or in combination with other ongoing treatments, even if there are no specific studies demonstrating the efficacy of that combination. In this situation, the assumption is that the previous ongoing treatment was partially effective, and the addition of the new agent will provide benefits in either an additive or synergistic manner. In contrast, agents specifically listed as adjunctive therapy may have no evidence for efficacy as monotherapy, and/or may have safety concerns if prescribed as monotherapy (eg. antidepressants), and are only recommended for use in combination with other evidence‐based agents.</p>
<p>As with previous editions, these guidelines also have a “not recommended” category which includes treatments that have clearly been shown to be ineffective in double‐blind RCTs. Further, we have included another category called “no specific recommendation/agents that require further study” to list treatments with insufficient evidence or clinical experience to make a recommendation, or where there is a reason to believe that negative trials failed because of methodological problems‐especially when the results are inconsistent with what is expected based on the pharmacological properties of treatment and clinical experience. Inclusion in this category means the efficacy of these agents is unknown at this time.</p>
<p>As in previous editions, these guidelines are organized into eight sections (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0003">3</xref>), including the Introduction. Foundations of management (Section 2) discusses the epidemiology of BD, screening and diagnostic considerations, the importance of monitoring risk for suicide, the chronic disease management model and patient‐centred care (including shared decision making), as well the importance of incorporating psychoeducation and other psychosocial treatment strategies into treatment. Additional information on presentation and hierarchical rankings of treatment options for acute mania (Section 3) and depression (Section 4) are reviewed, and include descriptions of clinical features that may help direct treatment choices. The importance of long‐term maintenance treatment and promotion of treatment adherence for mood stability, as well as hierarchical rankings of treatment options are discussed in Section 5. An expert review of the available evidence for treatments of bipolar II disorder (BDII) and recommendations based on those findings are presented in Section 6. The management issues related to specific populations, including women at various stages of the reproductive cycle, children and adolescents, older adults, and those with psychiatric or medical comorbidity are each discussed in Section 7. Finally, the principles of medical monitoring and an overview of safety and tolerability concerns for recommended treatments are provided in Section 8.</p>
<table-wrap id="bdi12609-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Sections</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Section 1: Introduction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 2: Foundations of management</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 3: Acute management of bipolar mania</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 4: Acute management of bipolar I depression</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 5: Maintenance therapy for bipolar I disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 6: Bipolar II disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 7: Specific populations</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Section 8: Safety and monitoring</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>For convenience and to avoid confusion, these guidelines also include a table of commonly used terms (with an explanation of the intended meaning) that may have overlapping definitions or criteria in the literature (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0004">4</xref>).</p>
<table-wrap id="bdi12609-tbl-0004" orientation="portrait" position="float" xml:lang="en">
<label>Table 4</label>
<caption>
<p>Clarifying overlapping terminology</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Term</th>
<th align="left" colspan="1" rowspan="1" valign="top">Use</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Mood stabilizer</td>
<td align="left" colspan="1" rowspan="1">Use in the literature is inconsistent, and so this term will not be used in these guidelines</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divalproex</td>
<td align="left" colspan="1" rowspan="1">Encompasses valproate, valpromide, valproic acid and divalproex sodium</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Conventional antipsychotics</td>
<td align="left" colspan="1" rowspan="1">Include first‐generation antipsychotics with high affinity for dopamine D2 receptors. Note these are referred to as dopamine receptor antagonists (D2) in the new neuroscience‐based nomenclature</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Atypical antipsychotics</td>
<td align="left" colspan="1" rowspan="1">Comprise second‐generation antipsychotics with affinity for dopamine D2 and serotonin 5‐HT2 receptors as well as those that have partial agonist effects at D2/D3 receptors. Note these are referred to as dopamine and serotonin receptor antagonists (D2 and 5‐HT2A), dopamine 2 partial agonists and serotonin receptor antagonists, and dopamine 2/3 partial agonists in the new neuroscience‐based nomenclature</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Recurrence</td>
<td align="left" colspan="1" rowspan="1">Re‐emerging episode(s) of mania or depression whether it be within the previous episode or a new episode. Note that, while the literature may use “relapse” and “recurrence”, respectively, inconsistencies in how they are applied and their irrelevance to treatment decisions mean we will use “recurrence” to refer to both</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Maintenance</td>
<td align="left" colspan="1" rowspan="1">Prophylactic therapy after stabilization of acute manic or depressive episodes</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>These guidelines are intended for use by psychiatrists and primary care providers who care for patients with BD throughout the lifespan, supporting them to provide evidence‐based assessment, treatment of acute symptoms, prevention of episode recurrence, and management of comorbidities. These guidelines are not meant to replace clinical judgement or define standards of care. While designed with Canadian physicians in mind, input from experts from the ISBD makes these guidelines applicable for practitioners from across the globe. As with previous publications, CANMAT will strive to publish regular updates to these guidelines, incorporating new knowledge useful for practising clinicians.</p>
<p>As not all medications included in these guidelines will be available in all countries, including Canada, clinicians are advised to follow the recommendations of local regulatory bodies.</p>
</sec>
<sec id="bdi12609-sec-0002">
<label>2</label>
<title>FOUNDATIONS OF MANAGEMENT</title>
<sec id="bdi12609-sec-0003">
<label>2.1</label>
<title>Epidemiology</title>
<sec id="bdi12609-sec-0004">
<label>2.1.1</label>
<title>Prevalence</title>
<p>Bipolar disorder is a common and disabling mental illness with significant morbidity and mortality. The estimates of prevalence of BD vary. The World Mental Health Survey Initiative reported total lifetime (and 12‐month) prevalence estimates of 2.4% (1.5%) across BDI, BDII and subthreshold BD subtypes. While the prevalence rates for each subtype varied across the nine countries studied, subthreshold BD was the most common at 1.4% (0.8%), followed by BDI at 0.6% (0.4%) and BDII at 0.4% (0.3%).<xref ref-type="ref" rid="bdi12609-bib-0006">6</xref> While Canada was not included in this study, similar results were reported from the Canadian Community Health Survey‐Mental Health, which found the lifetime prevalence of BDI was 0.87% and that of BDII was 0.67%.<xref ref-type="ref" rid="bdi12609-bib-0007">7</xref>
</p>
</sec>
<sec id="bdi12609-sec-0005">
<label>2.1.2</label>
<title>Age of onset</title>
<p>Bipolar disorder frequently manifests in late adolescence and young adulthood, with an overall average age of onset of 25 years. Statistical models suggest the presence of three age of onset subgroups within BDI and these can be categorized into a large early‐onset group (mean ± standard deviation (SD) 17.24 ± 3.20 years), and smaller middle‐onset (23.93 ± 5.12 years) and late‐onset (32.20 ± 11.96 years) groups, with the proportion of individuals falling into each category being 41.7%, 24.7% and 33.6% of the total sample, respectively.<xref ref-type="ref" rid="bdi12609-bib-0008">8</xref> However, the ages of onset tend to differ somewhat depending upon the origins of samples analysed. For instance, a recent study showed that the mean age of onset for a USA sample was 20 years, with ages of onset of 14.5 ± 4.9 years (63%), 26.5 ± 7.6 years (28.5%), and 39.5 ± 12.5 years (8.5%) for early‐, middle‐ and late‐onset groups, respectively; while a European sample showed a later mean age of onset of 29 years and a later onset in each of the three categories, with 19 ± 2.7 years (24.8%), 27.2 ± 6.3 years (50.7%), and 41.8 ± 10.7 years (24.5%) as the ages of onset for early, middle and late‐onset groups, respectively.<xref ref-type="ref" rid="bdi12609-bib-0009">9</xref> Those with an earlier age of onset tend to have a longer delay to treatment, greater depressive symptom severity, and higher levels of comorbid anxiety and substance use.<xref ref-type="ref" rid="bdi12609-bib-0010">10</xref> While manic episodes can occur for the first time after the age of 50 years as a part of BDI, the possibility of organic mania should be considered and investigated in these cases.<xref ref-type="ref" rid="bdi12609-bib-0011">11</xref>
</p>
</sec>
<sec id="bdi12609-sec-0006">
<label>2.1.3</label>
<title>Burden of illness</title>
<p>People living with BD experience substantial impairment, being symptomatic with syndromal or subsyndromal symptoms, particularly those of depression, for approximately half of their lives.<xref ref-type="ref" rid="bdi12609-bib-0012">12</xref>, <xref ref-type="ref" rid="bdi12609-bib-0013">13</xref> Patients are unable to maintain proper work role function approximately 30% or more of the time.<xref ref-type="ref" rid="bdi12609-bib-0014">14</xref> Quality of life is reduced in both symptomatic and non‐symptomatic patients when compared to healthy controls,<xref ref-type="ref" rid="bdi12609-bib-0015">15</xref>, <xref ref-type="ref" rid="bdi12609-bib-0016">16</xref>, <xref ref-type="ref" rid="bdi12609-bib-0017">17</xref> and several domains of functioning have been identified by patients as being of particular importance‐ including physical, sleep, mood, cognition, leisure, social, spirituality, finances, household, self‐esteem, independence, identity, work, and education.<xref ref-type="ref" rid="bdi12609-bib-0018">18</xref> For both psychosocial functioning and quality of life, impairments are more pronounced in patients with depressive symptoms,<xref ref-type="ref" rid="bdi12609-bib-0019">19</xref>, <xref ref-type="ref" rid="bdi12609-bib-0020">20</xref>, <xref ref-type="ref" rid="bdi12609-bib-0021">21</xref> in those with more previous episodes/longer duration of illness,<xref ref-type="ref" rid="bdi12609-bib-0020">20</xref>, <xref ref-type="ref" rid="bdi12609-bib-0022">22</xref> and in those with lower cognition.<xref ref-type="ref" rid="bdi12609-bib-0023">23</xref>
</p>
<p>Consistent with these observations, the Global Burden of Disease Study attributed 9.9 million years lost to disability (YLD) to BD, making it the 16<sup>th</sup> leading cause of YLD worldwide.<xref ref-type="ref" rid="bdi12609-bib-0024">24</xref> The impact that BD has on young people is even greater, with being the sixth leading cause of disability‐adjusted life years among people aged 10‐24 years worldwide.<xref ref-type="ref" rid="bdi12609-bib-0025">25</xref> The burden of this disease was further emphasized in a systematic review addressing cost of illness studies, with findings demonstrating that the worldwide annual costs per person with BD range from US $1904 to $33 090; higher per person costs associated with BDI, delayed or misdiagnosis, frequent psychiatric interventions, use of atypical antipsychotics, treatment non‐adherence, poor prognosis, relapse, and comorbidity.<xref ref-type="ref" rid="bdi12609-bib-0026">26</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0007">
<label>2.2</label>
<title>Diagnostic assessment</title>
<sec id="bdi12609-sec-0008">
<label>2.2.1</label>
<title>DSM‐5 diagnostic criteria</title>
<p>Bipolar disorder encompasses a spectrum of diagnostic subgroups primarily divided according to the severity of mood elevation experienced during acute episodes<xref ref-type="ref" rid="bdi12609-bib-0005">5</xref> On this spectrum, BDI is placed at one pole due to the presence of threshold manic episodes in which features include inflated self‐esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, psychomotor agitation, and risky behaviour that leads to significant functional impairment, and may include psychotic features, and/or necessitate hospitalization. At the other end of the spectrum, cyclothymia is characterized by subthreshold presentation of hypomanic and depressive symptoms that, while chronic, do not meet diagnostic criteria for a major depressive episode or manic/hypomanic episode. BDII sits between the two conditions with hypomanic episodes qualitatively like manic periods but, although distinct and observable, are not of a sufficient duration or severity to cause significant functional impairment, hospitalization, or psychosis. Individuals with BDII also experience threshold depressive episodes.</p>
<p>DSM‐5 has replaced the BD not otherwise specified (NOS) category in DSM‐IV with two new categories; other specified bipolar and related disorder and unspecified bipolar and related disorder. Also, DSM‐5 includes substance/medication‐induced bipolar and related disorder and bipolar and related disorder due to another medical condition. For more detailed discussion of diagnostic categories, the reader is advised to consult DSM‐5 and recent Royal Australian and New Zealand College of Psychiatrists guidelines for treatment of mood disorders.<xref ref-type="ref" rid="bdi12609-bib-0027">27</xref>
</p>
</sec>
<sec id="bdi12609-sec-0009">
<label>2.2.2</label>
<title>DSM‐5 specifiers for bipolar and related disorders</title>
<p>DSM‐5 also includes a range of specifiers that clinicians may use to further clarify the specific course, severity, and features of BDs. While a more detailed description can be found in the DSM‐5 manual, the available specifiers and their use across the spectrum are listed in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0005">5</xref> Many of these specifiers may also be used to guide treatment decisions for acute mania (Section 3) and depression (Section 4). Amongst these, the mixed features specifier, which has replaced mixed episodes, warrants consideration because of the multiple and complex presentations of mixed states it can give rise to. Furthermore, the nascency of this terminology has meant that treatment data are as yet sparse. DSM‐5 has added mixed features as a specifier during an episode of major depressive disorder (MDD) as well, which will probably pose some pragmatic diagnostic challenges and management dilemmas for clinicians.</p>
<table-wrap id="bdi12609-tbl-0005" orientation="portrait" position="float" xml:lang="en">
<label>Table 5</label>
<caption>
<p>DSM‐5 specifiers for bipolar and related disorders</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Specifier</th>
<th align="left" colspan="1" rowspan="1" valign="top">Manic episode</th>
<th align="left" colspan="1" rowspan="1" valign="top">Depressive episode</th>
<th align="left" colspan="1" rowspan="1" valign="top">Illness course</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Anxious distress</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mixed features</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rapid cycling</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Melancholic features</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Atypical features</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychotic features</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Catatonia</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Peripartum onset</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Seasonal pattern</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Remission</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Current episode severity</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1">X</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="bdi12609-sec-0010">
<label>2.2.3</label>
<title>Staging bipolar disorder</title>
<p>The course of BD is heterogeneous but, on average, the risk of recurrence increases with the number of previous episodes.<xref ref-type="ref" rid="bdi12609-bib-0028">28</xref> In addition, data examining the effect of episodes on the course of illness shows that the number of previous episodes is associated with increased duration and symptomatic severity of subsequent episodes. Moreover, the number of episodes is associated with a decreased threshold for developing further episodes and with an increased risk of dementia in the long term.<xref ref-type="ref" rid="bdi12609-bib-0028">28</xref> The progressive course of illness in patients with multiple episodes is called clinical progression and the biological basis of clinical progression is defined as neuroprogression.<xref ref-type="ref" rid="bdi12609-bib-0028">28</xref>, <xref ref-type="ref" rid="bdi12609-bib-0029">29</xref>
</p>
<p>The concepts of clinical progression and neuroprogression have provided the basis for the development of staging systems in BD.<xref ref-type="ref" rid="bdi12609-bib-0030">30</xref> Overall, the staging models describe three broad clinical stages: (I) individuals at increased risk for developing BD due to family history as well as certain subsyndromal symptoms predictive of conversion into full‐blown BD; (II) patients with fewer episodes and optimal functioning in the interepisodic periods, and (III) patients with recurrent episodes as well as decline in functioning and cognition.<xref ref-type="ref" rid="bdi12609-bib-0031">31</xref> So far, the heterogeneity intrinsic to BD has prevented the clinical use of staging systems.<xref ref-type="ref" rid="bdi12609-bib-0032">32</xref> In addition, the field of staging is in its infancy and the ability of staging systems to guide prognosis and treatment is still to be determined. Overall, the model of staging has helped clinicians to appreciate the importance of early identification and treatment as well as illness trajectories in BD.<xref ref-type="ref" rid="bdi12609-bib-0033">33</xref>
</p>
</sec>
<sec id="bdi12609-sec-0011">
<label>2.2.4</label>
<title>Screening and diagnosis of bipolar disorder</title>
<p>Due to frequent depressive onset, variable help seeking for hypomanic or manic periods, temporal instability of symptoms, and high rates of comorbidity; accurate the timely identification of BD can be difficult to achieve in many cases. Indeed, many individuals are not accurately diagnosed until up to 10 years after the onset of symptoms, with one to four alternate diagnoses typically being given prior to correct recognition and treatment<xref ref-type="ref" rid="bdi12609-bib-0034">34</xref>, <xref ref-type="ref" rid="bdi12609-bib-0035">35</xref> This delay has important consequences, including inadequate initial treatment and worse prognosis in terms of episode recurrence and functional outcome.<xref ref-type="ref" rid="bdi12609-bib-0036">36</xref>, <xref ref-type="ref" rid="bdi12609-bib-0037">37</xref>
</p>
<p>The most frequent misdiagnosis is that of MDD, as patients are more likely to present for the treatment of depressive symptoms and may not recall periods of hypomania or mania, or may not interpret them as being pathological. Recall and insight are particularly impaired during periods of acute depression, with pronounced memory or concentration difficulties. There are several features of depression that may increase suspicion of bipolarity, and prompt more careful investigation, including earlier age of illness onset, highly recurrent depressive episodes, a family history of BD, depression with psychotic features, psychomotor agitation, atypical depressive symptoms such as hypersomnia, hyperphagia, and leaden paralysis, postpartum depression and psychosis, past suicide attempts, and antidepressant‐induced manic symptoms or rapid cycling (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0006">6</xref>) Given the recent change in DSM‐5 to allow the possibility of depression symptoms with subthreshold simultaneous hypomanic symptoms (mixed specifier), it is also important to explore if an individual is experiencing mixed symptoms.<xref ref-type="ref" rid="bdi12609-bib-0038">38</xref>, <xref ref-type="ref" rid="bdi12609-bib-0039">39</xref> Schizophrenia and other psychotic disorders are the second most common misdiagnosis, occurring as the initial diagnosis in as many as 30% of patients.<xref ref-type="ref" rid="bdi12609-bib-0040">40</xref>
</p>
<table-wrap id="bdi12609-tbl-0006" orientation="portrait" position="float" xml:lang="en">
<label>Table 6</label>
<caption>
<p>Features of depression that may increase suspicion of a bipolar vs unipolar illness</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Feature</th>
<th align="left" colspan="1" rowspan="1" valign="top">Suggestive of bipolarity</th>
<th align="left" colspan="1" rowspan="1" valign="top">Suggestive of unipolarity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Symptomatology and mental state signs</td>
<td align="left" colspan="1" rowspan="1">
Hypersomnia and/or increased daytime napping<break></break>
Hyperphagia and/or increased weight<break></break>
Other “atypical” depressive symptoms such as leaden paralysis<break></break>
Psychomotor retardation<break></break>
Psychotic features and/or pathological guilt<break></break>
Lability of mood; irritability; psychomotor agitation; racing thoughts
</td>
<td align="left" colspan="1" rowspan="1">
Initial insomnia/reduced sleep<break></break>
Appetite and/or weight loss<break></break>
Normal or increased activity levels<break></break>
Somatic complaints
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Course of illness</td>
<td align="left" colspan="1" rowspan="1">
Early onset of first depression (&lt;25 years)<break></break>
Multiple prior episodes (≥5 episodes)
</td>
<td align="left" colspan="1" rowspan="1">
Late onset of first depression (&gt;25 years)<break></break>
Long duration of current episode (&gt;6 months)
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Family history</td>
<td align="left" colspan="1" rowspan="1">Positive family history of bipolar disorder</td>
<td align="left" colspan="1" rowspan="1">Negative family history of bipolar disorder</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0003">
<p>Adapted from Mitchell et al.<xref ref-type="ref" rid="bdi12609-bib-0038">38</xref> and Schaffer et al.<xref ref-type="ref" rid="bdi12609-bib-0039">39</xref>
</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>In addition to this under‐diagnosis, there are also concerns that BD may be over‐diagnosed in some circumstances.<xref ref-type="ref" rid="bdi12609-bib-0041">41</xref> For instance, the symptoms of borderline personality disorder, substance use disorder (SUD) and attention deficit hyperactivity disorder (ADHD) overlap significantly those of hypomania/mania, and some reports suggest that patients with these conditions often get misdiagnosed with BD. These conditions also are often comorbid with BD, which makes the diagnosis of this condition often challenging.<xref ref-type="ref" rid="bdi12609-bib-0042">42</xref>
</p>
<p>Validated self‐report instruments, such as the Mood Disorders Questionnaire (MDQ), may be used as a screening tool to flag patients for whom a more detailed assessment is needed. It is important to note, that such tools have poor sensitivity and specificity, especially in community or highly comorbid populations, and will thus have an elevated risk of also flagging those with borderline traits.<xref ref-type="ref" rid="bdi12609-bib-0043">43</xref> As such, tools such as the MDQ should be used only as an adjunct for screening clinical populations and not for diagnostic or treatment planning purposes.</p>
<p>To improve the accuracy of diagnosis, it is important that clinicians strictly adhere to diagnostic criteria rather than relying on heuristics.<xref ref-type="ref" rid="bdi12609-bib-0044">44</xref> It is important to complete a careful psychiatric history, including in first‐degree relatives, with attention paid to any suspected periods of increased activity, irritability, or other change in behaviours. Collateral information from friends and family members should be included wherever possible. Ongoing monitoring of symptoms, such as mood charting, can also help to detect bipolarity that may only become apparent over time. Confirmation of the diagnosis can then be made more confidently when episodes are prospectively observed.</p>
</sec>
<sec id="bdi12609-sec-0012">
<label>2.2.5</label>
<title>Comorbidities and mimics</title>
<p>As described in Section 6, patients diagnosed with BD very commonly have one or more comorbid psychiatric diagnoses, with SUDs, impulse control disorders, anxiety disorders, and personality disorders (especially cluster B disorders) particularly common.<xref ref-type="ref" rid="bdi12609-bib-0045">45</xref> The presence of comorbidity increases the complexity of the illness and can make an accurate diagnosis even more difficult.</p>
<p>In addition to differentiating BD from other psychiatric diagnoses, alternative causes of mood symptoms, such as personality disorders, medical or neurological conditions, substance use, and medications must be considered in the differential diagnosis (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0007">7</xref>).</p>
<table-wrap id="bdi12609-tbl-0007" orientation="portrait" position="float" xml:lang="en">
<label>Table 7</label>
<caption>
<p>Differential diagnosis of bipolar disorder</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Diagnosis</th>
<th align="left" colspan="1" rowspan="1" valign="top">Distinguishing features</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Major depressive disorder or persistent depressive disorder</td>
<td align="left" colspan="1" rowspan="1">Manic or hypomanic episodes probed for and not present</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bipolar or related disorder due to another medical condition</td>
<td align="left" colspan="1" rowspan="1">Episodes are judged to be a consequence of a medical condition such as traumatic brain injury, brain tumours such as frontal lobe meningiomas, multiple sclerosis, stroke, Cushing's disease or hyperthyroidism. Onset or exacerbation of mood coincides with that of the medical condition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Substance‐ or medication‐induced mood disorder</td>
<td align="left" colspan="1" rowspan="1">Episodes are judged to be a consequence of a substance such as an illicit drug, or a medication (stimulants, steroids, <sc>l</sc>‐dopa or antidepressants) or toxin exposure. Episodes may be related to intoxication or withdrawal</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cyclothymic disorder</td>
<td align="left" colspan="1" rowspan="1">Hypomanic symptoms do not meet the full criteria for a hypomanic episode, and depressive symptoms do not meet the criteria for a major depressive episode</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychotic disorders (schizoaffective disorder, schizophrenia and delusional disorder)</td>
<td align="left" colspan="1" rowspan="1">Periods of psychotic symptoms in the absence of prominent mood symptoms. Consider onset, accompanying symptoms, pervious course and family history</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Borderline personality disorder<xref ref-type="fn" rid="bdi12609-note-0005">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Instability of interpersonal relationships, self‐image and mood, with marked impulsivity and a central theme of intense abandonment fears. Early onset and long‐standing course. True euphoria and prolonged well‐functioning intervals are extremely rare</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Narcissistic personality disorder<xref ref-type="fn" rid="bdi12609-note-0005">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Grandiosity, need for admiration and lack of empathy of early onset. Grandiosity not associated with mood changes or functional impairments</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antisocial personality disorder<xref ref-type="fn" rid="bdi12609-note-0005">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Early onset of disregard for, and violation of, the rights of others, which does not occur only in the context of a manic episode</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0004">
<p>Adapted from Yatham et al. 2005<xref ref-type="ref" rid="bdi12609-bib-0002">2</xref>
</p>
</fn>
<fn id="bdi12609-note-0005">
<label>a</label>
<p>Can occur comorbidly with bipolar disorder.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
</sec>
<sec id="bdi12609-sec-0013">
<label>2.3</label>
<title>Suicide risk</title>
<p>It is important for clinicians to frequently monitor suicidal ideation and risk. Suicide is one of the leading causes of death in BD, with approximately 6%‐7% of identified patients with BD dying by suicide; thus, suicide risk is substantially higher in BD than in the general population (10.7 per 100 000 per year).<xref ref-type="ref" rid="bdi12609-bib-0046">46</xref>, <xref ref-type="ref" rid="bdi12609-bib-0047">47</xref> The fatality of suicide attempts is also higher in BD than in the general population.<xref ref-type="ref" rid="bdi12609-bib-0048">48</xref>, <xref ref-type="ref" rid="bdi12609-bib-0049">49</xref> Worldwide, approximately 43% of patients with BD report suicidal ideation, 21% a plan, and 16% a suicide attempt within the past year.<xref ref-type="ref" rid="bdi12609-bib-0006">6</xref> Men are at a higher risk of death by suicide, with an estimated rate of 0.366 per 100 person years, compared to 0.217 for women.<xref ref-type="ref" rid="bdi12609-bib-0047">47</xref>
</p>
<p>As reviewed in the ISBD Task Force on Suicide in Bipolar Disorder,<xref ref-type="ref" rid="bdi12609-bib-0050">50</xref> a number of sociodemographic and clinical risk factors need to be considered in determining the level of suicide risk (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0008">8</xref>). Factors reported to be significantly associated with suicidal attempt include female sex, younger age of illness onset, depressive polarity of first illness episode, depressive polarity of current or more recent episode, comorbid anxiety disorder, comorbid SUD, comorbid cluster B/borderline personality disorder, first‐degree family history of suicide, and previous suicide attempts. Only male sex and first‐degree family history of suicide have been significantly associated with suicide deaths.<xref ref-type="ref" rid="bdi12609-bib-0050">50</xref>, <xref ref-type="ref" rid="bdi12609-bib-0051">51</xref> The periods during and following hospital admission further represent times of particularly high risk, with 14% of suicides occurring during an inpatient stay and another 26% within 6 weeks of discharge.<xref ref-type="ref" rid="bdi12609-bib-0047">47</xref>, <xref ref-type="ref" rid="bdi12609-bib-0052">52</xref>
</p>
<table-wrap id="bdi12609-tbl-0008" orientation="portrait" position="float" xml:lang="en">
<label>Table 8</label>
<caption>
<p>Summary of main factors associated with suicide attempt and suicide deaths in bipolar disorder (BD)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Variable</th>
<th align="left" colspan="1" rowspan="1" valign="top">Increased likelihood of suicide attempts</th>
<th align="left" colspan="1" rowspan="1" valign="top">Increased likelihood of suicide deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Sex</td>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">Male</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Age</td>
<td align="left" colspan="1" rowspan="1">
Younger<break></break>
Older—higher lethality
</td>
<td align="left" colspan="1" rowspan="1">Older—higher ratio of deaths/attempts</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Race</td>
<td align="left" colspan="1" rowspan="1">Minorities—youth only</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Marital status</td>
<td align="left" colspan="1" rowspan="1">Single, divorced, single parents</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Age of onset</td>
<td align="left" colspan="1" rowspan="1">Younger</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">First episode polarity</td>
<td align="left" colspan="1" rowspan="1">
Depression<break></break>
Mixed symptoms<break></break>
Mania—more violent attempts
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Predominant polarity</td>
<td align="left" colspan="1" rowspan="1">Depressive</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Current episode polarity</td>
<td align="left" colspan="1" rowspan="1">
Depressive<break></break>
Mixed
</td>
<td align="left" colspan="1" rowspan="1">
Depressive<break></break>
Mixed<break></break>
Manic with psychotic features
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Other episode characteristics</td>
<td align="left" colspan="1" rowspan="1">
Mixed features<break></break>
Greater number/severity of episodes<break></break>
Rapid cycling<break></break>
Anxiety<break></break>
Atypical features<break></break>
Suicidal ideation
</td>
<td align="left" colspan="1" rowspan="1">
Hopelessness<break></break>
Psychomotor agitation
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Psychiatric comorbidity</td>
<td align="left" colspan="1" rowspan="1">
Substance use disorder<break></break>
Cigarette smoking<break></break>
Coffee intake<break></break>
Anxiety disorder<break></break>
Eating disorder
</td>
<td align="left" colspan="1" rowspan="1">Anxiety disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Personality disorders</td>
<td align="left" colspan="1" rowspan="1">Present—particularly borderline or cluster B</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Physical comorbidity</td>
<td align="left" colspan="1" rowspan="1">Obesity or high BMI</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">First‐degree family history</td>
<td align="left" colspan="1" rowspan="1">
Mood disorders<break></break>
BD<break></break>
Suicide
</td>
<td align="left" colspan="1" rowspan="1">
Mood disorders<break></break>
BD<break></break>
Suicide
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Prior suicide attempts</td>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1">Present</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Early life trauma</td>
<td align="left" colspan="1" rowspan="1">
Childhood abuse<break></break>
Early life stress
</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Psychosocial precipitants</td>
<td align="left" colspan="1" rowspan="1">
Interpersonal problems<break></break>
Occupational problems<break></break>
Bereavement<break></break>
Social isolation
</td>
<td align="left" colspan="1" rowspan="1">Present within 1 week of death</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Sexual dysfunction</td>
<td align="left" colspan="1" rowspan="1">Present</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0006">
<p>Adapted from Schaffer et al.<xref ref-type="ref" rid="bdi12609-bib-0050">50</xref>
</p>
</fn>
<fn id="bdi12609-note-0007">
<p>BMI, body mass index.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>A comprehensive assessment for suicide risk should occur during all clinical interactions. Risk stratification using assessment tools is not sufficiently accurate for prediction of suicide risk in clinical use; instead, clinical assessment should focus on modifiable risk factors that could be targeted to reduce the risk.<xref ref-type="ref" rid="bdi12609-bib-0053">53</xref> The ISBD has developed clinical tips and patient information sheets (translated into several languages) that can be useful tools for clinicians, patients and families to develop a comprehensive approach to suicide prevention ( <ext-link ext-link-type="uri" xlink:href="http://www.isbd.org/Files/Admin/Knowledge-Center-Documents/Suicide-Prevention-Tip-Sheet.pdf">http://www.isbd.org/Files/Admin/Knowledge-Center-Documents/Suicide-Prevention-Tip-Sheet.pdf</ext-link>).</p>
<p>The association between various treatments and suicide risk has been reviewed by the ISBD Task Force and others, which suggest that lithium<xref ref-type="ref" rid="bdi12609-bib-0054">54</xref> and, to a lesser extent, anticonvulsants may contribute to preventing suicide attempts and deaths; although more data are needed to determine their relative efficacies. There were limited data on both antipsychotics and antidepressant agents.<xref ref-type="ref" rid="bdi12609-bib-0047">47</xref> As the most common method of suicide in this population is self‐poisoning, the potential benefits of various treatments should be considered against their risk of toxicity and lethality. One small Canadian study indicated higher rates of lethal doses of antipsychotics (32%), opioids (29%), benzodiazepines (27%), carbamazepine (21%) and diphenhydramine (15%) compared to lithium (3%) in 34 self‐poisoning deaths.<xref ref-type="ref" rid="bdi12609-bib-0055">55</xref>
</p>
</sec>
<sec id="bdi12609-sec-0014">
<label>2.4</label>
<title>Chronic disease management</title>
<p>Due to the chronic, relapsing and remitting nature of BD, a long‐term, multidisciplinary approach to management is needed. The Chronic Disease Management Model<xref ref-type="ref" rid="bdi12609-bib-0056">56</xref> outlines several important principles to enhance long‐term care for these individuals and their families (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0009">9</xref>). After basic clinical management, including attention to diagnosis, comorbidity, and medical health has been established, patient health education and pharmacotherapy should be the initial and foundational steps for all patients. Ideally, the patient will be connected to a health care team which includes at least one other health care professional (typically a nurse) in addition to the psychiatrist for psychoeducation, ongoing monitoring, psychosocial support, and referral to community resources.<xref ref-type="ref" rid="bdi12609-bib-0057">57</xref> All patients should have access to a primary care provider to attend to mental and physical health needs. If the patient is stable and discharged to primary care, the mental health care system should provide support directly to the primary care provider with attention to continuity of care.<xref ref-type="ref" rid="bdi12609-bib-0058">58</xref> Additional psychosocial treatments (described below) may also be selected to fit the specific needs and preferences of the patient.</p>
<table-wrap id="bdi12609-tbl-0009" orientation="portrait" position="float" xml:lang="en">
<label>Table 9</label>
<caption>
<p>The chronic disease management model</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="2">Self‐management support</td>
<td align="left" colspan="1" rowspan="1">Empower and prepare patients to manage their health and health care</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Use effective self‐management support strategies that include assessment, goal setting, action planning, problem solving, and follow‐up</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Decision support</td>
<td align="left" colspan="1" rowspan="1">Promote clinical care that is consistent with scientific evidence and patient preferences</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Embed evidence‐based guidelines into daily clinical practice and share this and other information with patients to encourage their participation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Use proven provider education materials</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Community</td>
<td align="left" colspan="1" rowspan="1">Encourage patients to participate in effective community programs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Form partnerships with community organizations</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Delivery system design</td>
<td align="left" colspan="1" rowspan="1">Provide clinical care and self‐management support that patients understand and that fits with their cultural background</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ensure regular follow‐up by the care team, with defined tasks for different team members</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Provide clinical case management services for complex patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Clinical information systems</td>
<td align="left" colspan="1" rowspan="1">Provide timely reminders for providers and patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Facilitate individual patient care planning</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Share information with patients and providers to coordinate care</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Health system</td>
<td align="left" colspan="1" rowspan="1">Measure outcomes and use information to promote effective improvement strategies aimed at comprehensive system change</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Develop agreements that facilitate care coordination within and across organizations</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0008">
<p>Adapted from Wagner.<xref ref-type="ref" rid="bdi12609-bib-0056">56</xref>
</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>A strong therapeutic alliance is central to improve treatment adherence and outcomes.<xref ref-type="ref" rid="bdi12609-bib-0059">59</xref>, <xref ref-type="ref" rid="bdi12609-bib-0060">60</xref> Providers should encourage individuals to actively participate in treatment planning, using a shared decision‐making approach.<xref ref-type="ref" rid="bdi12609-bib-0061">61</xref>, <xref ref-type="ref" rid="bdi12609-bib-0062">62</xref> Whenever possible, family members or key friends should be included as part of the care team. There is evidence that specialized, team‐approach‐based interventions combining pharmacotherapy and psychoeducation are more effective than standard community care.<xref ref-type="ref" rid="bdi12609-bib-0063">63</xref>
</p>
<p>Regular, ongoing monitoring of mood symptoms and other measures related to the patient's own individual recovery, such as sleep, cognition, functioning, and quality of life is encouraged.<xref ref-type="ref" rid="bdi12609-bib-0018">18</xref> For many patients, daily recording of mood symptoms such as through a mood diary or National Institute of Mental Health (NIMH) Life Chart Method‐Self Rating Scale can help identify early warning signs of relapse, as well as outline relationships between mood and treatment or lifestyle factors such as diet, exercise, or stress.<xref ref-type="ref" rid="bdi12609-bib-0064">64</xref> While many patients will agree with the value of completing a mood diary, and this strategy has been shown to improve treatment, regular completion can be a burden.<xref ref-type="ref" rid="bdi12609-bib-0065">65</xref> Online solutions such as mobile apps may improve adherence,<xref ref-type="ref" rid="bdi12609-bib-0066">66</xref> such as the Self‐Monitoring and Psychoeducation In Bipolar Patients smartphone app (SIMPLE) which provides weekly and daily mood tests, with reminders to take medication or see their doctor.<xref ref-type="ref" rid="bdi12609-bib-0067">67</xref>, <xref ref-type="ref" rid="bdi12609-bib-0068">68</xref>, <xref ref-type="ref" rid="bdi12609-bib-0069">69</xref>
</p>
</sec>
<sec id="bdi12609-sec-0015">
<label>2.5</label>
<title>Dealing with stigma</title>
<p>Stigma is an important issue that will impact individuals with BD, as well as their family members, potentially preventing individuals from seeking or engaging in treatment or causing them to conceal their illness, reducing social support, functioning and quality of life.<xref ref-type="ref" rid="bdi12609-bib-0070">70</xref> Linked to stereotypical negative attitudes that mental illness is due to personal weaknesses or decisions, or associated with violent or criminal behaviour, stigma can be perceived or experienced with interactions with others, including health care providers, or internalized (self‐stigma). Specific strategies to reduce stigma, particularly self‐stigma, by enhancing coping skills through improvements in self‐esteem, empowerment, and help‐seeking behaviour can improve outcomes in this population.<xref ref-type="ref" rid="bdi12609-bib-0071">71</xref>
</p>
</sec>
<sec id="bdi12609-sec-0016">
<label>2.6</label>
<title>Psychosocial interventions</title>
<p>While pharmacotherapy is essential and forms the foundation for the successful treatment of BD, adjunctive psychosocial interventions may also be useful for acute depressive episodes, as well as in maintenance treatment to prevent relapse and to restore quality of life to the individual and family.<xref ref-type="ref" rid="bdi12609-bib-0072">72</xref>, <xref ref-type="ref" rid="bdi12609-bib-0073">73</xref> No evidence exists, and hence there are no recommendations, for specific psychosocial interventions in acute mania. Positive evidence has been found for psychoeducation, cognitive behavioural therapy (CBT), family‐focused therapy (FFT), interpersonal and social‐rhythm therapy (IPSRT), and peer support in the maintenance phase of BD and these interventions are included as recommended adjunctive treatment options. Additional studies are needed before conclusions can be drawn regarding other strategies such as family/caregiver interventions, dialectical behavioural therapy (DBT), mindfulness‐based cognitive therapy (MBCT), cognitive and functional remediation, and online interventions (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0010">10</xref>).</p>
<table-wrap id="bdi12609-tbl-0010" orientation="portrait" position="float" xml:lang="en">
<label>Table 10</label>
<caption>
<p>Strength of evidence and recommendations for adjunctive psychological treatments for bipolar disorder<xref ref-type="fn" rid="bdi12609-note-0009">a</xref>
</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Maintenance: Recommendation (Level of Evidence)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Depression: Recommendation (Level of Evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Psychoeducation (PE)</td>
<td align="left" colspan="1" rowspan="1">First‐line (Level 2)</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cognitive behavioural therapy (CBT)</td>
<td align="left" colspan="1" rowspan="1">Second‐line (Level 2)</td>
<td align="left" colspan="1" rowspan="1">Second‐line (Level 2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Family‐focused therapy (FFT)</td>
<td align="left" colspan="1" rowspan="1">Second‐line (Level 2)</td>
<td align="left" colspan="1" rowspan="1">Second‐line (Level 2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Interpersonal and social rhythm therapy (IPSRT)</td>
<td align="left" colspan="1" rowspan="1">Third‐line (Level 2)</td>
<td align="left" colspan="1" rowspan="1">Third‐line (Level 2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Peer support</td>
<td align="left" colspan="1" rowspan="1">Third‐line (Level 2)</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cognitive and functional remediation</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dialectical behavioural therapy (DBT)</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Family/caregiver interventions</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mindfulness‐based cognitive therapy (MBCT)</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Online interventions</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
<td align="left" colspan="1" rowspan="1">Insufficient evidence</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0009">
<label>a</label>
<p>See text for specific definitions of type of therapy and number of sessions needed (“dose of psychosocial intervention”) corresponding to this recommendation and evidence.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>In general, provision of psychoeducation to all patients and family members is recommended for prevention of relapse, particularly at illness onset, with selection of any additional psychosocial therapies based on individual concerns/presentations or deficits.</p>
<sec id="bdi12609-sec-0017">
<label>2.6.1</label>
<title>Psychoeducation</title>
<p>Psychoeducation broadly includes provision of information about the nature of the illness, its treatments, and key coping strategies to the patient and family.<xref ref-type="ref" rid="bdi12609-bib-0074">74</xref> Current psychoeducational models for BD teach skill development in detecting and managing prodromes of depression and mania, ongoing stress management, problem solving, how to diminish the effects of stigma and denial of the illness, and provide tips on enhancing medication adherence and developing healthy lifestyles (eg, minimizing the use of alcohol, tobacco, drugs, stimulants such as caffeine; getting regular exercise; and regulating sleep and wake times). A key goal is the creation of personalized coping strategies to prevent mood relapse.</p>
<p>Psychoeducation may be delivered individually or in group settings. Empirical models of psychoeducation involve face‐to‐face interaction with a therapist, but new models are being tested that involve online tools, smartphone apps, and workbooks.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref> Consistent with broader theories of learning, it is believed that psychoeducation is enhanced when it features active learning, with attention to monitoring the development of understanding, active skill development, and homework between sessions. Peer support and group learning are also postulated to add efficacy to psychoeducation. Regardless of the type of model and content included, priority should be given to maximize the therapeutic alliance, convey empathy, and consistently monitor symptoms.<xref ref-type="ref" rid="bdi12609-bib-0076">76</xref>
</p>
<p>Two models of psychoeducation, both delivered in group format to individuals who are well (euthymic), have published manuals and have substantial research support. These programmes, the Barcelona BDs Program<xref ref-type="ref" rid="bdi12609-bib-0077">77</xref> (21 sessions over 6 months) and the Life Goals Program<xref ref-type="ref" rid="bdi12609-bib-0078">78</xref> (phase I is six weekly sessions), also have tools to aid implementation with workbooks and handout materials, and both are first‐line psychoeducational interventions based on level 2 evidence for the prevention of relapse. Individual psychoeducation based on these manuals would probably be effective, and when individual trials utilizing several different approaches to psychoeducation are combined in a meta‐analysis, individual psychoeducation of at least five sessions would still be a first‐line intervention for relapse prevention, based on level 2 evidence.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref>, <xref ref-type="ref" rid="bdi12609-bib-0079">79</xref>, <xref ref-type="ref" rid="bdi12609-bib-0080">80</xref> One large study demonstrated that the six‐session Life Goals Program psychoeducational intervention was equivalent in relapse prevention to 20 sessions of individual CBT, at far lower cost,<xref ref-type="ref" rid="bdi12609-bib-0081">81</xref> with probable shared mechanisms.<xref ref-type="ref" rid="bdi12609-bib-0082">82</xref> Furthermore, that study demonstrated that integration of best practices in medication and psychotherapy simultaneously produced striking overall improvement in course of illness.<xref ref-type="ref" rid="bdi12609-bib-0083">83</xref> Psychoeducation does not have any significant evidence of utility in either acute depressive or manic episodes.</p>
</sec>
<sec id="bdi12609-sec-0018">
<label>2.6.2</label>
<title>Cognitive behavioural therapy</title>
<p>CBT in BD is supported by several published manuals and typically is given in 20 individual sessions over 6 months, often with additional booster sessions. Despite evidence of efficacy for CBT for MDD and psychosis, the results of CBT trials for BD have been mixed. One large RCT supports it use for acute bipolar depression<xref ref-type="ref" rid="bdi12609-bib-0084">84</xref> in a trial that compared the efficacy of up to 30 (mean 14) CBT sessions against those of FFT, IPSRT, and a three‐session control intervention, but it was not possible to identify whether the benefits came from changes in the medications prescribed or the psychosocial treatments. Efficacy of CBT in relapse prevention was observed in one RCT,<xref ref-type="ref" rid="bdi12609-bib-0085">85</xref> but not in another larger RCT, at least in patients who had multiple mood episodes.<xref ref-type="ref" rid="bdi12609-bib-0086">86</xref> From meta‐analyses, effects on either depressive symptoms or on relapse remain uncertain due to important methodological problems and study selection factors.<xref ref-type="ref" rid="bdi12609-bib-0087">87</xref>, <xref ref-type="ref" rid="bdi12609-bib-0088">88</xref>, <xref ref-type="ref" rid="bdi12609-bib-0089">89</xref> A promising new direction in CBT has been established by a pilot study of “recovery‐focused CBT” where 33 subjects received the novel CBT intervention, with evidence of reduction of relapse in the intervention group.<xref ref-type="ref" rid="bdi12609-bib-0090">90</xref> Group CBT in euthymic patients with BD is also a new direction and has shown to increase time in remission.<xref ref-type="ref" rid="bdi12609-bib-0091">91</xref>
</p>
<p>In MDD, CBT, interpersonal psychotherapy (IPT) and behavioural activation have been explored in multiple RCTs and in general display similar efficacies.<xref ref-type="ref" rid="bdi12609-bib-0092">92</xref> Based on this and the findings of the study by Miklowitz and colleagues in acute bipolar depression,<xref ref-type="ref" rid="bdi12609-bib-0084">84</xref> CBT is still recommended as an adjunctive second‐line treatment for acute bipolar depression (level 2). The recommendation is also second‐line for maintenance treatment (level 2) for patients with fewer episodes and less severe form of illness. No evidence exists, and hence no recommendation is made, for CBT in mania.</p>
</sec>
<sec id="bdi12609-sec-0019">
<label>2.6.3</label>
<title>Family‐focused therapy</title>
<p>FFT<xref ref-type="ref" rid="bdi12609-bib-0093">93</xref> presumes that outcomes in BD may be enhanced with the support and cooperation of family or significant others, particularly in families characterized by high levels of expressed emotion. FFT focuses on communication styles between patients and their families or marital relationships, with the goal of improving relationship functioning, and is delivered to the family and patient in 21 sessions over 9 months.</p>
<p>For acute bipolar depression in adults, an intensive FFT (up to 30 sessions; mean 14) out‐performed a three‐session control condition,<xref ref-type="ref" rid="bdi12609-bib-0094">94</xref> although this study was limited by the caveats identified for CBT and IPSRT. Given that the original creation of FFT targeted factors related to depression, it may have specific antidepressant activity, which is also suggested by reduced depression relapse in maintenance studies. For relapse prevention, four significant RCTs of varying sizes have been conducted, delivered to a mixed audience of young adults and adolescents.<xref ref-type="ref" rid="bdi12609-bib-0095">95</xref> In these studies, FFT demonstrated efficacy in reducing recurrence of new episodes of depression, but not mania. Overall, FFT is recommended as adjunctive second‐line treatment for acute depression (level 2) and for maintenance (level 2). No evidence exists, and hence no recommendation is made, for FFT for mania.</p>
</sec>
<sec id="bdi12609-sec-0020">
<label>2.6.4</label>
<title>Interpersonal and social rhythm therapy</title>
<p>IPSRT expands on the IPT focus on grief, interpersonal role transition, role dispute, and interpersonal deficits by including regulation of social and sleep rhythms, specifically targeted to the bipolar population. It is typically delivered in 24 individual sessions over 9 months.<xref ref-type="ref" rid="bdi12609-bib-0096">96</xref>, <xref ref-type="ref" rid="bdi12609-bib-0097">97</xref>
</p>
<p>Few controlled trials of IPSRT have been conducted, with limited evidence of acute efficacy. The first, large trial<xref ref-type="ref" rid="bdi12609-bib-0098">98</xref> showed no effect of IPSRT compared to a control condition but did show benefit for reduction of relapse and improved occupational functioning. An acute bipolar depression study<xref ref-type="ref" rid="bdi12609-bib-0084">84</xref> showed intensive IPSRT (up to 30 sessions; mean 14) out‐performed a three‐session control condition, but it is impossible to state whether the performance was related to the intensity and number of sessions, changes in medication use, or specific attributes of IPSRT. Two small studies failed to demonstrate specific benefits of IPSRT compared to control conditions.<xref ref-type="ref" rid="bdi12609-bib-0099">99</xref>, <xref ref-type="ref" rid="bdi12609-bib-0100">100</xref> Other open studies have shown some pre‐post benefits in very small samples.<xref ref-type="ref" rid="bdi12609-bib-0101">101</xref>, <xref ref-type="ref" rid="bdi12609-bib-0102">102</xref>, <xref ref-type="ref" rid="bdi12609-bib-0103">103</xref> Again, since many psychosocial treatments for bipolar disorder share common core elements that may be psychoeducational, it is possible that the relapse prevention aspects of psychoeducation may also result from IPSRT interventions, mediated by the same therapeutic processes.<xref ref-type="ref" rid="bdi12609-bib-0104">104</xref>
</p>
<p>Overall, IPSRT is recommended as an adjunctive third‐line treatment for acute depression and for maintenance, based on limited (effect size and small sample size) level 2 evidence in each phase. No evidence exists, and hence no recommendation is made, for IPSRT for mania.</p>
</sec>
<sec id="bdi12609-sec-0021">
<label>2.6.5</label>
<title>Peer interventions</title>
<p>Peer interventions, such as peer groups or one‐on‐one support, are an important strategy believed to reduce self‐stigma and isolation in BD, and to help improve engagement in treatment.<xref ref-type="ref" rid="bdi12609-bib-0105">105</xref> Some caution is needed when applying this strategy, however, as there may be risks if the peers delivering the intervention are not adequately trained or supported, and if they promote a viewpoint that does not support treatment compliance or promotes substance use.</p>
<p>Reviews of peer interventions for persons with serious mental illnesses, usually incorporating a small but significant number of individuals with BD, have demonstrated modest evidence from RCTs and other controlled studies suggesting that there are important improvements in self‐efficacy and reduction in self‐stigma.<xref ref-type="ref" rid="bdi12609-bib-0106">106</xref>, <xref ref-type="ref" rid="bdi12609-bib-0107">107</xref>, <xref ref-type="ref" rid="bdi12609-bib-0108">108</xref>, <xref ref-type="ref" rid="bdi12609-bib-0109">109</xref> The largest peer intervention study involving BD allocated 153 individuals to attend 21 weekly group psychoeducation events, with another 151 assigned to attend 21 weekly group peer support events. The two programmes achieved similar outcomes in terms of time to relapse, and increased knowledge about BD, although psychoeducation was more acceptable to the subjects and worked more effectively at preventing relapse in a subset of people with fewer previous episodes.<xref ref-type="ref" rid="bdi12609-bib-0110">110</xref>
</p>
<p>A significant source of peer support is emerging from online resources, particularly through the websites of peer advocacy organizations such as the Depression and Bipolar Support Alliance ( <ext-link ext-link-type="uri" xlink:href="http://www.dbsalliance.org/site/PageServer?pagename=peer_landing">http://www.dbsalliance.org/site/PageServer?pagename=peer_landing</ext-link>), the Mood Disorders Association of Ontario ( <ext-link ext-link-type="uri" xlink:href="https://www.mooddisorders.ca/">https://www.mooddisorders.ca/</ext-link>), the research and advocacy group CREST.BD ( <ext-link ext-link-type="uri" xlink:href="http://www.crestbd.ca/">http://www.crestbd.ca/</ext-link>), MoodSwings ( <ext-link ext-link-type="uri" xlink:href="http://www.moodswings.net.au/">http://www.moodswings.net.au/</ext-link>), and Revivre (http:/wwww.Revivre.org). YouTube is also emerging as an important source of peer support, along with other social media.<xref ref-type="ref" rid="bdi12609-bib-0111">111</xref>, <xref ref-type="ref" rid="bdi12609-bib-0112">112</xref>
</p>
<p>Overall, peer interventions receive a third‐line treatment recommendation (level 2) as an adjunctive maintenance therapy.</p>
</sec>
<sec id="bdi12609-sec-0022">
<label>2.6.6</label>
<title>Other psychosocial interventions</title>
<p>Various other approaches have been tried in BD, with a variety of aims, modalities, and outcome targets. None of the other interventions have been specifically targeted for bipolar depression or for mania. Some have been designed in part to reduce episode recurrence, but none have been successful in providing substantial evidence of efficacy. Because CANMAT recommendations are for the treatment of acute depression and mania, and maintenance treatment to prevent them, we do not make specific recommendations regarding these treatments. However, some of these approaches have been helpful in ameliorating some important symptoms in individuals with BD, (such as residual mood symptoms or anxiety) and so we will describe them briefly.</p>
<p>Although somewhat like FFT, family/caregiver interventions constitute a distinctly different psychosocial intervention in that the intervention is given to the family/caregiver, not the person with BD, and evidence exists that such interventions improve clinical outcomes in the patient.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref>, <xref ref-type="ref" rid="bdi12609-bib-0113">113</xref> Clinical wisdom and common practice, however, support the importance of family or caregivers being included in at least some sessions with the patient (particularly for psychoeducation), both to reduce symptom burden on the individual with BD and to reduce burnout and emotional burden on the caregiver. Validated caregiver resources are available online, such as <ext-link ext-link-type="uri" xlink:href="http://www.bipolarcaregivers.org">http://www.bipolarcaregivers.org</ext-link>.<xref ref-type="ref" rid="bdi12609-bib-0114">114</xref>
</p>
<p>DBT, which includes distress tolerance training, has several small studies showing its utility in the reduction of some depressive symptoms and suicidality.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref>
</p>
<p>One RCT of MBCT involving 95 patients did not demonstrate any difference in relapse prevention compared to a treatment‐as‐usual group, but did reveal fewer anxiety and depressive symptoms in the MBCT arm.<xref ref-type="ref" rid="bdi12609-bib-0115">115</xref> Coupled with the findings of other smaller studies, this suggests that MBCT may have a role to play in anxiety reduction in BD.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref>, <xref ref-type="ref" rid="bdi12609-bib-0116">116</xref>
</p>
<p>While not reviewed here, given that individuals with BD may have histories of childhood abuse and comorbid personality disorders, and experience various sequelae such as shame or conflict due to behaviours experienced during acute bipolar episodes, all of these may rightly be a target for psychosocial intervention in a very individualized manner.</p>
</sec>
<sec id="bdi12609-sec-0023">
<label>2.6.7</label>
<title>Cognitive and functional remediation</title>
<p>Functional impairment as well as cognitive deficits are found in many individuals with BD, not just during an acute episode but even between episodes, prompting the evaluation of various psychosocial and biological strategies to address these problems. One intervention, functional remediation (FR), involves a 21‐session group intervention over 6 months. In a large RCT, FR was shown to have a substantial impact on functioning, in comparison to treatment as usual.<xref ref-type="ref" rid="bdi12609-bib-0117">117</xref> Coupled with the results of other small studies involving other interventions, these findings suggest that there is considerable hope in addressing cognitive and functional deficits in BD.<xref ref-type="ref" rid="bdi12609-bib-0118">118</xref> Computer‐based cognitive remediation, though, may show positive effects on cognition but not on functioning.<xref ref-type="ref" rid="bdi12609-bib-0119">119</xref>
</p>
</sec>
<sec id="bdi12609-sec-0024">
<label>2.6.8</label>
<title>Online and digital strategies</title>
<p>Modern trends to rely on the internet and apps, along with access problems in mental health, have led to the study of various online tools and mobile phone apps.<xref ref-type="ref" rid="bdi12609-bib-0120">120</xref> Such strategies also build on strong traditions of self‐monitoring and self‐management developed formally in traditional psychoeducational interventions. In reviews, such internet and mobile health interventions have shown good adherence to validated psychological health principles, good acceptability to patients, ease of access, and ease of use. However, research is mostly limited to pilot studies and the relatively few larger studies have not shown unequivocal benefit.<xref ref-type="ref" rid="bdi12609-bib-0068">68</xref>, <xref ref-type="ref" rid="bdi12609-bib-0121">121</xref>
</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0025">
<label>3</label>
<title>ACUTE MANAGEMENT OF BIPOLAR MANIA</title>
<sec id="bdi12609-sec-0026">
<label>3.1</label>
<title>Presentations of mania</title>
<p>DSM‐5<xref ref-type="ref" rid="bdi12609-bib-0005">5</xref> made a change to “criterion A” for mania which now requires a distinct period of abnormally and persistently elevated, expansive, or irritable mood <italic>and</italic> abnormally and persistently increased activity or energy present most of the day, nearly every day for at least 1 week (or less time if hospitalization is necessary). In addition, a diagnosis of a “manic episode” requires at least three (or four if the mood is only irritable) of the following symptoms: inflated self‐esteem or grandiosity, decreased need for sleep, more talkative than usual or pressure of speech, flight of ideas or subjective experience that thoughts are racing, distractibility, increased goal‐directed activity or psychomotor agitation, or excessive involvement in activities with a high potential for painful consequences. The mood disturbance must lead to marked impairment in functioning, require hospitalization, or be accompanied by psychotic features.</p>
<p>Unlike DSM‐IV, DSM‐5 allows a diagnosis of BDI in patients with major depression whose mania emerges during treatment (eg, during medication or electroconvulsive therapy [ECT]) and persists at a fully syndromal level beyond the physiological effect of the treatment.</p>
<p>DSM‐5 has eliminated the categorical “mixed episode” specifier, replacing it with the more dimensional “mixed features”. DSM‐5 also includes other specifiers that can accompany a manic episode: anxious distress, rapid cycling, mood‐congruent or mood‐incongruent psychotic features, catatonia, peripartum onset, and seasonal pattern (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0005">5</xref>). The utility of several of these specifiers in selecting treatment options for mania is discussed later in this section (see “Clinical features that help direct treatment choice”).</p>
</sec>
<sec id="bdi12609-sec-0027">
<label>3.2</label>
<title>Management of agitation</title>
<p>Agitation is common in mania, and is particularly frequent in patients who have mixed features.<xref ref-type="ref" rid="bdi12609-bib-0122">122</xref> Defined in DSM‐5 as “excessive motor activity associated with a feeling of inner tension”,<xref ref-type="ref" rid="bdi12609-bib-0005">5</xref> agitation can manifest as pacing or fidgeting in mild cases to uncooperative, threatening, or aggressive behaviours in severe cases. Severe symptoms of agitation require prompt attention in order to reduce distress, mitigate potentially dangerous behaviour, and allow for an assessment and evaluation of underlying manic symptoms.<xref ref-type="ref" rid="bdi12609-bib-0123">123</xref>
</p>
<p>A key step in treating agitation is preventing it, or at least mitigating its severity, by rapidly treating the causative manic episode. When addressing agitation in patients with BDI, clinicians need to be aware that akathisia may present as agitation and, therefore, this must be excluded before implementing the general principles of management of acute mania described in step 1 (see “Pharmacological treatment of manic episodes”). Since agitation in this context is a manifestation of mania, it is assumed that effective interventions for treating mania that have rapid onset of efficacy would be effective in reducing agitation. Therefore, if the patient is agreeable to taking oral medications, antimanic agents with rapid onset of efficacy should be considered first.</p>
<p>When agitation persists despite administration of antimanic treatments, additional rapidly acting pharmacotherapy may often be needed. The evidence for specific efficacy of various agents in short‐term treatment of agitation is summarized in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0011">11</xref>. Some of these agents are either not available or rarely used in North America (eg, midazolam and promethazine). We further note that the dose ranges in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0011">11</xref> are based on the doses studied in the trials, and would probably be appropriate in most situations. However, a comprehensive evaluation of the agitated patient is necessary (ie, medical conditions, treatments, drugs, intoxication, etc.) to determine a safe and adequate dose.</p>
<table-wrap id="bdi12609-tbl-0011" orientation="portrait" position="float" xml:lang="en">
<label>Table 11</label>
<caption>
<p>Level of evidence and recommendations for short‐term pharmacological management of agitation<xref ref-type="fn" rid="bdi12609-note-0010">a</xref>
</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Level of recommendation</th>
<th align="left" colspan="1" rowspan="2" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="2" valign="top">Formulation</th>
<th align="left" colspan="1" rowspan="2" valign="top">Level of evidence</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Dose range of studies<xref ref-type="fn" rid="bdi12609-note-0011">b</xref>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Single dose</th>
<th align="left" colspan="1" rowspan="1" valign="top">Max/24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="4">First‐line</td>
<td align="left" colspan="1" rowspan="1">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">9.75 mg</td>
<td align="left" colspan="1" rowspan="1">15 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lorazepam</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="2" rowspan="1">2 mg IM</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Loxapine</td>
<td align="left" colspan="1" rowspan="1">Inhaled</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">5 mg</td>
<td align="left" colspan="1" rowspan="1">10 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Olanzapine</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2.5 mg</td>
<td align="left" colspan="1" rowspan="1">10 mg<xref ref-type="fn" rid="bdi12609-note-0012">c</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Second‐line</td>
<td align="left" colspan="1" rowspan="1">Asenapine</td>
<td align="left" colspan="1" rowspan="1">Sublingual</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="2" rowspan="1">10 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Haloperidol</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">5 mg</td>
<td align="left" colspan="1" rowspan="1">15 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Haloperidol + midazolam</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">2.5 mg (haloperidol) + 7.5 mg (midazolam)</td>
<td align="left" colspan="1" rowspan="1">5 mg (haloperidol) + 15mg (midazolam)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Haloperidol + promethazine</td>
<td align="left" colspan="1" rowspan="1">IM<xref ref-type="fn" rid="bdi12609-note-0014">e</xref>
</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">2.5 mg (haloperidol) + 25 mg (promethazine)</td>
<td align="left" colspan="1" rowspan="1">5 mg (haloperidol) + 50 mg (promethazine)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Risperidone</td>
<td align="left" colspan="1" rowspan="1">ODT<xref ref-type="fn" rid="bdi12609-note-0014">e</xref>
</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">2 mg</td>
<td align="left" colspan="1" rowspan="1">4 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ziprasidone</td>
<td align="left" colspan="1" rowspan="1">IM<xref ref-type="fn" rid="bdi12609-note-0014">e</xref>
</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">2 mg</td>
<td align="left" colspan="1" rowspan="1">20 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Haloperidol</td>
<td align="left" colspan="1" rowspan="1">PO<xref ref-type="fn" rid="bdi12609-note-0013">d</xref>
</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">5 mg</td>
<td align="left" colspan="1" rowspan="1">15 mg</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Loxapine</td>
<td align="left" colspan="1" rowspan="1">IM</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="2" rowspan="1">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Quetiapine</td>
<td align="left" colspan="1" rowspan="1">PO<xref ref-type="fn" rid="bdi12609-note-0013">d</xref>
</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="2" rowspan="1">Mean (SD) = 486.7 (317.2) mg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Risperidone</td>
<td align="left" colspan="1" rowspan="1">PO<xref ref-type="fn" rid="bdi12609-note-0014">e</xref>
</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="2" rowspan="1">2 mg</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0010">
<label>a</label>
<p>See text for recommendations about use of oral antipsychotics and divalproex. IM, intramuscular; ODT, orally disintegrating tablet; PO, per os.</p>
</fn>
<fn id="bdi12609-note-0011">
<label>b</label>
<p>Doses are reported as per studies.</p>
</fn>
<fn id="bdi12609-note-0012">
<label>c</label>
<p>26.3% received two or three 10 mg injections.</p>
</fn>
<fn id="bdi12609-note-0013">
<label>d</label>
<p>Assessed 2 h after the dose.</p>
</fn>
<fn id="bdi12609-note-0014">
<label>e</label>
<p>Doses are not specifically for bipolar disorder but included schizophrenia or other diagnoses.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>As can be seen from Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0011">11</xref>, the highest level of evidence available in short‐term treatment of agitation for oral formulations of any agent is level 3, and level 2 for intramuscular (IM) or inhaled formulations. In this context, it is important to remember that the absence of evidence does not constitute lack of efficacy. Indeed, clinical experience suggests that agitation in many patients with acute mania responds well to the oral medications. Thus, a loading dose of divalproex, oral formulations of atypical antipsychotics, conventional antipsychotics such as haloperidol or loxapine, and/or benzodiazepines such as lorazepam may be appropriate. If a patient indicates willingness to take oral treatment but there is a suspicion that the patient might “cheek” the medication, then either orally dispersing tablets (ODT), those that rapidly melt, oral liquid, or oral inhalation forms should be considered. In countries where inhaled loxapine is available, this could be considered if there are no contraindications.</p>
<p>If oral preparations are ineffective or if the agitation is severe and if the patient is refusing oral medications, or when oral therapy cannot be safely or reliably administered, then IM formulations should be considered.<xref ref-type="ref" rid="bdi12609-bib-0124">124</xref> Because of the strength of evidence for efficacy in alleviating agitation in this population, aripiprazole IM (level 2),<xref ref-type="ref" rid="bdi12609-bib-0125">125</xref>, <xref ref-type="ref" rid="bdi12609-bib-0126">126</xref> lorazepam IM (level 2),<xref ref-type="ref" rid="bdi12609-bib-0125">125</xref>, <xref ref-type="ref" rid="bdi12609-bib-0127">127</xref> loxapine inhaled (Level 1)<xref ref-type="ref" rid="bdi12609-bib-0128">128</xref>, <xref ref-type="ref" rid="bdi12609-bib-0129">129</xref> and olanzapine IM (level 2)<xref ref-type="ref" rid="bdi12609-bib-0127">127</xref>, <xref ref-type="ref" rid="bdi12609-bib-0130">130</xref>, <xref ref-type="ref" rid="bdi12609-bib-0131">131</xref>, <xref ref-type="ref" rid="bdi12609-bib-0132">132</xref>, <xref ref-type="ref" rid="bdi12609-bib-0133">133</xref> are recommended as the first‐line option. Sublingual asenapine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0134">134</xref> haloperidol IM (level 3),<xref ref-type="ref" rid="bdi12609-bib-0131">131</xref>, <xref ref-type="ref" rid="bdi12609-bib-0135">135</xref>, <xref ref-type="ref" rid="bdi12609-bib-0136">136</xref> haloperidol IM + midazolam IM (level 3),<xref ref-type="ref" rid="bdi12609-bib-0131">131</xref>, <xref ref-type="ref" rid="bdi12609-bib-0137">137</xref> haloperidol IM + promethazine IM (level 3),<xref ref-type="ref" rid="bdi12609-bib-0131">131</xref>, <xref ref-type="ref" rid="bdi12609-bib-0137">137</xref>, <xref ref-type="ref" rid="bdi12609-bib-0138">138</xref> risperidone ODT (level 3),<xref ref-type="ref" rid="bdi12609-bib-0136">136</xref> and ziprasidone IM (level 3)<xref ref-type="ref" rid="bdi12609-bib-0131">131</xref>, <xref ref-type="ref" rid="bdi12609-bib-0137">137</xref>, <xref ref-type="ref" rid="bdi12609-bib-0139">139</xref> are recommended as a second‐line treatment. Haloperidol per os (PO) (level 4),<xref ref-type="ref" rid="bdi12609-bib-0140">140</xref>, <xref ref-type="ref" rid="bdi12609-bib-0141">141</xref> loxapine IM (level 4) (clinical opinion), quetiapine PO (level 4),<xref ref-type="ref" rid="bdi12609-bib-0141">141</xref> and risperidone PO (level 4)<xref ref-type="ref" rid="bdi12609-bib-0140">140</xref> are included as third‐line options (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0011">11</xref>).</p>
</sec>
<sec id="bdi12609-sec-0028">
<label>3.3</label>
<title>Pharmacological treatment of manic episodes</title>
<p>There are a range of strategies that have been investigated for use in mania; including lithium, divalproex, other anticonvulsants, typical and atypical antipsychotics, and other agents and therapies. These treatments have been evaluated using the criteria for strength of evidence for efficacy (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>) as well as safety and tolerability (Section 8). The evidence for efficacy and the recommendations for treating acute mania are summarized in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0012">12</xref>.</p>
<table-wrap id="bdi12609-tbl-0012" orientation="portrait" position="float" xml:lang="en">
<label>Table 12</label>
<caption>
<p>Hierarchical rankings of first and second‐line treatments recommended for management of acute mania</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="BDI-20-97-g010"></graphic>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>As stated previously, the first and second‐line agents are listed hierarchically taking into consideration not only their efficacy for acute mania but also their efficacy in preventing mania or depression, treating acute bipolar depression, safety/tolerability and the risk of treatment‐emergent switch. The implication of this hierarchical recommendation is that those listed higher up in the table should be considered first before moving on to the next on the list, unless other factors such as history of previous non‐response or patient's preferences preclude such strategy in a given patient.</p>
<p>Monotherapy and combination therapy are listed separately as first‐line treatments for acute mania in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0012">12</xref>. This does not mean that all monotherapy agents should be tried first before considering combination therapy for acute mania. We suggest that the treating clinician make a decision as to whether to treat a given patient with monotherapy or combination therapy. That decision is typically based on the rapidity of response needed (eg, combination treatments tend to work faster), whether the patient had a previous history of partial response to monotherapy, severity of mania, tolerability concerns with combination therapy, and willingness of the patient to take combination therapy. Once a decision is made whether to treat the patient with monotherapy or combination therapy, then hierarchy related to monotherapy or combination therapy could be followed. We also suggest that clinicians evaluate the efficacy and tolerability at the end of weeks 1 and 2 and modify treatment options accordingly.</p>
<sec id="bdi12609-sec-0029">
<label>3.3.1</label>
<title>Step 1: review general principles and assess medication status</title>
<p>Examination of a patient presenting in a manic state should include an immediate assessment for risk of aggressive behaviour, violence and safety threat to others, suicide risk especially in those with mixed features, degree of insight and the ability to adhere to treatment, comorbidity (including substance use that may be aggravating or contributing to clinical presentation), and availability of a psychosocial support network. A physical examination with laboratory investigations (described in Section 8) should be conducted, but may be deferred for patients who are uncooperative. Results of the overall assessment should be used to establish the most appropriate treatment setting (eg, ambulatory or inpatient).</p>
<p>Before initiating pharmacological treatment for a manic episode, it is imperative to rule out symptoms secondary to drugs of abuse, medications, other treatments, or a general medical or neurological condition (although, even in these cases, symptomatic treatment may be applied on a short‐term basis). Steps should be taken to rule out any other factors that may be perpetuating symptoms such as prescribed medication, illicit drug use/abuse or an endocrine disorder. Any patients presenting with mania who have been taking antidepressants should have these medications discontinued. If there is a previous diagnosis of BD, it is appropriate to immediately commence antimanic agents. If this is the first emergence of manic symptoms, clinicians are advised to confirm the diagnosis of BD by monitoring patients for a period of time after antidepressant discontinuation and obtain collateral information to confirm whether symptoms remain and antimanic treatment is necessary. Patients should also be supported to discontinue stimulant use, including caffeine and alcohol. Current and prior therapies should be assessed, including appropriateness of medications, dosing, and trough serum levels (where indicated), as well as past response; and this should be used to direct subsequent therapeutic choices. Attention should be paid to managing withdrawal symptoms that may occur in manic patients with histories of substance abuse.</p>
<p>When the symptoms of mania have remitted, behavioural and educational strategies should be applied to promote ongoing medication adherence, reduce residual symptoms, help identify early signs of relapse, and support functional recovery (see Section 2).</p>
</sec>
<sec id="bdi12609-sec-0030">
<label>3.3.2</label>
<title>Step 2: initiate or optimize therapy and check adherence</title>
<p>It is recommended that, for all patients (including those who are untreated as well as those receiving a non‐first‐line treatment), therapy be initiated with one of the available first‐line monotherapy or combination treatments.</p>
<sec id="bdi12609-sec-0031">
<title>First‐line monotherapy</title>
<p>Approximately 50% of patients will respond to monotherapy with significant improvement in manic symptoms within 3‐4 weeks.<xref ref-type="ref" rid="bdi12609-bib-0142">142</xref> Lithium (level 1), quetiapine (level 1), divalproex (level 1), asenapine (level 1), aripiprazole (level 1), paliperidone (level 1 for doses &gt;6 mg), risperidone (level 1), and cariprazine (level 1) are all recommended as first‐line treatment options. Overall, these agents show comparable efficacy (Cohen's <italic>d</italic> 0.32‐0.66; small to medium effect size).<xref ref-type="ref" rid="bdi12609-bib-0143">143</xref>
</p>
<p>Although they have comparable efficacy for treating acute mania, we recommend that the agents listed first in the text and placed higher in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0012">12</xref> be tried first, in the order listed, unless there are patient‐specific reasons for choosing an agent lower down in the order (see “Clinical features that help direct treatment choices”). For instance, lithium should be considered first for acute mania unless there are specific reasons not to, such as mixed features, comorbid substance use or previous non‐response to lithium.</p>
<p>Carbamazepine, olanzapine, ziprasidone and haloperidol also have level 1 evidence for efficacy but they are downgraded to second‐line options due to safety/tolerability risks with these agents.</p>
</sec>
<sec id="bdi12609-sec-0032">
<title>First‐line combination therapy</title>
<p>Combination therapy with the atypical antipsychotics quetiapine (level 1), aripiprazole (level 2), risperidone (level 1), or asenapine (level 2) and lithium or divalproex is also recommended as first‐line treatment options with greater efficacy than monotherapy with lithium or divalproex alone, especially in those with higher index severity.<xref ref-type="ref" rid="bdi12609-bib-0144">144</xref>
</p>
<p>In general, combination therapy is preferred to mood stabilizer monotherapy because clinical trials suggest that on average about 20% more patients will respond to combination therapy.<xref ref-type="ref" rid="bdi12609-bib-0142">142</xref>, <xref ref-type="ref" rid="bdi12609-bib-0145">145</xref>, <xref ref-type="ref" rid="bdi12609-bib-0146">146</xref> There is also some evidence to suggest the benefit of combination therapy compared to atypical antipsychotic monotherapy, although there are fewer trials. Specifically, lithium plus quetiapine showed superiority to quetiapine alone.<xref ref-type="ref" rid="bdi12609-bib-0147">147</xref> While there is also level 1 evidence for olanzapine combination therapy over olanzapine monotherapy, this is downgraded to second‐line due to tolerability/safety concerns with olanzapine.</p>
<p>The decision to treat with one or a combination of available first‐line agents should be informed by current and prior medication use, with treatment previously shown to be successful in managing symptoms preferred. Safety and tolerability factors for each medication and clinical features predictive of better response (see “Clinical features that help direct treatment choices”) should also be considered. In general, combination therapy is associated with more adverse events than monotherapy. Whenever possible, options should be discussed with the patient and/or their caregiver and their preferences considered prior to treatment selection.</p>
<p>If symptoms are not controlled using monotherapy or combination therapy with first‐line agents, dosing should be optimized, issues of non‐adherence identified and addressed, and consideration given to possible substance use (Section 4) prior to adding or switching therapies (Step 3). Given that almost all antimanic agents separated from placebo within 1 week, some therapeutic response is expected with antimanic agents within 1‐2 weeks. If no response is observed within 2 weeks with therapeutic doses of antimanic agents, and other contributing factors for non‐response are excluded, then switch or add‐on strategies should be considered.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0033">
<label>3.3.3</label>
<title>Step 3: add on or switch therapy (alternate first‐line agents)</title>
<p>If therapy with one or a combination of the first‐line agents (lithium, divalproex and/or an atypical antipsychotic) at optimal doses is inadequate or not tolerated, the next step is to switch to or add on an alternate first‐line agent. An exception is that, despite level 1 evidence for monotherapy with paliperidone and ziprasidone, we do not recommend combination therapy with these agents due to lack of evidence for additional efficacy (see “No specific recommendation/agents that require further study” below). Because there are multiple first‐line agents with substantial efficacy data and relative safety and tolerability, the use of second‐ and third‐line agents is only recommended after unsuccessful trials of multiple first‐line strategies.</p>
</sec>
<sec id="bdi12609-sec-0034">
<label>3.3.4</label>
<title>Step 4: add on or switch therapy (second‐line agents)</title>
<sec id="bdi12609-sec-0035">
<title>Second‐line</title>
<p>In patients who are inadequately responsive to first‐line agents, second‐line choices include monotherapy with olanzapine (level 1), carbamazepine (level 1), ziprasidone (level 1), and haloperidol (level 1)<xref ref-type="ref" rid="bdi12609-bib-0143">143</xref> or combination therapy with olanzapine plus lithium or divalproex (level 1). While each of these strategies has strong support for their efficacy, as indicated above, safety and tolerability concerns relegate them to second‐line options. Although widely used in clinical practice, the combination of lithium and divalproex is also recommended as a second‐line choice, as evidence supporting its efficacy is limited to uncontrolled trials (level 3).<xref ref-type="ref" rid="bdi12609-bib-0148">148</xref>, <xref ref-type="ref" rid="bdi12609-bib-0149">149</xref>, <xref ref-type="ref" rid="bdi12609-bib-0150">150</xref>, <xref ref-type="ref" rid="bdi12609-bib-0151">151</xref>
</p>
<p>ECT is also recommended as a second‐line option (level 3)<xref ref-type="ref" rid="bdi12609-bib-0152">152</xref> and, although the number of controlled trials is limited, there is evidence to suggest that up to 80% of patients will show marked clinical improvements.<xref ref-type="ref" rid="bdi12609-bib-0153">153</xref> Brief pulse therapy with two or three treatments per week has been used. Bifrontal electrode placement is preferred over bitemporal as it is associated with faster treatment response and fewer cognitive side effects.<xref ref-type="ref" rid="bdi12609-bib-0154">154</xref>, <xref ref-type="ref" rid="bdi12609-bib-0155">155</xref>, <xref ref-type="ref" rid="bdi12609-bib-0156">156</xref>
</p>
<p>When all first‐line agents have failed, the hierarchy should be applied to second‐line agents as well. Hence, olanzapine, which is highest in the hierarchy amongst second‐line agents, should be first choice before moving down the list in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0012">12</xref>.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0036">
<label>3.3.5</label>
<title>Step 5: add on or switch therapy (third‐line agents)</title>
<sec id="bdi12609-sec-0037">
<title>Third‐line</title>
<p>Agents recommended as third‐line options for treatment of acute mania include monotherapy with chlorpromazine (level 2),<xref ref-type="ref" rid="bdi12609-bib-0157">157</xref> monotherapy with clonazepam (level 2),<xref ref-type="ref" rid="bdi12609-bib-0158">158</xref> monotherapy or adjunctive therapy with clozapine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0159">159</xref>, <xref ref-type="ref" rid="bdi12609-bib-0160">160</xref>, <xref ref-type="ref" rid="bdi12609-bib-0161">161</xref>, <xref ref-type="ref" rid="bdi12609-bib-0162">162</xref> and monotherapy with tamoxifen (level 2).<xref ref-type="ref" rid="bdi12609-bib-0143">143</xref> Tamoxifen is downgraded because of the risk of uterine cancer and the lack of clinical experience despite evidence for efficacy. Combination treatments with carbamazepine or oxcarbazepine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0163">163</xref> haloperidol (level 2),<xref ref-type="ref" rid="bdi12609-bib-0144">144</xref>, <xref ref-type="ref" rid="bdi12609-bib-0164">164</xref> or tamoxifen (level 2)<xref ref-type="ref" rid="bdi12609-bib-0165">165</xref> plus lithium or divalproex are also included as third‐line. Repetitive transcranial magnetic stimulation (rTMS) in the right prefrontal cortex at 110% motor threshold (level 3)<xref ref-type="ref" rid="bdi12609-bib-0166">166</xref> can also be considered in combination with pharmacotherapy.</p>
<p>The third‐line agents should only be used if a patient has not responded to adequate trials with all first and second‐line agents alone and in combination. Given that the evidence is very limited for third‐line agents, it was not possible to list them in any hierarchical order and they are thus listed alphabetically (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0013">13</xref>).</p>
<table-wrap id="bdi12609-tbl-0013" orientation="portrait" position="float" xml:lang="en">
<label>Table 13</label>
<caption>
<p>Additional agents evaluated for use in acute mania</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="1" valign="top">Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="8">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Carbamazepine/oxcarbazepine + Li/DVP</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chlorpromazine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Clonazepam</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Clozapine</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Haloperidol + Li/DVP</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rTMS</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tamoxifen</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tamoxifen + Li/DVP</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="8">Not recommended</td>
<td align="left" colspan="1" rowspan="1">Allopurinol</td>
<td align="left" colspan="1" rowspan="1">Level 1 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Eslicarbazepine/licarbazepine</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gabapentin</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1">Level 1 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Omega‐3 fatty acids</td>
<td align="left" colspan="1" rowspan="1">Level 1 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Topiramate</td>
<td align="left" colspan="1" rowspan="1">Level 1 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Valnoctamide</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zonisamide</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0022">
<p>DVP, divalproex; Li, lithium; rTMS, repetitive transcranial magnetic stimulation.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
</sec>
<sec id="bdi12609-sec-0038">
<label>3.3.6</label>
<title>Agents not recommended for the treatment of acute mania</title>
<p>Antimanic efficacy has not been demonstrated for allopurinol (level 1 negative),<xref ref-type="ref" rid="bdi12609-bib-0167">167</xref> eslicarbazepine/licarbazepine (level 2 negative),<xref ref-type="ref" rid="bdi12609-bib-0168">168</xref> gabapentin (Level 2 negative), lamotrigine (level 1 negative),<xref ref-type="ref" rid="bdi12609-bib-0143">143</xref> omega‐3 fatty acids (level 1 negative),<xref ref-type="ref" rid="bdi12609-bib-0169">169</xref> topiramate (level 1 negative),<xref ref-type="ref" rid="bdi12609-bib-0143">143</xref> valnoctamide (level 2 negative),<xref ref-type="ref" rid="bdi12609-bib-0170">170</xref>, <xref ref-type="ref" rid="bdi12609-bib-0171">171</xref> or zonisamide (level 2 negative)<xref ref-type="ref" rid="bdi12609-bib-0172">172</xref> (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0013">13</xref>).</p>
</sec>
<sec id="bdi12609-sec-0039">
<label>3.3.7</label>
<title>No specific recommendation/agents that require further study</title>
<p>Trials with paliperidone (level 2 negative) and ziprasidone (level 2 negative) adjunctive therapy to lithium or divalproex showed lack of efficacy.<xref ref-type="ref" rid="bdi12609-bib-0144">144</xref> This is surprising given that all other atypical antipsychotic agents that showed efficacy in monotherapy have also been shown to offer additional benefit when combined with lithium or divalproex. It is likely that methodological problems have contributed to failure in these studies; hence, further studies are needed before specific recommendations can be made about the use of these combinations for mania.</p>
<p>Studies of olanzapine (level 2 negative) <xref ref-type="ref" rid="bdi12609-bib-0173">173</xref> or risperidone (level 3 negative)<xref ref-type="ref" rid="bdi12609-bib-0174">174</xref> plus carbamazepine have been negative, although this is probably due to enzyme‐inducing effects of carbamazepine. While this may be overcome by dosing adjustments, because such interactions are unpredictable and effective doses have not been established, we are unable to provide a specific recommendation.</p>
<p>Nutraceuticals such as branched chain amino acids (level 3),<xref ref-type="ref" rid="bdi12609-bib-0175">175</xref> folic acid (level 2),<xref ref-type="ref" rid="bdi12609-bib-0176">176</xref> and <sc>l</sc>‐tryptophan (level 3),<xref ref-type="ref" rid="bdi12609-bib-0177">177</xref> as well as other experimental agents such as medroxyprogesterone (level 3),<xref ref-type="ref" rid="bdi12609-bib-0178">178</xref>, <xref ref-type="ref" rid="bdi12609-bib-0179">179</xref> memantine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0180">180</xref> mexiletine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0181">181</xref> levetiracetam (level 4)<xref ref-type="ref" rid="bdi12609-bib-0182">182</xref> and phenytoin (level 3),<xref ref-type="ref" rid="bdi12609-bib-0183">183</xref> have all shown indications of efficacy when used adjunctively with other antimanic agents, as have glasses that block blue light (level 3).<xref ref-type="ref" rid="bdi12609-bib-0184">184</xref> Larger controlled trials are needed, however, before a recommendation for their use in mania can be made. While an initial small RCT did not show anti‐manic efficacy for verapamil,<xref ref-type="ref" rid="bdi12609-bib-0185">185</xref> there is some evidence that it may work as an adjunctive therapy (level 4)<xref ref-type="ref" rid="bdi12609-bib-0186">186</xref> or as monotherapy in women (level 4).<xref ref-type="ref" rid="bdi12609-bib-0187">187</xref> Larger studies are needed before a conclusion can be made.</p>
</sec>
<sec id="bdi12609-sec-0040">
<label>3.3.8</label>
<title>Clinical features that help direct treatment choices</title>
<p>Clinical features, including DSM‐5 specifiers, may assist in making treatment choices between first and second‐line treatment options.</p>
<p>In general, lithium is preferred over divalproex for individuals who display classical euphoric grandiose mania (elated mood in the absence of depressive symptoms), few prior episodes of illness, a mania‐depression‐euthymia course,<xref ref-type="ref" rid="bdi12609-bib-0188">188</xref>, <xref ref-type="ref" rid="bdi12609-bib-0189">189</xref>, <xref ref-type="ref" rid="bdi12609-bib-0190">190</xref> and/or those with a family history of BD, especially with a family history of lithium response. Divalproex is equally effective in those with classical and dysphoric mania. Further, divalproex is recommended for those with multiple prior episodes, predominant irritable or dysphoric mood and/or comorbid substance abuse or those with a history of head trauma.<xref ref-type="ref" rid="bdi12609-bib-0188">188</xref>, <xref ref-type="ref" rid="bdi12609-bib-0191">191</xref>, <xref ref-type="ref" rid="bdi12609-bib-0192">192</xref>, <xref ref-type="ref" rid="bdi12609-bib-0193">193</xref>, <xref ref-type="ref" rid="bdi12609-bib-0194">194</xref>, <xref ref-type="ref" rid="bdi12609-bib-0195">195</xref> Because of its teratogenic potential, however, caution should be exercised when prescribing divalproex to women of childbearing age. Patients with specific factors such as a history of head trauma, comorbid anxiety and substance abuse, schizoaffective presentations with mood‐incongruent delusions, or negative history of bipolar illness in first‐degree relatives may respond to carbamazepine.<xref ref-type="ref" rid="bdi12609-bib-0196">196</xref>
</p>
<p>Combination therapy with lithium or divalproex and an atypical antipsychotic is recommended when a response is needed faster, in patients judged at risk, who have had a previous history of partial acute or prophylactic response to monotherapy or in those with more severe manic episodes.<xref ref-type="ref" rid="bdi12609-bib-0145">145</xref>
</p>
<sec id="bdi12609-sec-0041">
<title>Anxious distress</title>
<p>Symptoms of anxiety frequently co‐occur during a manic episode, and are a predictor of poor outcome; including greater severity of manic symptoms,<xref ref-type="ref" rid="bdi12609-bib-0197">197</xref> a longer time to remission,<xref ref-type="ref" rid="bdi12609-bib-0197">197</xref>, <xref ref-type="ref" rid="bdi12609-bib-0198">198</xref> and more reported side effects of medication.<xref ref-type="ref" rid="bdi12609-bib-0198">198</xref> There have been no studies specifically examining the efficacy of any agents in reducing symptoms of anxiety during a manic episode, although these symptoms do tend to improve concurrently with mood disturbance. Post hoc analyses suggest that divalproex, quetiapine, and olanzapine may have specific anxiolytic benefits<xref ref-type="ref" rid="bdi12609-bib-0199">199</xref> and carbamazepine may be useful as well.<xref ref-type="ref" rid="bdi12609-bib-0196">196</xref>
</p>
</sec>
<sec id="bdi12609-sec-0042">
<title>Mixed features</title>
<p>Depressive symptoms co‐occur alongside mania in 10%‐30% of cases,<xref ref-type="ref" rid="bdi12609-bib-0200">200</xref>, <xref ref-type="ref" rid="bdi12609-bib-0201">201</xref> with studies suggesting mixed features are indicative of a more severe and disabling course, as well as a higher rate of suicide.<xref ref-type="ref" rid="bdi12609-bib-0201">201</xref>, <xref ref-type="ref" rid="bdi12609-bib-0202">202</xref> Evidence supports the preferential use of atypical antipsychotics and divalproex in these cases, with combination therapy frequently required.<xref ref-type="ref" rid="bdi12609-bib-0195">195</xref>, <xref ref-type="ref" rid="bdi12609-bib-0203">203</xref> Atypical antipsychotics such as asenapine, aripiprazole, olanzapine and ziprasidone have been shown to be equally effective in treating manic symptoms in those with classical mania as well as in mixed mania or in manic patients with mixed features.<xref ref-type="ref" rid="bdi12609-bib-0196">196</xref>, <xref ref-type="ref" rid="bdi12609-bib-0204">204</xref>, <xref ref-type="ref" rid="bdi12609-bib-0205">205</xref>
</p>
</sec>
<sec id="bdi12609-sec-0043">
<title>Psychotic features (mood congruent or incongruent)</title>
<p>At least half of manic episodes are characterized by the presence of psychosis,<xref ref-type="ref" rid="bdi12609-bib-0206">206</xref> and theories suggest that it is a nonspecific feature which improves alongside underlying manic symptoms.<xref ref-type="ref" rid="bdi12609-bib-0207">207</xref> While the prognosis for patients experiencing mood‐congruent psychotic features may not differ from those with an absence of psychotic symptoms, limited evidence does suggest that those with mood‐incongruent features have a more severe illness with poorer long‐term prognosis.<xref ref-type="ref" rid="bdi12609-bib-0207">207</xref>, <xref ref-type="ref" rid="bdi12609-bib-0208">208</xref>, <xref ref-type="ref" rid="bdi12609-bib-0209">209</xref>, <xref ref-type="ref" rid="bdi12609-bib-0210">210</xref>, <xref ref-type="ref" rid="bdi12609-bib-0211">211</xref>, <xref ref-type="ref" rid="bdi12609-bib-0212">212</xref> There is no evidence of superiority of any first‐line monotherapy treatment in comparison to other monotherapy options in treating patients with psychotic features. Similarly, there is no evidence that any first‐line combination therapy of lithium or divalproex plus an atypical antipsychotic is more effective than other first‐line combination therapy.<xref ref-type="ref" rid="bdi12609-bib-0174">174</xref>, <xref ref-type="ref" rid="bdi12609-bib-0193">193</xref>, <xref ref-type="ref" rid="bdi12609-bib-0213">213</xref>, <xref ref-type="ref" rid="bdi12609-bib-0214">214</xref> However, clinical experience suggests that the combination of lithium or divalproex plus an atypical antipsychotic is more appropriate for manic patients with mood‐incongruent psychotic features (ie, other than grandiose delusions). Similarly, in patients where the diagnostic possibility of schizoaffective disorder with manic symptoms is considered, either use of an atypical antipsychotic or combination of an atypical antipsychotic with a mood stabilizer is more appropriate.</p>
</sec>
<sec id="bdi12609-sec-0044">
<title>Rapid cycling</title>
<p>Rapid cycling, or a course of illness that includes four or more mood episodes a year, affects up to one‐third of patients with BDI.<xref ref-type="ref" rid="bdi12609-bib-0215">215</xref>, <xref ref-type="ref" rid="bdi12609-bib-0216">216</xref>, <xref ref-type="ref" rid="bdi12609-bib-0217">217</xref>, <xref ref-type="ref" rid="bdi12609-bib-0218">218</xref> Hypothyroidism, antidepressant use and substance abuse are often associated with rapid cycling; thus assessing thyroid function and discontinuation of antidepressants, stimulants, and other psychotropic agents that are contributors to cycling are imperative. Consideration should be given to gradually withdrawing substances in order to prevent withdrawal, but this needs to be balanced against the severity of mood cycling and the need for rapid mood stabilization. As there is no evidence for the superiority of any first‐line treatment in addressing acute manic symptoms in patients with a rapid cycling course,<xref ref-type="ref" rid="bdi12609-bib-0219">219</xref> appropriate pharmacotherapy should be selected primarily based on effectiveness in the maintenance phase, if known (see Section 5). It is likely that combinations of mood‐stabilizing drugs may be more often necessary than monotherapies when rapid cycling is present,<xref ref-type="ref" rid="bdi12609-bib-0220">220</xref> but triple mood stabilizer therapy has not demonstrated superiority to double mood stabilizer therapy in a single RCT,<xref ref-type="ref" rid="bdi12609-bib-0221">221</xref> although methodological weaknesses probably limited interpretability of the findings.</p>
</sec>
<sec id="bdi12609-sec-0045">
<title>Seasonal pattern</title>
<p>While some individual patients may show a seasonal pattern, Canadian data are mixed as to whether episodes of mania or depression in BD follow a consistent seasonal variation.<xref ref-type="ref" rid="bdi12609-bib-0222">222</xref> There is no evidence for the superiority of any agent in patients with an observed seasonal pattern of manic episodes.</p>
</sec>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0046">
<label>4</label>
<title>ACUTE MANAGEMENT OF BIPOLAR DEPRESSION</title>
<sec id="bdi12609-sec-0047">
<label>4.1</label>
<title>Presentations of bipolar depression</title>
<p>The DSM‐5 criteria for bipolar depression are unchanged from DSM‐IV. Depression is characterized by a minimum of 2 weeks of depressed mood and/or anhedonia and at least four other symptoms that include changes in sleep, appetite/weight, energy, psychomotor activity, concentration, thought content (guilt and worthlessness), and suicidal intent. For many patients with BD, the depressive polarity is often more pervasive and more debilitating than manic states, with estimates that depressed mood accounts for up to two‐thirds of the time spent unwell, even with treatment.<xref ref-type="ref" rid="bdi12609-bib-0012">12</xref>, <xref ref-type="ref" rid="bdi12609-bib-0223">223</xref>, <xref ref-type="ref" rid="bdi12609-bib-0224">224</xref> Subsyndromal depressive symptoms, which persist despite treatment, are particularly common and a major source of functional impairment in these patients.<xref ref-type="ref" rid="bdi12609-bib-0225">225</xref>, <xref ref-type="ref" rid="bdi12609-bib-0226">226</xref>, <xref ref-type="ref" rid="bdi12609-bib-0227">227</xref>, <xref ref-type="ref" rid="bdi12609-bib-0228">228</xref>, <xref ref-type="ref" rid="bdi12609-bib-0229">229</xref> They should be treated aggressively.</p>
<p>DSM‐5 includes several specifiers that may accompany depressive episodes: anxious distress, mixed features, rapid cycling, melancholic features, atypical features, mood‐congruent or mood‐incongruent psychotic features, peripartum onset, and seasonal pattern (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0005">5</xref>). The utility of several of these specifiers in selecting treatment options for depression is discussed later in this section (see “Clinical features that help direct treatment choices”).</p>
</sec>
<sec id="bdi12609-sec-0048">
<label>4.2</label>
<title>Diagnostic and treatment challenges</title>
<sec id="bdi12609-sec-0049">
<label>4.2.1</label>
<title>Misdiagnosis and delayed diagnosis</title>
<p>Patients with depression occurring in the context of BD are frequently misdiagnosed as having MDD, since the presence of mania or hypomania (particularly mild or moderate episodes which do not require hospitalization) may be challenging to establish retrospectively. This is especially true in the absence of a comprehensive diagnostic interview or collateral information, as patients may often lack basic knowledge of what hypomania/mania is, and/or have limited insight into these symptoms; and thus may not disclose this information unless specifically asked. Alternatively, patients who will ultimately present with hypomanic or manic episodes may only have experienced episodes of depression. Thus, clinicians must be vigilant for a diagnosis of BD, and routinely ask for symptoms of a previous manic/hypomanic episode in every patient presenting with a major depressive episode. A diagnosis of MDD should be made only after excluding the possibility of BD.</p>
<p>In addition to overt manic/hypomanic symptoms, there are numerous features that increase the likelihood of a diagnosis of BD in depressed individuals. These include earlier age of illness onset (before 25 years), brief, highly recurrent depressive episodes, a family history of BD, depression with psychotic features, atypical features such as reverse vegetative symptoms of hypersomnia and hyperphagia, leaden paralysis, psychomotor agitation, postpartum depression or psychosis, and antidepressant‐induced irritability, manic symptoms or rapid cycling<xref ref-type="ref" rid="bdi12609-bib-0038">38</xref>, <xref ref-type="ref" rid="bdi12609-bib-0039">39</xref> (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0006">6</xref>).</p>
<p>Individuals with depression who are at high risk for BD, particularly those with a strong family history of BD, should be closely monitored for emergence of manic or mixed symptoms. Consideration should also be given to applying the BD depression treatment recommendations amongst those at very high risk, rather than risk potential iatrogenic effects of antidepressant monotherapy, although this recommendation is based on clinical experience as there is a lack of sufficient research addressing this issue. As discussed in Section 2, there are also several useful psychosocial interventions, such as individual and family psychoeducation and FFT, that have been shown to have some benefit in this population.</p>
</sec>
<sec id="bdi12609-sec-0050">
<label>4.2.2</label>
<title>Suicide risk</title>
<p>Principles related to management of suicidal ideation and risk (see Section 2 and<xref ref-type="ref" rid="bdi12609-bib-0047">47</xref>) are of utmost importance during depressive episodes, as &gt;70% of suicide deaths and suicide attempts in patients with BD occur during this phase.<xref ref-type="ref" rid="bdi12609-bib-0230">230</xref>, <xref ref-type="ref" rid="bdi12609-bib-0231">231</xref> Depressive episodes with mixed features are a particularly dangerous period associated with even higher short‐term risks of suicide attempts or death.<xref ref-type="ref" rid="bdi12609-bib-0232">232</xref> Overall, it is imperative for clinicians to review risk factors (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0009">9</xref>) and determine an appropriate treatment setting to address any safety issues. All patients at risk should be encouraged to develop and share a written safety plan listing coping strategies and sources of support which may be applied during times of crisis. As described in Section 2, the most common method of suicide in this population is self‐poisoning, and so potential benefits of various treatments should be considered against their risk of toxicity and lethality. One study found that there were fewer deaths due to lethal lithium levels compared to carbamazepine, and that opioids and benzodiazepines were the most common medication classes ingested at lethal levels—noteworthy given the lack of efficacy of these agents in the disorder.<xref ref-type="ref" rid="bdi12609-bib-0055">55</xref>
</p>
</sec>
<sec id="bdi12609-sec-0051">
<label>4.2.3</label>
<title>Cognitive and functional impairment</title>
<p>Part of the impact of acute and subsyndromal depressive symptoms on functional impairment is thought to be mediated through cognitive performance, which is both subjectively and objectively impaired in bipolar depression and linked to poor psychosocial function.<xref ref-type="ref" rid="bdi12609-bib-0233">233</xref>, <xref ref-type="ref" rid="bdi12609-bib-0234">234</xref>, <xref ref-type="ref" rid="bdi12609-bib-0235">235</xref>, <xref ref-type="ref" rid="bdi12609-bib-0236">236</xref>
</p>
<p>Because of the important link between cognition and functioning,<xref ref-type="ref" rid="bdi12609-bib-0237">237</xref> attention should be paid to avoiding treatments that may further exacerbate cognitive difficulties<xref ref-type="ref" rid="bdi12609-bib-0238">238</xref> (see Section 8). Although evidence for their efficacy is limited, cognitive enhancement therapies can be considered experimental in this population.<xref ref-type="ref" rid="bdi12609-bib-0072">72</xref>, <xref ref-type="ref" rid="bdi12609-bib-0239">239</xref>, <xref ref-type="ref" rid="bdi12609-bib-0240">240</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0052">
<label>4.3</label>
<title>Psychological interventions for acute bipolar I depression</title>
<p>While pharmacotherapy is essential and forms the foundation for successful treatment of BD, adjunctive psychosocial interventions may also be useful for acute depressive episodes. As described in Section 2, there are no first‐line psychosocial treatment options for acute bipolar depression. Selecting between second‐line options such as CBT (level 2) and FFT (level 2), as well as the third‐line option IPSRT (level 3), should be based on individual strengths and needs.</p>
</sec>
<sec id="bdi12609-sec-0053">
<label>4.4</label>
<title>Pharmacological treatment for acute bipolar depression</title>
<p>Lithium, anticonvulsants, atypical antipsychotics, and other agents such as antidepressants have all been investigated for efficacy in managing bipolar depression. These treatments have been evaluated using the criteria for strength of evidence for efficacy (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>) as well as safety and tolerability (Section 8). Recommendations are summarized in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0014">14</xref>.</p>
<table-wrap id="bdi12609-tbl-0014" orientation="portrait" position="float" xml:lang="en">
<label>Table 14</label>
<caption>
<p>Hierarchical rankings of first and second‐line treatments recommended for management of acute bipolar I depression</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="BDI-20-97-g011"></graphic>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="bdi12609-sec-0054">
<label>4.4.1</label>
<title>Step 1: review general principles and assess medication status</title>
<p>Examination of a patient presenting in a depressed state should include an assessment of the nature and severity of depression and associated symptoms, risk of suicide/self‐harm behaviour, ability to adhere to a treatment plan, availability of a psychosocial support network, and functional impairment. Laboratory investigations (described in Section 8) should also be completed. Results of the overall assessment should be used to establish the most appropriate treatment setting (eg, ambulatory or inpatient), with consideration given to management of safety risks. Before initiating pharmacological treatment for a depressive episode, it is imperative to rule out symptoms secondary to alcohol/drug use, medications, other treatments, or a general medical condition. Patients should be supported to discontinue stimulant use and limit nicotine, caffeine, drug, and alcohol use. Course of illness and treatments used in current and prior episodes should be assessed, including past response to and tolerability of specific medications and doses, and used to direct subsequent therapeutic choices. Consideration should be given to restarting medications if their recent discontinuation appeared to coincide with a depressive relapse.</p>
<p>Psychoeducation and other psychosocial strategies should also be offered alongside pharmacological treatment to promote ongoing medication adherence, reduce residual symptoms and suicidal behaviour, help identify early signs of relapse, and support functional recovery (see Section 2).</p>
</sec>
<sec id="bdi12609-sec-0055">
<label>4.4.2</label>
<title>Step 2: initiate or optimize therapy and check adherence</title>
<p>It is recommended for all patients that pharmacotherapy be initiated with one or more of the available first‐line agents. The choice of agent or agents to manage an acute bipolar depressive episode should be discussed with the patient and their supporters (as appropriate) and take into account current and prior medication use and response, personal preference, and the safety and tolerability of each agent, as well as clinical features that may influence prognosis (see “Clinical features that help direct treatment choices”).</p>
<sec id="bdi12609-sec-0056">
<title>First‐line</title>
<p>Quetiapine (level 1),<xref ref-type="ref" rid="bdi12609-bib-0241">241</xref>, <xref ref-type="ref" rid="bdi12609-bib-0242">242</xref>, <xref ref-type="ref" rid="bdi12609-bib-0243">243</xref> lithium (level 2),<xref ref-type="ref" rid="bdi12609-bib-0244">244</xref>, <xref ref-type="ref" rid="bdi12609-bib-0245">245</xref>, <xref ref-type="ref" rid="bdi12609-bib-0246">246</xref> lamotrigine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0242">242</xref>, <xref ref-type="ref" rid="bdi12609-bib-0247">247</xref>, <xref ref-type="ref" rid="bdi12609-bib-0248">248</xref> and lurasidone (level 2)<xref ref-type="ref" rid="bdi12609-bib-0249">249</xref> are all recommended as first‐line treatment options with evidence for efficacy as monotherapy.</p>
<p>Lurasidone (level 1)<xref ref-type="ref" rid="bdi12609-bib-0249">249</xref>, <xref ref-type="ref" rid="bdi12609-bib-0250">250</xref> and lamotrigine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0251">251</xref>, <xref ref-type="ref" rid="bdi12609-bib-0252">252</xref> are also recommended as first‐line adjunctive treatments (Figure <xref ref-type="fig" rid="bdi12609-fig-0002">2</xref>). Although quetiapine and lithium have not been assessed for efficacy as adjunctive treatments for acute bipolar depression, clinicians may choose to apply this combination in patients who experience depression when optimized on one of either of these medications.</p>
<fig fig-type="Figure" id="bdi12609-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Lithium and lamotrigine as first‐line agents for bipolar I depression: Summary of evidence&gt; [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="BDI-20-97-g002"></graphic>
</fig>
<p>Recommendations as to which first‐line treatment should be considered first are outlined in our hierarchy. We recommend that the agents listed first in the hierarchy be tried first, in the order listed, unless there are patient‐specific reasons for choosing an agent lower down in the order, such as previous history of response/ non‐response or clinical features (see Clinical features which help direct treatment choices). For instance, if a patient presents with an acute bipolar depressive episode and is not taking any treatment and has not been treated for this episode, that patient should be commenced on quetiapine monotherapy if there is no previous history of non‐response or tolerability concerns with quetiapine. However, if a patient had been taking lithium and either had a breakthrough acute bipolar depressive episode or did not respond to monotherapy with lithium, then lurasidone or lamotrigine or quetiapine add‐on or switch to quetiapine monotherapy or lurasidone monotherapy might be more appropriate in that order, given that lurasidone and lamotrigine adjunctive therapies have demonstrated efficacy in lithium non‐responders. Similarly, in non‐responders to lithium monotherapy, adjunctive lamotrigine could be another option.</p>
<p>Clinicians are advised to appropriately dose these medications for an adequate period of time before concluding lack of efficacy. Clinical trials have shown that there is no difference in efficacy between quetiapine 300mg and 600mg daily doses. Lower doses of quetiapine have not been studied in clinical trials for bipolar depression. Therefore, clinicians are advised to consider a target dose of 300 mg/day for quetiapine. For lithium, we suggest that serum lithium levels should be maintained between 0.8 and 1.2 meq/L, while for lamotrigine, the target should be a minimum of 200 mg/day.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0057">
<label>4.4.3</label>
<title>Step 3: add on or switch therapy (alternate first‐line agents)</title>
<p>Across several different medications for bipolar depression, early improvement (after 2 weeks) has been found to be a reasonable predictor of overall response, whereas lack of early improvement is a more robust predictor of non‐response.<xref ref-type="ref" rid="bdi12609-bib-0255">255</xref> Lamotrigine is the exception to this rule, given a necessary slow titration initiating the medication. In the case of non‐response, dosing should be optimized and issues of non‐adherence identified and addressed (see Section 2) prior to adjusting treatment strategies.</p>
<p>When determining whether an agent should be switched or another first‐line agent be added on to any current treatment, the effectiveness of each of the medications needs to be understood in the context of all the goals of managing BD. It is often the case that a medication may be selected to address several goals; for instance, lithium could be added for acute depression with intent to also bolster anti‐manic prophylaxis. In this scenario, if lithium is ineffective in the individual patient for an acute bipolar depression but is also being used over the long term for anti‐manic prophylaxis, then an “add‐on” intervention should be the next treatment for the acute bipolar depression. If, for instance, the anti‐manic prophylaxis is already being fully provided by an atypical antipsychotic, then the new medication could replace lithium via a switch strategy. Decision‐making must also address efficacy for comorbid conditions, as well as tolerability concerns. In principle, all things being equal, a switch is preferred over add‐on to limit the degree of polypharmacy, but the clinical reality is that medications may be helpful for some but not all components of the illness, and using rational polypharmacy via add‐on treatments is often required. For situations in which patients experience a depressive episode while already receiving an adequately dosed antidepressant, strong consideration should be given to discontinuing or switching the class of antidepressant, unless clear benefits are apparent in reducing the severity or frequency of depressive episodes. Switch of medications should be done in an overlap and taper manner unless there is medical necessity for abrupt discontinuation.<xref ref-type="ref" rid="bdi12609-bib-0257">257</xref>
</p>
<p>All first‐line options should be tried in adequate doses for an adequate duration of time before considering second‐line options either as an add‐on or switch strategy.</p>
</sec>
<sec id="bdi12609-sec-0058">
<label>4.4.4</label>
<title>Step 4: add on or switch therapy (second‐line agents)</title>
<sec id="bdi12609-sec-0059">
<title>Second‐line</title>
<p>In patients who are inadequately responsive to first‐line agents, monotherapy with divalproex (level 2)<xref ref-type="ref" rid="bdi12609-bib-0242">242</xref>, <xref ref-type="ref" rid="bdi12609-bib-0258">258</xref> is included as a second‐line option.</p>
<p>Adjunctive use of antidepressant therapy (selective serotonin reuptake inhibitors [SSRIs] or bupropion) with lithium/divalproex or an atypical antipsychotic may also be considered as a second‐line add‐on treatment. While some individual studies have failed to demonstrate the efficacy of adjunctive antidepressant therapy, a recent meta‐analysis (level 1) supports efficacy, albeit with a small effect size.<xref ref-type="ref" rid="bdi12609-bib-0259">259</xref>
</p>
<p>This is a key aspect of decision‐making regarding antidepressants, since historically much of the focus has been on risk of manic switch or rapid cycling, with an underappreciation of the relatively weak efficacy data. This new appreciation, exemplified by the small benefit seen in the above meta‐analysis, led to the change from the last CANMAT guidelines, which previously gave add‐on SSRI/bupropion antidepressants a first‐line recommendation. As per the ISBD Antidepressant Task Force recommendations,<xref ref-type="ref" rid="bdi12609-bib-0260">260</xref> antidepressants should ideally be avoided, or used cautiously if necessary, in patients with a history of antidepressant‐induced mania or hypomania, current or predominant mixed features, or recent rapid cycling. Patients and caregivers (as appropriate) should receive education regarding early warning symptoms of mood switching or cycle acceleration, and antidepressants should be discontinued if these emerge. Antidepressant <italic>monotherapy</italic> should NOT be used for the treatment of BDI depression.</p>
<p>ECT (level 3) is also a second‐line treatment, and should be considered particularly for treatment‐refractory patients and those for whom a rapid treatment response is needed, such as those with severe depression with imminent suicidal risk, catatonia or psychotic depression, and/or when a rapid response is important for medical stabilization. Data support efficacy for brief pulse right unilateral placement, although there are insufficient data to guide the decision of unilateral or bilateral placement for bipolar depression.<xref ref-type="ref" rid="bdi12609-bib-0261">261</xref> Additional second‐line options include cariprazine, with efficacy demonstrated through a large RCT<xref ref-type="ref" rid="bdi12609-bib-0262">262</xref> and a pooled analysis of a failed RCT and a positive RCT<xref ref-type="ref" rid="bdi12609-bib-0263">263</xref> (level 2), although there is less clinical experience supporting its use. Olanzapine‐fluoxetine combination (level 2)<xref ref-type="ref" rid="bdi12609-bib-0264">264</xref>, <xref ref-type="ref" rid="bdi12609-bib-0265">265</xref> is effective and is also recommended as a second‐line option.</p>
<p>Similar to the approach for treatment of a manic episode, multiple first‐ and second‐line agents and combinations should be trialled before considering initiating third‐line agents in step 5.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0060">
<label>4.4.5</label>
<title>Step 5: add on or switch therapy (third‐line agents)</title>
<sec id="bdi12609-sec-0061">
<title>Third‐line</title>
<p>Third‐line options are listed alphabetically in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0015">15</xref>. In patients who fail to respond to multiple first‐ and second‐line agents, third‐line choices include monotherapy with carbamazepine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0242">242</xref> or olanzapine (level 1).<xref ref-type="ref" rid="bdi12609-bib-0242">242</xref>
</p>
<table-wrap id="bdi12609-tbl-0015" orientation="portrait" position="float" xml:lang="en">
<label>Table 15</label>
<caption>
<p>Additional agents evaluated for use in acute bipolar I depression</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="1" valign="top">Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="14">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Aripiprazole (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Armodafinil (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Asenapine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Carbamazepine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Eicosapentaenoic acid (EPA) (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ketamine (IV) (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Light therapy +/− total sleep deprivation (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Levothyroxine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Modafinil (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>N</italic>‐acetylcysteine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Olanzapine</td>
<td align="left" colspan="1" rowspan="1">Level 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pramipexole (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Repetitive transmagnetic stimulation (rTMS) (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SNRI/MAOI (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Not recommended</td>
<td align="left" colspan="1" rowspan="1">Antidepressant monotherapy</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1">Level 1 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lamotrigine + folic acid</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mifepristone (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0029">
<p>adj, adjunctive; MAOI, monoamine oxidase inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Agents that may be applied adjunctively include aripiprazole (level 4),<xref ref-type="ref" rid="bdi12609-bib-0266">266</xref>, <xref ref-type="ref" rid="bdi12609-bib-0267">267</xref> armodafinil (level 4)<xref ref-type="ref" rid="bdi12609-bib-0268">268</xref>, <xref ref-type="ref" rid="bdi12609-bib-0269">269</xref> (Figure <xref ref-type="fig" rid="bdi12609-fig-0003">3</xref>), asenapine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0270">270</xref> levothyroxine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0271">271</xref>, <xref ref-type="ref" rid="bdi12609-bib-0272">272</xref> modafinil (level 2)<xref ref-type="ref" rid="bdi12609-bib-0268">268</xref> (Figure <xref ref-type="fig" rid="bdi12609-fig-0003">3</xref>), and pramipexole (level 3).<xref ref-type="ref" rid="bdi12609-bib-0273">273</xref>, <xref ref-type="ref" rid="bdi12609-bib-0274">274</xref> rTMS targeted at the left or right dorsolateral prefrontal cortex (level 3)<xref ref-type="ref" rid="bdi12609-bib-0275">275</xref> may also be used in addition to medication. Other classes of antidepressants such as serotonin‐ norepinephrine reuptake inhibitors [SNRIs] and monoamine oxidase inhibitors [MAOIs] could be used adjunctively but clinicians need to ensure adequate anti‐manic prophylaxis in such situations, as SNRIs and MAOIs have a higher propensity than other antidepressants to induce manic switch and cause mood destabilization (level 2).<xref ref-type="ref" rid="bdi12609-bib-0276">276</xref>, <xref ref-type="ref" rid="bdi12609-bib-0277">277</xref>, <xref ref-type="ref" rid="bdi12609-bib-0278">278</xref>
</p>
<fig fig-type="Figure" id="bdi12609-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Armodafinil and modafinil as third‐line agents for bipolar I depression: Summary of evidence [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="BDI-20-97-g003"></graphic>
</fig>
<p>Ancillary treatments such as adjunctive eicosapentaenoic acid (EPA) (level 2),<xref ref-type="ref" rid="bdi12609-bib-0169">169</xref>, <xref ref-type="ref" rid="bdi12609-bib-0279">279</xref>, <xref ref-type="ref" rid="bdi12609-bib-0280">280</xref>
<italic>N</italic>‐acetylcysteine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0281">281</xref> and light therapy (level 3),<xref ref-type="ref" rid="bdi12609-bib-0282">282</xref> including bright light delivered midday (level 3),<xref ref-type="ref" rid="bdi12609-bib-0283">283</xref> are also recommended as third‐line treatment options to use adjunctively to other medications. There may be additional benefits to using light therapy in combination with total sleep deprivation (level 2), although there is little clinical experience with this technique. While there is evidence from several small studies that intravenous ketamine (level 3)<xref ref-type="ref" rid="bdi12609-bib-0284">284</xref> is a highly effective and fast‐acting antidepressant, due to its invasive nature, short duration of effect, and lack of long‐term safety data, it has been relegated to a third‐line treatment, with recommendations that it be reserved for patients with severe symptoms or significant suicidal ideation for whom other treatments have been unsuccessful. In clinical situations that prioritize rapidity of response to treatment, ketamine may be considered earlier in the treatment order, although clinicians need to be aware that the data for efficacy are limited and the effects do not appear to last longer. Further, there are case reports of manic switch, but the clinical trial data have not provided any confirmatory evidence.<xref ref-type="ref" rid="bdi12609-bib-0284">284</xref> Also, clinicians need to be aware of potential abuse of ketamine, especially in domiciliary use situations.<xref ref-type="ref" rid="bdi12609-bib-0285">285</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0062">
<label>4.4.6</label>
<title>Agents not recommended for the treatment of acute bipolar depression</title>
<p>Antidepressants should not be used as monotherapy in patients with BDI depression, as available trials do not support their efficacy and there are concerns about their safety in terms of mood switching (level 2 negative).<xref ref-type="ref" rid="bdi12609-bib-0260">260</xref>, <xref ref-type="ref" rid="bdi12609-bib-0289">289</xref>, <xref ref-type="ref" rid="bdi12609-bib-0290">290</xref>, <xref ref-type="ref" rid="bdi12609-bib-0291">291</xref>
</p>
<p>Aripiprazole monotherapy failed to separate from placebo in two bipolar depression trials.<xref ref-type="ref" rid="bdi12609-bib-0292">292</xref> Although the pooled analysis reported separation,<xref ref-type="ref" rid="bdi12609-bib-0293">293</xref> the mean difference in Montgomery–Åsberg Depression Rating Scale (MADRS) change score was only 1.12 points, which is not clinically meaningful and it is thus not recommended (level 1 negative). Ziprasidone monotherapy or adjunctive therapy (level 1 negative),<xref ref-type="ref" rid="bdi12609-bib-0242">242</xref>, <xref ref-type="ref" rid="bdi12609-bib-0294">294</xref> lamotrigine in combination with folic acid (level 2 negative),<xref ref-type="ref" rid="bdi12609-bib-0251">251</xref> and mifepristone (adjunctive) (Leve 2 negative)<xref ref-type="ref" rid="bdi12609-bib-0295">295</xref> are also not recommended due to evidence for lack of antidepressant efficacy (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0015">15</xref>).</p>
</sec>
<sec id="bdi12609-sec-0063">
<label>4.4.7</label>
<title>No specific recommendation/agents that require further study</title>
<p>There are insufficient data to make a recommendation regarding the use of aspirin (adjunctive) (level 3 negative),<xref ref-type="ref" rid="bdi12609-bib-0296">296</xref> celecoxib (adjunctive) (level 3 negative),<xref ref-type="ref" rid="bdi12609-bib-0297">297</xref> gabapentin (monotherapy) (level 3 negative),<xref ref-type="ref" rid="bdi12609-bib-0298">298</xref> leviteracitam (adjunctive) (level 3 negative),<xref ref-type="ref" rid="bdi12609-bib-0299">299</xref> lisdexamfetamine (adjunctive) (level 3 negative),<xref ref-type="ref" rid="bdi12609-bib-0300">300</xref> memantine (adjunctive) (level 3),<xref ref-type="ref" rid="bdi12609-bib-0301">301</xref> pioglitazone (adjunctive) (level 3),<xref ref-type="ref" rid="bdi12609-bib-0302">302</xref>, <xref ref-type="ref" rid="bdi12609-bib-0303">303</xref> riluzole (level 4 negative),<xref ref-type="ref" rid="bdi12609-bib-0304">304</xref> and risperidone (adjunctive) (level 3).<xref ref-type="ref" rid="bdi12609-bib-0305">305</xref> Although adjunctive therapy with pregnenolone separated from placebo at week 6, the change in depressive symptoms was not significantly different from week 8 to week 12 between the two groups (level 2).<xref ref-type="ref" rid="bdi12609-bib-0306">306</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0064">
<label>4.5</label>
<title>Clinical features that help direct treatment choices</title>
<p>There are limited data on predictors of treatment response in bipolar depression. However, clinical features of a depressive episode including DSM‐5 specifiers may assist clinicians in choosing among recommended treatment options.</p>
<sec id="bdi12609-sec-0065">
<title>Need for rapid response</title>
<p>Amongst the first‐line options recommended, quetiapine and lurasidone have separated from placebo in clinical trials at as early as week 1.<xref ref-type="ref" rid="bdi12609-bib-0249">249</xref>, <xref ref-type="ref" rid="bdi12609-bib-0307">307</xref>, <xref ref-type="ref" rid="bdi12609-bib-0308">308</xref> Thus, these medications may be preferable when a rapid response is required, for example in patients who are at increased risk of suicide or who have medical complications, including dehydration. While ECT is recommended as a second‐line option, this may also be used earlier when a rapid response is imperative. Second‐line options such as cariprazine and olanzapine‐fluoxetine have also separated from placebo at as early as week 1 and may also be considered when a rapid response is desirable, but this needs to be balanced against the potential side effects. Lamotrigine administration requires slower titration due to the risk of skin rashes, Stevens‐Johnson syndrome, and toxic epidermal necrolysis, and is thus not ideal for patients requiring a rapid response. Lamotrigine, however, is well tolerated, and there is some evidence that its effectiveness may be more pronounced in patients experiencing depressive cognitions and psychomotor slowing.<xref ref-type="ref" rid="bdi12609-bib-0309">309</xref>
</p>
</sec>
<sec id="bdi12609-sec-0066">
<title>Previous treatment response</title>
<p>Adjunctive antidepressant use may be appropriate in those with prior antidepressant response if there was no history of treatment‐emergent switch.<xref ref-type="ref" rid="bdi12609-bib-0310">310</xref>
</p>
</sec>
<sec id="bdi12609-sec-0067">
<title>Anxious distress</title>
<p>Symptoms of anxiety are often experienced during a depressive episode, and are predictive of more persistent depressive symptoms<xref ref-type="ref" rid="bdi12609-bib-0311">311</xref> and increased suicidal ideation.<xref ref-type="ref" rid="bdi12609-bib-0312">312</xref> A pooled analysis of two double‐blind RCTs demonstrated that quetiapine is more effective than placebo in relieving symptoms of anxiety co‐occurring alongside bipolar depression,<xref ref-type="ref" rid="bdi12609-bib-0313">313</xref> and olanzapine‐fluoxetine combination has also been shown to be effective.<xref ref-type="ref" rid="bdi12609-bib-0314">314</xref> In a post hoc analysis, lurasidone was effective in improving depressive as well as anxiety symptoms in patients with MDD who had mixed features and anxiety.<xref ref-type="ref" rid="bdi12609-bib-0315">315</xref> The anxiolytic effects of divalproex, risperidone, and lamotrigine appear to be limited.<xref ref-type="ref" rid="bdi12609-bib-0199">199</xref>, <xref ref-type="ref" rid="bdi12609-bib-0316">316</xref>
</p>
</sec>
<sec id="bdi12609-sec-0068">
<title>Mixed features</title>
<p>Many patients with bipolar depression will also experience at least subsyndromal hypomanic or manic features, and this presentation is associated with more severe depressive symptoms, as well as a higher rate of substance use and cardiovascular disease.<xref ref-type="ref" rid="bdi12609-bib-0317">317</xref> For many of these patients, combination therapy will be necessary to adequately address symptoms.<xref ref-type="ref" rid="bdi12609-bib-0318">318</xref> Pooled analysis indicates that atypical antipsychotics show a class effect in alleviating mixed features in bipolar depression, with olanzapine‐fluoxetine combination, asenapine, and lurasidone all demonstrating efficacy.<xref ref-type="ref" rid="bdi12609-bib-0319">319</xref> Lurasidone has further been shown to have efficacy in treating both depressive and hypomanic symptoms in MDD with mixed features.<xref ref-type="ref" rid="bdi12609-bib-0320">320</xref> The ISBD Task Force recommends avoiding antidepressants in patients with mixed features<xref ref-type="ref" rid="bdi12609-bib-0260">260</xref> and the CANMAT/ISBD group concurs with this recommendation.</p>
</sec>
<sec id="bdi12609-sec-0069">
<title>Melancholic features</title>
<p>No specific studies assessed the predictive ability of melancholic features; however, clinical experience suggests that ECT is very effective in this population.</p>
</sec>
<sec id="bdi12609-sec-0070">
<title>Atypical features</title>
<p>There is some evidence for efficacy of tranylcypromine in patients with anergic bipolar depression.<xref ref-type="ref" rid="bdi12609-bib-0321">321</xref> However, given the risks of potential manic switch, this agent should only be used in conjunction with lithium or divalproex or an atypical antipsychotic. Clinicians also must consider adverse events of this agent related to its interactions with food and other medications.</p>
</sec>
<sec id="bdi12609-sec-0071">
<title>Psychotic features (mood congruent or incongruent)</title>
<p>Up to 20% of inpatients experience psychosis in the context of an acute bipolar depressive episode.<xref ref-type="ref" rid="bdi12609-bib-0322">322</xref> The relative efficacy of various medications to treat these features in this phase of illness has not been examined, although clinical experience suggests that ECT and antipsychotics are highly effective for this population.</p>
</sec>
<sec id="bdi12609-sec-0072">
<title>Rapid cycling</title>
<p>As described in Section 3, hypothyroidism, antidepressants and substance abuse may be associated with rapid cycling, thus making assessment of thyroid function and discontinuation of antidepressants, drugs of abuse, stimulants, and other psychotropic agents imperative. As there is no evidence to support any specific agent to treat acute depression during a rapid cycling phase, appropriate pharmacotherapy should be selected based on effectiveness in the acute and maintenance phases. Lithium, divalproex, olanzapine, and quetiapine all appear to have comparable maintenance efficacies in these patients.<xref ref-type="ref" rid="bdi12609-bib-0219">219</xref> In contrast, lamotrigine did not separate from placebo in maintenance treatment in patients with rapid cycling BDI.<xref ref-type="ref" rid="bdi12609-bib-0323">323</xref> Antidepressants are not recommended, as they have been shown to destabilize patients, even with concurrent mood stabilizer use.<xref ref-type="ref" rid="bdi12609-bib-0324">324</xref>
</p>
</sec>
<sec id="bdi12609-sec-0073">
<title>Seasonal pattern</title>
<p>While some individual patients may show a seasonal pattern, Canadian data are mixed as to whether episodes of mania or depression in BD follow a consistent seasonal variation.<xref ref-type="ref" rid="bdi12609-bib-0222">222</xref> There is no evidence for the superiority of any agent in patients with an observed seasonal pattern of manic episodes.</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0074">
<label>5</label>
<title>MAINTENANCE THERAPY FOR BIPOLAR DISORDER</title>
<sec id="bdi12609-sec-0075">
<label>5.1</label>
<title>Need for long‐term strategies</title>
<p>Almost all individuals with BD require maintenance treatment to prevent subsequent episodes, reduce residual symptoms, and restore functioning and quality of life. There is increasing evidence to suggest that, for a subgroup of patients, BD may be a neuroprogressive disease in which recurrences are associated with reductions in brain grey and white matter volumes, worsening cognitive impairment, a decrease in inter‐episodic recovery and functioning, a higher rate and severity of relapse, and a reduced rate of treatment response to both pharmacotherapy and psychotherapy.<xref ref-type="ref" rid="bdi12609-bib-0325">325</xref> It is therefore important that comprehensive treatment be initiated even after a first episode.<xref ref-type="ref" rid="bdi12609-bib-0063">63</xref> Effective maintenance treatment, early in the course of illness, has been shown to reverse cognitive impairment and preserve brain plasticity, particularly in those who remain episode free,<xref ref-type="ref" rid="bdi12609-bib-0326">326</xref>, <xref ref-type="ref" rid="bdi12609-bib-0327">327</xref> and may therefore lead to improved prognosis and minimization of illness progression.<xref ref-type="ref" rid="bdi12609-bib-0328">328</xref> There are preliminary data suggesting that, after a first episode, lithium might be superior to quetiapine in both volumetric and cognitive outcomes.<xref ref-type="ref" rid="bdi12609-bib-0329">329</xref>, <xref ref-type="ref" rid="bdi12609-bib-0330">330</xref>
</p>
<p>With treatment, 19%‐25% of patients will experience a recurrence every year, compared to 23%‐40% of those on placebo.<xref ref-type="ref" rid="bdi12609-bib-0331">331</xref> Risk factors for recurrence include younger age of onset,<xref ref-type="ref" rid="bdi12609-bib-0332">332</xref> psychotic features,<xref ref-type="ref" rid="bdi12609-bib-0212">212</xref> rapid cycling,<xref ref-type="ref" rid="bdi12609-bib-0331">331</xref> more (and more frequent) previous episodes,<xref ref-type="ref" rid="bdi12609-bib-0333">333</xref> comorbid anxiety,<xref ref-type="ref" rid="bdi12609-bib-0334">334</xref> and comorbid SUDs.<xref ref-type="ref" rid="bdi12609-bib-0335">335</xref> Persistent subthreshold symptoms also increase risk for subsequent mood episodes,<xref ref-type="ref" rid="bdi12609-bib-0334">334</xref>, <xref ref-type="ref" rid="bdi12609-bib-0336">336</xref>, <xref ref-type="ref" rid="bdi12609-bib-0337">337</xref> and the presence of residual symptoms should therefore be an indicator of a need for further treatment optimization. Availability of psychosocial support and lower levels of stress are also protective against recurrence.<xref ref-type="ref" rid="bdi12609-bib-0337">337</xref>, <xref ref-type="ref" rid="bdi12609-bib-0338">338</xref>
</p>
</sec>
<sec id="bdi12609-sec-0076">
<label>5.2</label>
<title>Treatment adherence</title>
<p>Concordance between clinician and patient views of illness and treatment is a crucial determinant of adherence,<xref ref-type="ref" rid="bdi12609-bib-0339">339</xref> and reinforces the need for a collaborative approach to the treatment alliance.<xref ref-type="ref" rid="bdi12609-bib-0340">340</xref> Asking about adherence behaviour and attitudes in a non‐judgemental manner and exploring the reasoning behind poor adherence are important parts of treatment,<xref ref-type="ref" rid="bdi12609-bib-0341">341</xref> as up to half of patients do not take their medications as prescribed.<xref ref-type="ref" rid="bdi12609-bib-0342">342</xref>, <xref ref-type="ref" rid="bdi12609-bib-0343">343</xref>, <xref ref-type="ref" rid="bdi12609-bib-0344">344</xref> Unrecognized treatment non‐adherence can lead physicians to believe that the patient is non‐responsive, resulting in unnecessary dose increases (especially problematic for drugs with a narrow therapeutic index), medication switches, or adjunctive medications.<xref ref-type="ref" rid="bdi12609-bib-0341">341</xref> Treatment withdrawal may precipitate recurrence; 50%‐90% of patients discontinuing lithium experience a recurrence within 3‐5 months,<xref ref-type="ref" rid="bdi12609-bib-0345">345</xref>, <xref ref-type="ref" rid="bdi12609-bib-0346">346</xref> with rapid lithium discontinuation associated with greater recurrence risk than gradual discontinuation.<xref ref-type="ref" rid="bdi12609-bib-0347">347</xref> Withdrawal of other mood stabilizers also predicts recurrence.<xref ref-type="ref" rid="bdi12609-bib-0348">348</xref>, <xref ref-type="ref" rid="bdi12609-bib-0349">349</xref> Risks for hospitalization, suicide, and lost productivity are also increased with non‐adherence or discontinuation.<xref ref-type="ref" rid="bdi12609-bib-0350">350</xref>, <xref ref-type="ref" rid="bdi12609-bib-0351">351</xref>, <xref ref-type="ref" rid="bdi12609-bib-0352">352</xref> A variety of patient, disorder, and treatment‐related risk factors for non‐adherence or partial adherence are outlined in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0016">16</xref>.<xref ref-type="ref" rid="bdi12609-bib-0353">353</xref>
</p>
<table-wrap id="bdi12609-tbl-0016" orientation="portrait" position="float" xml:lang="en">
<label>Table 16</label>
<caption>
<p>Risk factors for partial adherence or non‐adherence to medication</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Sociodemographics</td>
<td align="left" colspan="1" rowspan="1">Male, younger age, low level of education, single</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychological</td>
<td align="left" colspan="1" rowspan="1">Poor insight, lack of awareness of disease, negative attitude to treatment, fear of side effects, negative attitude to medication, low overall life satisfaction, low cognitive functioning</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Comorbidity</td>
<td align="left" colspan="1" rowspan="1">Alcohol or cannabis use, obsessive compulsive disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Social</td>
<td align="left" colspan="1" rowspan="1">No social activities, work impairment</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chronology</td>
<td align="left" colspan="1" rowspan="1">Younger age of onset, current inpatient status, hospitalization or suicide attempt in past 12 months</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Disease characteristics</td>
<td align="left" colspan="1" rowspan="1">Mixed episode, rapid cycling, delusions and hallucinations, greater severity of illness, BDI diagnosis, higher number of episodes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment‐related factors</td>
<td align="left" colspan="1" rowspan="1">Side effects of medications, inadequate efficacy of medication, use of antidepressants, low treatment doses</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0030">
<p>Adapted from Leclerc et al.<xref ref-type="ref" rid="bdi12609-bib-0353">353</xref>
</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Meta‐analyses suggest that interventions aimed at engaging patients in treatment may more than double adherence compared to treatment as usual or other control groups.<xref ref-type="ref" rid="bdi12609-bib-0354">354</xref> Brief psychoeducational interventions focusing specifically on medication adherence can be integrated into clinical practice.<xref ref-type="ref" rid="bdi12609-bib-0354">354</xref> Flexible and collaborative engagement to address individual risk factors for non‐adherence is recommended to optimize acceptability of pharmacological therapies.<xref ref-type="ref" rid="bdi12609-bib-0353">353</xref>, <xref ref-type="ref" rid="bdi12609-bib-0355">355</xref>, <xref ref-type="ref" rid="bdi12609-bib-0356">356</xref>, <xref ref-type="ref" rid="bdi12609-bib-0357">357</xref>
</p>
</sec>
<sec id="bdi12609-sec-0077">
<label>5.3</label>
<title>Psychosocial interventions for maintenance therapy</title>
<p>Although pharmacotherapy is the foundation of maintenance treatment in BD, it is often insufficient to prevent recurrence. Over the last two decades, several controlled trials have examined the efficacy of adjunctive psychosocial treatments in reducing recurrence. On average, adjunctive psychosocial treatments reduce recurrence rates by about 15%. Therefore, adjunctive psychosocial interventions are an important component of management of BD and should be offered for all patients.</p>
<p>As described in more detail in Section 2, psychoeducation is the only first‐line psychosocial intervention for the maintenance phase (level 1), which should be offered to all patients. Additional second‐line options such as CBT (level 2) and FFT (level 2), and third‐line options such as IPSRT (level 2) and peer support (level 2) should be offered based on individual strengths and needs.</p>
</sec>
<sec id="bdi12609-sec-0078">
<label>5.4</label>
<title>Efficacy ratings for pharmacological agents used as maintenance therapy: importance of naturalistic and cohort studies</title>
<p>Evidence from RCTs is at the core of the recommendations in these guidelines. Nonetheless, RCTs are not the only source of clinically useful information, particularly when evaluating maintenance therapy. RCTs offer relatively limited follow‐up time‐frames while, for some patients, maintenance therapy may extend across decades. Furthermore, new medications are often assessed in studies with an enriched design (including only patients who have responded to the medication under study in the acute phase), limiting the generalizability of positive findings to patients who responded to the medication acutely.</p>
<p>Useful data can be obtained from large, often whole‐population databases constructed from electronic medical records or electronic patient registries with large numbers of patients that would be difficult to obtain in RCTs. In some instances, they allow comparisons of multiple treatments.<xref ref-type="ref" rid="bdi12609-bib-0358">358</xref>, <xref ref-type="ref" rid="bdi12609-bib-0359">359</xref>, <xref ref-type="ref" rid="bdi12609-bib-0360">360</xref> These large numbers make it possible to evaluate differences in rates of rare events such as less common side effects or suicide.<xref ref-type="ref" rid="bdi12609-bib-0361">361</xref>, <xref ref-type="ref" rid="bdi12609-bib-0362">362</xref>
</p>
<p>Patient cohorts followed in a specific setting provide another source of informative data. Their main advantage usually is the length of observation, in some instances reaching several decades.<xref ref-type="ref" rid="bdi12609-bib-0363">363</xref>, <xref ref-type="ref" rid="bdi12609-bib-0364">364</xref>, <xref ref-type="ref" rid="bdi12609-bib-0365">365</xref> This comes at the cost of generalizability, in terms of both patient selection and non‐random treatment allocation.</p>
</sec>
<sec id="bdi12609-sec-0079">
<label>5.5</label>
<title>Pharmacological treatments for maintenance therapy</title>
<p>As in earlier sections, pharmacological treatments for maintenance therapy have been evaluated using the criteria for strength of evidence for efficacy (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>) as well as safety and tolerability (Section 8). Results are summarized in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0017">17</xref>.</p>
<table-wrap id="bdi12609-tbl-0017" orientation="portrait" position="float" xml:lang="en">
<label>Table 17</label>
<caption>
<p>Hierarchical rankings of first‐ and second‐line treatments recommended for maintenance treatment in bipolar disorder</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="BDI-20-97-g012"></graphic>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="bdi12609-sec-0080">
<label>5.5.1</label>
<title>Step 1: review general principles and assess medication status</title>
<p>Many agents recommended for management of acute manic or depressive episodes have prophylactic efficacy. Generally, medications that have been found to be effective in the acute phase should be continued during the maintenance phase. However, there are exceptions to this: the efficacy of adjunctive antidepressant therapy has not been examined systematically in large double‐blind placebo‐controlled trials; hence, long‐term antidepressant use is not recommended, especially in light of the concerns about potential risk of manic/hypomanic switch and mood instability. However, in the subgroups of patients who have responded to combination treatment and are stable, preliminary evidence suggests that withdrawal of antidepressants may contribute to destabilization.<xref ref-type="ref" rid="bdi12609-bib-0366">366</xref>
</p>
<p>Clinical trials have shown that many atypical antipsychotics are effective in preventing relapse of mood episodes; with many agents, this efficacy is related to prevention of manic episodes but not depressive episodes. However, many of these trials have been conducted in patients with an index manic episode and, given that the polarity of an index episode predicts the polarity of relapse, depressive relapse rates in placebo groups in such studies have been low‐ compromising the statistical power to test the efficacy of these agents in prevention of depressive relapses. Thus, the efficacy of many of these agents in preventing depressive relapses remains unknown.</p>
<p>For patients who are currently not receiving or responding to pharmacological treatment, a careful history including details of clinical course, response (or lack thereof) to previously used medications, and family history should be collected. Other variables to be considered include psychiatric comorbidity (including substance use), the predominant illness polarity, and the polarity of the most recent episode.</p>
<p>Ongoing clinical monitoring, including medication blood levels as appropriate, is also a crucial part of maintenance treatment that should be used to support enhanced medication adherence, detection of early symptoms of recurrence, and monitoring of side effects (see Section 8).</p>
</sec>
<sec id="bdi12609-sec-0081">
<label>5.5.2</label>
<title>Step 2: initiate or optimize therapy and check adherence</title>
<p>The choice of agent or agents used in maintenance treatment should be discussed with the patient and their caregivers (as appropriate) and, based on knowledge of current and prior medication use and response, safety and tolerability of each agent, predominant episode polarity, and clinical features that may influence prognosis (see “Clinical features that help direct treatment choices”). As with treatment for mania and acute depression, we recommend that treatment choices for maintenance treatment of BD should follow the hierarchy listed in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0017">17</xref> unless patient preference or other considerations such as previous response/non‐response, tolerability or predominant polarity justify other choices. Similarly, as a general rule, if a patient has been treated for an acute mood episode and responded to a first‐line maintenance treatment, we recommend continuing that treatment for maintenance even if lower down in the hierarchy. As an example, if a patient responded to asenapine in an acute manic episode, asenapine should be continued, even if it is lower down in the hierarchy for maintenance treatment. It may be necessary to lower the dose to some degree once in maintenance treatment as patients often experience greater side effects once out of the acute episode.</p>
<p>There is evidence that the risk of recurrence is reduced when an antipsychotic is combined with lithium/divalproex. When a combination therapy of an atypical antipsychotic with lithium/divalproex was used to treat acute mania, continuing the atypical antipsychotic for the first 6 months following response offered clear benefit in reducing risk of mood episode recurrence (level 2),<xref ref-type="ref" rid="bdi12609-bib-0367">367</xref> but the benefits beyond 6 months remain uncertain. Therefore, clinicians are advised to re‐evaluate risks and benefits after 6 months of sustained response to determine whether maintenance combination therapy with an atypical antipsychotic is justified.</p>
<sec id="bdi12609-sec-0082">
<title>First‐line</title>
<p>Lithium (level 1),<xref ref-type="ref" rid="bdi12609-bib-0368">368</xref>, <xref ref-type="ref" rid="bdi12609-bib-0369">369</xref> quetiapine (level 1),<xref ref-type="ref" rid="bdi12609-bib-0369">369</xref>, <xref ref-type="ref" rid="bdi12609-bib-0370">370</xref> divalproex (level 1) <xref ref-type="ref" rid="bdi12609-bib-0369">369</xref>, <xref ref-type="ref" rid="bdi12609-bib-0371">371</xref>, <xref ref-type="ref" rid="bdi12609-bib-0372">372</xref> (Figure <xref ref-type="fig" rid="bdi12609-fig-0004">4</xref>) and lamotrigine (level 1)<xref ref-type="ref" rid="bdi12609-bib-0369">369</xref>, <xref ref-type="ref" rid="bdi12609-bib-0373">373</xref> monotherapies have the best combination of clinical trials, administrative data, and clinical experience to support their use as first‐line therapies for maintenance treatment of BD. Recent data suggest that asenapine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0374">374</xref> is effective in preventing both manic and depressive episodes, and thus is recommended as a first‐line treatment. Finally, aripiprazole oral (level 2)<xref ref-type="ref" rid="bdi12609-bib-0375">375</xref>, <xref ref-type="ref" rid="bdi12609-bib-0376">376</xref> or once monthly (level 2)<xref ref-type="ref" rid="bdi12609-bib-0377">377</xref> is also recommended as a first‐line monotherapy in view of its efficacy in preventing any mood or manic episode as well as its safety/tolerability profile, although it has not been shown to be effective in preventing depression.</p>
<fig fig-type="Figure" id="bdi12609-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>Divalproex as a first‐line maintenance therapy for bipolar I disorder: Summary of evidence RCT, randomized controlled trial [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-13" xlink:href="BDI-20-97-g004"></graphic>
</fig>
<p>Additional combination therapies included as first‐ line include quetiapine adjunctive therapy with lithium/divalproex (level 1),<xref ref-type="ref" rid="bdi12609-bib-0378">378</xref>, <xref ref-type="ref" rid="bdi12609-bib-0379">379</xref> which has demonstrated efficacy in preventing any mood, manic or depressive episode. Aripiprazole plus lithium/divalproex (level 2)<xref ref-type="ref" rid="bdi12609-bib-0380">380</xref> should also be considered as a first‐line option.</p>
<p>For patients who experience a recurrence or who remain symptomatic while on a first‐line agent or a combination, dosing should be optimized and issues of non‐adherence identified and addressed prior to moving to step 3.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0083">
<label>5.5.3</label>
<title>Step 3: add on or switch therapy (alternate first‐line agents)</title>
<p>If therapy with one or a combination of the first‐line agents at optimal doses is inadequate or not tolerated, the next step is to switch to or add on an alternate first‐line agent. Because there are multiple first‐line agents with substantial efficacy data and relative safety and tolerability, the use of second‐line agents is only recommended after unsuccessful trials of multiple first‐line strategies.</p>
</sec>
<sec id="bdi12609-sec-0084">
<label>5.5.4</label>
<title>Step 4: add on or switch therapy (second‐line agents)</title>
<sec id="bdi12609-sec-0085">
<title>Second‐line</title>
<p>Although olanzapine (level 1)<xref ref-type="ref" rid="bdi12609-bib-0381">381</xref>, <xref ref-type="ref" rid="bdi12609-bib-0382">382</xref> is effective in preventing any mood, manic or depressive episode, it is considered second‐line treatment because of safety issues such as metabolic syndrome. Biweekly long‐acting injectable risperidone monotherapy (level 1)<xref ref-type="ref" rid="bdi12609-bib-0383">383</xref> or adjunctive therapy (level 2)<xref ref-type="ref" rid="bdi12609-bib-0384">384</xref> has demonstrated efficacy in preventing any mood or manic episode, but had no clear efficacy in depressive episode prevention in these trials. Further, there was a trend for superiority of oral risperidone adjunctive therapy at 6 months in preventing any mood episode and in preventing mania but not depression.<xref ref-type="ref" rid="bdi12609-bib-0367">367</xref> Carbamazepine (level 2) has not been assessed in any large placebo‐controlled trials, but active comparator trials support its efficacy.<xref ref-type="ref" rid="bdi12609-bib-0385">385</xref> Paliperidone (level 2) was more effective than placebo in preventing any mood or manic episode but less effective than olanzapine.<xref ref-type="ref" rid="bdi12609-bib-0386">386</xref>
</p>
<p>Ziprasidone oral adjunctive therapy (level 2)<xref ref-type="ref" rid="bdi12609-bib-0387">387</xref> has been shown to be effective in preventing any mood or manic episode, although there are conflicting (positive and negative) data for acute treatment (see Sections 3 and 4). There was a trend for superiority of lurasidone adjunctive therapy in preventing any mood episode (but not manic or depressive episodes individually) in a controlled trial with significant separation from placebo in preventing mood episodes in those with an index depressive episode.<xref ref-type="ref" rid="bdi12609-bib-0388">388</xref> Thus, lurasidone adjunctive therapy may be appropriate for those who responded to this medication during an index depressive episode.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0086">
<label>5.5.5</label>
<title>Step 5: add on or switch therapy (third‐line agents)</title>
<sec id="bdi12609-sec-0087">
<title>Third‐line</title>
<p>Third‐line agents are listed alphabetically in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0018">18</xref>. There was a trend for superiority of adjunctive aripiprazole with lamotrigine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0389">389</xref> compared to lamotrigine monotherapy in preventing mania; thus, this combination may provide additional prophylaxis for patients on lamotrigine monotherapy in preventing manic relapses. Clozapine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0162">162</xref> and gabapentin (level 4)<xref ref-type="ref" rid="bdi12609-bib-0390">390</xref> may also be useful adjunctive treatments for those who incompletely respond to first‐ or second‐line therapies. The olanzapine/fluoxetine combination appears to maintain mood stability over a 6‐month period in patients with bipolar depression who respond acutely to this combination (level 2).<xref ref-type="ref" rid="bdi12609-bib-0391">391</xref>
</p>
<table-wrap id="bdi12609-tbl-0018" orientation="portrait" position="float" xml:lang="en">
<label>Table 18</label>
<caption>
<p>Additional agents evaluated for use in maintenance treatment of bipolar I disorder</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="1" valign="top">Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="4">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Aripiprazole + lamotrigine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Clozapine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gabapentin (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Olanzapine + fluoxetine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Not recommended</td>
<td align="left" colspan="1" rowspan="1">Perphenazine</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tricyclic antidepressants</td>
<td align="left" colspan="1" rowspan="1">Level 2 negative</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0038">
<p>adj, adjunctive.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
</sec>
<sec id="bdi12609-sec-0088">
<label>5.5.6</label>
<title>No specific recommendation/agents that require further study</title>
<p>We do not provide specific recommendations for the use of cariprazine, as there is currently only evidence for efficacy in acute manic and depressive episodes<xref ref-type="ref" rid="bdi12609-bib-0262">262</xref>, <xref ref-type="ref" rid="bdi12609-bib-0392">392</xref> and not yet for maintenance treatment (level 4). While a small RCT suggests a lack of efficacy for flupenthixol as maintenance treatment, larger studies are needed before definite conclusions can be drawn (level 3 negative).<xref ref-type="ref" rid="bdi12609-bib-0393">393</xref> Likewise, oxcarbazepine adjunctive therapy requires further evaluation (level 4).<xref ref-type="ref" rid="bdi12609-bib-0394">394</xref>, <xref ref-type="ref" rid="bdi12609-bib-0395">395</xref>, <xref ref-type="ref" rid="bdi12609-bib-0396">396</xref> No recommendation is made for topiramate as there is an absence of controlled data supporting its efficacy in maintenance (level 4 negative), and a lack of efficacy in acute mania<xref ref-type="ref" rid="bdi12609-bib-0381">381</xref>; however, its use may be indicated as it has efficacy for many syndromes that are often comorbid with BD (Section 7).</p>
</sec>
<sec id="bdi12609-sec-0089">
<label>5.5.7</label>
<title>Agents not recommended for maintenance treatment</title>
<p>Perphenazine is not recommended for maintenance based on evidence that patients treated with perphenazine and a mood stabilizer following an episode are more likely to have emergent depressive symptoms or intolerable side effects, compared to those maintained on the mood stabilizer alone (level 2 negative).<xref ref-type="ref" rid="bdi12609-bib-0397">397</xref> Tricyclic antidepressant mono or adjunctive maintenance therapy is not recommended due to an increased risk of manic switch (level 2 negative)<xref ref-type="ref" rid="bdi12609-bib-0398">398</xref>, <xref ref-type="ref" rid="bdi12609-bib-0399">399</xref>, <xref ref-type="ref" rid="bdi12609-bib-0400">400</xref> (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0018">18</xref>).</p>
</sec>
<sec id="bdi12609-sec-0090">
<label>5.5.8</label>
<title>Clinical features that direct treatment choices</title>
<p>Clinical trials tell us how efficacious one drug is in comparison with another (or placebo) in groups of patients. To determine the degree of long‐term response in an individual patient requires a different evaluation and may take a considerable amount of time. Few patients manage a lifetime of BD with monotherapy—most will require short‐ or long‐term combination therapies to address acute or subsyndromal symptoms as well as to reduce rates of recurrence. Some,<xref ref-type="ref" rid="bdi12609-bib-0359">359</xref>, <xref ref-type="ref" rid="bdi12609-bib-0401">401</xref>, <xref ref-type="ref" rid="bdi12609-bib-0402">402</xref> but not all,<xref ref-type="ref" rid="bdi12609-bib-0403">403</xref>, <xref ref-type="ref" rid="bdi12609-bib-0404">404</xref> reports suggest that long‐term treatment becomes less effective with longer duration of untreated illness, an argument for finding an effective treatment as early as possible.</p>
<p>In most instances, it is difficult to differentiate nonspecific correlates of good prognosis of the illness from factors specific to the response to a particular mood stabilizer. Available data come mostly from naturalistic/cohort studies and few randomized trials.<xref ref-type="ref" rid="bdi12609-bib-0405">405</xref> Nevertheless, several tentative predictors are emerging from the available data.</p>
<p>Factors associated with overall good prognosis of BD include good treatment adherence, lack of early adversity, intermediate age at onset, good social support, and the absence of spontaneous rapid cycling<xref ref-type="ref" rid="bdi12609-bib-0406">406</xref>, <xref ref-type="ref" rid="bdi12609-bib-0407">407</xref> or features of a personality disorder.<xref ref-type="ref" rid="bdi12609-bib-0408">408</xref>
</p>
<p>In general, lithium is the gold standard for maintenance treatment, as it is effective in preventing both manic and depressive episodes (magnitude of prophylactic efficacy greater against mania vs depression) and appears to have a degree of anti‐suicidal effects.<xref ref-type="ref" rid="bdi12609-bib-0352">352</xref>, <xref ref-type="ref" rid="bdi12609-bib-0369">369</xref>, <xref ref-type="ref" rid="bdi12609-bib-0409">409</xref>, <xref ref-type="ref" rid="bdi12609-bib-0410">410</xref>, <xref ref-type="ref" rid="bdi12609-bib-0411">411</xref>, <xref ref-type="ref" rid="bdi12609-bib-0412">412</xref>, <xref ref-type="ref" rid="bdi12609-bib-0413">413</xref> Patients who respond well to lithium treatment usually have an episodic remitting pre‐treatment clinical course, a family history of BD (especially BD responsive to lithium), low rates of comorbidity (especially anxiety and substance abuse disorders), and a pattern of mania‐depression‐euthymia in biphasic episodes, as well as a typical clinical presentation.<xref ref-type="ref" rid="bdi12609-bib-0414">414</xref>, <xref ref-type="ref" rid="bdi12609-bib-0415">415</xref>, <xref ref-type="ref" rid="bdi12609-bib-0416">416</xref> Responsiveness may also be a familial trait, with a study showing that patients who have a lithium‐responsive relative have a 67% likelihood of also being lithium responsive, versus 35% of those without a responsive relative.<xref ref-type="ref" rid="bdi12609-bib-0417">417</xref> Among biological measures, lack of electroencephalogram (EEG) abnormalities, higher brain lithium concentration, increased <italic>N</italic>‐acetyl aspartate and lower myo‐inositol peaks on magnetic resonance spectroscopy, as well as several variants in candidate gene studies, may predict response,<xref ref-type="ref" rid="bdi12609-bib-0418">418</xref> but these studies require confirmation. Response to lithium in particular seems to be quite specific, as shown in a study of neurons derived from induced pluripotent stem cells. The neurons from people with BD were hyperexcitable and their activity was selectively modified by <italic>in vitro</italic> lithium in accordance with clinical response.<xref ref-type="ref" rid="bdi12609-bib-0419">419</xref>
</p>
<p>Responders to lamotrigine have a predominantly depressive polarity as well as comorbid anxiety.<xref ref-type="ref" rid="bdi12609-bib-0420">420</xref>, <xref ref-type="ref" rid="bdi12609-bib-0421">421</xref> Lamotrigine monotherapy is not appropriate for patients with frequent manic episodes, as it has limited efficacy in preventing mania.</p>
<p>Quetiapine has been shown to be effective in preventing manic, depressive and mixed episodes in patients with index manic, depressive and mixed episodes, and thus may be particularly valuable in those with mixed features.<xref ref-type="ref" rid="bdi12609-bib-0422">422</xref> Asenapine appears to be effective in preventing both mania and depression, although the magnitude of prophylactic efficacy is greater for mania relative to depression. In a randomized open trial of carbamazepine versus lithium, responders to carbamazepine were more likely to have an atypical illness, BDII or schizoaffective disorder.<xref ref-type="ref" rid="bdi12609-bib-0405">405</xref>
</p>
<p>Data to differentiate anti‐psychotic medication responders from non‐responders are lacking.</p>
<p>Overall, some of these possible predictors can have clinical utility, but not all are practical. For instance, it is difficult to evaluate a pre‐treatment course in patients who started their treatment after one or two episodes (practice recommended by most treatment guidelines), and biomarkers are intriguing but lack sufficient replication and are not readily available.</p>
<p>In patients with a history of a rapid cycling course, as indicated in previous sections, factors associated with rapid cycling must be addressed. These include discontinuation of stimulants and antidepressants and treating hypothyroidism if present. With regard to treatment options, the evidence suggests that monotherapy with a single mood stabilizer is often ineffective and patients may require a combination of mood stabilizers to achieve mood stability.</p>
<sec id="bdi12609-sec-0091">
<title>Treatment‐refractory bipolar disorder</title>
<p>Treatment refractoriness may be related to non‐adherence to oral medications, failure to optimize evidence‐based oral medication therapy/therapies, comorbidities complicating therapeutic response or true resistance to pharmacotherapy. Clinicians are advised to make a comprehensive assessment to determine factors responsible for treatment refractoriness. Adequate doses of first and second‐line agents should be employed for an adequate period of time (eg, this is typically individualized based on the previous course of mood episodes in each patient) to assess prophylactic response. Comorbidities should be addressed with pharmacological or psychological strategies as appropriate. While genotyping for cytochrome P450 enzymes such as 2D6 and 3A4 which metabolize most psychotropic drugs is not routinely recommended, clinicians are advised to consider this in patients with refractory BD who have not responded to high doses of various first, second, and third‐line treatments or their combinations in order to exclude the possibility of ultra rapid metabolic status contributing to poor response.</p>
<p>In patients who are non‐adherent, psychosocial strategies such as psychoeducation should be used to improve treatment adherence. If ineffective, long‐acting injectable medications should be offered. Risperidone long‐acting injectable monotherapy<xref ref-type="ref" rid="bdi12609-bib-0383">383</xref> or adjunctive therapy (level 2)<xref ref-type="ref" rid="bdi12609-bib-0384">384</xref> once every 2 weeks or aripiprazole once‐monthly injectable monotherapy (level 2)<xref ref-type="ref" rid="bdi12609-bib-0377">377</xref> has been shown to be effective in preventing relapse of mood episodes in patients with BD.</p>
<p>There is a dearth of clinical trial data to inform treatment options for management of patients with refractory BD. Clozapine adjunctive therapy has been shown to be effective in reducing symptoms and total medication use in treatment‐resistant patients.<xref ref-type="ref" rid="bdi12609-bib-0162">162</xref>
</p>
</sec>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0092">
<label>6</label>
<title>BIPOLAR II DISORDER</title>
<sec id="bdi12609-sec-0093">
<label>6.1</label>
<title>Presentation of bipolar II disorder</title>
<p>BDII is a distinct disorder from BDI, with a similar Canadian prevalence (0.67% compared to 0.87% for BDI).<xref ref-type="ref" rid="bdi12609-bib-0007">7</xref> The diagnosis of BDII requires one or more episodes of hypomania, one or more episodes of depression, and an absence of manic episodes. The DSM‐5 criteria for hypomania are similar to those for mania, with symptoms being uncharacteristic of the individual, observable by others, and lasting at least 4 consecutive days. In contrast to mania, they cannot be severe enough to cause marked impairment or require hospitalization, and there must be an absence of psychosis. Further, DSM‐5 has added a mixed feature specifier to hypomania as well. The diagnosis of BDII is generally stable over time, although there may be a higher risk of conversion to BDI early in the illness, suggesting that BDII may be a risk factor or prodrome of BDI in some patients.<xref ref-type="ref" rid="bdi12609-bib-0423">423</xref>
</p>
<p>Although hypomania is, by definition, less severe than mania, the disability associated with BDII is comparable to that associated with BDI,<xref ref-type="ref" rid="bdi12609-bib-0014">14</xref>, <xref ref-type="ref" rid="bdi12609-bib-0424">424</xref> and the economic burden of BDII is up to four times greater.<xref ref-type="ref" rid="bdi12609-bib-0425">425</xref>, <xref ref-type="ref" rid="bdi12609-bib-0426">426</xref> This is because patients with BDII spend as much time symptomatic as those with BDI, with mood symptoms predominantly in the depressive phase.<xref ref-type="ref" rid="bdi12609-bib-0427">427</xref>, <xref ref-type="ref" rid="bdi12609-bib-0428">428</xref> Rates of attempted and completed suicide are similar in BDI and BDII, with approximately one‐third of patients with BDII attempting suicide over the course of their illnesses<xref ref-type="ref" rid="bdi12609-bib-0429">429</xref> and one in twenty‐five completing suicide.<xref ref-type="ref" rid="bdi12609-bib-0430">430</xref>
</p>
</sec>
<sec id="bdi12609-sec-0094">
<label>6.2</label>
<title>Pharmacological treatment of bipolar II disorder</title>
<sec id="bdi12609-sec-0095">
<label>6.2.1</label>
<title>General considerations for interpreting recommendations</title>
<p>The treatment of BDII has been understudied relative to BDI. This is probably due to the long‐standing but discredited impression of BDII as a less severe form of BD. The number of RCTs in BDII is substantially smaller than that in BDI, and those studies that do exist are frequently under‐powered. It also remains common for trials to enrol patients with both BDII and BDI without reporting results separately, making it difficult to determine if there are clinically meaningful differences in treatment response between the two illnesses. This is important because, while clinical experience and the results of many studies suggest that response to mood stabilizers and antipsychotics is similar in BDII and BDI, there are enough exceptions to suggest this should not be taken for granted.<xref ref-type="ref" rid="bdi12609-bib-0248">248</xref>, <xref ref-type="ref" rid="bdi12609-bib-0405">405</xref>, <xref ref-type="ref" rid="bdi12609-bib-0431">431</xref> This is also the case for antidepressants, which may have a more favourable risk‐benefit ratio in BDII (reviewed below). Therefore, in formulating our recommendations, studies that enrolled patients with both BDII and BDI but did not report results for BDII separately are assigned level 4 status (expert opinion) if the proportion of patients with BDII was less than 50%.</p>
<p>The relative paucity of large, methodologically sound clinical trials in BDII creates challenges in formulating evidence‐based guidelines. As will be seen, there are fewer treatments with high‐quality evidence in BDII compared to BDI and fewer first‐line treatment recommendations. The limitations of the evidence base necessitate an awareness of the nuances of the available studies, and a greater reliance on clinical experience. We thus have endeavoured to be clear in outlining the rationale for selecting first, second, and third‐line treatments for hypomania, depression, and maintenance treatment of this important illness. There is clearly a pressing need for adequately powered trials in BDII across all illness phases.</p>
</sec>
<sec id="bdi12609-sec-0096">
<label>6.2.2</label>
<title>Acute management of hypomania</title>
<p>The general principles for assessing mania apply to hypomania. For some patients, hypomania causes no to minimal functional impairment and may even be associated with brief periods of above‐normal functioning. However, prolonged, relatively severe, or mixed or irritable hypomania may be impairing.<xref ref-type="ref" rid="bdi12609-bib-0423">423</xref> Treatment should include discontinuing agents that can worsen or prolong symptoms, including antidepressants and stimulants, and initiating appropriate pharmacotherapy.</p>
<p>Unfortunately, many standard medications for mania, including lithium and most atypical antipsychotics, have not been studied in hypomania. There are four placebo‐controlled trials that investigated divalproex (level 4),<xref ref-type="ref" rid="bdi12609-bib-0432">432</xref>
<italic>N</italic>‐acetylcysteine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0433">433</xref> and quetiapine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0434">434</xref>, <xref ref-type="ref" rid="bdi12609-bib-0435">435</xref>; and one open‐label study of risperidone (level 4)<xref ref-type="ref" rid="bdi12609-bib-0436">436</xref> in acute hypomania. The studies generally suggested efficacy but all had significant weaknesses, including one or more of: (i) small sample sizes, (ii) mixed samples with BDI, BDII, and BD NOS; (iii) mixed samples with hypomania and mania, and (iv) positive findings on some but not all outcomes. The small numbers of patients and mixed samples mean that even the placebo‐controlled trials only met criteria for level 4 evidence (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>).</p>
<p>These methodological limitations, coupled with the lack of clinical trial evidence for many medications, make it difficult to make specific suggestions for the treatment of hypomania. Clinical experience suggests that all anti‐manic medications are also efficacious in hypomania. Thus, when hypomania is frequent, severe, or impairing enough to require treatment, clinicians should consider mood stabilizers such as lithium or divalproex and/or atypical antipsychotics. <italic>N</italic>‐acetylcysteine may also be of benefit, but further studies are needed.</p>
</sec>
<sec id="bdi12609-sec-0097">
<label>6.2.3</label>
<title>Acute management of bipolar II depression</title>
<p>The general principles for assessing depression in patients with BDI apply to those with BDII. First, second, and third‐line treatment options are listed below and shown in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0019">19</xref>. Specific considerations regarding each treatment are highlighted in the relevant sections.</p>
<table-wrap id="bdi12609-tbl-0019" orientation="portrait" position="float" xml:lang="en">
<label>Table 19</label>
<caption>
<p>Strength of evidence and treatment recommendations for acute management of bipolar II depression</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Recommendation</th>
<th align="left" colspan="1" rowspan="1" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="1" valign="top">Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">First‐line</td>
<td align="left" colspan="1" rowspan="1">Quetiapine</td>
<td align="left" colspan="1" rowspan="1">Level 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Second‐line</td>
<td align="left" colspan="1" rowspan="1">Lithium</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bupropion (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ECT</td>
<td align="left" colspan="1" rowspan="1">(Level 3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sertraline<xref ref-type="fn" rid="bdi12609-note-0040">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Venlafaxine<xref ref-type="fn" rid="bdi12609-note-0040">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="11">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Agomelatine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bupropion (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divalproex</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EPA (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fluoxetine<xref ref-type="fn" rid="bdi12609-note-0040">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ketamine (IV or sublingual) (adj)<sup>c</sup>
</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N‐acetylcysteine (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pramipexole (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T3/T4 thyroid hormones (adj)</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tranylcypromine</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ziprasidone<xref ref-type="fn" rid="bdi12609-note-0041">b</xref>
</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not recommended</td>
<td align="left" colspan="1" rowspan="1">Paroxetine</td>
<td align="left" colspan="1" rowspan="1">2 negative</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0039">
<p>adj, adjunctive; ECT, electroconvulsive therapy; EPA, eicosapentaenoic acid.</p>
</fn>
<fn id="bdi12609-note-0040">
<label>a</label>
<p>For patients with pure depression (non‐mixed).</p>
</fn>
<fn id="bdi12609-note-0041">
<label>b</label>
<p>For patients with depression and mixed hypomania.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="bdi12609-sec-0098">
<title>First‐line</title>
<p>Quetiapine is the only recommended first‐line treatment for BDII depression (level 1). Pooled analyses of five identically designed trials demonstrated that quetiapine was superior to placebo, and moreover was equally effective for acute depression in BDI and BDII.<xref ref-type="ref" rid="bdi12609-bib-0243">243</xref>, <xref ref-type="ref" rid="bdi12609-bib-0437">437</xref> The latter finding must be reconciled with the fact that quetiapine beat placebo in only three of the five individual trials in patients with BDII, compared to all five in patients with BDI.<xref ref-type="ref" rid="bdi12609-bib-0253">253</xref>, <xref ref-type="ref" rid="bdi12609-bib-0290">290</xref>, <xref ref-type="ref" rid="bdi12609-bib-0438">438</xref>, <xref ref-type="ref" rid="bdi12609-bib-0439">439</xref>, <xref ref-type="ref" rid="bdi12609-bib-0440">440</xref> This is probably because the smaller sample of BDII patients—only about half as many patients with BDII as BDI were enrolled in each of the trials—provided less statistical power for BDII. Finally, open‐label studies also suggest efficacy for adjunctive quetiapine (level 4).<xref ref-type="ref" rid="bdi12609-bib-0441">441</xref>, <xref ref-type="ref" rid="bdi12609-bib-0442">442</xref>
</p>
</sec>
<sec id="bdi12609-sec-0099">
<title>Second‐line</title>
<p>Second‐line treatments include lithium, ideally at a serum level of 0.8‐1.2 mEq/L (level 2) (Figure <xref ref-type="fig" rid="bdi12609-fig-0005">5</xref>), and the antidepressants sertraline (level 2) <xref ref-type="ref" rid="bdi12609-bib-0426">426</xref> and venlafaxine (level 2),<xref ref-type="ref" rid="bdi12609-bib-0443">443</xref>, <xref ref-type="ref" rid="bdi12609-bib-0444">444</xref> mainly for patients with pure (non‐mixed) depression (Figure <xref ref-type="fig" rid="bdi12609-fig-0006">6</xref>). Lamotrigine (level 2) is also recommended as a second‐line agent despite conflicting evidence, with the rationale for this provided in Figure <xref ref-type="fig" rid="bdi12609-fig-0007">7</xref>. ECT (level 3)<sup>261</sup> can also be considered second‐line and is a good option, particularly for treatment refractory patients and those in need of rapid response.</p>
<fig fig-type="Figure" id="bdi12609-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>Lithium as a second‐line agent for bipolar II depression: Summary of evidence. BDI, bipolar disorder type I; BDII, bipolar disorder type II; BDNOS, bipolar disorder not otherwise specified; RCT, randomized controlled trial [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-15" xlink:href="BDI-20-97-g005"></graphic>
</fig>
<fig fig-type="Figure" id="bdi12609-fig-0006" orientation="portrait" position="float" xml:lang="en">
<label>Figure 6</label>
<caption>
<p>Antidepressants for bipolar II depression: What is their role? BDI, bipolar disorder type I; BDII, bipolar disorder type II; ISBD, International Society for Bipolar Disorders; MDD, major depressive disorder; RCT, randomized controlled trial [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-17" xlink:href="BDI-20-97-g006"></graphic>
</fig>
<fig fig-type="Figure" id="bdi12609-fig-0007" orientation="portrait" position="float" xml:lang="en">
<label>Figure 7</label>
<caption>
<p>Lamotrigine as a second‐line agent for bipolar II depression: Summary of evidence BDI, bipolar disorder type I; BDII, bipolar disorder type II; RCT, randomized controlled trial [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-19" xlink:href="BDI-20-97-g007"></graphic>
</fig>
</sec>
<sec id="bdi12609-sec-0100">
<title>Third‐line</title>
<p>The third‐line options include monotherapy with divalproex (level 4)<xref ref-type="ref" rid="bdi12609-bib-0258">258</xref>, <xref ref-type="ref" rid="bdi12609-bib-0459">459</xref>, <xref ref-type="ref" rid="bdi12609-bib-0461">461</xref>,<xref ref-type="ref" rid="bdi12609-bib-0462">462</xref>, <xref ref-type="ref" rid="bdi12609-bib-0463">463</xref>, <xref ref-type="ref" rid="bdi12609-bib-0464">464</xref>, <xref ref-type="ref" rid="bdi12609-bib-0465">465</xref>, <xref ref-type="ref" rid="bdi12609-bib-0466">466</xref> fluoxetine (mainly for patients with pure depression) (level 3)<xref ref-type="ref" rid="bdi12609-bib-0467">467</xref>, <xref ref-type="ref" rid="bdi12609-bib-0468">468</xref>, <xref ref-type="ref" rid="bdi12609-bib-0469">469</xref> tranylcypromine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0278">278</xref> or ziprasidone (solely for patients with depression and mixed hypomania) (level 3).<xref ref-type="ref" rid="bdi12609-bib-0470">470</xref>, <xref ref-type="ref" rid="bdi12609-bib-0471">471</xref> Adjunctive agomelatine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0472">472</xref> bupropion (level 4)<xref ref-type="ref" rid="bdi12609-bib-0276">276</xref> eicosapentaenoic acid (EPA) (level 4),<xref ref-type="ref" rid="bdi12609-bib-0473">473</xref>, <xref ref-type="ref" rid="bdi12609-bib-0474">474</xref>, <xref ref-type="ref" rid="bdi12609-bib-0475">475</xref>
<italic>N</italic>‐acetylcysteine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0476">476</xref> pramipexole (level 3),<xref ref-type="ref" rid="bdi12609-bib-0274">274</xref> or thyroid hormones (level 4)<xref ref-type="ref" rid="bdi12609-bib-0272">272</xref> may also be considered.</p>
<p>Intravenous ketamine (level 3)<xref ref-type="ref" rid="bdi12609-bib-0477">477</xref>, <xref ref-type="ref" rid="bdi12609-bib-0478">478</xref> has rapid onset of efficacy and may be considered for patients who are refractory to first and second‐line treatments, as well as for those in need of rapid response.</p>
</sec>
<sec id="bdi12609-sec-0101">
<title>No specific recommendation/agents that require further study</title>
<p>A number of agents do not have sufficient data to warrant specific recommendations for BDII depression, including cranial electrotherapy stimulation (CES),<xref ref-type="ref" rid="bdi12609-bib-0479">479</xref> dextromethorphan + quinidine,<xref ref-type="ref" rid="bdi12609-bib-0480">480</xref> light therapy,<xref ref-type="ref" rid="bdi12609-bib-0481">481</xref>, <xref ref-type="ref" rid="bdi12609-bib-0482">482</xref>, <xref ref-type="ref" rid="bdi12609-bib-0483">483</xref>, <xref ref-type="ref" rid="bdi12609-bib-0484">484</xref>, <xref ref-type="ref" rid="bdi12609-bib-0485">485</xref> lisdexamfetamine (adjunctive),<xref ref-type="ref" rid="bdi12609-bib-0300">300</xref> olanzapine,<xref ref-type="ref" rid="bdi12609-bib-0486">486</xref> pioglitazone,<xref ref-type="ref" rid="bdi12609-bib-0302">302</xref> adjunctive pregnenolone,<xref ref-type="ref" rid="bdi12609-bib-0306">306</xref> celecoxib,<xref ref-type="ref" rid="bdi12609-bib-0297">297</xref> levetiracetam,<xref ref-type="ref" rid="bdi12609-bib-0487">487</xref> adjunctive lisdexamfetamine,<xref ref-type="ref" rid="bdi12609-bib-0300">300</xref> s‐adenosylmethionine,<xref ref-type="ref" rid="bdi12609-bib-0488">488</xref>, <xref ref-type="ref" rid="bdi12609-bib-0489">489</xref>, <xref ref-type="ref" rid="bdi12609-bib-0490">490</xref> acetyl‐<sc>l</sc>‐carnitine + alpha‐lipoic acid,<xref ref-type="ref" rid="bdi12609-bib-0491">491</xref> adjunctive modafinil,<xref ref-type="ref" rid="bdi12609-bib-0268">268</xref> rTMS,<xref ref-type="ref" rid="bdi12609-bib-0275">275</xref>, <xref ref-type="ref" rid="bdi12609-bib-0492">492</xref>, <xref ref-type="ref" rid="bdi12609-bib-0493">493</xref> and memantine.<xref ref-type="ref" rid="bdi12609-bib-0494">494</xref>
</p>
</sec>
<sec id="bdi12609-sec-0102">
<title>Not recommended</title>
<p>Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).<xref ref-type="ref" rid="bdi12609-bib-0245">245</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0103">
<label>6.2.4</label>
<title>Maintenance treatment</title>
<p>Maintenance treatment is important to prevent relapse, reduce subsyndromal symptoms, and improve quality of life. As with BDI, selection of an agent should be informed by acute phase treatment. Recommended agents and their evidence ratings are listed in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0020">20</xref>.</p>
<table-wrap id="bdi12609-tbl-0020" orientation="portrait" position="float" xml:lang="en">
<label>Table 20</label>
<caption>
<p>Strength of evidence and treatment recommendations for maintenance treatment of bipolar II disorder</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Recommendation</th>
<th align="left" colspan="1" rowspan="1" valign="top">Agent</th>
<th align="left" colspan="1" rowspan="1" valign="top">Evidence level</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="3">First‐line</td>
<td align="left" colspan="1" rowspan="1">Quetiapine</td>
<td align="left" colspan="1" rowspan="1">Level 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lithium</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Second‐line</td>
<td align="left" colspan="1" rowspan="1">Venlafaxine</td>
<td align="left" colspan="1" rowspan="1">Level 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Third‐line</td>
<td align="left" colspan="1" rowspan="1">Carbamazepine</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divalproex</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Escitalopram</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fluoxetine</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other antidepressants</td>
<td align="left" colspan="1" rowspan="1">Level 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Risperidone<xref ref-type="fn" rid="bdi12609-note-0043">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">Level 4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0043">
<label>a</label>
<p>Primarily for prevention of hypomania.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="bdi12609-sec-0104">
<title>First‐line</title>
<p>Monotherapy with quetiapine (level 1),<xref ref-type="ref" rid="bdi12609-bib-0495">495</xref> lithium (level 2),<xref ref-type="ref" rid="bdi12609-bib-0399">399</xref>, <xref ref-type="ref" rid="bdi12609-bib-0450">450</xref>, <xref ref-type="ref" rid="bdi12609-bib-0452">452</xref> and lamotrigine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0323">323</xref> are first‐line options.</p>
<p>
<italic>Quetiapine</italic>. In two 52‐week maintenance studies, patients with BDII who achieved remission from depression with quetiapine monotherapy continued it or switched to placebo.<xref ref-type="ref" rid="bdi12609-bib-0495">495</xref> A pooled analysis reported that patients treated with quetiapine had a significantly longer time to relapse into any mood episode (hazard ratio [HR] 0.33, or a 67% reduction in the risk of relapse) and into depression (HR 0.28 or a 72% risk reduction). Time to relapse into hypomania was not significantly greater (HR 0.65 or a 35% risk reduction). The latter finding may be related to the low base rate of hypomania, which occurred in only 10% of all study participants. Quetiapine was at least as effective in BDII as in BDI, for which the risk reductions were 42% for any relapse, 48% for depression, and 30% for mania. Adjunctive quetiapine was also studied in a 6‐month single‐blind trial which randomly assigned patients with either BDI or BDII to lithium or quetiapine added to treatment as usual. They were equally effective in preventing relapse.<xref ref-type="ref" rid="bdi12609-bib-0453">453</xref> Results were not presented separately for BDII, but BDII patients responded better to both treatments than did BDI patients.</p>
<p>
<italic>Lithium</italic>. In three placebo‐controlled RCTs conducted in the 1970s and 1980s (duration = 11‐25 months), lithium decreased the frequency and/or severity of hypomanic and depressive episodes.<xref ref-type="ref" rid="bdi12609-bib-0399">399</xref>, <xref ref-type="ref" rid="bdi12609-bib-0450">450</xref>, <xref ref-type="ref" rid="bdi12609-bib-0452">452</xref> Serum lithium levels were 0.8‐1.2 mEq/L. A number of active comparator studies also support lithium. As noted above, lithium was as effective as quetiapine in preventing relapse in a 6‐month single‐blind trial.<xref ref-type="ref" rid="bdi12609-bib-0453">453</xref> A 20‐month study comparing lithium and divalproex in rapid cycling BDI + BDII found the two drugs to be equally effective in preventing relapses.<xref ref-type="ref" rid="bdi12609-bib-0496">496</xref> The authors noted that findings were similar for BDII and BDI, but results were otherwise not reported separately for BDII. In a 2.5‐year study in BDII + BD NOS, lithium and carbamazepine were equally effective on most outcomes, although a numerical advantage favoured carbamazepine for reducing clinical plus subclinical recurrence.<xref ref-type="ref" rid="bdi12609-bib-0405">405</xref> In contrast, head‐to‐head comparisons with antidepressants (reviewed below) found that lithium was not as effective in preventing depressive relapse as fluoxetine or venlafaxine.<xref ref-type="ref" rid="bdi12609-bib-0469">469</xref>, <xref ref-type="ref" rid="bdi12609-bib-0497">497</xref> This may be explained by the mean lithium levels, which were 0.7 mEq/L in both studies, while the fluoxetine trial was also enriched for fluoxetine responders.</p>
<p>Long‐term naturalistic data also provide strong support for lithium. In a 6‐year study of patients with either BDI or BDII (39% with BDII), lithium reduced time in hypomania/mania by 61% and time in depression by 53% in the entire sample, compared with the period before lithium treatment was initiated.<xref ref-type="ref" rid="bdi12609-bib-0498">498</xref> The authors noted that the proportion of time with mood symptoms was significantly lower for BDII than for BDI.</p>
<p>
<italic>Lamotrigine</italic>. In a 6‐month placebo‐controlled RCT of lamotrigine monotherapy in rapid cycling BDI + BDII, post hoc analysis showed that significantly more lamotrigine‐treated than placebo‐treated patients with BDII were stable without recurrence into any mood episode,<xref ref-type="ref" rid="bdi12609-bib-0323">323</xref> although lamotrigine was not superior to placebo in BDI. In a large 52‐week RCT in BDI + BDII, adjunctive lamotrigine was superior to placebo for improving depression severity and remission rates. However, results were not presented separately for BDII.<xref ref-type="ref" rid="bdi12609-bib-0251">251</xref> Open‐label trials and retrospective chart reviews also support lamotrigine.<xref ref-type="ref" rid="bdi12609-bib-0248">248</xref>, <xref ref-type="ref" rid="bdi12609-bib-0499">499</xref>, <xref ref-type="ref" rid="bdi12609-bib-0500">500</xref>, <xref ref-type="ref" rid="bdi12609-bib-0501">501</xref>, <xref ref-type="ref" rid="bdi12609-bib-0502">502</xref>
</p>
</sec>
<sec id="bdi12609-sec-0105">
<title>Second‐line</title>
<p>Monotherapy with venlafaxine (level 2) or fluoxetine (level 3) are second‐line options.</p>
<p>
<italic>Venlafaxine</italic>. In a small 6‐month RCT in patients with BDII who responded acutely to venlafaxine or lithium without hypomanic switch, there was a trend for lower rates of relapse into depression for patients treated with venlafaxine. Further, the rate of sustained response was significantly greater in those who continued venlafaxine compared to those who continued lithium.<xref ref-type="ref" rid="bdi12609-bib-0497">497</xref> No hypomanic episodes occurred in either group.</p>
<p>
<italic>Fluoxetine</italic>. In a 50‐week RCT, the mean time to relapse into depression was significantly longer for fluoxetine than for lithium or placebo. Patients had responded acutely to open‐label fluoxetine, making the sample enriched for fluoxetine response. Hypomanic episodes occurred in a similarly low frequency in the three groups.<xref ref-type="ref" rid="bdi12609-bib-0469">469</xref> In a separate small 6‐month placebo‐controlled trial, there was a statistical trend for lower relapse rates with fluoxetine compared to placebo.<xref ref-type="ref" rid="bdi12609-bib-0503">503</xref> Finally, a post hoc analysis of a large 12‐month placebo‐controlled trial found that response rates to fluoxetine were similar in BDII and MDD.<xref ref-type="ref" rid="bdi12609-bib-0468">468</xref> However, it did not report whether fluoxetine was superior to placebo in BDII.</p>
</sec>
<sec id="bdi12609-sec-0106">
<title>Third‐line</title>
<p>Divalproex (level 4),<xref ref-type="ref" rid="bdi12609-bib-0504">504</xref> carbamazepine (level 3),<xref ref-type="ref" rid="bdi12609-bib-0405">405</xref> escitalopram (level 3),<xref ref-type="ref" rid="bdi12609-bib-0505">505</xref> other antidepressants (level 3),<xref ref-type="ref" rid="bdi12609-bib-0454">454</xref> and risperidone (mainly for prevention of hypomania) (level 4)<xref ref-type="ref" rid="bdi12609-bib-0436">436</xref> may be considered as third‐line options.</p>
</sec>
<sec id="bdi12609-sec-0107">
<label>6.2.4.1</label>
<title>No specific recommendation/agents that require further study</title>
<p>There are insufficient data to make a recommendation regarding olanzapine.<xref ref-type="ref" rid="bdi12609-bib-0506">506</xref>
</p>
</sec>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0108">
<label>7</label>
<title>SPECIFIC POPULATIONS</title>
<sec id="bdi12609-sec-0109">
<label>7.1</label>
<title>Management of bipolar disorder in women at various stages of the reproductive cycle</title>
<sec id="bdi12609-sec-0110">
<label>7.1.1</label>
<title>Pre‐conception, psychoeducation and contraceptive counselling</title>
<p>The importance of pre‐conception counselling should be raised with all women of child bearing age. It should be provided for all patients at least 3 months prior to considering pregnancy or immediately for those already pregnant. The issues most frequently raised are fear of adverse effects of medications on the fetus, fear of illness recurrence, and genetic transmission to offspring.<xref ref-type="ref" rid="bdi12609-bib-0507">507</xref> Other important topics to review include the effect of BD on risk for gestational hypertension, antepartum haemorrhage, induction of labour, caesarean section, instrumental delivery, preterm delivery, and neonatal size.<xref ref-type="ref" rid="bdi12609-bib-0508">508</xref>, <xref ref-type="ref" rid="bdi12609-bib-0509">509</xref> Discussion of modifiable risk factors is critical in pre‐conception management of BD. For instance, pregnant women with BD are more often overweight, more often smoke tobacco during pregnancy, have poorer diet quality, and present more often with a history of drug and alcohol misuse in pregnancy.<xref ref-type="ref" rid="bdi12609-bib-0509">509</xref> Modification of these risk factors may have a significant positive impact on outcomes for both the mother and child.</p>
<p>Decisions should be made collaboratively on whether medications should be continued, discontinued, or switched; and whether any dosage changes are needed. Conventional antipsychotics and risperidone may need to be discontinued to increase the likelihood of conception, as these medications often increase serum prolactin levels and thus interfere with ovulation and decrease fertility.<xref ref-type="ref" rid="bdi12609-bib-0510">510</xref> For women who wish to have a medication‐free pregnancy, it might be appropriate to have one or more psychotropic medications gradually tapered off prior to conception provided they have been clinically stable for a minimum of 4‐6 months and are considered at low risk of relapse. Information regarding potential teratogenic effects of different psychotropic medications, as well as limitations of the scientific evidence, should be discussed and carefully considered. The decision to stop medications pre‐conceptually should ideally occur only after careful individualized risk‐benefit analysis for a given patient.<xref ref-type="ref" rid="bdi12609-bib-0511">511</xref>, <xref ref-type="ref" rid="bdi12609-bib-0512">512</xref>, <xref ref-type="ref" rid="bdi12609-bib-0513">513</xref> If pharmacotherapy is required, monotherapy at minimum effective dose is recommended whenever possible.<xref ref-type="ref" rid="bdi12609-bib-0514">514</xref>, <xref ref-type="ref" rid="bdi12609-bib-0515">515</xref>
</p>
<p>Contraceptive counselling, including emphasis on its effectiveness in reducing the likelihood of unintended pregnancies, should be included as part of a comprehensive treatment plan for women with BD.</p>
<p>Several anticonvulsants, including carbamazepine, topiramate, and lamotrigine, can affect the pharmacokinetics of oral contraceptives and some might significantly reduce the effectiveness of oral contraceptives, and this should be considered when making treatment decisions.<xref ref-type="ref" rid="bdi12609-bib-0516">516</xref>, <xref ref-type="ref" rid="bdi12609-bib-0517">517</xref> Oral contraceptives might also have effects on the efficacy of lamotrigine via reduction in lamotrigine levels.<xref ref-type="ref" rid="bdi12609-bib-0516">516</xref>
</p>
<p>While folic acid supplementation is protective against spontaneous spina bifida, there is not enough evidence to indicate that folic acid, even in high doses, protects against spina bifida following the use of anticonvulsants.<xref ref-type="ref" rid="bdi12609-bib-0518">518</xref> In addition, Health Canada recommends that “Valproate products (valproic acid, divalproex sodium) should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated because of its high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate.” Health Canada also recommends that women of childbearing potential must use effective contraception during treatment and be informed of the risks associated with the use of valproate products during pregnancy, and in women planning to become pregnant every effort should be made to switch to appropriate alternative treatment prior to conception.<xref ref-type="ref" rid="bdi12609-bib-0519">519</xref>
</p>
<p>Regardless of treatment decisions made prior to or following conception, it is also important to work with the patient to develop and agree upon a monitoring schedule and treatment plan to be implemented should clinically significant symptoms emerge. Education about the risks of psychotropic medications is critical, and careful discussion is needed regarding the magnitude of risks and benefits and limitations with the data. It is important to acknowledge the patient's desire to do what is right for the child and support the decision made. Whenever appropriate, involve partners in the discussion and review the decision and supporting evidence for it directly or through educational materials.<xref ref-type="ref" rid="bdi12609-bib-0520">520</xref>
</p>
</sec>
<sec id="bdi12609-sec-0111">
<label>7.1.2</label>
<title>Screening for bipolar disorder during pregnancy and postpartum</title>
<p>All women with depressive symptoms should be screened for BD during pregnancy and the postpartum period.<xref ref-type="ref" rid="bdi12609-bib-0521">521</xref>, <xref ref-type="ref" rid="bdi12609-bib-0522">522</xref> Standardized screening tools such as the Mood Disorder Questionnaire alone or in conjunction with the Edinburgh Postnatal Depression Scale are useful.<xref ref-type="ref" rid="bdi12609-bib-0521">521</xref>, <xref ref-type="ref" rid="bdi12609-bib-0522">522</xref>, <xref ref-type="ref" rid="bdi12609-bib-0523">523</xref>, <xref ref-type="ref" rid="bdi12609-bib-0524">524</xref> Importantly, screening should be followed by a clinical interview to confirm or exclude a diagnosis of BD. Women should also be assessed for other psychiatric disorders that commonly co‐occur with BD, such as anxiety disorders or obsessive compulsive disorder (OCD).<xref ref-type="ref" rid="bdi12609-bib-0525">525</xref>
</p>
</sec>
<sec id="bdi12609-sec-0112">
<label>7.1.3</label>
<title>Pharmacological management of bipolar disorder during pregnancy</title>
<p>Given the complexity of the risks faced by women with BD in pregnancy and puerperium, it is good clinical practice to encourage liaison between the mental health and obstetrics/gynecology teams. A longitudinal study conducted in a tertiary care centre found a high risk of recurrence during pregnancy: 85% of pregnant women with BD who discontinued a mood stabilizer and 37% of those who were maintained on one or more mood stabilizers experienced a mood episode—predominately depressive or mixed—during pregnancy. For nearly half of the patients, recurrence occurred in the first trimester, with the median time for recurrence for those abruptly discontinuing treatment being 2 weeks, compared to 22 weeks for those who were gradually tapered off.<xref ref-type="ref" rid="bdi12609-bib-0511">511</xref> However, studies from primary care, as well as obstetric centres, found low rates of relapse or hospitalizations in pregnancy.<xref ref-type="ref" rid="bdi12609-bib-0526">526</xref>
</p>
<p>The hierarchies presented throughout these guidelines should be followed for management of the various phases of BD, with consideration given to specific risks associated with the use of each medication using the most up‐to‐date information available from the US Food and Drug Administration (FDA) website ( <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ForConsumers/ByAudience/ForWomen/WomensHealthTopics/ucm117976.htm">http://www.fda.gov/ForConsumers/ByAudience/ForWomen/WomensHealthTopics/ucm117976.htm</ext-link>).</p>
<p>Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0021">21</xref> includes a brief overview of medications commonly used in BD and the risk categories. This list should not be viewed as complete or comprehensive. Further, the FDA has replaced these risk categories in 2015 with Pregnancy and Lactation Labeling Final Rule (PLLR) with narrative sections and subsections. For instance, for pregnancy, the information for each medication is provided using the following subheadings: Pregnancy exposure registry, Risk summary, Clinical considerations, and Data. The last three subsections apply to medication risks during lactation. The FDA has not finalized and published the data for all medications as of completion date of these guidelines (February 2018), and new data appear to suggest that risks may have been overestimated for some medications such as lithium.<xref ref-type="ref" rid="bdi12609-bib-0527">527</xref> Thus clinicians are strongly advised to use all the current data, including the FDA PLLR information if available, in collaboration with patient and family members to make final treatment decisions.</p>
<table-wrap id="bdi12609-tbl-0021" orientation="portrait" position="float" xml:lang="en">
<label>Table 21</label>
<caption>
<p>US Food and Drug Administration (FDA) classification of teratogenicity for medications commonly used in bipolar disorder<xref ref-type="fn" rid="bdi12609-note-0044">a</xref>
</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Pregnancy risk category<xref ref-type="fn" rid="bdi12609-note-0045">b</xref>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Lactation risk category<xref ref-type="fn" rid="bdi12609-note-0046">c</xref>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Lithium</td>
<td align="left" colspan="1" rowspan="1">D</td>
<td align="left" colspan="1" rowspan="1">L4</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1">Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Carbamazepine</td>
<td align="left" colspan="1" rowspan="1">D<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Divalproex</td>
<td align="left" colspan="1" rowspan="1">D<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1">Atypical antipsychotics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Clozapine</td>
<td align="left" colspan="1" rowspan="1">B<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Olanzapine</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Quetiapine</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Risperidone</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Ziprasidone</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1">SSRI antidepressants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Citalopram</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Escitalopram</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Fluoxetine</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Fluvoxamine</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Paroxetine</td>
<td align="left" colspan="1" rowspan="1">D<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Sertraline</td>
<td align="left" colspan="1" rowspan="1">C<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L2</td>
</tr>
<tr>
<td align="left" colspan="3" rowspan="1">Other antidepressants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Bupropion</td>
<td align="left" colspan="1" rowspan="1">B<sub>m</sub>
</td>
<td align="left" colspan="1" rowspan="1">L3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0044">
<label>a</label>
<p>FDA has replaced these risk categories in 2015 with Pregnancy and Lactation Labeling Final Rule (PLLR). SEE TEXT FOR DETAILS.</p>
</fn>
<fn id="bdi12609-note-0045">
<label>b</label>
<p>Adapted from ACOG Committee on Practice Bulletins–Obstetrics<xref ref-type="ref" rid="bdi12609-bib-0878">878</xref>: US Food and Drug Administration Rating. A = controlled studies show no risk; B = no evidence of risk in humans; C = risk cannot be ruled out (human data lacking, animal studies positive or not done); D = positive evidence of risk (benefit may outweigh risk). The “m” subscript is for data taken from the manufacturer's package insert.</p>
</fn>
<fn id="bdi12609-note-0046">
<label>c</label>
<p>Hale TW and Rowe HE.<xref ref-type="ref" rid="bdi12609-bib-0879">879</xref> Lactation risk categories are listed as follows: L1, safest; L2, safer; L3, moderately safe; L4, possibly hazardous; L5, contraindicated.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Wherever possible, psychosocial strategies should be preferred over medications in the first trimester as this period holds the highest risk for teratogenicity. When medications are deemed necessary, preference should be given to monotherapy using the lowest effective dose.</p>
<p>Each pregnancy should be closely monitored and appropriate screening tests (eg, foetal ultrasound if lithium is used in the first trimester) should be performed.<xref ref-type="ref" rid="bdi12609-bib-0528">528</xref> Divalproex should be avoided during pregnancy due to elevated risk of neural tube defects (up to 5%), even higher incidences of other congenital abnormalities, and evidence of striking degrees of neurodevelopmental delay in children at 3 years of age and loss of an average of nine IQ points.<xref ref-type="ref" rid="bdi12609-bib-0529">529</xref>, <xref ref-type="ref" rid="bdi12609-bib-0530">530</xref>, <xref ref-type="ref" rid="bdi12609-bib-0531">531</xref> Because of changes in physiology in the second and early third trimesters, such as increased plasma volume, hepatic activity, and renal clearance, patients may require higher doses of medications towards the later part of the pregnancy. Prenatal vitamins, including high‐dose (5 mg/day) folic acid, are also recommended, preferably even before conception and continuously through pregnancy; and preparations containing choline have recently been recommended as possibly preventive of the later development of schizophrenia.<xref ref-type="ref" rid="bdi12609-bib-0532">532</xref> While it is important to note that folic acid may reduce the effectiveness of lamotrigine,<xref ref-type="ref" rid="bdi12609-bib-0251">251</xref> the anti‐teratogenic effects of folate may outweigh the potential for this loss of effectiveness. However, recent concerns have been raised regarding a potential association between very high plasma levels of maternal folate and risk of autism spectrum disorders.<xref ref-type="ref" rid="bdi12609-bib-0533">533</xref>
</p>
</sec>
<sec id="bdi12609-sec-0113">
<label>7.1.4</label>
<title>Pharmacological management of bipolar disorder during the postpartum period</title>
<p>The postpartum period is a time of elevated risk for recurrence, with 66% of women who were medication free during pregnancy and 23% of those on treatment experiencing a mood episode following the delivery.<xref ref-type="ref" rid="bdi12609-bib-0534">534</xref> The risk of postpartum relapse is highest in women who also experienced a mood episode during pregnancy and those who are not on prophylactic treatment.<xref ref-type="ref" rid="bdi12609-bib-0535">535</xref> Despite the high prevalence of postpartum episodes, there is a dearth of studies investigating the efficacy of medications during this period. There is evidence of efficacy of benzodiazepines, antipsychotics, and lithium for postpartum mania,<xref ref-type="ref" rid="bdi12609-bib-0535">535</xref> and quetiapine for postpartum bipolar depression (level 4).<xref ref-type="ref" rid="bdi12609-bib-0536">536</xref> There are no studies of psychotherapy in the acute or preventative treatment of bipolar postpartum depression.<xref ref-type="ref" rid="bdi12609-bib-0537">537</xref>
</p>
<p>Patients should be encouraged to initiate or optimize maintenance treatment as soon after giving birth as possible, with preference given to medications that have previously been shown to be successful. Near delivery, close monitoring is essential for early detection and management of symptoms that might signal onset of a mood or psychotic episode.<xref ref-type="ref" rid="bdi12609-bib-0538">538</xref> If an acute mood episode emerges in the postpartum period, the hierarchies for non‐postpartum episodes should be followed, but, because most psychotropic medications are excreted in breast milk, treatment choice should take into consideration safety in breastfeeding when applicable.</p>
<p>The FDA website mentioned in the previous section as well as Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0021">21</xref> also include information on lactation. The FDA PLLR should be consulted for further information about medication risks, as many are secreted in milk, if breastfeeding is being considered.</p>
<p>The potential risks and benefits of taking medications while breastfeeding should be discussed with the patient. Education about early recognition of drug toxicity and requirement for ongoing monitoring of infants is also critical.<xref ref-type="ref" rid="bdi12609-bib-0539">539</xref> A recent systematic review suggested quetiapine and olanzapine as preferred choices for breastfeeding, considering their relatively lower infant dosages.<xref ref-type="ref" rid="bdi12609-bib-0540">540</xref> The impact of medication on the infant can be reduced by scheduling medication administration after breastfeeding.<xref ref-type="ref" rid="bdi12609-bib-0541">541</xref>
</p>
<p>Replacing or supplementing breast milk with formula can also be considered. Although there are many benefits to breastfeeding, associated sleep disruption may increase the risk of mood episodes in women with BD. If possible, bottle feeding at night by the woman's partner or a support can be beneficial to allow the woman to maintain a better sleeping schedule. In women with postpartum psychosis or mania, breastfeeding may be more risky, and therefore may not be indicated, as the mother may be too disorganized to safely breastfeed.<xref ref-type="ref" rid="bdi12609-bib-0542">542</xref>
</p>
<p>As childbirth can be a trigger for first onset of hypomania/mania in women with MDD, antidepressants should be used cautiously, especially in women with a family history of BD.<xref ref-type="ref" rid="bdi12609-bib-0543">543</xref> Women with first onset of depression in the postpartum period or those who have recurrence of depression during the early postpartum period, may also be at a high risk of switching to BD following treatment with antidepressants.<xref ref-type="ref" rid="bdi12609-bib-0537">537</xref>
</p>
</sec>
<sec id="bdi12609-sec-0114">
<label>7.1.5</label>
<title>Impact of the menstrual cycle on symptoms</title>
<p>Despite the paucity of large, well‐designed research studies examining the impact of the menstrual cycle on mood symptoms in BD, accumulating evidence suggests that hormonal changes can impact the course of illness. Several case reports and prospective studies suggest that women who experience premenstrual symptom exacerbation are more likely to have a highly symptomatic and relapse prone illness.<xref ref-type="ref" rid="bdi12609-bib-0544">544</xref>, <xref ref-type="ref" rid="bdi12609-bib-0545">545</xref> One of the largest studies (n = 1099) found that women who met DSM‐5 provisional criteria for premenstrual dysphoric disorder (PMDD) had an earlier illness onset, more comorbid Axis I disorders, a higher number of hypomanic/manic and depressive episodes, and higher rates of rapid cycling.<xref ref-type="ref" rid="bdi12609-bib-0546">546</xref> In this study, there was a closer gap between BD onset and age of menarche in women with comorbid PMDD, which suggests that sensitivity to endogenous hormones may influence the onset and the clinical course of BD. Premenstrual syndrome (PMS) and PMDD also occur more frequently in women with BD.<xref ref-type="ref" rid="bdi12609-bib-0547">547</xref>, <xref ref-type="ref" rid="bdi12609-bib-0548">548</xref> Importantly, an accurate diagnosis of comorbid PMDD in women with BD is made during euthymia, with a minimum of 2 months of prospective symptom charting.<xref ref-type="ref" rid="bdi12609-bib-0549">549</xref>
</p>
</sec>
<sec id="bdi12609-sec-0115">
<label>7.1.6</label>
<title>Menopause</title>
<p>For many women, stress and hormonal changes associated with the transition to menopause may increase or trigger mood symptoms.<xref ref-type="ref" rid="bdi12609-bib-0550">550</xref>, <xref ref-type="ref" rid="bdi12609-bib-0551">551</xref>, <xref ref-type="ref" rid="bdi12609-bib-0552">552</xref> A post hoc analysis of the prospective Systematic Treatment Enhancement Program for Bipolar disorder (STEP‐BD) study showed increased rates of depressive, but not manic episodes during menopause transition.<xref ref-type="ref" rid="bdi12609-bib-0553">553</xref> However, due to the paucity of clinical trials in this area, more data are needed before treatment recommendations can be made.<xref ref-type="ref" rid="bdi12609-bib-0554">554</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0116">
<label>7.2</label>
<title>Management of bipolar disorder in children and adolescents</title>
<sec id="bdi12609-sec-0117">
<label>7.2.1</label>
<title>Presentation and diagnosis</title>
<p>As the following section comprises only a brief overview of the epidemiology, phenomenology, and differential diagnosis of BD in children and adolescents, the reader is referred to more detailed reviews for further information.<xref ref-type="ref" rid="bdi12609-bib-0555">555</xref>, <xref ref-type="ref" rid="bdi12609-bib-0556">556</xref>, <xref ref-type="ref" rid="bdi12609-bib-0557">557</xref>, <xref ref-type="ref" rid="bdi12609-bib-0558">558</xref>, <xref ref-type="ref" rid="bdi12609-bib-0559">559</xref>, <xref ref-type="ref" rid="bdi12609-bib-0560">560</xref>
</p>
<p>Between one‐third (community samples) and two‐thirds (clinical samples) of patients with BD experience their first mood episode during childhood or adolescence, with an earlier onset related to a more severe illness characterized by increased symptom burden and comorbidity.<xref ref-type="ref" rid="bdi12609-bib-0561">561</xref>, <xref ref-type="ref" rid="bdi12609-bib-0562">562</xref> In contrast to the controversies of as recently as a decade ago, there is now far greater consensus in the field that, although there are developmental differences in the manner in which symptoms manifest themselves, the actual diagnosis of BD in children and adolescents should be made based on the same set of symptoms as applied to adults.<xref ref-type="ref" rid="bdi12609-bib-0563">563</xref> When defined rigorously according to DSM‐5 criteria, the course of illness in childhood and adolescence is characterized by eventual high rates of symptomatic recovery, but also high rates of recurrence, even in the context of naturalistic treatment.<xref ref-type="ref" rid="bdi12609-bib-0564">564</xref> While the concepts of “over‐diagnosis” and “over‐treatment” in pediatric BD have received substantial attention,<xref ref-type="ref" rid="bdi12609-bib-0565">565</xref> representative population studies demonstrate that adolescent BD is characterized by low rates of treatment, alongside high rates of suicidality and comorbidity.<xref ref-type="ref" rid="bdi12609-bib-0566">566</xref>, <xref ref-type="ref" rid="bdi12609-bib-0567">567</xref> Risks of incorrectly diagnosing and treating BD in a child or adolescent should thus be carefully weighed against the risk of incorrectly or not diagnosing or treating,<xref ref-type="ref" rid="bdi12609-bib-0568">568</xref> keeping in mind that the duration of treatment delay has been shown to be an independent risk factor for a poor outcome in adulthood.<xref ref-type="ref" rid="bdi12609-bib-0569">569</xref>
</p>
<p>Distinguishing early‐onset mania or hypomania from other psychiatric disorders is important as there is a high level of symptomatic overlap for multiple conditions including but not limited to ADHD, oppositional defiant disorder (ODD), disruptive mood dysregulation disorder (DMDD), substance abuse, personality disorders and generalized anxiety disorder<xref ref-type="ref" rid="bdi12609-bib-0555">555</xref>, <xref ref-type="ref" rid="bdi12609-bib-0570">570</xref> (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0022">22</xref>). The discrete episodes of mania/hypomania and the non‐overlapping symptoms can facilitate accurate diagnosis. When a comorbidity is present, such as ADHD, overlapping symptoms (eg, distractibility and hyperactivity) should only count towards a diagnosis of mania or hypomania if they intensify during intervals of elation or irritability. Notably, ADHD is an ongoing condition whereas BD is episodic, and decreased sleep, hypersexuality, hallucinations or delusions, and homicidal or suicidal thoughts and actions occur with childhood mania, but are rare or absent in uncomplicated ADHD.</p>
<table-wrap id="bdi12609-tbl-0022" orientation="portrait" position="float" xml:lang="en">
<label>Table 22</label>
<caption>
<p>Differential diagnosis of manic symptoms in children and adolescents</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Symptom</th>
<th align="left" colspan="1" rowspan="1" valign="top">Bipolar mania hypomania</th>
<th align="left" colspan="1" rowspan="1" valign="top">Attention deficit hyperactivity disorder</th>
<th align="left" colspan="1" rowspan="1" valign="top">Oppositional defiant disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Elation</td>
<td align="left" colspan="1" rowspan="1">Episodic, prolonged, pathological (inappropriate to context or uncharacteristic), associated with change in functioning, “travels” with ≥3 other manic symptoms</td>
<td align="left" colspan="1" rowspan="1">If present, not clearly episodic or pathological</td>
<td align="left" colspan="1" rowspan="1">If present, not clearly episodic or pathological</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Irritability</td>
<td align="left" colspan="1" rowspan="1">Episodic, prolonged, pathological, associated with change in functioning, “travels” with ≥4 other manic symptoms</td>
<td align="left" colspan="1" rowspan="1">Can be an associated feature, related to stimulant rebound, or due to a comorbid illness (eg, ODD)</td>
<td align="left" colspan="1" rowspan="1">Diagnostic criterion, lacks distinct prolonged episodes, does not “travel” with other manic symptoms</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sleep</td>
<td align="left" colspan="1" rowspan="1">Reduced need for sleep (ie, significantly less sleep than usual without increased daytime fatigue or somnolence); change must be mood‐related</td>
<td align="left" colspan="1" rowspan="1">Insomnia (ie, difficulty falling asleep); can be an associated feature or associated with stimulants, but need for sleep is unchanged</td>
<td align="left" colspan="1" rowspan="1">Not a symptom or common characteristic; may defy bedtime rules or routine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grandiosity</td>
<td align="left" colspan="1" rowspan="1">Distinct uncharacteristic increase in confidence or self‐importance; change must be mood‐related</td>
<td align="left" colspan="1" rowspan="1">Not a symptom or common characteristic</td>
<td align="left" colspan="1" rowspan="1">Defiance toward authority figures is common but not necessarily mood‐related</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hyperactivity and distractibility</td>
<td align="left" colspan="1" rowspan="1">Episodic; if comorbid ADHD is diagnosed, then distinctly “worse than usual” change must be mood‐related</td>
<td align="left" colspan="1" rowspan="1">Diagnostic criteria, nonepisodic</td>
<td align="left" colspan="1" rowspan="1">Not prominent or episodic</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0047">
<p>ADHD, attention‐deficit hyperactivity disorder; ODD, oppositional defiant disorder (Adapted from Goldstein and Birmaher 2012<xref ref-type="ref" rid="bdi12609-bib-0555">555</xref>).</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>It is important to note that, while chronic irritability with episodic behavioural outbursts or rages can be seen in multiple paediatric psychiatric disorders (including emerging personality disorders, substance abuse, ODD, pervasive developmental disorders, and major depressive episodes), such irritability and explosiveness are not sufficient to make a diagnosis, even when severe. The recent DSM‐5 diagnosis DMDD—which includes chronic irritability as a defining feature—lists BD as an exclusion criterion. However, the DMDD phenotype is evident in about 25% of adolescents with episodic BD, and is associated with factors such as greater family conflict and ADHD comorbidity.<xref ref-type="ref" rid="bdi12609-bib-0571">571</xref> Classical BD and chronic irritability are therefore not mutually exclusive, the nonspecific nature of the latter notwithstanding.</p>
<p>A significant minority of children or youth with MDD will eventually go on to develop BD, with an average rate of 28% being reported.<xref ref-type="ref" rid="bdi12609-bib-0572">572</xref>, <xref ref-type="ref" rid="bdi12609-bib-0573">573</xref> Risk factors for switch to mania following a depressive episode include a family history of mood disorders, emotional and behavioural dysregulation, subthreshold manic symptoms, cyclothymia, atypical depression and psychosis.<xref ref-type="ref" rid="bdi12609-bib-0572">572</xref> A recent meta‐analysis suggested that the most potent predictors were family history, an earlier age of onset and the presence of psychotic symptoms.<xref ref-type="ref" rid="bdi12609-bib-0574">574</xref> There is an increased prevalence of BD among offspring of parents with BD.<xref ref-type="ref" rid="bdi12609-bib-0575">575</xref>, <xref ref-type="ref" rid="bdi12609-bib-0576">576</xref>, <xref ref-type="ref" rid="bdi12609-bib-0577">577</xref> Although there is no uniform strategy for managing depression (or ADHD, anxiety, etc.) in the child of a parent with BD, increased caution is warranted when prescribing antidepressant or stimulant medications as these have the potential to precipitate mania/hypomania.<xref ref-type="ref" rid="bdi12609-bib-0578">578</xref> Patients and their parents should be informed of the potential switch risk and close monitoring for treatment‐emergent manic/hypomanic switch should be instituted.</p>
<p>Self‐report and/or parent‐reported questionnaires can be informative and can raise the index of suspicion for BD.<xref ref-type="ref" rid="bdi12609-bib-0579">579</xref> However, scores on such questionnaires as the Child Behaviour Checklist (CBCL) “dysregulation phenotype”, previously described as “BD phenotype”, have poor capacity for differentiating BD from other complex and severe symptomatic presentations.<xref ref-type="ref" rid="bdi12609-bib-0580">580</xref> Questionnaires can be used as screeners, but do not substitute for a thorough diagnostic evaluation. Longitudinal rating by parents may be most helpful in diagnosis and assessment of treatment response. An online program for weekly parental ratings (of depression, anxiety, ADHD, oppositional behaviour, and mania) of children aged 2‐12 years is available at <ext-link ext-link-type="uri" xlink:href="http://www.bipolarnews.org">http://www.bipolarnews.org</ext-link>, click on Child Network.<xref ref-type="ref" rid="bdi12609-bib-0581">581</xref>
</p>
</sec>
<sec id="bdi12609-sec-0118">
<label>7.2.2</label>
<title>Pharmacological management</title>
<sec id="bdi12609-sec-0119">
<title>General principles</title>
<p>The general principles for managing adults with BD also apply to children and youth. In youth, themes of comorbidity and tolerability are accentuated. Comorbid ADHD is more common in children and adolescents as compared to adults with BD. Moreover, ADHD symptoms often do not improve following mood stabilization, and may require concurrent ADHD treatment. In addition, due to elevated risk for accelerated atherosclerosis and early cardiovascular disease in this population, cardiovascular risk factors should also be assessed regularly and intervention implemented. Lifestyle management including attention to diet, substance use, smoking and physical activity should be implemented alongside any psychological or pharmacological interventions.<xref ref-type="ref" rid="bdi12609-bib-0582">582</xref> Relatedly, children and adolescents are more susceptible than adults to the metabolic side effects of psychiatric medications, particularly the atypical antipsychotics that are considered first‐line treatments.<xref ref-type="ref" rid="bdi12609-bib-0583">583</xref> Taken together, these distinguishing features underscore the importance of ensuring that polypharmacy, as often required, is judicious and informed by a balance of factors including mood symptom burden, global functioning, and physical health.</p>
</sec>
<sec id="bdi12609-sec-0120">
<title>Acute management of mania</title>
<p>
<italic>First‐line</italic>. Lithium (level 1),<xref ref-type="ref" rid="bdi12609-bib-0583">583</xref>, <xref ref-type="ref" rid="bdi12609-bib-0584">584</xref>, <xref ref-type="ref" rid="bdi12609-bib-0585">585</xref> risperidone (level 1),<xref ref-type="ref" rid="bdi12609-bib-0584">584</xref>, <xref ref-type="ref" rid="bdi12609-bib-0586">586</xref> aripiprazole (level 2),<xref ref-type="ref" rid="bdi12609-bib-0587">587</xref> asenapine (level 2),<xref ref-type="ref" rid="bdi12609-bib-0588">588</xref> and quetiapine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0583">583</xref>, <xref ref-type="ref" rid="bdi12609-bib-0589">589</xref> are recommended as first‐line options. Risperidone may be preferable to lithium for non‐obese youth, and youth with ADHD.<xref ref-type="ref" rid="bdi12609-bib-0584">584</xref>
</p>
<p>
<italic>Second‐line</italic>. Due to safety and tolerability concerns, olanzapine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0590">590</xref> and ziprasidone (level 2)<xref ref-type="ref" rid="bdi12609-bib-0591">591</xref> should be considered second‐line options. Quetiapine adjunctive therapy (level 3)<xref ref-type="ref" rid="bdi12609-bib-0592">592</xref> is also recommended as a second‐line treatment.</p>
<p>
<italic>Third‐line</italic>. Despite low response rates in two RCTs, a long history of use among adults with BD, combined with positive findings in open‐label studies are grounds for considering divalproex as a third‐line option for youth who do not respond to or tolerate first or second‐line agents (level 4).<xref ref-type="ref" rid="bdi12609-bib-0593">593</xref>
</p>
<p>
<italic>Not recommended</italic>. Oxcarbazepine was not superior to placebo in a large RCT (level 2 negative).<xref ref-type="ref" rid="bdi12609-bib-0594">594</xref>
</p>
</sec>
<sec id="bdi12609-sec-0121">
<title>Acute management of bipolar depression</title>
<p>The data in paediatric samples are very limited, and complicated by extremely high placebo‐response rates in RCTs. These recommendations are therefore to a greater extent informed by clinical experience and studies in adults than the above acute mania recommendations (see Figure <xref ref-type="fig" rid="bdi12609-fig-0008">8</xref>).</p>
<fig fig-type="Figure" id="bdi12609-fig-0008" orientation="portrait" position="float" xml:lang="en">
<label>Figure 8</label>
<caption>
<p>Treatments for pediatric bipolar depression: Summary of evidence [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-21" xlink:href="BDI-20-97-g008"></graphic>
</fig>
<p>
<italic>First‐line</italic>. A recently published RCT found that lurasidone was superior to placebo (level 2)<xref ref-type="ref" rid="bdi12609-bib-0595">595</xref> in improving depressive symptoms in children and adolescents with acute bipolar depression; however there is comparatively little clinical experience in this population. Nevertheless, given its efficacy and clinical experience in adult bipolar depression, lurasidone is recommended as a first‐line treatment.</p>
<p>
<italic>Second‐line</italic>. Although lithium and lamotrigine were recommended as first‐line agents for bipolar depression in adults, there are only open‐label data for lithium (level 4)<xref ref-type="ref" rid="bdi12609-bib-0596">596</xref> and lamotrigine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0597">597</xref> in children and youth. Despite limited RCT data, there is, however, substantial clinical experience with these agents as they are widely used in clinical practice. For this reason, together with the strength of evidence in adults, lithium and lamotrigine are recommended as second‐line, rather than third‐line agents (see Figure <xref ref-type="fig" rid="bdi12609-fig-0008">8</xref>).</p>
<p>
<italic>Third‐line</italic>. There is a positive RCT of olanzapine‐fluoxetine combination among youth with bipolar depression (level 1)<xref ref-type="ref" rid="bdi12609-bib-0598">598</xref>; however, metabolic concerns regarding olanzapine, and limited clinical experience with olanzapine‐fluoxetine combination in youth lead to the positioning of this option as third‐line. Despite negative findings in paediatric samples, quetiapine (level 2 negative)<xref ref-type="ref" rid="bdi12609-bib-0599">599</xref>, <xref ref-type="ref" rid="bdi12609-bib-0600">600</xref> is also recommended as third‐line for this population due to the abundance of evidence from adult studies combined with substantial clinical experience. There are also several methodological concerns with the studies done in pediatric samples (see Figure <xref ref-type="fig" rid="bdi12609-fig-0008">8</xref>).</p>
<p>Despite limited knowledge regarding the precise risks of antidepressant‐induced mania in youth with BD, observational pharmaco‐epidemiology studies support the conclusion that antidepressants should be used with caution in BDI and BDII, and in combination with mood‐stabilizing medication (level 4).<xref ref-type="ref" rid="bdi12609-bib-0578">578</xref>, <xref ref-type="ref" rid="bdi12609-bib-0601">601</xref>
</p>
<p>
<italic>Not recommended</italic>. A large RCT found that oxcarbazepine was not superior to placebo (level 2 negative)<xref ref-type="ref" rid="bdi12609-bib-0594">594</xref> although it was effective in the youngest group of patients but not the older adolescents.</p>
</sec>
<sec id="bdi12609-sec-0122">
<title>Maintenance treatment</title>
<p>The data in paediatric samples are very limited. These recommendations are therefore informed by clinical experience and studies in adults to a greater extent than the above acute mania recommendations.</p>
<p>
<italic>First‐line</italic>. Preferred maintenance treatment options for this population are aripiprazole (level 2),<xref ref-type="ref" rid="bdi12609-bib-0602">602</xref>, <xref ref-type="ref" rid="bdi12609-bib-0603">603</xref> lithium (level 2)<xref ref-type="ref" rid="bdi12609-bib-0604">604</xref> and divalproex (level 2).<xref ref-type="ref" rid="bdi12609-bib-0604">604</xref>, <xref ref-type="ref" rid="bdi12609-bib-0605">605</xref> However, it should be noted that follow‐up duration for the aripiprazole study was only 30 weeks, and the sample size in the 18‐month maintenance study of lithium vs divalproex was only 30 participants. It is important to note that few patients continued to do well upon the switch to either lithium or divalproex monotherapy and the majority re‐responded when the combination was reinstated. Further, other studies have also suggested the efficacy of combination therapy (eg, risperidone plus lithium or divalproex<xref ref-type="ref" rid="bdi12609-bib-0584">584</xref> and lithium plus divalproex or carbamazepine<xref ref-type="ref" rid="bdi12609-bib-0606">606</xref>) to achieve and maintain remission. Adjunctive lamotrigine may also be considered for those aged ≥ 13 years (level 2).<xref ref-type="ref" rid="bdi12609-bib-0607">607</xref>
</p>
<p>
<italic>Second‐line</italic>. No treatments with level 3 or higher evidence are available to recommend as second‐line options for maintenance.</p>
<p>
<italic>Third‐line</italic>. Although there has been far less experience with asenapine than with other medications discussed in this section, a recent open‐label extension study suggests continual reduction in manic symptoms over 50 weeks (level 4).<xref ref-type="ref" rid="bdi12609-bib-0608">608</xref> Further, a recent RCT in adults confirmed its efficacy in preventing relapse of mood episodes.<xref ref-type="ref" rid="bdi12609-bib-0374">374</xref> Although there have not been maintenance studies for quetiapine, risperidone, or ziprasidone in this population, clinical experience and open‐label studies indicate that continuation and maintenance treatment with these medications is another option, particularly for those patients who have responded well to acute treatment (level 4).<xref ref-type="ref" rid="bdi12609-bib-0591">591</xref>, <xref ref-type="ref" rid="bdi12609-bib-0609">609</xref>, <xref ref-type="ref" rid="bdi12609-bib-0610">610</xref> Further, there is evidence that oral quetiapine and long‐acting injectable risperidone monotherapy and adjunctive therapy and oral ziprasidone adjunctive therapy are effective in preventing mood episodes in adults with BD.<xref ref-type="ref" rid="bdi12609-bib-0369">369</xref>, <xref ref-type="ref" rid="bdi12609-bib-0370">370</xref>, <xref ref-type="ref" rid="bdi12609-bib-0383">383</xref>, <xref ref-type="ref" rid="bdi12609-bib-0384">384</xref>, <xref ref-type="ref" rid="bdi12609-bib-0387">387</xref>
</p>
</sec>
<sec id="bdi12609-sec-0123">
<title>Treatment of comorbid conditions</title>
<p>
<italic>ADHD</italic>. Stimulants may also be used for comorbid ADHD in stable/euthymic youth taking optimal doses of anti‐manic medications. Adjunctive mixed amphetamine salts (level 3)<xref ref-type="ref" rid="bdi12609-bib-0611">611</xref> and methylphenidate (level 3)<xref ref-type="ref" rid="bdi12609-bib-0612">612</xref> have both been shown to be effective in addressing attention symptoms and have been well tolerated overall within the RCTs completed to date, theoretical and epidemiological data regarding risks of induction of mood elevation notwithstanding.<xref ref-type="ref" rid="bdi12609-bib-0613">613</xref> Although open trials suggest potential benefits of atomoxetine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0614">614</xref>, <xref ref-type="ref" rid="bdi12609-bib-0615">615</xref> the possibility of inducing mania or hypomania remains,<xref ref-type="ref" rid="bdi12609-bib-0616">616</xref> suggesting the need for RCTs before clinical recommendations can be made.</p>
<p>
<italic>Substance use</italic>. Comorbid substance use should be treated concurrently to mood symptoms, with inpatient hospital or community residential treatment employed as clinically indicated. A small study suggests that lithium may be effective for reducing substance use in this population (level 3),<xref ref-type="ref" rid="bdi12609-bib-0617">617</xref> and FFT should also be considered (Section 2). Positive trials of <italic>N</italic>‐acetylcysteine for cannabis use disorders among adolescents,<xref ref-type="ref" rid="bdi12609-bib-0618">618</xref> smoking,<xref ref-type="ref" rid="bdi12609-bib-0619">619</xref> and bipolar depression among adults <xref ref-type="ref" rid="bdi12609-bib-0281">281</xref> suggest that <italic>N</italic>‐acetylcysteine may benefit adolescents with comorbid bipolar and SUDs; however, studies examining this hypothesis have not yet been completed (level 4).</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0124">
<label>7.3</label>
<title>Management of bipolar disorder in older age</title>
<sec id="bdi12609-sec-0125">
<label>7.3.1</label>
<title>Presentation and course</title>
<p>Because of the aging population in Canada and many countries around the world, knowledge of pertinent issues related to the management of older adults is becoming increasingly important. Approximately 6% of geriatric psychiatry outpatients and 10% of inpatients have BD,<xref ref-type="ref" rid="bdi12609-bib-0620">620</xref> and proportionally this population is one of the highest users of psychiatric and physical health services.<xref ref-type="ref" rid="bdi12609-bib-0621">621</xref> Approximately 25% of the patients with BD in the USA in 2005 were over the age of 60 years,<xref ref-type="ref" rid="bdi12609-bib-0622">622</xref> and by 2030 &gt;50% of patients with BD are expected to be aged &gt;60 years.<xref ref-type="ref" rid="bdi12609-bib-0623">623</xref>
</p>
<p>The lifetime prevalence of late‐life BD is about 1%‐2% with a 1‐year prevalence of 0.1%‐0.7% in the general population. About 90%‐95% of older adults with bipolar disorder have their initial episode prior to age 50 years, although there is a minority who will have a later onset.<xref ref-type="ref" rid="bdi12609-bib-0624">624</xref>, <xref ref-type="ref" rid="bdi12609-bib-0625">625</xref> Late onset is often related to neurological or physical comorbidity,<xref ref-type="ref" rid="bdi12609-bib-0626">626</xref> and may carry a negative prognosis,<xref ref-type="ref" rid="bdi12609-bib-0627">627</xref> although this is not a consistent finding.<xref ref-type="ref" rid="bdi12609-bib-0628">628</xref>
</p>
<p>While symptoms of mania or hypomania are generally less prominent in older adults, depressive and cognitive symptoms are more often observed, and hyperactivity, aggression, insomnia, impulsivity, and self‐neglect may pose a significant risk to the patient and others.<xref ref-type="ref" rid="bdi12609-bib-0629">629</xref>, <xref ref-type="ref" rid="bdi12609-bib-0630">630</xref> Psychiatric comorbidity is also generally lower than in younger patients, with anxiety and substance use being the most common.<xref ref-type="ref" rid="bdi12609-bib-0631">631</xref> Compared to younger patients, older adults are less likely to utilize inpatient, outpatient, and emergency room services and more likely to use case‐management and conservator services.<xref ref-type="ref" rid="bdi12609-bib-0632">632</xref>
</p>
<p>Cognitive dysfunction is a significant concern for this population, with &gt;30% showing significant deficits across all mood states, including euthymia.<xref ref-type="ref" rid="bdi12609-bib-0633">633</xref> This cognitive dysfunction is relatively stable, related to the number of mood episodes earlier in life, and does not appear to exceed normal aging in 2‐5‐year follow‐up.<xref ref-type="ref" rid="bdi12609-bib-0634">634</xref>, <xref ref-type="ref" rid="bdi12609-bib-0635">635</xref>, <xref ref-type="ref" rid="bdi12609-bib-0636">636</xref> Lithium use has been associated with lower rates of cognitive disorders in BD,<xref ref-type="ref" rid="bdi12609-bib-0637">637</xref> and higher lithium levels in drinking water may be associated with lower dementia risks,<xref ref-type="ref" rid="bdi12609-bib-0638">638</xref>, <xref ref-type="ref" rid="bdi12609-bib-0639">639</xref> although prospective trials are required to definitively assess this. Standardized instruments, such as the Montreal Cognitive Assessment (MoCA), should be used to quantify cognitive dysfunction. Because of the link between cognition and functioning in BD,<xref ref-type="ref" rid="bdi12609-bib-0634">634</xref>, <xref ref-type="ref" rid="bdi12609-bib-0640">640</xref> the impact of medications (particularly those with a high anticholinergic burden) on cognition should be considered when making treatment decisions. Furthermore, improvement of modifiable risk factors such as diet, exercise, and mental stimulation should also be promoted in order to further diminish the risk of cognitive decline.</p>
</sec>
<sec id="bdi12609-sec-0126">
<label>7.3.2</label>
<title>Medical comorbidity</title>
<p>Older adults with BD have an average of three to four medical comorbidities, with metabolic syndrome, hypertension, diabetes, cardiovascular disease, arthritis, and endocrine abnormalities being the most common.<xref ref-type="ref" rid="bdi12609-bib-0631">631</xref>, <xref ref-type="ref" rid="bdi12609-bib-0641">641</xref> Together, these contribute to a reduction in life expectancy of 10‐15 years in BD compared to non‐psychiatric populations.<xref ref-type="ref" rid="bdi12609-bib-0642">642</xref> Because of these high rates of comorbidities, assessment of an older adult with BD should include a thorough physical and neurological examination, including clinical laboratory tests. Neuroimaging should also be applied as indicated, particularly in the presence of focal neurological signs and symptoms or abrupt late onset, or if the presentation is different from prior episodes. Coordination with other health care providers is also imperative, as this can optimize physical health,<xref ref-type="ref" rid="bdi12609-bib-0643">643</xref> as can smoking cessation.</p>
</sec>
<sec id="bdi12609-sec-0127">
<label>7.3.3</label>
<title>Pharmacological treatment</title>
<p>The data supporting efficacy of medications in various mood states in this population are limited, with only a single RCT exclusively in geriatric patients completed to date, comparing lithium vs divalproex for the treatment of mania/hypomania.<xref ref-type="ref" rid="bdi12609-bib-0644">644</xref> Despite this, open‐label trials, naturalistic studies, and post hoc analyses of mixed aged RCTs suggest that medications efficacious in adults overall will also be effective in older adults, although additional considerations regarding medication tolerability and age‐related changes in pharmacokinetics and pharmacodynamics must be taken into account. Because of the high number of medical comorbidities as well as physical changes related to the aging process, strict attention must be paid in these patients to potential pharmacokinetic issues, drug‐drug interactions, side effects, and the need for ongoing monitoring (see Section 8).</p>
<p>Amongst other effects, lithium has been associated with adverse neurological effects<xref ref-type="ref" rid="bdi12609-bib-0645">645</xref> and renal disease.<xref ref-type="ref" rid="bdi12609-bib-0646">646</xref> Divalproex has been associated with motor side effects<xref ref-type="ref" rid="bdi12609-bib-0645">645</xref> and metabolic effects (weight gain and diabetes mellitus).<xref ref-type="ref" rid="bdi12609-bib-0647">647</xref> Carbamazepine induces cytochrome P450 enzymes and can reduce the levels of divalproex and other medications.<xref ref-type="ref" rid="bdi12609-bib-0648">648</xref> Regarding antipsychotics, which are now very commonly used for BD in older adults, dose reduction may be beneficial in some aging patients to lower the risk of motor, sedation, metabolic syndrome, and cognitive effects.<xref ref-type="ref" rid="bdi12609-bib-0649">649</xref> There is an association between mortality and antipsychotics in patients with dementia<xref ref-type="ref" rid="bdi12609-bib-0650">650</xref> but it is unclear how this should be managed for patients with BD. Recently there have also been data linking antipsychotics with acute kidney injury.<xref ref-type="ref" rid="bdi12609-bib-0651">651</xref>
</p>
<p>In particular, when lithium is used in this population, lithium level and renal monitoring should occur at least every 3‐6 months, as well as 5‐7 days following a lithium dose adjustment or adjustment of non‐steroidal anti‐inflammatory drugs (NSAIDs), antiontensin II receptor blockers (ARBs), angiotensin‐converting enzyme inhibitors (ACEIs), or thiazide diuretic dosing.<xref ref-type="ref" rid="bdi12609-bib-0652">652</xref> Special consideration also needs to be given to dose selection. A post hoc analysis of the STEP‐BD study found that while, on average, older patients required a similar number of medications to younger patients to achieve recovery, lower doses were used. In that sample, over twice as many older patients as younger ones recovered using lithium alone (42% vs 21%, respectively).<xref ref-type="ref" rid="bdi12609-bib-0653">653</xref> In general, starting at a lower dose (eg, 150 mg nightly for lithium) is recommended, with gradual adjustments to reach the lowest end of the therapeutic range for adults, with subsequent titration based on tolerability and effectiveness; keeping in mind that some older patients will require similar blood levels as the general adult population in order to achieve remission. Further discussion, including clinical guidance and more detailed treatment recommendations, can be found in the ISBD Task Force report.<xref ref-type="ref" rid="bdi12609-bib-0654">654</xref> In light of very limited international guidelines for maintenance treatment of older adults with BD, an ISBD Task Force is currently undertaking a Delphi survey of international experts, and clinicians are advised to consult this as results become available in the future (Shulman K, personal communication).</p>
<p>Pharmacological treatments have been evaluated using the criteria for strength of evidence for efficacy (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0001">1</xref>) in older adults as well as safety and tolerability (Section 8). Unfortunately, there is a dearth of literature for efficacy of treatments in older adults. However, clinical experience supports the notion that treatments known to work in general adult populations are also effective in older adults. Tolerability may be different and this is an important consideration in treatment selection in older adults. General principles for management of acute episodes described in Sections 3 and 4 also apply to this population.</p>
<sec id="bdi12609-sec-0128">
<title>Acute mania</title>
<p>Monotherapy with lithium (level 2)<xref ref-type="ref" rid="bdi12609-bib-0644">644</xref> or divalproex (level 2)<xref ref-type="ref" rid="bdi12609-bib-0644">644</xref> is recommended as a first‐line treatment. Quetiapine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0655">655</xref> can be considered as second‐line. Asenapine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0656">656</xref>, <xref ref-type="ref" rid="bdi12609-bib-0657">657</xref> aripiprazole (level 4),<xref ref-type="ref" rid="bdi12609-bib-0658">658</xref> risperidone (level 4),<xref ref-type="ref" rid="bdi12609-bib-0659">659</xref> or carbamazepine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0654">654</xref> may be applied as third‐line treatments. For treatment‐resistant episodes, clozapine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0660">660</xref> and ECT (level 4)<xref ref-type="ref" rid="bdi12609-bib-0654">654</xref> should also be considered.</p>
</sec>
<sec id="bdi12609-sec-0129">
<title>Bipolar depression</title>
<p>There are no RCTs of any agents in older adults with acute bipolar depression. Post hoc analyses of RCTs suggest efficacy of quetiapine (level 2)<xref ref-type="ref" rid="bdi12609-bib-0661">661</xref> and lurasidone (level 2)<xref ref-type="ref" rid="bdi12609-bib-0662">662</xref> monotherapy and hence these are recommended as first‐line options. However, in older adults, given the concerns about side effects of atypical antipsychotics, clinicians may wish to try lithium or lamotrigine first based on their efficacy in adult populations, although the evidence of efficacy is limited in older adults (lithium, level 4; lamotrigine, level 4).<xref ref-type="ref" rid="bdi12609-bib-0663">663</xref>, <xref ref-type="ref" rid="bdi12609-bib-0664">664</xref> Divalproex (level 4), aripiprazole (level 4),<xref ref-type="ref" rid="bdi12609-bib-0658">658</xref> and carbamazepine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0665">665</xref> are third‐line options. ECT (level 4)<xref ref-type="ref" rid="bdi12609-bib-0654">654</xref> is an important option that should be considered in treatment‐resistant cases, for suicidal patients, or for patients with inadequate food or fluid intake.</p>
<p>While the use of antidepressants in BD remains controversial<xref ref-type="ref" rid="bdi12609-bib-0260">260</xref>, <xref ref-type="ref" rid="bdi12609-bib-0426">426</xref> and there have been no studies in older age BD; antidepressants are frequently used in this population (&gt;40% of patients).<xref ref-type="ref" rid="bdi12609-bib-0666">666</xref> Antidepressants with lower manic switch potential (eg, SSRIs and bupropion)<xref ref-type="ref" rid="bdi12609-bib-0260">260</xref> used in combination with mood stabilizers may be beneficial in selected patients who cannot tolerate/do not respond to other agents with a stronger geriatric evidence base. Possible medication interactions with ongoing medications for non‐psychiatric conditions must always be considered.</p>
</sec>
<sec id="bdi12609-sec-0130">
<title>Maintenance</title>
<p>Choice of agents should be based on what has been effective in the acute phase, with recommended options with geriatric efficacy data being lithium (level 2),<xref ref-type="ref" rid="bdi12609-bib-0667">667</xref>, <xref ref-type="ref" rid="bdi12609-bib-0668">668</xref> lamotrigine (level 2),<xref ref-type="ref" rid="bdi12609-bib-0668">668</xref> and divalproex (level 3).<xref ref-type="ref" rid="bdi12609-bib-0667">667</xref>
</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0131">
<label>7.4</label>
<title>Management of comorbid conditions in bipolar disorder</title>
<sec id="bdi12609-sec-0132">
<label>7.4.1</label>
<title>Comorbid psychiatric disorders</title>
<sec id="bdi12609-sec-0133">
<label>7.4.1.1</label>
<title>Epidemiology</title>
<p>Most patients diagnosed with BD will also have at least one comorbid psychiatric diagnosis. The most common comorbid conditions are substance use disorder, anxiety disorder, personality disorder, and impulse control disorder (such as ADHD, ODD, and CD).<xref ref-type="ref" rid="bdi12609-bib-0045">45</xref> Comorbidity impacts the course of BDs by increasing the likelihood of treatment resistance and suicide risk, and also by increasing the time spent with impairing symptoms.<xref ref-type="ref" rid="bdi12609-bib-0034">34</xref>, <xref ref-type="ref" rid="bdi12609-bib-0050">50</xref>, <xref ref-type="ref" rid="bdi12609-bib-0669">669</xref>, <xref ref-type="ref" rid="bdi12609-bib-0670">670</xref>
</p>
<p>When treating comorbid conditions, determining which disorder to address first requires careful consideration. Some comorbid disorders may be managed with the same treatment employed to manage bipolar symptoms (eg, quetiapine for comorbid anxiety and BD), while other comorbid disorders (eg, ADHD) may require distinct treatments. Importantly, some treatments for comorbid disorders may lead to bipolar symptom destabilization; for instance, an antidepressant employed to treat an anxiety disorder may provoke mood elevation.</p>
<p>Safely and effectively managing comorbid conditions often necessitates the implementation of a hierarchical approach, depending on each patient's individual needs and preferences. In general, the disorder or symptom associated with the greatest morbidity and mortality—such as acute mania, psychosis, or suicidal ideation—should be managed first. Substance use disorders may be addressed concurrently or sequentially, depending on severity and contribution to mood instability. Once mood stability is established, the treatment of additional comorbid conditions, such as ADHD or metabolic disorders, should follow based on their impact and the patient's preference.</p>
<p>There is a dearth of research to guide the best management of BD in the context of comorbid conditions. There have been few trials designed with comorbid symptoms as the primary target for mood‐stabilizing treatments—evidence is mainly derived from secondary analysis of published data. Thus, the limited research informing the treatment of comorbidities constrains our ability to make definitive recommendations. However, because comorbidity is so common and burdensome for patients, appropriate management is a challenging daily reality in clinical practice. Therefore, CANMAT decided to provide a brief overview of relevant clinical issues and the evidence base for pharmacological treatments for treating comorbid populations. The reader is advised to consult the following references for the role of psychological treatments in managing comorbidity.<xref ref-type="ref" rid="bdi12609-bib-0671">671</xref>, <xref ref-type="ref" rid="bdi12609-bib-0672">672</xref>, <xref ref-type="ref" rid="bdi12609-bib-0673">673</xref>
</p>
</sec>
<sec id="bdi12609-sec-0134">
<title>Substance use disorders</title>
<p>Two recent reviews indicated that the prevalence rate of comorbid SUD in BD is about 33% in general population surveys<xref ref-type="ref" rid="bdi12609-bib-0674">674</xref> and approximately 45% in clinical settings.<xref ref-type="ref" rid="bdi12609-bib-0675">675</xref> SUD can negatively impact the course of BD, resulting in lower rates of remission,<xref ref-type="ref" rid="bdi12609-bib-0407">407</xref> a higher number of hospitalizations,<xref ref-type="ref" rid="bdi12609-bib-0676">676</xref>, <xref ref-type="ref" rid="bdi12609-bib-0677">677</xref> and an increased risk of suicide attempts<xref ref-type="ref" rid="bdi12609-bib-0429">429</xref> and perhaps suicide deaths.<xref ref-type="ref" rid="bdi12609-bib-0678">678</xref>
</p>
<p>Substance use should be addressed as early as possible, as it is likely to interfere with treatment for BD. However, the presence of a SUD should not preclude an attempt to treat BD, which might result in an individual being more amenable to treatment. As the directionality of the interaction between SUD and BD is rarely clear in the reality of clinical practice, it is recommended that the two conditions be treated simultaneously.</p>
<p>A more detailed discussion on the impact of and the general principles of the treatment of substance use comorbidity can be found in a CANMAT Task Force publication,<xref ref-type="ref" rid="bdi12609-bib-0679">679</xref> and other reviews<xref ref-type="ref" rid="bdi12609-bib-0673">673</xref>, <xref ref-type="ref" rid="bdi12609-bib-0681">681</xref> and a meta‐analysis<xref ref-type="ref" rid="bdi12609-bib-0680">680</xref> published on the topic since 2012. Here we provide a brief update on the pharmacological treatments identified in the CANMAT Task Force publication. It is important to note that the criteria for level of evidence used here are more stringent than those applied to the Task Force report.</p>
<p>The levels of evidence for treatment of comorbid SUD are low. This is because of (i) the paucity of data, (ii) complexity of study designs (given the fact that many patients will be using more than one substance), and, most importantly (iii) inconsistency of the outcome variables used in these studies; hindering direct comparison of results. Nevertheless, some evidence‐based recommendations are available for clinicians, starting with general principles of treatment: if at all possible, avoid medications that could increase the risk of destabilizing the BD, and choose treatments that could help both conditions.</p>
</sec>
<sec id="bdi12609-sec-0135">
<title>Alcohol use disorder</title>
<p>A combination of divalproex and lithium is the only treatment for alcohol use disorder comorbid with BD that meets criteria for level 2 evidence.<xref ref-type="ref" rid="bdi12609-bib-0682">682</xref>, <xref ref-type="ref" rid="bdi12609-bib-0683">683</xref> In a small RCT, there was a significant reduction in the number of drinks per drinking day, as well as per heavy drinking day, in the combination group compared to the group with lithium alone when adherence to treatment was added as a covariate. There is only level 3 evidence for lamotrigine,<xref ref-type="ref" rid="bdi12609-bib-0684">684</xref> and divalproex monotherapy or add‐on.<xref ref-type="ref" rid="bdi12609-bib-0685">685</xref>, <xref ref-type="ref" rid="bdi12609-bib-0686">686</xref>, <xref ref-type="ref" rid="bdi12609-bib-0687">687</xref> While lithium may also show some benefits (level 3),<xref ref-type="ref" rid="bdi12609-bib-0617">617</xref> it has to be used with caution in heavy drinkers because of potential electrolyte imbalance; and anticonvulsants warrant liver function tests and lipase levels before initiating treatment. Agents for primary alcohol use disorder may also show benefits in BD, such as disulfiram (level 3),<xref ref-type="ref" rid="bdi12609-bib-0688">688</xref>, <xref ref-type="ref" rid="bdi12609-bib-0689">689</xref>, <xref ref-type="ref" rid="bdi12609-bib-0690">690</xref>, <xref ref-type="ref" rid="bdi12609-bib-0691">691</xref> naltrexone (level 3)<xref ref-type="ref" rid="bdi12609-bib-0692">692</xref>, <xref ref-type="ref" rid="bdi12609-bib-0693">693</xref>, <xref ref-type="ref" rid="bdi12609-bib-0694">694</xref>, <xref ref-type="ref" rid="bdi12609-bib-0695">695</xref> and gabapentin (level 4).<xref ref-type="ref" rid="bdi12609-bib-0696">696</xref>, <xref ref-type="ref" rid="bdi12609-bib-0697">697</xref> Furthermore, guidelines for pharmacotherapy in alcohol dependence alone can offer some guidance in the absence of comorbidity‐specific trials.<xref ref-type="ref" rid="bdi12609-bib-0698">698</xref>
</p>
<p>Quetiapine is not recommended for the treatment of alcohol use disorder comorbid to BD because of lack of efficacy. Quetiapine add‐on therapy was not more effective than placebo add‐on in reducing the number of drinks per day or other alcohol‐related measures in patients with BDI<xref ref-type="ref" rid="bdi12609-bib-0699">699</xref> or BDI and BDII with alcohol dependence (level 1 negative).<xref ref-type="ref" rid="bdi12609-bib-0700">700</xref> In another RCT, quetiapine monotherapy or add‐on therapy to mood stabilizers was compared with placebo monotherapy or add‐on therapy in patients with bipolar depression with comorbid anxiety and substance use disorders.<xref ref-type="ref" rid="bdi12609-bib-0701">701</xref> No significant improvement was found in depressive or anxiety symptoms but alcohol or substance use‐related outcomes were not reported separately.</p>
<p>No specific recommendations are given regarding acamprosate at this time. In a smaller RCT, acamprosate add‐on was ineffective in improving drinking‐related outcomes in BDI/BDII patients with alcohol dependence (level 3 negative)<xref ref-type="ref" rid="bdi12609-bib-0702">702</xref> but a post hoc analysis showed a small decrease of the Clinical Global Impression scores for substance use severity towards the end of the trial. Further studies are needed.</p>
</sec>
<sec id="bdi12609-sec-0136">
<title>Cannabis use disorder</title>
<p>About 20% of patients with BD have cannabis use disorder at some point in their life.<xref ref-type="ref" rid="bdi12609-bib-0675">675</xref> Cannabis use disorder is associated with younger age, manic/mixed episode polarity, presence of psychotic features, and comorbid nicotine dependence, alcohol use disorder, and other SUDs.<xref ref-type="ref" rid="bdi12609-bib-0703">703</xref> Cannabis use is also associated with more time in affective episodes and rapid cycling.<xref ref-type="ref" rid="bdi12609-bib-0704">704</xref>
</p>
<p>There is limited research into treatment options for this frequent SUD. Lithium and/or divalproex have level 3 evidence.<xref ref-type="ref" rid="bdi12609-bib-0617">617</xref>, <xref ref-type="ref" rid="bdi12609-bib-0682">682</xref>, <xref ref-type="ref" rid="bdi12609-bib-0685">685</xref>, <xref ref-type="ref" rid="bdi12609-bib-0686">686</xref>, <xref ref-type="ref" rid="bdi12609-bib-0687">687</xref> Quetiapine failed to provide any benefit in terms of mood and anxiety symptoms in a small subsample of highly comorbid patients with BD. generalized anxiety disorder (GAD) and cannabis use disorder<xref ref-type="ref" rid="bdi12609-bib-0701">701</xref> (level 3 negative). The effect of quetiapine on specific cannabis use‐related outcomes was not reported.</p>
</sec>
<sec id="bdi12609-sec-0137">
<title>Stimulants: cocaine, amphetamine, and methamphetamine use disorders</title>
<p>Citicoline adjunctive therapy had a positive outcome in two RCTs in patients with BD with comorbid cocaine use disorder, although the benefits of citicoline decreased over time in the more recent study (level 2).<xref ref-type="ref" rid="bdi12609-bib-0705">705</xref>, <xref ref-type="ref" rid="bdi12609-bib-0706">706</xref>
</p>
<p>Lithium or divalproex, either alone or in combination, were proven useful in small studies addressing cocaine use disorder<xref ref-type="ref" rid="bdi12609-bib-0682">682</xref>, <xref ref-type="ref" rid="bdi12609-bib-0685">685</xref>, <xref ref-type="ref" rid="bdi12609-bib-0686">686</xref>, <xref ref-type="ref" rid="bdi12609-bib-0687">687</xref>, <xref ref-type="ref" rid="bdi12609-bib-0707">707</xref>, <xref ref-type="ref" rid="bdi12609-bib-0708">708</xref> (level 4). Quetiapine in monotherapy or in combination with the ongoing treatment shows evidence of efficacy for cocaine, amphetamine and methamphetamine use disorder<xref ref-type="ref" rid="bdi12609-bib-0709">709</xref>, <xref ref-type="ref" rid="bdi12609-bib-0710">710</xref>, <xref ref-type="ref" rid="bdi12609-bib-0711">711</xref> (level 3). Risperidone has been studied alone and as an add‐on agent for cocaine and for methamphetamine use disorders with level 3 evidence for efficacy.<xref ref-type="ref" rid="bdi12609-bib-0711">711</xref>, <xref ref-type="ref" rid="bdi12609-bib-0712">712</xref>
</p>
<p>Bupropion has anecdotal reports favouring efficacy in cocaine use disorders (level 4).<xref ref-type="ref" rid="bdi12609-bib-0713">713</xref> Citicoline improved depressive symptoms in patients with methamphetamine use disorder and bipolar depression.<xref ref-type="ref" rid="bdi12609-bib-0714">714</xref>
</p>
<p>Lamotrigine has been studied in a 10‐week RCT of lamotrigine vs placebo added to ongoing medication. While results were negative for the <italic>a priori</italic> outcome variable (positive urine drug screens), they were positive on the secondary outcome of the amount of dollars spent per week on cocaine purchases (level 2 negative).<xref ref-type="ref" rid="bdi12609-bib-0715">715</xref>
</p>
</sec>
<sec id="bdi12609-sec-0138">
<title>Opioid use disorder</title>
<p>While methadone has the most evidence of efficacy in comorbid BD and opioid use disorder (level 3),<xref ref-type="ref" rid="bdi12609-bib-0716">716</xref>, <xref ref-type="ref" rid="bdi12609-bib-0717">717</xref> because of the lack of research in this area and increasing concern related to risk of overdose, clinicians should consult the Canadian Research Initiative in Substance Misuse (CRISM) national treatment guidelines on primary opioid use disorder when available (anticipated 2018) for further advice on managing opioid use disorders in their patients.</p>
</sec>
<sec id="bdi12609-sec-0139">
<title>Others</title>
<p>Olanzapine add‐on therapy was effective in decreasing manic symptoms and measures of substance use such as reduction in cravings in hospitalized inpatients (level 2).<xref ref-type="ref" rid="bdi12609-bib-0718">718</xref> Aripiprazole has level 4 evidence to decrease craving of alcohol, but not consumption, and level 4 evidence to decrease cocaine use in polysubstance users.<xref ref-type="ref" rid="bdi12609-bib-0719">719</xref>
</p>
</sec>
<sec id="bdi12609-sec-0140">
<title>Anxiety disorders</title>
<p>Patients with BD frequently experience symptoms of anxiety and comorbid anxiety disorders (GAD, panic disorder, post‐traumatic stress disorder and others). Clinical samples indicate that 24%‐56% of patients with BD meet criteria for one or more anxiety disorders, with the highest rates in women.<xref ref-type="ref" rid="bdi12609-bib-0720">720</xref> Comorbid anxiety symptoms and anxiety disorders are associated with a higher number of mood episodes and depressive symptoms, including suicidality and sleep disturbance, and greater impairment of psychosocial functioning and quality of life.<xref ref-type="ref" rid="bdi12609-bib-0721">721</xref> The presence of a comorbid anxiety disorder is also associated with high rates of use of antidepressants,<xref ref-type="ref" rid="bdi12609-bib-0722">722</xref> which should be employed with caution due to their potential for mood destabilization (Section 4).</p>
<p>While the CANMAT Task Force report<xref ref-type="ref" rid="bdi12609-bib-0720">720</xref> described key studies and treatment recommendations in length, those recommendations have been updated below. However, it remains the case that there are few studies that have focused exclusively on anxiety symptoms or disorders comorbid with BD, whether for treatment efficacy or safety. While there are treatment options, the limitations resulting from a paucity of data prevent the development of clear guidelines or treatment algorithms.</p>
<p>A “step‐wise” approach was recommended in the 2012 CANMAT recommendations for managing comorbid anxiety. In general, mood stabilization is the priority before specific anxiety treatments are considered (Figure <xref ref-type="fig" rid="bdi12609-fig-0009">9</xref>). Despite clinical experience, antidepressants, particularly serotoninergic agents, should be employed with caution due to their potential to provoke mood destabilization. While benzodiazepines are an important clinical tool because they can rapidly alleviate anxiety, clinicians should strive to prescribe them at the lowest possible dose for the shortest period possible, given the concerns about suicide risk, abuse and dependence. CBT continues to be an appropriate first‐line treatment for anxiety.</p>
<fig fig-type="Figure" id="bdi12609-fig-0009" orientation="portrait" position="float" xml:lang="en">
<label>Figure 9</label>
<caption>
<p>What is the role of primary treatments for anxiety disorders in treating co‐morbid anxiety in bipolar disorder? RCT, randomized controlled trial [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com">http://wileyonlinelibrary.com</ext-link>]</p>
</caption>
<graphic id="nlm-graphic-23" xlink:href="BDI-20-97-g009"></graphic>
</fig>
</sec>
<sec id="bdi12609-sec-0141">
<title>Generalized anxiety disorder and panic disorder</title>
<p>Quetiapine was superior to placebo and divalproex in improving anxiety symptoms in patients with comorbid GAD and/or panic disorder (level 2).<xref ref-type="ref" rid="bdi12609-bib-0724">724</xref> Further, secondary analyses from several RCTs indicate that quetiapine monotherapy significantly reduces symptoms of GAD and panic disorder in patients with bipolar depression.<xref ref-type="ref" rid="bdi12609-bib-0290">290</xref>, <xref ref-type="ref" rid="bdi12609-bib-0313">313</xref>, <xref ref-type="ref" rid="bdi12609-bib-0725">725</xref> Negative trials include risperidone versus placebo in patients with BD and comorbid GAD and/or panic disorder<xref ref-type="ref" rid="bdi12609-bib-0726">726</xref> and ziprasidone versus placebo in a similar trial.<xref ref-type="ref" rid="bdi12609-bib-0727">727</xref>
</p>
<p>For patients who are euthymic and treated with lithium, the addition of lamotrigine or olanzapine has demonstrated similar anxiolytic effects (level 3).<xref ref-type="ref" rid="bdi12609-bib-0728">728</xref> In a secondary post hoc analysis, combinations of olanzapine and fluoxetine (level 3), and to a lesser extent olanzapine monotherapy, were effective in reducing anxiety in patients with bipolar depression.<xref ref-type="ref" rid="bdi12609-bib-0314">314</xref>
</p>
<p>Gabapentin employed as an adjunctive therapy in open‐label studies reduced anxiety symptoms in patients with BD (level 4).<xref ref-type="ref" rid="bdi12609-bib-0696">696</xref>, <xref ref-type="ref" rid="bdi12609-bib-0729">729</xref> Given its relatively benign side effect profile and efficacy in other primary anxiety disorders, gabapentin is an appropriate strategy.</p>
</sec>
<sec id="bdi12609-sec-0142">
<title>Obsessive compulsive disorder</title>
<p>Obsessive compulsive disorder was re‐categorized in DSM‐5 and is no longer characterized as an anxiety disorder; however, anxiety is a cardinal feature. OCD is a comorbid condition in 10%‐20% of patients with BD<xref ref-type="ref" rid="bdi12609-bib-0730">730</xref>, <xref ref-type="ref" rid="bdi12609-bib-0731">731</xref>, <xref ref-type="ref" rid="bdi12609-bib-0732">732</xref>, <xref ref-type="ref" rid="bdi12609-bib-0733">733</xref> compared with 2%‐3% in the general population.<xref ref-type="ref" rid="bdi12609-bib-0734">734</xref> However, the prevalence appears to vary widely, depending on the clinical setting and bipolar subtype.<xref ref-type="ref" rid="bdi12609-bib-0731">731</xref> Comorbid OCD may be more common in children and adolescents with BD than in adults<xref ref-type="ref" rid="bdi12609-bib-0731">731</xref> and has been reported to co‐occur more commonly with BD than other anxiety disorders,<xref ref-type="ref" rid="bdi12609-bib-0735">735</xref> although other studies have not found that association.<xref ref-type="ref" rid="bdi12609-bib-0736">736</xref>
</p>
<p>When diagnosed comorbidly with BD, OCD has been associated with an earlier onset of BD, a higher number of previous mood episodes, rapid cycling, seasonality, substance misuse, and lower overall functioning.<xref ref-type="ref" rid="bdi12609-bib-0732">732</xref>, <xref ref-type="ref" rid="bdi12609-bib-0737">737</xref>, <xref ref-type="ref" rid="bdi12609-bib-0738">738</xref>, <xref ref-type="ref" rid="bdi12609-bib-0739">739</xref>, <xref ref-type="ref" rid="bdi12609-bib-0740">740</xref>, <xref ref-type="ref" rid="bdi12609-bib-0741">741</xref>, <xref ref-type="ref" rid="bdi12609-bib-0742">742</xref> Jeon et al recently conducted a comprehensive review of patients diagnosed with BD and comorbid OCD and found twice the rate of pharmacological switch to mania or hypomania, but suggested this could be due to the more frequent use of antidepressants in that population.<xref ref-type="ref" rid="bdi12609-bib-0732">732</xref> Other authors have raised similar concerns.<xref ref-type="ref" rid="bdi12609-bib-0743">743</xref>
</p>
<p>Symptoms of OCD may precede or follow mood symptoms and the severity of OCD symptoms tends to fluctuate with mood changes.<xref ref-type="ref" rid="bdi12609-bib-0744">744</xref> The high rate of co‐occurrence and the many shared clinical features of OCD and BD suggest a shared neurobiology. Some researchers have posited that the high rate of co‐occurrence might reflect a distinct bipolar phenotype rather than separate disorders.<xref ref-type="ref" rid="bdi12609-bib-0736">736</xref>, <xref ref-type="ref" rid="bdi12609-bib-0745">745</xref>
</p>
<p>OCD symptoms may remit during effective treatment of BD; mood stabilizers alone or with atypical antipsychotics may be adequate to resolve comorbid symptoms of OCD and antidepressants might not be necessary for the majority of patients.<xref ref-type="ref" rid="bdi12609-bib-0730">730</xref>, <xref ref-type="ref" rid="bdi12609-bib-0736">736</xref> If antidepressants are used, clinical experience suggests that SSRIs are preferred, but because of the potential risk of manic switch clinicians need to optimize prophylactic antimanic agents before initiation. The CANMAT Task Force 2012 report included several small case reports indicating the potential benefit of lithium,<xref ref-type="ref" rid="bdi12609-bib-0743">743</xref> anticonvulsants,<xref ref-type="ref" rid="bdi12609-bib-0743">743</xref>, <xref ref-type="ref" rid="bdi12609-bib-0746">746</xref> olanzapine,<xref ref-type="ref" rid="bdi12609-bib-0747">747</xref>, <xref ref-type="ref" rid="bdi12609-bib-0748">748</xref> risperidone,<xref ref-type="ref" rid="bdi12609-bib-0749">749</xref>, <xref ref-type="ref" rid="bdi12609-bib-0750">750</xref> quetiapine<xref ref-type="ref" rid="bdi12609-bib-0751">751</xref> and aripiprazole <xref ref-type="ref" rid="bdi12609-bib-0752">752</xref> for the treatment of comorbid OCD (all level 4 evidence).</p>
<p>Since the 2012 CANMAT publication, there has been very limited new evidence regarding the treatment of comorbid BD and OCD. Two published case reports described successfully employing aripiprazole once monthly<xref ref-type="ref" rid="bdi12609-bib-0753">753</xref> and orally<xref ref-type="ref" rid="bdi12609-bib-0754">754</xref> for patients with intractable bipolar and OCD symptoms. Another case report described benefits of ECT,<xref ref-type="ref" rid="bdi12609-bib-0755">755</xref> and a small trial also found benefits with adjunctive topiramate (level 3).<xref ref-type="ref" rid="bdi12609-bib-0756">756</xref>
</p>
</sec>
<sec id="bdi12609-sec-0143">
<title>Personality disorders</title>
<p>A meta‐analysis indicates that 42% of patients with BD also have a comorbid personality disorder, and this feature can be both a diagnostic confound and predictor of poorer treatment response. The most prevalent was obsessive compulsive personality disorder (18%), followed by borderline (16%), avoidant (12%) paranoid (11%), and histrionic (10%) personality disorders.<xref ref-type="ref" rid="bdi12609-bib-0757">757</xref> Despite the high prevalence of these comorbidities, research assessing the effectiveness of treatments is sparse. The CANMAT Task Force recommendations describe key issues in the management of personality disorders, including the relationship between personality and mood disorders, accurate diagnosis, and the effect on treatment response and clinical course.<xref ref-type="ref" rid="bdi12609-bib-0758">758</xref>
</p>
<p>The 2012 CANMAT Task Force recommendations for comorbid personality disorder concluded that divalproex (level 3)<xref ref-type="ref" rid="bdi12609-bib-0466">466</xref> and lamotrigine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0759">759</xref> may provide some symptomatic relief for comorbid borderline personality disorder. Psychoeducation might be of value, as one small RCT that included patients with any comorbid personality disorder (level 3)<xref ref-type="ref" rid="bdi12609-bib-0760">760</xref> demonstrated. That study, along with another small trial that combined psychoeducation and skills training for patients with a mood disorder plus a personality disorder and suicidal ideation (level 3),<xref ref-type="ref" rid="bdi12609-bib-0761">761</xref> showed a modest long‐term benefit. Larger, more specific studies are needed. There are also data to support the utility of DBT for the treatment of BD, which has robust data for efficacy in the treatment of borderline personality disorder.<xref ref-type="ref" rid="bdi12609-bib-0075">75</xref>, <xref ref-type="ref" rid="bdi12609-bib-0762">762</xref>, <xref ref-type="ref" rid="bdi12609-bib-0763">763</xref>
</p>
<p>Since those CANMAT recommendations were published in 2012, few new studies have significantly contributed to our understanding of the appropriate treatment of these highly comorbid disorders. Alesiani and colleagues assessed the value of the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program for 32 subjects with personality disorder and mood disorder (half MDD and half BD, mostly BDII), and a history of suicide attempts or self‐harm and emotional and behavioural dysregulation. Although results are preliminary due to small sample size and high drop‐out rate, findings suggest that such group treatment may improve symptoms, as well as reduce suicide attempts and hospitalizations.<xref ref-type="ref" rid="bdi12609-bib-0761">761</xref>
</p>
</sec>
<sec id="bdi12609-sec-0144">
<label>7.4.1.2</label>
<title>ADHD</title>
<p>ADHD and BD co‐occur far more commonly than would be expected based on their individual prevalences in the general population. Approximately 10%‐20% of patients with BD meet the criteria for adult ADHD and up to 20% of adults with ADHD also meet the criteria for BD.<xref ref-type="ref" rid="bdi12609-bib-0764">764</xref> BD and ADHD have a high degree of symptom overlap, making the comorbid diagnosis difficult and requiring careful attention to childhood history and lifetime course of illness. Patients with comorbid ADHD often experience a more treatment‐refractory course, more mood episodes, greater functional impairment and a heightened risk of suicide.<xref ref-type="ref" rid="bdi12609-bib-0765">765</xref>
</p>
<p>The treatment of ADHD presenting comorbidity with BD is discussed in detail in a previous CANMAT Task Force Recommendation paper.<xref ref-type="ref" rid="bdi12609-bib-0765">765</xref> Recommendations were to treat bipolar symptoms first with mood stabilizers and/or atypical antipsychotics to stabilize mood before considering treatment for ADHD symptoms. Mixed amphetamine salts (level 3),<xref ref-type="ref" rid="bdi12609-bib-0611">611</xref> methylphenidate (level 3),<xref ref-type="ref" rid="bdi12609-bib-0612">612</xref> atomoxetine (level 4),<xref ref-type="ref" rid="bdi12609-bib-0615">615</xref> bupropion (level 4),<xref ref-type="ref" rid="bdi12609-bib-0766">766</xref> or lisdexamfetamine (level 4)<xref ref-type="ref" rid="bdi12609-bib-0767">767</xref> add‐ons to mood‐stabilizing treatments have been reported to be efficacious in improving ADHD symptoms.</p>
<p>In a s Swedish national patient registry study of patients with BD and ADHD, methylphenidate monotherapy significantly increased the risk of mania, while those patients treated concurrently with a mood stabilizer experienced a significantly reduced risk of mania when methylphenidate was employed.<xref ref-type="ref" rid="bdi12609-bib-0289">289</xref>
</p>
</sec>
</sec>
<sec id="bdi12609-sec-0145">
<label>7.4.2</label>
<title>Comorbid metabolic disorders</title>
<sec id="bdi12609-sec-0146">
<label>7.4.2.1</label>
<title>Epidemiology</title>
<p>While there is consistent evidence showing the high prevalence of comorbid medical conditions in BD<xref ref-type="ref" rid="bdi12609-bib-0768">768</xref>, <xref ref-type="ref" rid="bdi12609-bib-0769">769</xref>, <xref ref-type="ref" rid="bdi12609-bib-0770">770</xref>, <xref ref-type="ref" rid="bdi12609-bib-0771">771</xref>, <xref ref-type="ref" rid="bdi12609-bib-0772">772</xref>, <xref ref-type="ref" rid="bdi12609-bib-0773">773</xref>, <xref ref-type="ref" rid="bdi12609-bib-0774">774</xref> and the negative impact these diagnoses have on longevity,<xref ref-type="ref" rid="bdi12609-bib-0775">775</xref>, <xref ref-type="ref" rid="bdi12609-bib-0776">776</xref> these conditions frequently go undiagnosed or undertreated. In a large UK cross‐sectional analysis of electronic data sets involving 1.7 million patients in primary care, those diagnosed with BD, when compared with healthy controls, had lower rates of diagnoses (odds ratio [OR] 0.59, 95% confidence interval [CI] 0.54‐0.63) and treatment of medical conditions, despite higher rates of one (OR 1.2, 95% CI 1.16‐1.39) or multiple illnesses (OR 1.44, 95% CI 1.3‐1.64).<xref ref-type="ref" rid="bdi12609-bib-0769">769</xref>
</p>
<p>Metabolic syndrome in particular is a highly prevalent comorbidity, present in 20‐65% of patients with BD.<xref ref-type="ref" rid="bdi12609-bib-0777">777</xref> Defined as a cluster of clinical and biochemical features, including abdominal adiposity, hypertension, impaired fasting glucose, diabetes mellitus, and atherogenic dyslipidaemia,<xref ref-type="ref" rid="bdi12609-bib-0778">778</xref> metabolic syndrome not only greatly increases an individual's risk for cardiovascular disease, diabetes mellitus, and premature mortality<xref ref-type="ref" rid="bdi12609-bib-0779">779</xref> but also worsens bipolar clinical outcomes.<xref ref-type="ref" rid="bdi12609-bib-0780">780</xref>, <xref ref-type="ref" rid="bdi12609-bib-0781">781</xref> Increased body mass index (BMI) is an important contributor to metabolic syndrome, although metabolic dysfunction is not always accompanied by overweight/obesity, and so patients with normal BMI should also receive regular monitoring (Section 8).</p>
<p>It has been hypothesized that BD and metabolic syndrome share a set of common risk factors and overlapping pathophysiology.<xref ref-type="ref" rid="bdi12609-bib-0782">782</xref>, <xref ref-type="ref" rid="bdi12609-bib-0783">783</xref>, <xref ref-type="ref" rid="bdi12609-bib-0784">784</xref> While medications used to treat BD, particularly atypical antipsychotics, can also lead to metabolic dysfunction and weight problems (Section 8), insufficient access to primary and preventative health care, low socioeconomic status, habitual inactivity, insulin dysfunction, peripheral inflammation and neuroinflammation, oxidative stress, and childhood adversity are also important contributors.<xref ref-type="ref" rid="bdi12609-bib-0785">785</xref>
</p>
</sec>
<sec id="bdi12609-sec-0147">
<title>Principles of management</title>
<p>As noted in previously in these guidelines, older adults commonly have three or more medical comorbidities that contribute to the 10‐15 year lower life expectancy compared to non‐psychiatric populations.<xref ref-type="ref" rid="bdi12609-bib-0642">642</xref> The most common medical comorbidities are metabolic syndrome, hypertension, diabetes, cardiovascular disease, arthritis, and endocrine disorders.<xref ref-type="ref" rid="bdi12609-bib-0631">631</xref>, <xref ref-type="ref" rid="bdi12609-bib-0641">641</xref> This highlights the necessity for vigilance when treating all patients with BD, including regular assessments of their metabolic parameters.</p>
<p>Working collaboratively with other members of a patient's health care team is as essential aspect of good clinical care. Comprehensive management of comorbid medical conditions should include a multidisciplinary team‐based approach, including primary care, medical specialists, nurses, psychologists, and social workers as appropriate, with patients taking an active role in their care. Treatment strategies should focus both on the psychiatric symptoms and medical issues and risk factors.</p>
<p>A promising strategy for improving the medical care of people with BD is through “primary care‐based medical homes” where those with a serious mental illness and at least one other chronic condition receive integrated care. While most studies do not separate BD from other major mental illnesses in analyses, matched samples in the North Carolina Medical Homes programme indicate that patients with BD (n = 13 406) in primary care medical homes had greater use of primary care and specialty mental health care compared with propensity‐matched controls, and marginally lower use of emergency services. However, of three diagnostic groups studied (depression, schizophrenia and BD), use of preventative services such as lipid screening and cancer screening was only greater in the subgroup with depression.<xref ref-type="ref" rid="bdi12609-bib-0786">786</xref> At the same time, a cross‐sectional Canadian study examining patient‐centred medical homes in naturalistic practice found that, where rostering was elective, individuals with BD and psychosis were differentially excluded (relative risk [RR] 0.92, 95% CI 0.90‐0.93),<xref ref-type="ref" rid="bdi12609-bib-0787">787</xref> suggesting that concentrated efforts should be made to ensure appropriate access to these services.</p>
</sec>
<sec id="bdi12609-sec-0148">
<title>Treatment recommendations</title>
<p>Treatment strategies that target metabolic disorders should include non‐pharmacological lifestyle interventions. Replacing “high metabolic risk” psychiatric medications with medications that have a more favourable profile is highly recommended if the therapeutic advantage of the high‐risk agent over the alternative is minimal and metabolic/weight issues persist. Bariatric surgery should be considered following unsuccessful attempts at the aforementioned strategies if the individual has a BMI ≥27 with weight‐related morbidity or a BMI ≥30 without significant metabolic morbidity. Readers are referred to the CANMAT Task Force report<xref ref-type="ref" rid="bdi12609-bib-0785">785</xref> for further detailed discussion on foundational principles for managing metabolic conditions in patients with BD.</p>
<p>While there is no evidence specifically regarding treatment of comorbid dyslipidaemia or hypertension in BD, it is noteworthy that many of the medications used to manage these comorbid medical disorders have epidemiological or even clinical trial evidence that they may benefit mood. Examples include statins, aspirin and angiotensin antagonists.<xref ref-type="ref" rid="bdi12609-bib-0788">788</xref>, <xref ref-type="ref" rid="bdi12609-bib-0789">789</xref>, <xref ref-type="ref" rid="bdi12609-bib-0790">790</xref>, <xref ref-type="ref" rid="bdi12609-bib-0791">791</xref>, <xref ref-type="ref" rid="bdi12609-bib-0792">792</xref>, <xref ref-type="ref" rid="bdi12609-bib-0793">793</xref> The implications are that clinicians should be actively engaged in the management of these disorders, and should select therapies from those agents that may have benefit in mood symptoms. This again is concordant with the notion of shared risk pathways for these non‐communicable disorders.</p>
</sec>
</sec>
<sec id="bdi12609-sec-0149">
<label>7.4.3</label>
<title>Other comorbid medical conditions</title>
<p>Two studies from a random sample of 1 million people, taken from a large population‐based retrospective cohort in Taiwan, demonstrated a reduced risk of both stroke and cancer associated with lithium treatment for BD. The lithium group was compared with propensity‐matched controls.</p>
<p>The first study reported hazard ratio for stroke over 11 years of 0.39 (95% CI 0.22‐0.68) for those prescribed lithium, even when adjusting for the risks associated with typical and atypical antipsychotics. The reduced risk was also correlated with a higher dose, longer treatment duration and a higher rate of exposure to lithium.<xref ref-type="ref" rid="bdi12609-bib-0794">794</xref> In the second study, in a sample of 4729 patients diagnosed with BD, lithium exposure was associated with a reduced risk of cancer, compared to a group prescribed anticonvulsant medications. (Lithium with or without anticonvulsant HR = 0.735, 95% CI 0.55‐0.97). The study also demonstrated a dose‐response relationship.<xref ref-type="ref" rid="bdi12609-bib-0795">795</xref> In a subsequent large BD cohort study (n = 9651) focusing on genitourinary cancer, however, lithium was not associated with any change in risk.<xref ref-type="ref" rid="bdi12609-bib-0796">796</xref>
</p>
<p>A recent meta‐analysis suggests increased risk of dementia in BD.<xref ref-type="ref" rid="bdi12609-bib-0797">797</xref> There is some evidence that lithium in drinking water reduces the risk of dementia in the general population<xref ref-type="ref" rid="bdi12609-bib-0638">638</xref> as does the use of lithium in patients with BD.<xref ref-type="ref" rid="bdi12609-bib-0798">798</xref>
</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0150">
<label>8</label>
<title>SAFETY AND MONITORING</title>
<sec id="bdi12609-sec-0151">
<label>8.1</label>
<title>Medical evaluation and laboratory investigations</title>
<p>A complete medical history including assessment of BMI and baseline laboratory investigations (Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0023">23</xref>) should be performed prior to initiating pharmacological treatment for BD or, in the case of an acute clinical situation, as soon as the patient is cooperative. For more detail, readers are referred to comprehensive guidelines for safety monitoring in BD.<xref ref-type="ref" rid="bdi12609-bib-0652">652</xref> In women of childbearing age, pregnancy should be ruled out, and they should be counselled about the possibility of lamotrigine and carbamazepine affecting the efficacy of oral contraceptives before initiating pharmacotherapy.</p>
<table-wrap id="bdi12609-tbl-0023" orientation="portrait" position="float" xml:lang="en">
<label>Table 23</label>
<caption>
<p>Baseline laboratory investigations in patients with bipolar disorder</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">CBC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fasting glucose</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fasting lipid profile (TC, vLDL, LDL, HDL, TG)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Platelets</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Electrolytes and calcium</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Liver enzymes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Serum bilirubin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prothrombin time and partial thromboplastin time</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urinalysis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urine toxicology for substance use</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Serum creatinine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">eGFR</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">24h creatinine clearance (if history of renal disease)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Thyroid‐stimulating hormone</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Electrocardiogram (&gt;40 years or if indicated)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pregnancy test (if relevant)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Prolactin</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0048">
<p>CBC, complete blood count; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; TC, total cholesterol; TG, triglyceride; vLDL, very low density lipoprotein (Adapted from Yatham et al. 2006<xref ref-type="ref" rid="bdi12609-bib-0002">2</xref>).</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>For those on maintenance therapy with lithium, thyroid and renal function as well as plasma calcium<xref ref-type="ref" rid="bdi12609-bib-0799">799</xref> should be assessed at 6 months and at least annually thereafter or as clinically indicated. Menstrual history (to assess for polycystic ovary syndrome), haematology profile, and liver function tests should be obtained at 3‐6 month intervals during the first year, and yearly thereafter and as clinically indicated, in patients on maintenance treatment with divalproex. Patients initiated on lamotrigine or carbamazepine should be routinely educated about the risks of skin rashes and the potential for Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). They should be advised to contact the treating physician if they observe any type of skin rashes or mucosal ulcers as they require urgent medical evaluation to determine the nature of rashes/ulcers and implementation of most appropriate treatment options which might include discontinuation of these medications and instituting other therapeutic strategies to treat serious rashes and prevent destabilization of BD. Further, prior to commencing carbamazepine, patients with ancestry in genetically at‐risk populations such as Han Chinese and other Asian patients should have genotyping performed to ensure that they do not have the human leucocyte antigen (HLA)‐B*1502 allele, which confers a high risk for SJS/TEN with carbamazepine.<xref ref-type="ref" rid="bdi12609-bib-0800">800</xref> In addition, those on carbamazepine therapy should have serum sodium levels measured at least annually and as clinically indicated given the risk of hyponatraemia with this compound. Patients on atypical antipsychotics should have their weight monitored monthly in the first 3 months and every 3 months thereafter. Blood pressure, fasting glucose and lipid profile should be assessed at 3 and 6 months, and yearly thereafter. Children under 10 years of age, seniors, medically ill patients, and patients on combination treatments should receive more frequent monitoring. Re‐emergence of clinical symptoms, as well as signs of haematological, hepatic, cardiovascular, and neurological dysfunction, should also signal the need for additional investigations.</p>
<p>Patients receiving treatment should be regularly monitored for side effects, including weight changes and other adverse events such as extrapyramidal symptoms (EPS).</p>
</sec>
<sec id="bdi12609-sec-0152">
<label>8.2</label>
<title>Monitoring medication serum levels</title>
<p>Patients on lithium, divalproex, or carbamazepine need to have their serum medication levels monitored regularly. This is particularly important for those who may be non‐adherent to treatment. Measurement of serum levels should be repeated at the trough point, which is approximately 12 h after the last dose. It is recommended that two consecutive serum levels be established in the therapeutic range during the acute phase for lithium and divalproex, and then measurement be repeated every 3‐6 months or more frequently if clinically indicated. For carbamazepine, serum level monitoring is mainly done to ensure that the levels are not in the toxic range and to check for treatment adherence as there is no established relationship between efficacy and serum level; thus, monitoring for serum carbamazepine levels may be done at 6‐12 monthly intervals and as clinically indicated.</p>
<p>The target serum level for lithium in acute treatment is 0.8‐1.2 mEq/L (0.4‐0.8 mEq/L in older adults) while in maintenance treatment, serum levels of 0.6‐1 mEq/L may be sufficient<xref ref-type="ref" rid="bdi12609-bib-0801">801</xref>, <xref ref-type="ref" rid="bdi12609-bib-0802">802</xref>; serum levels should be obtained about 5 days after the most recent dose titration. Clinicians may wish to consult the “lithiumeter” schematic for further guidance.<xref ref-type="ref" rid="bdi12609-bib-0803">803</xref> It is important to avoid toxic levels as these are associated with an increased risk of kidney damage in the long term.<xref ref-type="ref" rid="bdi12609-bib-0804">804</xref> The target serum level for divalproex is 350‐700 mM/L (50‐100 ug/mL) in the acute phase and should be obtained 3‐5 days after the most recent dose titration. There is some evidence for a linear relationship between serum divalproex level and therapeutic efficacy in acute mania, with higher levels associated with greater efficacy.<xref ref-type="ref" rid="bdi12609-bib-0805">805</xref> It is currently unknown what levels of divalproex offer optimum efficacy in maintenance treatment as no study to date has systematically assessed the relationship between serum divalproex level and the maintenance efficacy. Therefore, clinician are advised to maintain serum divalproex levels within the accepted laboratory range values during maintenance treatment and carefully monitor patients for emerging mood symptoms and tolerability and adjust the dose of divalproex as needed in order to achieve optimum efficacy and tolerability.</p>
<p>Patients who are treated with concurrent carbamazepine or other hepatic enzyme‐inducing agents should have serum levels of all psychotropic medications monitored, particularly in cases of inadequate response or non‐response, to determine whether efficacy has been compromised because of reduced serum levels.</p>
</sec>
<sec id="bdi12609-sec-0153">
<label>8.3</label>
<title>Safety and tolerability of pharmacotherapy</title>
<p>Safety and tolerability issues, in addition to efficacy data, have been considered when determining recommendations for each phase of illness. The most notable concerns are described below and a summary of their potential impact on treatment selection is included in Table <xref ref-type="table-wrap" rid="bdi12609-tbl-0024">24</xref>, as well as in treatment hierarchy tables in Sections 2‐4. As medication side effects are an important contributor to medication non‐adherence, these potential concerns should be discussed with patients receiving or considering treatment with various agents to help inform decision making.</p>
<table-wrap id="bdi12609-tbl-0024" orientation="portrait" position="float" xml:lang="en">
<label>Table 24</label>
<caption>
<p>Safety/tolerability concerns and risks of treatment‐emergent switch with pharmacological agents indicated for use in bipolar disorder</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top"></th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Safety concerns</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Tolerability concerns</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Risk of treatment emergent switch</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Acute</th>
<th align="left" colspan="1" rowspan="1" valign="top">Maintenance</th>
<th align="left" colspan="1" rowspan="1" valign="top">Acute</th>
<th align="left" colspan="1" rowspan="1" valign="top">Maintenance</th>
<th align="left" colspan="1" rowspan="1" valign="top">Mania/hypomania</th>
<th align="left" colspan="1" rowspan="1" valign="top">Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Lithium</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Carbamazepine</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++<xref ref-type="fn" rid="bdi12609-note-0051">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Divalproex</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++<xref ref-type="fn" rid="bdi12609-note-0051">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Gabapentin</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Oxcarbazepine</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Atypical antipsychotics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Asenapine</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Cariprazine</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Clozapine</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Lurasidone</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Olanzapine</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Paliperidone</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Quetiapine</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Risperidone</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Ziprasidone</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Conventional antipsychotics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Haloperidol</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Loxapine</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">nk</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Antidepressants (adjunctive<xref ref-type="fn" rid="bdi12609-note-0052">b</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Agomelatine</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Bupropion</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Ketamine IV</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">nk</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">nk</td>
<td align="left" colspan="1" rowspan="1">nk</td>
<td align="left" colspan="1" rowspan="1">nk</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">MAOIs</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">SNRIs</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">SSRIs</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">TCAs</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Stimulants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Amphetamines</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+++</td>
<td align="left" colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Modafinil</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">nk</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1">Dopamine agonists</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Pramipexole</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">−</td>
<td align="left" colspan="1" rowspan="1">++</td>
<td align="left" colspan="1" rowspan="1">nk</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="bdi12609-note-0049">
<p>MAOIs, monoamine oxidase inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.</p>
</fn>
<fn id="bdi12609-note-0050">
<p>−, limited impact on treatment selection; +, minor impact on treatment selection; ++, moderate impact on treatment selection; +++, significant impact on treatment selection; nk, not known.</p>
</fn>
<fn id="bdi12609-note-0051">
<label>a</label>
<p>divalproex and carbamazepine should be used cautiously in women of child bearing age (Section 7).</p>
</fn>
<fn id="bdi12609-note-0052">
<label>b</label>
<p>Antidepressant monotherapy is not recommended in bipolar I disorder; for more information on bipolar II disorder, see Section 6.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="bdi12609-sec-0154">
<label>8.3.1</label>
<title>Weight gain</title>
<p>As described in Section 6, despite normal weight at illness onset,<xref ref-type="ref" rid="bdi12609-bib-0806">806</xref> it is common for patients with BD to become overweight or obese, and several medications used to treat the illness may also exacerbate this effect. The likelihood of medications to cause weight gain should be carefully considered, as this is one of the most frequent treatment‐related factors of non‐adherence; contributing to upwards of 60% of cases.<xref ref-type="ref" rid="bdi12609-bib-0807">807</xref> The medications most commonly associated with weight gain are olanzapine, clozapine, risperidone, quetiapine, gabapentin, divalproex and lithium; with carbamazepine, lamotrigine, and ziprasidone being the safer or options associated with less weight gain.<xref ref-type="ref" rid="bdi12609-bib-0808">808</xref> Recent reviews further suggest that asenapine and aripiprazole (longer term use) <xref ref-type="ref" rid="bdi12609-bib-0809">809</xref> also may lead to weight gain, but the impact of lurasidone on weight is minimal.<xref ref-type="ref" rid="bdi12609-bib-0810">810</xref> All patients should be regularly monitored for weight changes.</p>
</sec>
<sec id="bdi12609-sec-0155">
<label>8.3.2</label>
<title>Gastrointestinal symptoms</title>
<p>Both lithium and divalproex are commonly associated with nausea, vomiting, and diarrhoea, with 35%‐45% of patient experiencing these side effects.<xref ref-type="ref" rid="bdi12609-bib-0372">372</xref>, <xref ref-type="ref" rid="bdi12609-bib-0811">811</xref> For lithium, this is particularly pronounced during treatment initiation, or rapid dose increases.<xref ref-type="ref" rid="bdi12609-bib-0812">812</xref> Gradual dose titration, taking the medication at bedtime, taking medications with food, and slow release preparations may reduce nausea and other side effects.<xref ref-type="ref" rid="bdi12609-bib-0813">813</xref>
</p>
</sec>
<sec id="bdi12609-sec-0156">
<label>8.3.3</label>
<title>Renal toxicity</title>
<p>Lithium has a well‐recognized potential for renal toxicity, including nephrogenic diabetes insipidus (NDI), chronic tubulointerstitial nephropathy, and acute tubular necrosis, with NDI reported in 20%‐40% of patients.<xref ref-type="ref" rid="bdi12609-bib-0814">814</xref>, <xref ref-type="ref" rid="bdi12609-bib-0815">815</xref>, <xref ref-type="ref" rid="bdi12609-bib-0816">816</xref> Upwards of 70% of patients on chronic lithium treatment will experience polyuria, which can cause impairment in work and daily functioning. This side effect is commonly underreported, unless it is directly inquired about.<xref ref-type="ref" rid="bdi12609-bib-0817">817</xref> Long‐term administration (ie, 10‐20+ years) is further associated with decreased glomerular filtration rate and chronic kidney disease.<xref ref-type="ref" rid="bdi12609-bib-0818">818</xref> While long‐term lithium administration is probably an important risk factor for developing chronic kidney disease, factors that may increase susceptibility include higher plasma lithium levels, multiple daily lithium doses (vs once daily), concurrent medications (eg NSAIDs, ARBs, ACEIs and diuretics), somatic illnesses (eg, hypertension, diabetes mellitus and coronary artery disease) and older age.<xref ref-type="ref" rid="bdi12609-bib-0819">819</xref>, <xref ref-type="ref" rid="bdi12609-bib-0820">820</xref> Instances of lithium toxicity will also greatly increase risk of renal dysfunction.<xref ref-type="ref" rid="bdi12609-bib-0821">821</xref> Lithium use is associated with a two‐fold higher risk of chronic kidney disease in older adults (&gt;66 years).<xref ref-type="ref" rid="bdi12609-bib-0822">822</xref> While the overall risk for progressive renal failure is low, plasma creatinine concentrations and ideally estimated glomerular filtration rate (eGFR) for these patients should be measured at least every 3‐6 months.<xref ref-type="ref" rid="bdi12609-bib-0652">652</xref> Since 37% of patients aged &gt;70 years have an eGFR &lt;60 mL/min per 1.73 m<sup>2</sup>,<xref ref-type="ref" rid="bdi12609-bib-0823">823</xref> a strict eGFR cut‐off for lithium discontinuation is difficult. The UK National Institute for Healthcare and Excellence (NICE) guidelines for chronic kidney disease (CKD) recommend nephrologist consultation if there is rapidly declining eGFR (&gt;5 mL/min per 1.73 m<sup>2</sup> in 1 year, or &gt;10 mL/min per 1.73 m<sup>2</sup> within 5 years), if the eGFR falls below 45 in two consecutive readings, or if the clinician is concerned.<xref ref-type="ref" rid="bdi12609-bib-0646">646</xref>, <xref ref-type="ref" rid="bdi12609-bib-0824">824</xref>
</p>
<p>Because of its narrow therapeutic window, acute lithium intoxication is also a complication, which, though reversible, can lead to reductions in glomerular filtration rate.<xref ref-type="ref" rid="bdi12609-bib-0825">825</xref>, <xref ref-type="ref" rid="bdi12609-bib-0826">826</xref> Drugs that alter renal function and general medical conditions characterized by decreased circulating volume all contribute to increased risk.<xref ref-type="ref" rid="bdi12609-bib-0827">827</xref>
</p>
</sec>
<sec id="bdi12609-sec-0157">
<label>8.3.4</label>
<title>Haematological effects</title>
<p>Carbamazepine may be a risk factor for leucopenia,<xref ref-type="ref" rid="bdi12609-bib-0828">828</xref>, <xref ref-type="ref" rid="bdi12609-bib-0829">829</xref>, <xref ref-type="ref" rid="bdi12609-bib-0830">830</xref> although this finding is not robust.<xref ref-type="ref" rid="bdi12609-bib-0831">831</xref> This side effect is generally reversible with dose reduction or discontinuation. There is also some concern about rapidly developing bone marrow suppression resulting from hypersensitivity, particularly in older patients.<xref ref-type="ref" rid="bdi12609-bib-0831">831</xref>, <xref ref-type="ref" rid="bdi12609-bib-0832">832</xref>
</p>
<p>Clozapine carries the greatest risk for drug‐induced changes in white blood cell counts, with approximately 0.18% of patients experiencing changes rated as probably or definitely drug induced.<xref ref-type="ref" rid="bdi12609-bib-0828">828</xref> All patients started on clozapine should have a baseline haematological profile established and be enrolled in the clozapine monitoring programme which requires regular monitoring of haematological parameters: weekly at first and then every 2‐4 weeks later in the course of treatment.<xref ref-type="ref" rid="bdi12609-bib-0833">833</xref>
</p>
</sec>
<sec id="bdi12609-sec-0158">
<label>8.3.5</label>
<title>Cardiovascular effects</title>
<p>Lithium can increase the risk of abnormal QT prolongation or T‐wave abnormalities,<xref ref-type="ref" rid="bdi12609-bib-0834">834</xref> an impact more pronounced with age, as almost 60% of older patients on lithium maintenance therapy have ECG abnormalities.<xref ref-type="ref" rid="bdi12609-bib-0835">835</xref> Several antipsychotics, including risperidone, olanzapine, ziprasidone and asenapine, are also associated with arrhythmias, QTc prolongation, and other cardiovascular adverse events. Clozapine may increase the risk of several rare but serious events such as dilated cardiomyopathy, myocarditis, and pericarditis. Of the antipsychotics, lurasidone and aripiprazole are considered safe from a cardiac perspective, although aripiprazole may increase the risk for hypotension.<xref ref-type="ref" rid="bdi12609-bib-0810">810</xref>
</p>
</sec>
<sec id="bdi12609-sec-0159">
<label>8.3.6</label>
<title>Endocrine effects</title>
<p>There is also a strong link between lithium maintenance treatment and hypothyroidism, which is also associated with increased risk of affective episodes, rapid cycling, and more severe depression.<xref ref-type="ref" rid="bdi12609-bib-0836">836</xref>, <xref ref-type="ref" rid="bdi12609-bib-0837">837</xref> Routine screening of thyroid function is therefore recommended for all patients on lithium treatment. Since lithium can also cause hyperparathyroidism, routine monitoring for serum calcium is recommended, and, if elevated, further investigations should be performed to evaluate for hyperparathyroidisim.<xref ref-type="ref" rid="bdi12609-bib-0838">838</xref> Hypothyroidism is ordinarily not an indication for lithium cessation in a patient with a good response; rather, thyroid supplementation is recommended.</p>
<p>New onset oligomenorrhoea or hyperandronism is more common in divalproex users.<xref ref-type="ref" rid="bdi12609-bib-0839">839</xref> While there are reports of an increased incidence of polycystic ovary syndrome (PCOS) in divalproex treatment, a recent meta‐analysis did not support this.<xref ref-type="ref" rid="bdi12609-bib-0840">840</xref> In those who develop PCOS on divalproex, there is evidence from a small sample that discontinuing divalproex results in remission of some of the aspects of PCOS.<xref ref-type="ref" rid="bdi12609-bib-0841">841</xref>
</p>
<p>Hyperprolactinaemia is common with some antipsychotics, and can have short‐term and long‐term adverse effects. Risperidone, amisulpride and paliperidone are more likely than other compounds to cause it.<xref ref-type="ref" rid="bdi12609-bib-0842">842</xref> Hyperprolactinaemia can induce amenorrhoea, sexual dysfunction, and galactorrhoea, amongst other effects. In the long term, it can cause gynaecomastia and osteoporosis.<xref ref-type="ref" rid="bdi12609-bib-0843">843</xref> When such effects are seen, it may advisable to reduce the dose or switch to a different medication.<xref ref-type="ref" rid="bdi12609-bib-0844">844</xref>
</p>
</sec>
<sec id="bdi12609-sec-0160">
<label>8.3.7</label>
<title>Cognition</title>
<p>While many patients experience cognitive impairment, these deficits may be attributable to the disease itself, with more pronounced effects in those with more severe or chronic illness.<xref ref-type="ref" rid="bdi12609-bib-0845">845</xref> While a small study has led to suggestions that medicated patients who are euthymic do perform similarly to those not receiving treatment,<xref ref-type="ref" rid="bdi12609-bib-0846">846</xref> other naturalistic trials point towards the potential negative impact of several medications, with the effects of antipsychotics being the most significant.<xref ref-type="ref" rid="bdi12609-bib-0845">845</xref> Lithium can also lead to impairment in processing speed and memory, which patients may find distressing,<xref ref-type="ref" rid="bdi12609-bib-0847">847</xref> although recent randomized controlled data suggest lithium is superior to quetiapine in this regard.<xref ref-type="ref" rid="bdi12609-bib-0329">329</xref> Indeed, the effects of lithium on neurocognition are complex and further research is needed to fully elucidate its neurocognitive impact.<xref ref-type="ref" rid="bdi12609-bib-0848">848</xref> Anticonvulsants, except for lamotrigine, are also linked to subjective cognitive impairment.<xref ref-type="ref" rid="bdi12609-bib-0847">847</xref> Given the importance of cognition on a patient's function and quality of life, further studies are needed in this area.</p>
</sec>
<sec id="bdi12609-sec-0161">
<label>8.3.8</label>
<title>Sedation</title>
<p>Sedation is a concern for many, and is reported by over half of patients as a reason for treatment non‐adherence.<xref ref-type="ref" rid="bdi12609-bib-0807">807</xref> Divalproex and atypical antipsychotics are most likely to lead to these effects, with 30%‐50% of patients on atypical antipsychotics experiencing sedation, compared to 8%‐13% with placebo<xref ref-type="ref" rid="bdi12609-bib-0164">164</xref>, <xref ref-type="ref" rid="bdi12609-bib-0214">214</xref>, <xref ref-type="ref" rid="bdi12609-bib-0849">849</xref>, <xref ref-type="ref" rid="bdi12609-bib-0850">850</xref>, <xref ref-type="ref" rid="bdi12609-bib-0851">851</xref> and 21%‐29% of patients on divalproex.<xref ref-type="ref" rid="bdi12609-bib-0852">852</xref>, <xref ref-type="ref" rid="bdi12609-bib-0853">853</xref> This is not a concern with all antipsychotics, however; quetiapine, clozapine, and olanzapine will generally have higher rates of sedation compared to ziprasidone, risperidone, and aripiprazole.<xref ref-type="ref" rid="bdi12609-bib-0810">810</xref> Lamotrigine and lithium have both been found to be less likely to cause sedation than divalproex.<xref ref-type="ref" rid="bdi12609-bib-0854">854</xref>, <xref ref-type="ref" rid="bdi12609-bib-0855">855</xref>
</p>
</sec>
<sec id="bdi12609-sec-0162">
<label>8.3.9</label>
<title>Neurological effects, including EPS</title>
<p>Tremor can be a significant cause of frustration for many patients, and is experienced by up to 10% of those treated with lithium or divalproex.<xref ref-type="ref" rid="bdi12609-bib-0668">668</xref>, <xref ref-type="ref" rid="bdi12609-bib-0856">856</xref>, <xref ref-type="ref" rid="bdi12609-bib-0857">857</xref> New onset neurological symptoms in patients on divalproex should raise suspicion of hyperammonaemic encephalopathy, which, while rare, can be potentially fatal, and hence early detection and discontinuation of divalproex is critical to prevent morbidity and mortality<xref ref-type="ref" rid="bdi12609-bib-0858">858</xref> Sustained release formulations and dose reductions may limit symptoms.<xref ref-type="ref" rid="bdi12609-bib-0802">802</xref>, <xref ref-type="ref" rid="bdi12609-bib-0859">859</xref>, <xref ref-type="ref" rid="bdi12609-bib-0860">860</xref> While conventional antipsychotics such as haloperidol are often associated with EPS (including pseudoparkinsonism, akathisia, acute dystonia, and tardive dyskinesia),<xref ref-type="ref" rid="bdi12609-bib-0861">861</xref> this risk is either absent or low with atypical antipsychotic agents.<xref ref-type="ref" rid="bdi12609-bib-0862">862</xref>, <xref ref-type="ref" rid="bdi12609-bib-0863">863</xref> Among the atypical agents, risperidone, aripiprazole, cariprazine, ziprasidone and lurasidone are more likely to cause EPS, particularly at higher doses.<xref ref-type="ref" rid="bdi12609-bib-0810">810</xref> In older patients, impaired swallowing function and dysphagia have also been linked to atypical agents, particularly at higher doses.<xref ref-type="ref" rid="bdi12609-bib-0864">864</xref>, <xref ref-type="ref" rid="bdi12609-bib-0865">865</xref>
</p>
<p>Although rare, neuroleptic malignant syndrome (NMS) is a potentially life‐threatening adverse event associated with antipsychotic agents. The risk with atypical agents was considered negligible initially; however, while the risk is very low, several atypical agents have nevertheless been associated with NMS.<xref ref-type="ref" rid="bdi12609-bib-0866">866</xref> While generally unpredictable, the risk is greatest during the initial phase of treatment or change of dosage, with intravenous or intramuscular administration, with high dosages or polypharmacy, when the patient is physically restrained or dehydrated, in high ambient temperatures, in older patients and in patients with medical or psychiatric comorbidities. Patients with a previous history of NMS and/or a personal or family history of catatonia are also at higher risk.<xref ref-type="ref" rid="bdi12609-bib-0867">867</xref> Antipsychotics may also impact thermoregulation, with case studies indicating the potential for both heat‐related illnesses<xref ref-type="ref" rid="bdi12609-bib-0868">868</xref> and hypothermia<xref ref-type="ref" rid="bdi12609-bib-0869">869</xref>; thus, patients should be made aware and monitored for these risks during periods of extreme temperatures.</p>
</sec>
<sec id="bdi12609-sec-0163">
<label>8.3.10</label>
<title>Dermatological reactions</title>
<p>Approximately 10% of patients being treated with lamotrigine will experience a non‐serious rash, with 0.3%‐1% developing a serious rash such as toxic epidermal necrolysis and SJS,<xref ref-type="ref" rid="bdi12609-bib-0870">870</xref> although for those initiated on a dose of 25 mg with a gradual titration increasing the dose by 25 mg biweekly, the risk of developing serious rash may be as low as 0.02% or 1 in 5000.<xref ref-type="ref" rid="bdi12609-bib-0871">871</xref> In some cases, an even lower rate of titration may be used (ie 12.5 mg/day and then gradually increase as per instructions. Carbamazepine is also associated with increased risk of rash and SJS, especially in the first 8 weeks of therapy,<xref ref-type="ref" rid="bdi12609-bib-0872">872</xref> although the baseline risk is extremely low. Similarly, while these can also occur with divalproex, the risk is extremely low. Nevertheless, it is important that patients be informed of these risks and told to report any rash immediately, and these treatments should be discontinued if a serious rash is suspected.</p>
<p>Lithium is also linked with a variety of potentially distressing skin conditions, including acne, psoriasis, eczema, hair loss, hidradenitis suppurativa, nail dystrophy and mucosal lesions, with overall estimates ranging from 3% to 45% depending on the criteria applied. Most cases can be managed without treatment discontinuation.<xref ref-type="ref" rid="bdi12609-bib-0873">873</xref>
</p>
</sec>
<sec id="bdi12609-sec-0164">
<label>8.3.11</label>
<title>Metabolic syndrome, hyperglycaemia, type 2 diabetes and dyslipidaemia</title>
<p>As described in Section 6, patients with BD are already at elevated risk for these physical illnesses and this risk is further exacerbated by some atypical antipsychotic agents and mood stabilizers. Clozapine and olanzapine are associated with the greatest level of risk, followed by quetiapine (particularly in higher doses) and risperidone, with a more minimal impact of aripiprazole, ziprasidone, asenapine, and lurasidone.<xref ref-type="ref" rid="bdi12609-bib-0810">810</xref> Lithium and divalproex are also associated with weight gain.<xref ref-type="ref" rid="bdi12609-bib-0791">791</xref> All patients on atypical antipsychotics should be monitored for changes in blood glucose and lipid profiles as indicated previously in this section, and if disturbances are detected, the atypical antipsychotic should be discontinued if possible and appropriate treatment initiated if necessary.</p>
</sec>
<sec id="bdi12609-sec-0165">
<label>8.3.12</label>
<title>Fracture risk and osteoporosis</title>
<p>Some anticonvulsants, antidepressants, and antipsychotics may decrease bone mineral density and increase the risk of fracture in high‐risk patients.<xref ref-type="ref" rid="bdi12609-bib-0874">874</xref>, <xref ref-type="ref" rid="bdi12609-bib-0875">875</xref> This risk is increased by the presence of mood disorders, as well as known risks for mood disorders such as physical inactivity, smoking and poor diet quality.<xref ref-type="ref" rid="bdi12609-bib-0876">876</xref> Thus, screening for this population may be indicated.<xref ref-type="ref" rid="bdi12609-bib-0877">877</xref>
</p>
</sec>
</sec>
</sec>
<sec id="bdi12609-sec-0166">
<label>9</label>
<title>CONCLUDING REMARKS</title>
<p>The diagnosis and management of BD is complex, and effective, evidence‐based care requires knowledge of current research as well as lessons gained from years of clinical experience. Members of the CANMAT guidelines committee hope this document does an effective job at providing an easy to understand narrative of both, thus aiding both specialists and primary care providers in delivering evidence‐based care to their patients. As with previous editions of these guidelines, CANMAT will strive to provide regular updates capturing emerging trends and evaluating new evidence; and readers are encouraged to consult those as they become available to stay up to date in the field.</p>
</sec>
<sec id="bdi12609-sec-0167">
<label>10</label>
<title>CONFLICT OF INTEREST</title>
<p>Dr. Martin Alda has received grant support from Canadian Institutes of Health Research, Genome Quebec, Nova Scotia Health Authority, Nova Scotia Health Research Foundation, and Stanley Medical Research Institute; Dr. Serge Beaulieu has received peer‐reviewed research funding from Canadian Institutes of Health Research, Pfizer Research Award, NARSAD, and support for KT and research contracts from Astra‐Zeneca, Bristol‐Myers‐Squibb, Lundbeck, Otsuka, Sunovion; been a consultant or part of an advisory board for Allergan, Astra Zeneca, BMS, Forest Laboratories, Janssen‐Ortho, Lundbeck, Merck, Otsuka, Pfizer, Sunovion; and part of the speaker bureau for Allergan, Astra Zeneca, BMS, Janssen‐Ortho, Lundbeck, Otsuka, Pfizer, Purdue, Sunovion; Dr. Michael Berk has received grant/research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eli Lilly, Grunbiotics, Glaxo SmithKline, Janssen Cilag, LivaNova, Lundbeck, Merck, Mylan, Otsuka, Pfizer and Servier. MB is supported by a NHMRC Senior Principal Research Fellowship 1059660; Dr. David Bond has served on advisory boards and/or received research support from Myriad Genetics; Dr. Joseph Calabrese has received grants and/or served as consultant, advisor or CME speaker for the following entities: Alkermes Inc., the Cleveland Foundation, Janssen Pharmaceuticals Inc., Lundbeck, the National Institute of Mental Health, Otsuka Pharmaceutical, Sumitomo Dainippon and Sunovion Pharmaceuticals Canada Inc.; Dr. Benicio Frey has served on advisory boards for Lundbeck, Pfizer, Sunovion and received research support from Pfizer; Dr. Benjamin Goldstein has received grant support from Brain Canada, CIHR, Heart and Stroke Foundation, Ontario Ministry of Research, Innovation, and Science, NIMH; Dr. Shigenobu Kanba has received research funding from Dainippon‐Sumitomo Pharma, Jansen Pharma, Asteras Pharma, Nipponchemipha, Pfizer, Mochida Pharma, Esai, Tanabe‐Mitsubishi Pharma, Meiji Seika Pharma, Yoshitomi Pharma, Shionogi Pharma, and Tanabe Mitsubishi. He has received honorarium from MSD, Asteras Pharma, Mochida Pharma, Esai, Takeda Pharma, Dainippon‐Sumitomo Pharma, Otsuka Pharma, Taisho‐Toyama Pharma, Jansen Pharma, Meiji Seika Pharma, Yoshitomi Pharma, Takeda Pharma, Nipponchemipha, Daiichi‐Sankyo, Pfizer, Mochida Pharma, Shionogi Pharma, and Tanabe‐Mitsubishi Pharma; Dr. Flavio Kapczinski has received grants/research support from AstraZeneca, Eli Lilly, Janssen‐Cilag, Servier, NARSAD, and the Stanley Medical Research Institute; has been a member of the speakers’ boards of Astra Zeneca, Eli Lilly, Janssen and Servier; and has served as a consultant for Servier; Dr. Sidney Kennedy has received research funding or honoraria from the following sources: Abbott, Allergan, AstraZeneca, BMS, Brain Canada, Canadian Institutes for Health Research (CIHR), Janssen, Lundbeck, Lundbeck Institute, OMHF, Ontario Brain Institute, Ontario Research Fund(ORF), Otsuka, Pfizer, Servier, St. Jude Medical, Sunovion and Xian‐Janssen; Dr. Jan Kozicky is an employee of Indivior Canada Ltd; Dr. Beny Lafer is supported by Brazilian Federal research grants and scholarships from CNPq and CAPES and a grant from the Brain &amp; Behavior Research Foundation (NARSAD); Dr. Raymond Lam has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Akili, Asia‐Pacific Economic Cooperation, AstraZeneca, BC Leading Edge Foundation, Brain Canada, Bristol Myers Squibb, Canadian Institutes of Health Research, Canadian Depression Research and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Janssen, Lundbeck, Lundbeck Institute, Medscape, Pfizer, St. Jude Medical, Takeda, University Health Network Foundation, Vancouver Coastal Health Research Institute, and VGH Foundation; Dr. Glenda MacQueen has received honoraria for speaking or consulting from: AstraZeneca, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Janssen, Lundbeck, Pfizer, Allergen, Sunovion; Dr. Gin Malhi has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca and Servier; has been a speaker for AstraZeneca, Janssen‐Cilag, Lundbeck, and Servier; and has been a consultant for AstraZeneca, Janssen Cilag, Lundbeck and Servier; Dr. Roger McIntyre has received research or grant support from Allergen Lundbeck, Purdue, Shire, Stanley Medical Research Institute, fees for speaking/consultation fromShire, Purdue, Otsuka, Janssen‐Ortho, Lundbeck, Pfizer, Neurocrine, Neuralstem, Sunovion, Takeda, Allergan; Dr. Diane McIntosh has received honoraria for speaking or consulting for Janssen, Shire, Purdue, Lundbeck, BMS, Sunovion, Pfizer, Otsuka, Allergan, Valeant; Dr. Roumen Milev has received grant support from, participated on scientific advisory boards for or served on speakers bureaus of Lundbeck, Janssen, Pfizer, Forum, CIHR, Ontario Brain Institute, OMHF, Otsuka, Sunovion and Bristol Meyers Squibb; Dr. Claire O'Donovan has no conflict of interest; Dr. Sagar Parikh has received honoraria for consulting from Assurex and Takeda, honoraria for speaking from CANMAT, research grants from Assurex, Takeda, the Ontario Brain Institute, the Canadian Institutes for Health Research, the Ethel and James Flinn Foundation, and has shares in Mensante; Dr. Robert Post has spoken for AstraZeneca, Validus, Sunovion, Pamlabs, and Tekada; Dr. Arun Ravindran has received grant and research support from AstraZeneca, Bristol‐Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Janssen‐Ortho, Lundbeck, Pfizer, Roche, Servier and Wyeth. Current industry grant awards: Janssen‐Ortho. Dr Ravindran has also served as a consultant for some of the above institutions and on their Advisory Boards. He has also participated in CME programs sponsored by these and other pharmaceutical companies, such as Sunovion. He also holds or have held peer‐reviewed funding from Canadian Institutes of Health Research, Grand Challenges Canada, Ontario Brain Institute, Ontario Mental Health Foundation, Canadian Foundation for Innovation and Ministry of Economic Development and Innovation, and National Institutes of Mental Health; Dr. Rej has received research support from Satellite Healthcare (US dialysis company). Otherwise, Dr. Soham Rej has received research support from the Canadian Institutes for Health Research (CIHR), Fonds de Recherche Quebec Sante (FRQS), Ontario Mental Health Foundation, Kidney Foundation of Canada, Physicians Services Incorporated Foundation, Mind and Life Institute, Brain Canada, Lady Davis Institute, McGill University, and Charitable donations to the Jewish General Hospital Division of Geriatric Psychiatry; Dr. Ayal Schaffer has received honoraria or other fees from Allergan, Asofarma, Lundbeck, and Sunovion; received research support from Ontario Mental Health Foundation; Canadian Institute of Health Research; American Foundation for Suicide Prevention; Ontario Ministry of Health and Long‐Term Care (IMPACT Award); Dr. Verinder Sharma has received grant support from, participated on scientific advisory boards for, or served on speakers bureaus of Assurex, Genome Canada, Neurocrine Biosciences, Sage Therapeutics, Stanley Medical Research Institute, and Sunovion Pharmaceuticals; Dr. Trisha Suppes in the past 36 months has reported grants from National Institute of Mental Health, Sunovion Pharamaceuticals, Elan Pharma International Limited, VA Cooperative Studies Program, Pathway Genomics, Stanley Medical Research Institute, National Institute of Health, Palo Alto Health Sciences, and National Institute on Drug Abuse; consulting fees from A/S H. Lundbeck, Sunovion, and Merck &amp; Co; honoraria from Medscape Education, Global Medical Education, and CMEology; royalties from Jones and Bartlett and UpToDate; and travel reimbursement from A/S H. Lundbeck, Sunovion Pharmaceuticals, Inc., Global Medication Education, CMEology, and Merck &amp; Co.; Dr. Gustavo Vazquez has no conflict of interest; Dr. Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB‐Biotics, Allergan, Angelini, AstraZeneca, Bristol‐Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo‐Smith‐Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi‐Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute; Dr. Lakshmi Yatham has received research grants from or has been on speaker ⁄ advisory boards for Allergan, AstraZeneca, Alkermes, Bristol‐Myers Squibb, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Dainippon Sumitomo Inc, Eli Lilly &amp; Co., Forrest, GlaxoSmithKline, Janssen, Lundbeck, Michael Smith Foundation for Health Research, Novartis, Otsuka, Pfizer, Ranbaxy, Servier, Sunovion, the Stanley Foundation, and Valeant Pharmaceuticals.</p>
</sec>
</body>
<back>
<ack id="bdi12609-sec-0168">
<title>ACKNOWLEDGEMENTS</title>
<p>We thank the six anonymous reviewers who provided helpful suggestions and critical feedback to improve these guideline.</p>
</ack>
<ref-list content-type="cited-references" id="bdi12609-bibl-0001">
<title>REFERENCES</title>
<ref id="bdi12609-bib-0001">
<label>1</label>
<mixed-citation id="bdi12609-cit-0001" publication-type="journal">
<string-name>
<surname>Kusumakar</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Haslam</surname>
<given-names>DRS</given-names>
</string-name>, et al. <article-title>The foundations of effective management of bipolar disorder</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>1997</year>;<volume>42</volume>:<fpage>S69</fpage>‐<lpage>S73</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0002">
<label>2</label>
<mixed-citation id="bdi12609-cit-0002" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>O'Donovan</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2006</year>;<volume>8</volume>:<fpage>721</fpage>‐<lpage>39</lpage>.<pub-id pub-id-type="pmid">17156158</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0003">
<label>3</label>
<mixed-citation id="bdi12609-cit-0003" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>225</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">19419382</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0004">
<label>4</label>
<mixed-citation id="bdi12609-cit-0004" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, et al. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>1</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">23237061</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0005">
<label>5</label>
<mixed-citation id="bdi12609-cit-0005" publication-type="book">
<source xml:lang="en"/>Diagnostic and Statistical Manual of Mental Disorders: DSM‐5. <edition>5th edn</edition>
<publisher-loc>Arlington, VA</publisher-loc>: <publisher-name>American Psychiatric Publishing</publisher-name>; <year>2013</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0006">
<label>6</label>
<mixed-citation id="bdi12609-cit-0006" publication-type="journal">
<string-name>
<surname>Merikangas</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>J‐P</given-names>
</string-name>, et al. <article-title>Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2011</year>;<volume>68</volume>:<fpage>241</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">21383262</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0007">
<label>7</label>
<mixed-citation id="bdi12609-cit-0007" publication-type="journal">
<string-name>
<surname>McDonald</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Bulloch</surname>
<given-names>AGM</given-names>
</string-name>, <string-name>
<surname>Duffy</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Prevalence of bipolar I and II disorder in Canada</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>2015</year>;<volume>60</volume>:<fpage>151</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">25886691</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0008">
<label>8</label>
<mixed-citation id="bdi12609-cit-0008" publication-type="journal">
<string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glenn</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Alda</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Influence of birth cohort on age of onset cluster analysis in bipolar I disorder</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2015</year>;<volume>30</volume>:<fpage>99</fpage>‐<lpage>105</lpage>.<pub-id pub-id-type="pmid">25498240</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0009">
<label>9</label>
<mixed-citation id="bdi12609-cit-0009" publication-type="journal">
<string-name>
<surname>Bellivier</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Etain</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Malafosse</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Age at onset in bipolar I affective disorder in the USA and Europe</article-title>. <source xml:lang="en"/>World J Biol Psychiatry. <year>2014</year>;<volume>15</volume>:<fpage>369</fpage>‐<lpage>76</lpage>.<pub-id pub-id-type="pmid">22188366</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0010">
<label>10</label>
<mixed-citation id="bdi12609-cit-0010" publication-type="journal">
<string-name>
<surname>Joslyn</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hawes</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>PB</given-names>
</string-name>. <article-title>Is age of onset associated with severity, prognosis, and clinical features in bipolar disorder? A meta‐analytic review</article-title>
<source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>389</fpage>‐<lpage>403</lpage>.<pub-id pub-id-type="pmid">27530107</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0011">
<label>11</label>
<mixed-citation id="bdi12609-cit-0011" publication-type="journal">
<string-name>
<surname>Sami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nilforooshan</surname>
<given-names>R</given-names>
</string-name>. <article-title>Late onset mania as an organic syndrome: a review of case reports in the literature</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>188</volume>:<fpage>226</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">26368947</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0012">
<label>12</label>
<mixed-citation id="bdi12609-cit-0012" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, et al. <article-title>The long‐term natural history of the weekly symptomatic status of bipolar I disorder</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2002</year>;<volume>59</volume>:<fpage>530</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12044195</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0013">
<label>13</label>
<mixed-citation id="bdi12609-cit-0013" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Long‐term symptomatic status of bipolar I vs. bipolar II disorders</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2003</year>;<volume>6</volume>:<fpage>127</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">12890306</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0014">
<label>14</label>
<mixed-citation id="bdi12609-cit-0014" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>Psychosocial disability and work role function compared across the long‐term course of bipolar I, bipolar II and unipolar major depressive disorders</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2008</year>;<volume>108</volume>:<fpage>49</fpage>‐<lpage>58</lpage>.<pub-id pub-id-type="pmid">18006071</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0015">
<label>15</label>
<mixed-citation id="bdi12609-cit-0015" publication-type="journal">
<string-name>
<surname>Gutierrez‐Rojas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gurpegui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ayuso‐Mateos</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Gutierrez‐Ariza</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ruiz‐Veguilla</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jurado</surname>
<given-names>D</given-names>
</string-name>. <article-title>Quality of life in bipolar disorder patients: a comparison with a general population sample</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>625</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">18657247</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0016">
<label>16</label>
<mixed-citation id="bdi12609-cit-0016" publication-type="journal">
<string-name>
<surname>Bonnin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Moreno</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Martinez‐Aran</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>136</volume>:<fpage>650</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">22051075</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0017">
<label>17</label>
<mixed-citation id="bdi12609-cit-0017" publication-type="journal">
<string-name>
<surname>Maina</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Bellodi</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Health‐related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2007</year>;<volume>68</volume>:<fpage>207</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">17335318</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0018">
<label>18</label>
<mixed-citation id="bdi12609-cit-0018" publication-type="journal">
<string-name>
<surname>Michalak</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Crest</surname>
<given-names>BD</given-names>
</string-name>. <article-title>Development of the QoL.BD: a disorder‐specific scale to assess quality of life in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2010</year>;<volume>12</volume>:<fpage>727</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">21040290</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0019">
<label>19</label>
<mixed-citation id="bdi12609-cit-0019" publication-type="journal">
<string-name>
<surname>Van Rheenen</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Rossell</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Objective and subjective psychosocial functioning in bipolar disorder: an investigation of the relative importance of neurocognition, social cognition and emotion regulation</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>162</volume>:<fpage>134</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">24767018</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0020">
<label>20</label>
<mixed-citation id="bdi12609-cit-0020" publication-type="journal">
<string-name>
<surname>Rosa</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Gonzalez‐Ortega</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gonzalez‐Pinto</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>One‐year psychosocial functioning in patients in the early vs. late stage of bipolar disorder</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2012</year>;<volume>125</volume>:<fpage>335</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">22283440</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0021">
<label>21</label>
<mixed-citation id="bdi12609-cit-0021" publication-type="journal">
<string-name>
<surname>Oldis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Macneil</surname>
<given-names>CA</given-names>
</string-name>, et al. <article-title>Trajectory and predictors of quality of life in first episode psychotic mania</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>195</volume>:<fpage>148</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">26896807</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0022">
<label>22</label>
<mixed-citation id="bdi12609-cit-0022" publication-type="journal">
<string-name>
<surname>Michalak</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>The relationship between clinical outcomes and quality of life in first‐episode mania: a longitudinal analysis</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>188</fpage>‐<lpage>98</lpage>.<pub-id pub-id-type="pmid">23437962</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0023">
<label>23</label>
<mixed-citation id="bdi12609-cit-0023" publication-type="journal">
<string-name>
<surname>Simonsen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sundet</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vaskinn</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Psychosocial function in schizophrenia and bipolar disorder: relationship to neurocognition and clinical symptoms</article-title>. <source xml:lang="en"/>J Int Neuropsychol Soc. <year>2010</year>;<volume>16</volume>:<fpage>771</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">20509984</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0024">
<label>24</label>
<mixed-citation id="bdi12609-cit-0024" publication-type="journal">
<string-name>
<surname>Ferrari</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Stockings</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Khoo</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>440</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">27566286</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0025">
<label>25</label>
<mixed-citation id="bdi12609-cit-0025" publication-type="journal">
<string-name>
<surname>Gore</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Bloem</surname>
<given-names>PJN</given-names>
</string-name>, <string-name>
<surname>Patton</surname>
<given-names>GC</given-names>
</string-name>, et al. <article-title>Global burden of disease in young people aged 10‐24 years: a systematic analysis</article-title>. <source xml:lang="en"/>Lancet. <year>2011</year>;<volume>377</volume>:<fpage>2093</fpage>‐<lpage>102</lpage>.<pub-id pub-id-type="pmid">21652063</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0026">
<label>26</label>
<mixed-citation id="bdi12609-cit-0026" publication-type="journal">
<string-name>
<surname>Jin</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>McCrone</surname>
<given-names>P</given-names>
</string-name>. <article-title>Cost‐of‐illness studies for bipolar disorder: systematic review of international studies</article-title>. <source xml:lang="en"/>Pharmacoeconomics. <year>2015</year>;<volume>33</volume>:<fpage>341</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">25576148</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0027">
<label>27</label>
<mixed-citation id="bdi12609-cit-0027" publication-type="journal">
<string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Boyce</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2015</year>;<volume>49</volume>:<fpage>1087</fpage>‐<lpage>206</lpage>.<pub-id pub-id-type="pmid">26643054</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0028">
<label>28</label>
<mixed-citation id="bdi12609-cit-0028" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>. <article-title>Evidence for clinical progression of unipolar and bipolar disorders</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2017</year>;<volume>135</volume>:<fpage>51</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">27858964</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0029">
<label>29</label>
<mixed-citation id="bdi12609-cit-0029" publication-type="journal">
<string-name>
<surname>Passos</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Mwangi</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>. <article-title>Areas of controversy in neuroprogression in bipolar disorder</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2016</year>;<volume>134</volume>:<fpage>91</fpage>‐<lpage>103</lpage>.<pub-id pub-id-type="pmid">27097559</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0030">
<label>30</label>
<mixed-citation id="bdi12609-cit-0030" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ratheesh</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Staging in bipolar disorder: from theoretical framework to clinical utility</article-title>. <source xml:lang="en"/>World Psychiatry. <year>2017</year>;<volume>16</volume>:<fpage>236</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">28941093</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0031">
<label>31</label>
<mixed-citation id="bdi12609-cit-0031" publication-type="journal">
<string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Magalhaes</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Balanza‐Martinez</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2014</year>;<volume>130</volume>:<fpage>354</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">24961757</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0032">
<label>32</label>
<mixed-citation id="bdi12609-cit-0032" publication-type="journal">
<string-name>
<surname>Alda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>. <article-title>Staging model raises fundamental questions about the nature of bipolar disorder</article-title>. <source xml:lang="en"/>J Psychiatry Neurosci. <year>2016</year>;<volume>41</volume>:<fpage>291</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">27575857</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0033">
<label>33</label>
<mixed-citation id="bdi12609-cit-0033" publication-type="journal">
<string-name>
<surname>Duffy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goodday</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Passos</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>. <article-title>Changing the bipolar illness trajectory</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2017</year>;<volume>4</volume>:<fpage>11</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">28012467</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0034">
<label>34</label>
<mixed-citation id="bdi12609-cit-0034" publication-type="journal">
<string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vornik</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic‐Depressive Association 2000 survey of individuals with bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>161</fpage>‐<lpage>74</lpage>.<pub-id pub-id-type="pmid">12633125</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0035">
<label>35</label>
<mixed-citation id="bdi12609-cit-0035" publication-type="journal">
<string-name>
<surname>Scott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Leboyer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Consequences of delayed diagnosis of bipolar disorders</article-title>. <source xml:lang="en"/>Encephale. <year>2011</year>;<volume>37</volume>:<fpage>S173</fpage>‐<lpage>S5</lpage>.<pub-id pub-id-type="pmid">22212870</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0036">
<label>36</label>
<mixed-citation id="bdi12609-cit-0036" publication-type="journal">
<string-name>
<surname>Knezevic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Nedic</surname>
<given-names>A</given-names>
</string-name>. <article-title>Influence of misdiagnosis on the course of bipolar disorder</article-title>. <source xml:lang="en"/>Eur Rev Med Pharmacol Sci. <year>2013</year>;<volume>17</volume>:<fpage>1542</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">23771544</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0037">
<label>37</label>
<mixed-citation id="bdi12609-cit-0037" publication-type="journal">
<string-name>
<surname>Altamura</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Buoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caldiroli</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>182</volume>:<fpage>70</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">25978716</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0038">
<label>38</label>
<mixed-citation id="bdi12609-cit-0038" publication-type="journal">
<string-name>
<surname>Mitchell</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>. <article-title>Diagnostic guidelines for bipolar depression: a probabilistic approach</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>144</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">18199233</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0039">
<label>39</label>
<mixed-citation id="bdi12609-cit-0039" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cairney</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Veldhuizen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kurdyak</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levitt</surname>
<given-names>A</given-names>
</string-name>. <article-title>A population‐based analysis of distinguishers of bipolar disorder from major depressive disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>125</volume>:<fpage>103</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">20223522</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0040">
<label>40</label>
<mixed-citation id="bdi12609-cit-0040" publication-type="journal">
<string-name>
<surname>Gonzalez‐Pinto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mosquera</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>First episode in bipolar disorder: misdiagnosis and psychotic symptoms</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1998</year>;<volume>50</volume>:<fpage>41</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">9716278</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0041">
<label>41</label>
<mixed-citation id="bdi12609-cit-0041" publication-type="journal">
<string-name>
<surname>Zimmerman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ruggero</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Chelminski</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>D</given-names>
</string-name>. <article-title>Is bipolar disorder overdiagnosed?</article-title>
<source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>935</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">18466044</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0042">
<label>42</label>
<mixed-citation id="bdi12609-cit-0042" publication-type="journal">
<string-name>
<surname>Ghouse</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Sanches</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zunta‐Soares</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Soares</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Overdiagnosis of bipolar disorder: a critical analysis of the literature</article-title>. <source xml:lang="en"/>ScientificWorldJournal. <year>2013</year>;<volume>2013</volume>:<fpage>1</fpage>‐<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0043">
<label>43</label>
<mixed-citation id="bdi12609-cit-0043" publication-type="journal">
<string-name>
<surname>Cyprien</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Guillaume</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jaussent</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Impact of axis‐I comorbidity and suicidal behavior disorders on sensitivity and specificity of the Mood Disorder Questionnaire in complex depressed inpatients</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2014</year>;<volume>55</volume>:<fpage>876</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">24625765</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0044">
<label>44</label>
<mixed-citation id="bdi12609-cit-0044" publication-type="journal">
<string-name>
<surname>Meyer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>TD</given-names>
</string-name>. <article-title>The misdiagnosis of bipolar disorder as a psychotic disorder: some of its causes and their influence on therapy</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>112</volume>:<fpage>174</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">18555536</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0045">
<label>45</label>
<mixed-citation id="bdi12609-cit-0045" publication-type="journal">
<string-name>
<surname>Merikangas</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Angst</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Lifetime and 12‐month prevalence of bipolar spectrum disorder in the national comorbidity survey replication</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2007</year>;<volume>64</volume>:<fpage>543</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">17485606</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0046">
<label>46</label>
<mixed-citation id="bdi12609-cit-0046" publication-type="journal">
<string-name>
<surname>Webb</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Larsson</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Fazel</surname>
<given-names>S</given-names>
</string-name>. <article-title>Suicide, hospital‐presenting suicide attempts, and criminality in bipolar disorder: examination of risk for multiple adverse outcomes</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>e809</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">25191918</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0047">
<label>47</label>
<mixed-citation id="bdi12609-cit-0047" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Isometsa</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2015</year>;<volume>49</volume>:<fpage>785</fpage>‐<lpage>802</lpage>.<pub-id pub-id-type="pmid">26185269</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0048">
<label>48</label>
<mixed-citation id="bdi12609-cit-0048" publication-type="journal">
<string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lepri</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Suicidal risks among 2826 sardinian major affective disorder patients</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2007</year>;<volume>116</volume>:<fpage>419</fpage>‐<lpage>28</lpage>.<pub-id pub-id-type="pmid">17997721</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0049">
<label>49</label>
<mixed-citation id="bdi12609-cit-0049" publication-type="journal">
<string-name>
<surname>Singhal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Seminog</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Hawton</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Goldacre</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Risk of self‐harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage</article-title>. <source xml:lang="en"/>J R Soc Med. <year>2014</year>;<volume>107</volume>:<fpage>194</fpage>‐<lpage>204</lpage>.<pub-id pub-id-type="pmid">24526464</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0050">
<label>50</label>
<mixed-citation id="bdi12609-cit-0050" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Isometsa</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Azorin</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2015</year>;<volume>49</volume>:<fpage>1006</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">26175498</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0051">
<label>51</label>
<mixed-citation id="bdi12609-cit-0051" publication-type="journal">
<string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Dennehy</surname>
<given-names>EB</given-names>
</string-name>, et al. <article-title>Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2006</year>;<volume>8</volume>:<fpage>566</fpage>‐<lpage>75</lpage>.<pub-id pub-id-type="pmid">17042830</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0052">
<label>52</label>
<mixed-citation id="bdi12609-cit-0052" publication-type="journal">
<string-name>
<surname>Keks</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sundram</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Evaluation of treatment in 35 cases of bipolar suicide</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2009</year>;<volume>43</volume>:<fpage>503</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">19440881</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0053">
<label>53</label>
<mixed-citation id="bdi12609-cit-0053" publication-type="journal">
<string-name>
<surname>Carter</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Milner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McGill</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pirkis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kapur</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Spittal</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Predicting suicidal behaviours using clinical instruments: systematic review and meta‐analysis of positive predictive values for risk scales</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2017</year>;<volume>210</volume>:<fpage>387</fpage>.<pub-id pub-id-type="pmid">28302700</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0054">
<label>54</label>
<mixed-citation id="bdi12609-cit-0054" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Cipriani</surname>
<given-names>A</given-names>
</string-name>. <article-title>Lithium and suicide in mood disorders: updated meta‐review of the scientific literature</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2017</year>;<volume>19</volume>:<fpage>575</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">28895269</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0055">
<label>55</label>
<mixed-citation id="bdi12609-cit-0055" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sinyor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Howlett</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>A</given-names>
</string-name>. <article-title>Suicide by overdose in a bipolar disorder cohort</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>122</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0056">
<label>56</label>
<mixed-citation id="bdi12609-cit-0056" publication-type="journal">
<string-name>
<surname>Wagner</surname>
<given-names>EH</given-names>
</string-name>. <article-title>Chronic disease management: what will it take to improve care for chronic illness?</article-title>
<source xml:lang="en"/>Eff Clin Pract. <year>1998</year>;<volume>1</volume>:<fpage>2</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">10345255</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0057">
<label>57</label>
<mixed-citation id="bdi12609-cit-0057" publication-type="book">
<string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>. <source xml:lang="en"/>Integration of Patient, Provider, and Systems Treatment Approaches in Bipolar Disorder: Where Evidence Meets Practice Reality. <publisher-loc>West Sussex, England</publisher-loc>: <publisher-name>John Wiley &amp; Sons Ltd</publisher-name>; <year>2004</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0058">
<label>58</label>
<mixed-citation id="bdi12609-cit-0058" publication-type="book">
<source xml:lang="en"/>Consensus Statement on Improving Mental Health Transitions. <publisher-loc>Alberta</publisher-loc>: <publisher-name>Institute of Health Economics</publisher-name>; <year>2014</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0059">
<label>59</label>
<mixed-citation id="bdi12609-cit-0059" publication-type="journal">
<string-name>
<surname>Sylvia</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Hay</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ostacher</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2013</year>;<volume>33</volume>:<fpage>343</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">23609394</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0060">
<label>60</label>
<mixed-citation id="bdi12609-cit-0060" publication-type="journal">
<string-name>
<surname>Strauss</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2006</year>;<volume>145</volume>:<fpage>215</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">17079023</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0061">
<label>61</label>
<mixed-citation id="bdi12609-cit-0061" publication-type="journal">
<string-name>
<surname>Elwyn</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Frosch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Shared decision making: a model for clinical practice</article-title>. <source xml:lang="en"/>J Gen Intern Med. <year>2012</year>;<volume>27</volume>:<fpage>1361</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">22618581</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0062">
<label>62</label>
<mixed-citation id="bdi12609-cit-0062" publication-type="journal">
<string-name>
<surname>Drake</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Cimpean</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Torrey</surname>
<given-names>WC</given-names>
</string-name>. <article-title>Shared decision making in mental health: prospects for personalized medicine</article-title>. <source xml:lang="en"/>Dialogues Clin Neurosci. <year>2009</year>;<volume>11</volume>:<fpage>455</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">20135903</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0063">
<label>63</label>
<mixed-citation id="bdi12609-cit-0063" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>HV</given-names>
</string-name>, <string-name>
<surname>Hvenegaard</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Treatment in a specialised out‐patient mood disorder clinic v. standard out‐patient treatment in the early course of bipolar disorder: randomised clinical trial</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2013</year>;<volume>202</volume>:<fpage>212</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23349295</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0064">
<label>64</label>
<mixed-citation id="bdi12609-cit-0064" publication-type="journal">
<string-name>
<surname>Denicoff</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>SO</given-names>
</string-name>, <string-name>
<surname>Sollinger</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Smith‐Jackson</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Utility of the daily prospective National Institute of Mental Health Life‐Chart Method (NIMH‐LCM‐p) ratings in clinical trials of bipolar disorder</article-title>. <source xml:lang="en"/>Depress Anxiety. <year>2002</year>;<volume>15</volume>:<fpage>1</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">11816046</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0065">
<label>65</label>
<mixed-citation id="bdi12609-cit-0065" publication-type="journal">
<string-name>
<surname>van Bendegem</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>van den Heuvel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Goossens</surname>
<given-names>PJJ</given-names>
</string-name>. <article-title>Attitudes of patients with bipolar disorder toward the life chart methodology: a phenomenological study</article-title>. <source xml:lang="en"/>J Am Psychiatr Nurs Assoc. <year>2014</year>;<volume>20</volume>:<fpage>376</fpage>‐<lpage>85</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0066">
<label>66</label>
<mixed-citation id="bdi12609-cit-0066" publication-type="journal">
<string-name>
<surname>Lieberman</surname>
<given-names>DZ</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>. <article-title>A randomized comparison of online and paper mood charts for people with bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>124</volume>:<fpage>85</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19896202</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0067">
<label>67</label>
<mixed-citation id="bdi12609-cit-0067" publication-type="journal">
<string-name>
<surname>Hidalgo‐Mazzei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mateu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Self‐monitoring and psychoeducation in bipolar patients with a smart‐phone application (SIMPLe) project: design, development and studies protocols</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2015</year>;<volume>15</volume>:<fpage>52</fpage>.<pub-id pub-id-type="pmid">25884824</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0068">
<label>68</label>
<mixed-citation id="bdi12609-cit-0068" publication-type="journal">
<string-name>
<surname>Hidalgo‐Mazzei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mateu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>. <article-title>Internet‐based psychological interventions for bipolar disorder: review of the present and insights into the future</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>188</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">26342885</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0069">
<label>69</label>
<mixed-citation id="bdi12609-cit-0069" publication-type="journal">
<string-name>
<surname>Hidalgo‐Mazzei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mateu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Psychoeducation in bipolar disorder with a SIMPLe smartphone application: feasibility, acceptability and satisfaction</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>200</volume>:<fpage>58</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">27128358</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0070">
<label>70</label>
<mixed-citation id="bdi12609-cit-0070" publication-type="journal">
<string-name>
<surname>Hawke</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Michalak</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Stigma and bipolar disorder: a review of the literature</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>150</volume>:<fpage>181</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">23759420</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0071">
<label>71</label>
<mixed-citation id="bdi12609-cit-0071" publication-type="journal">
<string-name>
<surname>Yanos</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Lucksted</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Drapalski</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Roe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lysaker</surname>
<given-names>P</given-names>
</string-name>. <article-title>Interventions targeting mental health self‐stigma: a review and comparison</article-title>. <source xml:lang="en"/>Psychiatr Rehabil J. <year>2015</year>;<volume>38</volume>:<fpage>171</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">25313530</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0072">
<label>72</label>
<mixed-citation id="bdi12609-cit-0072" publication-type="journal">
<string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Moreno</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fountoulakis</surname>
<given-names>KN</given-names>
</string-name>. <article-title>Psychosocial interventions in bipolar disorder: what, for whom, and when</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>156</volume>:<fpage>46</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">24439829</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0073">
<label>73</label>
<mixed-citation id="bdi12609-cit-0073" publication-type="journal">
<string-name>
<surname>Murray</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Leitan</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Towards recovery‐oriented psychosocial interventions for bipolar disorder: quality of life outcomes, stage‐sensitive treatments, and mindfulness mechanisms</article-title>. <source xml:lang="en"/>Clin Psychol Rev. <year>2017</year>;<volume>52</volume>:<fpage>148</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">28129636</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0074">
<label>74</label>
<mixed-citation id="bdi12609-cit-0074" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>S</given-names>
</string-name>. <article-title>Psychoeducation for bipolar disorder</article-title>. <source xml:lang="en"/>Adv Psychiatr Treat. <year>2010</year>;<volume>16</volume>:<fpage>147</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0075">
<label>75</label>
<mixed-citation id="bdi12609-cit-0075" publication-type="journal">
<string-name>
<surname>Salcedo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gold</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Sheikh</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Empirically supported psychosocial interventions for bipolar disorder: current state of the research</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>201</volume>:<fpage>203</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">27243619</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0076">
<label>76</label>
<mixed-citation id="bdi12609-cit-0076" publication-type="journal">
<string-name>
<surname>Norcross</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Wampold</surname>
<given-names>BE</given-names>
</string-name>. <article-title>Evidence‐based therapy relationships: research conclusions and clinical practices</article-title>. <source xml:lang="en"/>Psychotherapy (Chic). <year>2011</year>;<volume>48</volume>:<fpage>98</fpage>‐<lpage>102</lpage>.<pub-id pub-id-type="pmid">21401280</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0077">
<label>77</label>
<mixed-citation id="bdi12609-cit-0077" publication-type="book">
<string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>. <source xml:lang="en"/>Psychoeducation Manual for Bipolar Disorders. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>2006</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0078">
<label>78</label>
<mixed-citation id="bdi12609-cit-0078" publication-type="book">
<string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>L</given-names>
</string-name>. <source xml:lang="en"/>Structured Group Psychotherapy for Bipolar Disorder. The Life Goals Program 2ed. <publisher-loc>Berlin, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2003</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0079">
<label>79</label>
<mixed-citation id="bdi12609-cit-0079" publication-type="journal">
<string-name>
<surname>Oud</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mayo‐Wilson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Braidwood</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Psychological interventions for adults with bipolar disorder: systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2016</year>;<volume>208</volume>:<fpage>213</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">26932483</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0080">
<label>80</label>
<mixed-citation id="bdi12609-cit-0080" publication-type="journal">
<string-name>
<surname>Bond</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>IM</given-names>
</string-name>. <article-title>Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>349</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">25594775</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0081">
<label>81</label>
<mixed-citation id="bdi12609-cit-0081" publication-type="journal">
<string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Zaretsky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beaulieu</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A randomized controlled trial of psychoeducation or cognitive‐behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) Study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2012</year>;<volume>73</volume>:<fpage>803</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">22795205</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0082">
<label>82</label>
<mixed-citation id="bdi12609-cit-0082" publication-type="journal">
<string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Hawke</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Zaretsky</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Psychosocial interventions for bipolar disorder and coping style modification: similar clinical outcomes, similar mechanisms?</article-title>
<source xml:lang="en"/>Can J Psychiatry. <year>2013</year>;<volume>58</volume>:<fpage>482</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">23972110</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0083">
<label>83</label>
<mixed-citation id="bdi12609-cit-0083" publication-type="journal">
<string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Hawke</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Velyvis</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>86</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">25046246</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0084">
<label>84</label>
<mixed-citation id="bdi12609-cit-0084" publication-type="journal">
<string-name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Otto</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9‐month randomized controlled trial</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2007</year>;<volume>164</volume>:<fpage>1340</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">17728418</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0085">
<label>85</label>
<mixed-citation id="bdi12609-cit-0085" publication-type="journal">
<string-name>
<surname>Lam</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Watkins</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Hayward</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder – Outcome of the first year</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2003</year>;<volume>60</volume>:<fpage>145</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">12578431</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0086">
<label>86</label>
<mixed-citation id="bdi12609-cit-0086" publication-type="journal">
<string-name>
<surname>Scott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Paykel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Morriss</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Cognitive‐behavioural therapy for severe and recurrent bipolar disorders – Randomised controlled trial</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2006</year>;<volume>188</volume>:<fpage>313</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">16582056</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0087">
<label>87</label>
<mixed-citation id="bdi12609-cit-0087" publication-type="journal">
<string-name>
<surname>Lynch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Laws</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>McKenna</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta‐analytical review of well‐controlled trials</article-title>. <source xml:lang="en"/>Psychol Med. <year>2010</year>;<volume>40</volume>:<fpage>9</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">19476688</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0088">
<label>88</label>
<mixed-citation id="bdi12609-cit-0088" publication-type="journal">
<string-name>
<surname>Ye</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>ZY</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Effectiveness of cognitive behavioral therapy in treating bipolar disorder: an updated meta‐analysis with randomized controlled trials</article-title>. <source xml:lang="en"/>Psychiatry Clin Neurosci. <year>2016</year>;<volume>70</volume>:<fpage>351</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">27177717</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0089">
<label>89</label>
<mixed-citation id="bdi12609-cit-0089" publication-type="journal">
<string-name>
<surname>Szentagotai</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>D</given-names>
</string-name>. <article-title>The efficacy of cognitive‐behavioral therapy in bipolar disorder: a quantitative meta‐analysis</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>66</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">19852904</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0090">
<label>90</label>
<mixed-citation id="bdi12609-cit-0090" publication-type="journal">
<string-name>
<surname>Jones</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mulligan</surname>
<given-names>LD</given-names>
</string-name>, et al. <article-title>Recovery‐focused cognitive‐behavioural therapy for recent‐onset bipolar disorder: randomised controlled pilot trial</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2015</year>;<volume>206</volume>:<fpage>58</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">25213157</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0091">
<label>91</label>
<mixed-citation id="bdi12609-cit-0091" publication-type="journal">
<string-name>
<surname>Gomes</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Abreu</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Brietzke</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder</article-title>. <source xml:lang="en"/>Psychother Psychosom. <year>2011</year>;<volume>80</volume>:<fpage>144</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">21372622</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0092">
<label>92</label>
<mixed-citation id="bdi12609-cit-0092" publication-type="journal">
<string-name>
<surname>Cuijpers</surname>
<given-names>P</given-names>
</string-name>. <article-title>Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies</article-title>. <source xml:lang="en"/>Evid Based Ment Health. <year>2016</year>;<volume>19</volume>:<fpage>39</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">26984413</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0093">
<label>93</label>
<mixed-citation id="bdi12609-cit-0093" publication-type="book">
<string-name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>MJ</given-names>
</string-name>. <source xml:lang="en"/>Bipolar Disorder: A Family‐Focused Treatment Approach. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Guilford Publications</publisher-name>; <year>1997</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0094">
<label>94</label>
<mixed-citation id="bdi12609-cit-0094" publication-type="journal">
<string-name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Otto</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Psychosocial treatments for bipolar depression – A 1‐year randomized trial from the systematic treatment enhancement program</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2007</year>;<volume>64</volume>:<fpage>419</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">17404119</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0095">
<label>95</label>
<mixed-citation id="bdi12609-cit-0095" publication-type="journal">
<string-name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>B</given-names>
</string-name>. <article-title>Family‐focused therapy for bipolar disorder: reflections on 30 years of research</article-title>. <source xml:lang="en"/>Fam Process. <year>2016</year>;<volume>55</volume>:<fpage>483</fpage>‐<lpage>99</lpage>.<pub-id pub-id-type="pmid">27471058</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0096">
<label>96</label>
<mixed-citation id="bdi12609-cit-0096" publication-type="journal">
<string-name>
<surname>McMahon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Herr</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Zerubavel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hoertel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Neacsiu</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Psychotherapeutic treatment of bipolar depression</article-title>. <source xml:lang="en"/>Psychiatr Clin North Am. <year>2016</year>;<volume>39</volume>:<fpage>35</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">26876317</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0097">
<label>97</label>
<mixed-citation id="bdi12609-cit-0097" publication-type="journal">
<string-name>
<surname>Haynes</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Gengler</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>M</given-names>
</string-name>. <article-title>Social rhythm therapies for mood disorders: an update</article-title>. <source xml:lang="en"/>Curr Psychiatry Rep. <year>2016</year>;<volume>18</volume>:<fpage>75</fpage>.<pub-id pub-id-type="pmid">27338753</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0098">
<label>98</label>
<mixed-citation id="bdi12609-cit-0098" publication-type="journal">
<string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kupfer</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>Two‐year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2005</year>;<volume>62</volume>:<fpage>996</fpage>‐<lpage>1004</lpage>.<pub-id pub-id-type="pmid">16143731</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0099">
<label>99</label>
<mixed-citation id="bdi12609-cit-0099" publication-type="journal">
<string-name>
<surname>Inder</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Crowe</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Luty</surname>
<given-names>SE</given-names>
</string-name>, et al. <article-title>Randomized, controlled trial of Interpersonal and Social Rhythm Therapy for young people with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>128</fpage>‐<lpage>38</lpage>.<pub-id pub-id-type="pmid">25346391</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0100">
<label>100</label>
<mixed-citation id="bdi12609-cit-0100" publication-type="journal">
<string-name>
<surname>Swartz</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Levenson</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>. <article-title>Psychotherapy for bipolar II disorder: the role of interpersonal and social rhythm therapy</article-title>. <source xml:lang="en"/>Prof Psychol Res Pr. <year>2012</year>;<volume>43</volume>:<fpage>145</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">26612968</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0101">
<label>101</label>
<mixed-citation id="bdi12609-cit-0101" publication-type="journal">
<string-name>
<surname>Bouwkamp</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>de Kruiff</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>van Troost</surname>
<given-names>TM</given-names>
</string-name>, et al. <article-title>Interpersonal and social rhythm group therapy for patients with bipolar disorder</article-title>. <source xml:lang="en"/>Int J Group Psychother. <year>2013</year>;<volume>63</volume>:<fpage>97</fpage>‐<lpage>115</lpage>.<pub-id pub-id-type="pmid">23252817</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0102">
<label>102</label>
<mixed-citation id="bdi12609-cit-0102" publication-type="journal">
<string-name>
<surname>Hoberg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Vickers</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Ericksen</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Feasibility evaluation of an interpersonal and social rhythm therapy group delivery model</article-title>. <source xml:lang="en"/>Arch Psychiatr Nurs. <year>2013</year>;<volume>27</volume>:<fpage>271</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">24238006</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0103">
<label>103</label>
<mixed-citation id="bdi12609-cit-0103" publication-type="journal">
<string-name>
<surname>Swartz</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>O'Toole</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Implementing interpersonal and social rhythm therapy for mood disorders across a continuum of care</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2011</year>;<volume>62</volume>:<fpage>1377</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">22211221</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0104">
<label>104</label>
<mixed-citation id="bdi12609-cit-0104" publication-type="book">
<string-name>
<surname>Parikh</surname>
<given-names>VS</given-names>
</string-name>, <string-name>
<surname>Velyvis</surname>
<given-names>V</given-names>
</string-name>. <source xml:lang="en"/>Psychosocial Interventions in Bipolar Disorder: Theories, Mechanisms and Key Clinical Trials. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>2010</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0105">
<label>105</label>
<mixed-citation id="bdi12609-cit-0105" publication-type="journal">
<string-name>
<surname>Proudfoot</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Jayawant</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Whitton</surname>
<given-names>AE</given-names>
</string-name>, et al. <article-title>Mechanisms underpinning effective peer support: a qualitative analysis of interactions between expert peers and patients newly‐diagnosed with bipolar disorder</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2012</year>;<volume>12</volume>:<fpage>196</fpage>.<pub-id pub-id-type="pmid">23140497</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0106">
<label>106</label>
<mixed-citation id="bdi12609-cit-0106" publication-type="journal">
<string-name>
<surname>Lloyd‐Evans</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mayo‐Wilson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>A systematic review and meta‐analysis of randomised controlled trials of peer support for people with severe mental illness</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2014</year>;<volume>14</volume>:<fpage>12</fpage>.<pub-id pub-id-type="pmid">24438222</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0107">
<label>107</label>
<mixed-citation id="bdi12609-cit-0107" publication-type="journal">
<string-name>
<surname>Chinman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dougherty</surname>
<given-names>RH</given-names>
</string-name>, et al. <article-title>Peer support services for individuals with serious mental illnesses: assessing the evidence</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2014</year>;<volume>65</volume>:<fpage>429</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">24549400</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0108">
<label>108</label>
<mixed-citation id="bdi12609-cit-0108" publication-type="journal">
<string-name>
<surname>Mahlke</surname>
<given-names>CI</given-names>
</string-name>, <string-name>
<surname>Priebe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Heumann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Daubmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wegscheider</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bock</surname>
<given-names>T</given-names>
</string-name>. <article-title>Effectiveness of one‐to‐one peer support for patients with severe mental illness – a randomised controlled trial</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2017</year>;<volume>42</volume>:<fpage>103</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">28364685</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0109">
<label>109</label>
<mixed-citation id="bdi12609-cit-0109" publication-type="journal">
<string-name>
<surname>Cabassa</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Camacho</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Velez‐Grau</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Stefancic</surname>
<given-names>A</given-names>
</string-name>. <article-title>Peer‐based health interventions for people with serious mental illness: a systematic literature review</article-title>. <source xml:lang="en"/>J Psychiatr Res. <year>2017</year>;<volume>84</volume>:<fpage>80</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">27701013</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0110">
<label>110</label>
<mixed-citation id="bdi12609-cit-0110" publication-type="journal">
<string-name>
<surname>Morriss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lobban</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Riste</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Clinical effectiveness and acceptability of structured group psychoeducation versus optimised unstructured peer support for patients with remitted bipolar disorder (PARADES): a pragmatic, multicentre, observer‐blind, randomised controlled superiority trial</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2016</year>;<volume>3</volume>:<fpage>1029</fpage>‐<lpage>38</lpage>.<pub-id pub-id-type="pmid">27688021</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0111">
<label>111</label>
<mixed-citation id="bdi12609-cit-0111" publication-type="journal">
<string-name>
<surname>Naslund</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Grande</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Aschbrenner</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Elwyn</surname>
<given-names>G</given-names>
</string-name>. <article-title>Naturally occurring peer support through social media: the experiences of individuals with severe mental illness using YouTube</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2014</year>;<volume>9</volume>:<fpage>e110171</fpage>.<pub-id pub-id-type="pmid">25333470</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0112">
<label>112</label>
<mixed-citation id="bdi12609-cit-0112" publication-type="journal">
<string-name>
<surname>Naslund</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Aschbrenner</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>How people with serious mental illness use smartphones, mobile apps, and social media</article-title>. <source xml:lang="en"/>Psychiatr Rehabil J. <year>2016</year>;<volume>39</volume>:<fpage>364</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">27845533</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0113">
<label>113</label>
<mixed-citation id="bdi12609-cit-0113" publication-type="journal">
<string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Moreno</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>511</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">18452447</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0114">
<label>114</label>
<mixed-citation id="bdi12609-cit-0114" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dodd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cvetkovski</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jorm</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Evaluation of the acceptability and usefulness of an information website for caregivers of people with bipolar disorder</article-title>. <source xml:lang="en"/>BMC Med. <year>2013</year>;<volume>11</volume>:<fpage>162</fpage>.<pub-id pub-id-type="pmid">23844755</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0115">
<label>115</label>
<mixed-citation id="bdi12609-cit-0115" publication-type="journal">
<string-name>
<surname>Perich</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Manicavasagar</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Ball</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Hadzi‐Pavlovic</surname>
<given-names>D</given-names>
</string-name>. <article-title>A randomized controlled trial of mindfulness‐based cognitive therapy for bipolar disorder</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2013</year>;<volume>127</volume>:<fpage>333</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">23216045</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0116">
<label>116</label>
<mixed-citation id="bdi12609-cit-0116" publication-type="journal">
<string-name>
<surname>Ives‐Deliperi</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Howells</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Meintjes</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Horn</surname>
<given-names>N</given-names>
</string-name>. <article-title>The effects of mindfulness‐based cognitive therapy in patients with bipolar disorder: a controlled functional MRI investigation</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>150</volume>:<fpage>1152</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">23790741</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0117">
<label>117</label>
<mixed-citation id="bdi12609-cit-0117" publication-type="journal">
<string-name>
<surname>Torrent</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bonnin Cdel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martinez‐Aran</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2013</year>;<volume>170</volume>:<fpage>852</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23511717</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0118">
<label>118</label>
<mixed-citation id="bdi12609-cit-0118" publication-type="journal">
<string-name>
<surname>Sole</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jimenez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Torrent</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Cognitive impairment in bipolar disorder: treatment and prevention strategies</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2017</year>;<volume>20</volume>:<fpage>670</fpage>‐<lpage>680</lpage>.<pub-id pub-id-type="pmid">28498954</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0119">
<label>119</label>
<mixed-citation id="bdi12609-cit-0119" publication-type="journal">
<string-name>
<surname>Lewandowski</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Sperry</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</string-name>, et al. <article-title>Treatment to enhance cognition in bipolar disorder (TREC‐BD): efficacy of a randomized controlled trial of cognitive remediation versus active control</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2017</year>;<volume>78</volume>:<fpage>e1242</fpage>‐<lpage>e1249</lpage>.<pub-id pub-id-type="pmid">29045770</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0120">
<label>120</label>
<mixed-citation id="bdi12609-cit-0120" publication-type="journal">
<string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Huniewicz</surname>
<given-names>P</given-names>
</string-name>. <article-title>E‐health: an overview of the uses of the Internet, social media, apps, and websites for mood disorders</article-title>. <source xml:lang="en"/>Curr Opin Psychiatry. <year>2015</year>;<volume>28</volume>:<fpage>13</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">25420193</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0121">
<label>121</label>
<mixed-citation id="bdi12609-cit-0121" publication-type="journal">
<string-name>
<surname>Leitan</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Michalak</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>G</given-names>
</string-name>. <article-title>Optimizing delivery of recovery‐oriented online self‐management strategies for bipolar disorder: a review</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>115</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">25238632</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0122">
<label>122</label>
<mixed-citation id="bdi12609-cit-0122" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Eberhard</surname>
<given-names>J</given-names>
</string-name>. <article-title>Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder</article-title>. <source xml:lang="en"/>Neuropsychiatr Dis Treat. <year>2015</year>;<volume>11</volume>:<fpage>1137</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">25995638</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0123">
<label>123</label>
<mixed-citation id="bdi12609-cit-0123" publication-type="journal">
<string-name>
<surname>Dundar</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Greenhalgh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dwan</surname>
<given-names>K</given-names>
</string-name>. <article-title>Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2016</year>;<volume>31</volume>:<fpage>268</fpage>‐<lpage>85</lpage>.<pub-id pub-id-type="pmid">27151529</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0124">
<label>124</label>
<mixed-citation id="bdi12609-cit-0124" publication-type="journal">
<string-name>
<surname>Garriga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kasper</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Assessment and management of agitation in psychiatry: expert consensus</article-title>. <source xml:lang="en"/>World J Biol Psychiatry. <year>2016</year>;<volume>17</volume>:<fpage>86</fpage>‐<lpage>128</lpage>.<pub-id pub-id-type="pmid">26912127</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0125">
<label>125</label>
<mixed-citation id="bdi12609-cit-0125" publication-type="journal">
<string-name>
<surname>Zimbroff</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Marcus</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Manos</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Management of acute agitation in patients with bipolar disorder – Efficacy and safety of intramuscular aripiprazole</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2007</year>;<volume>27</volume>:<fpage>171</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">17414241</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0126">
<label>126</label>
<mixed-citation id="bdi12609-cit-0126" publication-type="journal">
<string-name>
<surname>De Filippis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cuomo</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lionetto</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Intramuscular aripiprazole in the acute management of psychomotor agitation</article-title>. <source xml:lang="en"/>Pharmacotherapy. <year>2013</year>;<volume>33</volume>:<fpage>603</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">23505124</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0127">
<label>127</label>
<mixed-citation id="bdi12609-cit-0127" publication-type="journal">
<string-name>
<surname>Meehan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A double‐blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2001</year>;<volume>21</volume>:<fpage>389</fpage>‐<lpage>97</lpage>.<pub-id pub-id-type="pmid">11476123</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0128">
<label>128</label>
<mixed-citation id="bdi12609-cit-0128" publication-type="journal">
<string-name>
<surname>Citrome</surname>
<given-names>L</given-names>
</string-name>. <article-title>Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder</article-title>. <source xml:lang="en"/>Int J Clin Pract. <year>2012</year>;<volume>66</volume>:<fpage>318</fpage>‐<lpage>25</lpage>.<pub-id pub-id-type="pmid">22226343</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0129">
<label>129</label>
<mixed-citation id="bdi12609-cit-0129" publication-type="journal">
<string-name>
<surname>Kwentus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Riesenberg</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Marandi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>31</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">22329470</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0130">
<label>130</label>
<mixed-citation id="bdi12609-cit-0130" publication-type="journal">
<string-name>
<surname>Battaglia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lindborg</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Alaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Meehan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>P</given-names>
</string-name>. <article-title>Calming versus sedative effects of intramuscular olanzapine in agitated patients</article-title>. <source xml:lang="en"/>Am J Emerg Med. <year>2003</year>;<volume>21</volume>:<fpage>192</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">12811711</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0131">
<label>131</label>
<mixed-citation id="bdi12609-cit-0131" publication-type="journal">
<string-name>
<surname>Baldacara</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sanches</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cordeiro</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Jackoswski</surname>
<given-names>AP</given-names>
</string-name>. <article-title>Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone</article-title>. <source xml:lang="en"/>Revista Brasileira De Psiquiatria. <year>2011</year>;<volume>33</volume>:<fpage>30</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">21537720</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0132">
<label>132</label>
<mixed-citation id="bdi12609-cit-0132" publication-type="journal">
<string-name>
<surname>Perrin</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Anand</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dyachkova</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wagner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Frediani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ballerini</surname>
<given-names>A</given-names>
</string-name>. <article-title>A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2012</year>;<volume>27</volume>:<fpage>234</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">20620029</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0133">
<label>133</label>
<mixed-citation id="bdi12609-cit-0133" publication-type="journal">
<string-name>
<surname>Kishi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Matsunaga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iwata</surname>
<given-names>N</given-names>
</string-name>. <article-title>Intramuscular olanzapine for agitated patients: a systematic review and meta‐analysis of randomized controlled trials</article-title>. <source xml:lang="en"/>J Psychiatr Res. <year>2015</year>;<volume>68</volume>:<fpage>198</fpage>‐<lpage>209</lpage>.<pub-id pub-id-type="pmid">26228420</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0134">
<label>134</label>
<mixed-citation id="bdi12609-cit-0134" publication-type="journal">
<string-name>
<surname>Pratts</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Citrome</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Leso</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Opler</surname>
<given-names>LA</given-names>
</string-name>. <article-title>A single‐dose, randomized, double‐blind, placebo‐controlled trial of sublingual asenapine for acute agitation</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2014</year>;<volume>130</volume>:<fpage>61</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">24606117</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0135">
<label>135</label>
<mixed-citation id="bdi12609-cit-0135" publication-type="journal">
<string-name>
<surname>Lenox</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Newhouse</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Creelman</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Whitaker</surname>
<given-names>TM</given-names>
</string-name>. <article-title>Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double‐blind study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1992</year>;<volume>53</volume>:<fpage>47</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">1541605</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0136">
<label>136</label>
<mixed-citation id="bdi12609-cit-0136" publication-type="journal">
<string-name>
<surname>Lim</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Pae</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Paik</surname>
<given-names>IH</given-names>
</string-name>. <article-title>Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study</article-title>. <source xml:lang="en"/>Neuropsychobiology. <year>2010</year>;<volume>62</volume>:<fpage>81</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">20523078</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0137">
<label>137</label>
<mixed-citation id="bdi12609-cit-0137" publication-type="journal">
<string-name>
<surname>Mantovani</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Labate</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Sponholz</surname>
<given-names>A</given-names>
<suffix>Jr</suffix>
</string-name>, et al. <article-title>Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated‐blind trial of 4 intramuscular interventions</article-title>
<source xml:lang="en"/>J Clin Psychopharmacol. <year>2013</year>;<volume>33</volume>:<fpage>306</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">23609398</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0138">
<label>138</label>
<mixed-citation id="bdi12609-cit-0138" publication-type="journal">
<string-name>
<surname>Raveendran</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Tharyan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>CE</given-names>
</string-name>. <article-title>Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine</article-title>. <source xml:lang="en"/>BMJ. <year>2007</year>;<volume>335</volume>:<fpage>865</fpage>.<pub-id pub-id-type="pmid">17954514</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0139">
<label>139</label>
<mixed-citation id="bdi12609-cit-0139" publication-type="journal">
<string-name>
<surname>Lesem</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Zajecka</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Swift</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Reeves</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Harrigan</surname>
<given-names>EP</given-names>
</string-name>. <article-title>Intramuscular ziprasidone, 2 mg versus 10 mg, in the short‐term management of agitated psychotic patients</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2001</year>;<volume>62</volume>:<fpage>12</fpage>‐<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0140">
<label>140</label>
<mixed-citation id="bdi12609-cit-0140" publication-type="journal">
<string-name>
<surname>Currier</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Feifel</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2004</year>;<volume>65</volume>:<fpage>386</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">15096079</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0141">
<label>141</label>
<mixed-citation id="bdi12609-cit-0141" publication-type="journal">
<string-name>
<surname>Villari</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Rocca</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Fonzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Montemagni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pandullo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bogetto</surname>
<given-names>F</given-names>
</string-name>. <article-title>Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation</article-title>. <source xml:lang="en"/>Prog Neuropsychopharmacol Biol Psychiatry. <year>2008</year>;<volume>32</volume>:<fpage>405</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">17900775</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0142">
<label>142</label>
<mixed-citation id="bdi12609-cit-0142" publication-type="journal">
<string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Monotherapy versus combined treatment with second‐generation antipsychotics in bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>(<issue>Suppl.5</issue>):<fpage>9</fpage>‐<lpage>15</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0143">
<label>143</label>
<mixed-citation id="bdi12609-cit-0143" publication-type="journal">
<string-name>
<surname>Yildiz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nikodem</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Correll</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>A network meta‐analysis on comparative efficacy and all‐cause discontinuation of antimanic treatments in acute bipolar mania</article-title>. <source xml:lang="en"/>Psychol Med. <year>2015</year>;<volume>45</volume>:<fpage>299</fpage>‐<lpage>317</lpage>.<pub-id pub-id-type="pmid">25036226</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0144">
<label>144</label>
<mixed-citation id="bdi12609-cit-0144" publication-type="journal">
<string-name>
<surname>Ogawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tajika</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Takeshima</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hayasaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>T</given-names>
</string-name>. <article-title>Mood stabilizers and antipsychotics for acute mania: a systematic review and meta‐analysis of combination/augmentation therapy versus monotherapy</article-title>. <source xml:lang="en"/>CNS Drugs. <year>2014</year>;<volume>28</volume>:<fpage>989</fpage>‐<lpage>1003</lpage>.<pub-id pub-id-type="pmid">25160685</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0145">
<label>145</label>
<mixed-citation id="bdi12609-cit-0145" publication-type="journal">
<string-name>
<surname>Lin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mok</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Polytherapy in bipolar disorder</article-title>. <source xml:lang="en"/>CNS Drugs. <year>2006</year>;<volume>20</volume>:<fpage>29</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">16396522</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0146">
<label>146</label>
<mixed-citation id="bdi12609-cit-0146" publication-type="journal">
<string-name>
<surname>Geoffroy</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Etain</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bellivier</surname>
<given-names>F</given-names>
</string-name>. <article-title>Combination therapy for manic phases: a critical review of a common practice</article-title>. <source xml:lang="en"/>CNS Neurosci Ther. <year>2012</year>;<volume>18</volume>:<fpage>957</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">23095277</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0147">
<label>147</label>
<mixed-citation id="bdi12609-cit-0147" publication-type="journal">
<string-name>
<surname>Bourin</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Severus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Schronen</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Lithium as add‐on to quetiapine XR in adult patients with acute mania: a 6‐week, multicenter, double‐blind, randomized, placebo‐controlled study</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2014</year>;<volume>2</volume>:<fpage>14</fpage>.<pub-id pub-id-type="pmid">25505693</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0148">
<label>148</label>
<mixed-citation id="bdi12609-cit-0148" publication-type="journal">
<string-name>
<surname>Reischies</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Hartikainen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berghoefer</surname>
<given-names>A</given-names>
</string-name>. <article-title>Initial lithium and valproate combination therapy in acute mania</article-title>. <source xml:lang="en"/>Neuropsychobiology. <year>2002</year>;<volume>46</volume>:<fpage>22</fpage>‐<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0149">
<label>149</label>
<mixed-citation id="bdi12609-cit-0149" publication-type="journal">
<string-name>
<surname>Reischies</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Hartikainen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berghofer</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2002</year>;<volume>35</volume>:<fpage>244</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">12518274</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0150">
<label>150</label>
<mixed-citation id="bdi12609-cit-0150" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Persad</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mazmanian</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Karunaratne</surname>
<given-names>K</given-names>
</string-name>. <article-title>Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>1993</year>;<volume>38</volume>:<fpage>137</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">8467440</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0151">
<label>151</label>
<mixed-citation id="bdi12609-cit-0151" publication-type="journal">
<string-name>
<surname>Granneman</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Schneck</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Cavanaugh</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Witt</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1996</year>;<volume>57</volume>:<fpage>204</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">8626351</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0152">
<label>152</label>
<mixed-citation id="bdi12609-cit-0152" publication-type="journal">
<string-name>
<surname>Sikdar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kulhara</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Avasthi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>H</given-names>
</string-name>. <article-title>Combined chlorpromazine and electroconvulsive‐therapy in mania</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>1994</year>;<volume>164</volume>:<fpage>806</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">7952988</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0153">
<label>153</label>
<mixed-citation id="bdi12609-cit-0153" publication-type="journal">
<string-name>
<surname>Small</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Klapper</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Kellams</surname>
<given-names>JJ</given-names>
</string-name>, et al. <article-title>Electroconvulsive treatment compared with lithium in the management of manic states</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1988</year>;<volume>45</volume>:<fpage>727</fpage>‐<lpage>32</lpage>.<pub-id pub-id-type="pmid">2899425</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0154">
<label>154</label>
<mixed-citation id="bdi12609-cit-0154" publication-type="journal">
<string-name>
<surname>Mohan</surname>
<given-names>TSP</given-names>
</string-name>, <string-name>
<surname>Tharyan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Raveendran</surname>
<given-names>NS</given-names>
</string-name>. <article-title>Effects of stimulus intensity on the efficacy and safety of twice‐weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>126</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">19267695</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0155">
<label>155</label>
<mixed-citation id="bdi12609-cit-0155" publication-type="journal">
<string-name>
<surname>Hiremani</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Thirthalli</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tharayil</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Gangadhar</surname>
<given-names>BN</given-names>
</string-name>. <article-title>Double‐blind randomized controlled study comparing short‐term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>701</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">18837864</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0156">
<label>156</label>
<mixed-citation id="bdi12609-cit-0156" publication-type="journal">
<string-name>
<surname>Barekatain</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jahangard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Haghighi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ranjkesh</surname>
<given-names>F</given-names>
</string-name>. <article-title>Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients</article-title>. <source xml:lang="en"/>J ECT. <year>2008</year>;<volume>24</volume>:<fpage>199</fpage>‐<lpage>202</lpage>.<pub-id pub-id-type="pmid">18772704</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0157">
<label>157</label>
<mixed-citation id="bdi12609-cit-0157" publication-type="journal">
<string-name>
<surname>Prien</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Caffey</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Klett</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Comparison of lithium carbonate and chlorpromazine in treatment of mania – report of veterans‐administration and National‐Institute of Mental Health Collaborative Study Group</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1972</year>;<volume>26</volume>:<fpage>146</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">4551257</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0158">
<label>158</label>
<mixed-citation id="bdi12609-cit-0158" publication-type="journal">
<string-name>
<surname>Curtin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>P</given-names>
</string-name>. <article-title>Clonazepam and lorazepam in acute mania: a Bayesian meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2004</year>;<volume>78</volume>:<fpage>201</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">15013244</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0159">
<label>159</label>
<mixed-citation id="bdi12609-cit-0159" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Kimmel</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Woyshville</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Clozapine for treatment‐refractory mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1996</year>;<volume>153</volume>:<fpage>759</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">8633686</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0160">
<label>160</label>
<mixed-citation id="bdi12609-cit-0160" publication-type="journal">
<string-name>
<surname>Kimmel</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Woyshville</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Meltzer</surname>
<given-names>HY</given-names>
</string-name>. <article-title>Clozapine in treatment‐refractory mood disorders</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1994</year>;<volume>55</volume>:<fpage>91</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">7961583</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0161">
<label>161</label>
<mixed-citation id="bdi12609-cit-0161" publication-type="journal">
<string-name>
<surname>Barbini</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Scherillo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Crespi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</string-name>. <article-title>Response to clozapine in acute mania is more rapid than that of chlorpromazine</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>1997</year>;<volume>12</volume>:<fpage>109</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">9219046</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0162">
<label>162</label>
<mixed-citation id="bdi12609-cit-0162" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kraemer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Clinical outcome in a randomized 1‐year trial of clozapine versus treatment as usual for patients with treatment‐resistant illness and a history of mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1999</year>;<volume>156</volume>:<fpage>1164</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">10450255</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0163">
<label>163</label>
<mixed-citation id="bdi12609-cit-0163" publication-type="journal">
<string-name>
<surname>Juruena</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Ottoni</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Machado‐Vieira</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add‐on treatment to lithium in a double‐blind, randomized trial</article-title>. <source xml:lang="en"/>Prog Neuropsychopharmacol Biol Psychiatry. <year>2009</year>;<volume>33</volume>:<fpage>94</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19007842</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0164">
<label>164</label>
<mixed-citation id="bdi12609-cit-0164" publication-type="journal">
<string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double‐blind, placebo‐controlled comparison of efficacy and safety</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2002</year>;<volume>159</volume>:<fpage>1146</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">12091192</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0165">
<label>165</label>
<mixed-citation id="bdi12609-cit-0165" publication-type="journal">
<string-name>
<surname>Talaei</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pourgholami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Khatibi‐Moghadam</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Tamoxifen: a protein kinase C inhibitor to treat mania a systematic review and meta‐analysis of randomized, placebo‐controlled trials</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2016</year>;<volume>36</volume>:<fpage>272</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">27088436</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0166">
<label>166</label>
<mixed-citation id="bdi12609-cit-0166" publication-type="journal">
<string-name>
<surname>Praharaj</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Ram</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>M</given-names>
</string-name>. <article-title>Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>117</volume>:<fpage>146</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">19178948</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0167">
<label>167</label>
<mixed-citation id="bdi12609-cit-0167" publication-type="journal">
<string-name>
<surname>Weiser</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Burshtein</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gershon</surname>
<given-names>AA</given-names>
</string-name>, et al. <article-title>Allopurinol for mania: a randomized trial of allopurinol versus placebo as add‐on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>441</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">24712840</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0168">
<label>168</label>
<mixed-citation id="bdi12609-cit-0168" publication-type="journal">
<string-name>
<surname>Grunze</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kotlik</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double‐blind, randomised phase II clinical studies in patients with bipolar disorder I</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>174</volume>:<fpage>70</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">25484179</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0169">
<label>169</label>
<mixed-citation id="bdi12609-cit-0169" publication-type="journal">
<string-name>
<surname>Sarris</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mischoulon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schweitzer</surname>
<given-names>I</given-names>
</string-name>. <article-title>Omega‐3 for bipolar disorder: meta‐analyses of use in mania and bipolar depression</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2012</year>;<volume>73</volume>:<fpage>81</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">21903025</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0170">
<label>170</label>
<mixed-citation id="bdi12609-cit-0170" publication-type="journal">
<string-name>
<surname>Bersudsky</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Applebaum</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gaiduk</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double‐blind, controlled, add‐on clinical trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2010</year>;<volume>12</volume>:<fpage>376</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">20636634</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0171">
<label>171</label>
<mixed-citation id="bdi12609-cit-0171" publication-type="journal">
<string-name>
<surname>Weiser</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Levi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>SZ</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐ and risperidone‐controlled study on valnoctamide for acute mania</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2017</year>;<volume>19</volume>:<fpage>285</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">28605109</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0172">
<label>172</label>
<mixed-citation id="bdi12609-cit-0172" publication-type="journal">
<string-name>
<surname>Dauphinais</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Knable</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Polanski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>N</given-names>
</string-name>. <article-title>Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo‐controlled adjunctive trial</article-title>. <source xml:lang="en"/>Psychopharmacol Bull. <year>2011</year>;<volume>44</volume>:<fpage>5</fpage>‐<lpage>17</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0173">
<label>173</label>
<mixed-citation id="bdi12609-cit-0173" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, et al. <article-title>Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12‐week, double‐blind study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>1776</fpage>‐<lpage>89</lpage>.<pub-id pub-id-type="pmid">19014751</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0174">
<label>174</label>
<mixed-citation id="bdi12609-cit-0174" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Augustyns</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ravindran</surname>
<given-names>A</given-names>
</string-name>. <article-title>Mood stabilisers plus risperidone or placebo in the treatment of acute mania – International, double‐blind, randomised controlled trial</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2003</year>;<volume>182</volume>:<fpage>141</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12562742</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0175">
<label>175</label>
<mixed-citation id="bdi12609-cit-0175" publication-type="journal">
<string-name>
<surname>Sarris</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mischoulon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schweitzer</surname>
<given-names>I</given-names>
</string-name>. <article-title>Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2011</year>;<volume>13</volume>:<fpage>454</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">22017215</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0176">
<label>176</label>
<mixed-citation id="bdi12609-cit-0176" publication-type="journal">
<string-name>
<surname>Behzadi</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Omrani</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chalian</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Asadi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ghadiri</surname>
<given-names>M</given-names>
</string-name>. <article-title>Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double‐blind randomized controlled trial</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2009</year>;<volume>120</volume>:<fpage>441</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">19392814</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0177">
<label>177</label>
<mixed-citation id="bdi12609-cit-0177" publication-type="journal">
<string-name>
<surname>Chouinard</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Annable</surname>
<given-names>L</given-names>
</string-name>. <article-title>A controlled clinical trial of <sc>l</sc>‐tryptophan in acute mania</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>1985</year>;<volume>20</volume>:<fpage>546</fpage>‐<lpage>57</lpage>.<pub-id pub-id-type="pmid">3886024</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0178">
<label>178</label>
<mixed-citation id="bdi12609-cit-0178" publication-type="journal">
<string-name>
<surname>Kulkarni</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania</article-title>. <source xml:lang="en"/>Psychoneuroendocrinology. <year>2014</year>;<volume>43</volume>:<fpage>52</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">24703170</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0179">
<label>179</label>
<mixed-citation id="bdi12609-cit-0179" publication-type="journal">
<string-name>
<surname>Kulkarni</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Garland</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Scaffidi</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder</article-title>. <source xml:lang="en"/>Psychoneuroendocrinology. <year>2006</year>;<volume>31</volume>:<fpage>543</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">16356651</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0180">
<label>180</label>
<mixed-citation id="bdi12609-cit-0180" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>H‐A</given-names>
</string-name>, <string-name>
<surname>Papadakis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation</article-title>. <source xml:lang="en"/>Clin Neuropharmacol. <year>2009</year>;<volume>32</volume>:<fpage>199</fpage>‐<lpage>204</lpage>.<pub-id pub-id-type="pmid">19620854</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0181">
<label>181</label>
<mixed-citation id="bdi12609-cit-0181" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levitt</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Joffe</surname>
<given-names>RT</given-names>
</string-name>. <article-title>Mexiletine in treatment‐resistant bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2000</year>;<volume>57</volume>:<fpage>249</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">10708839</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0182">
<label>182</label>
<mixed-citation id="bdi12609-cit-0182" publication-type="journal">
<string-name>
<surname>Bersani</surname>
<given-names>G</given-names>
</string-name>. <article-title>Levetiracetam in bipolar spectrum disorders: first evidence of efficacy in an open, add‐ on study</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2004</year>;<volume>19</volume>:<fpage>355</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">15252830</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0183">
<label>183</label>
<mixed-citation id="bdi12609-cit-0183" publication-type="journal">
<string-name>
<surname>Mishory</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yaroslavsky</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Bersudsky</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Belmaker</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Phenytoin as an antimanic anticonvulsant: a controlled study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2000</year>;<volume>157</volume>:<fpage>463</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">10698828</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0184">
<label>184</label>
<mixed-citation id="bdi12609-cit-0184" publication-type="journal">
<string-name>
<surname>Henriksen</surname>
<given-names>TEG</given-names>
</string-name>, <string-name>
<surname>Skrede</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fasmer</surname>
<given-names>OB</given-names>
</string-name>, et al. <article-title>Blue‐blocking glasses as additive treatment for mania: a randomized placebo‐controlled trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>221</fpage>‐<lpage>32</lpage>.<pub-id pub-id-type="pmid">27226262</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0185">
<label>185</label>
<mixed-citation id="bdi12609-cit-0185" publication-type="journal">
<string-name>
<surname>Janicak</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Pandey</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Verapamil for the treatment of acute mania: a double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1998</year>;<volume>155</volume>:<fpage>972</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">9659868</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0186">
<label>186</label>
<mixed-citation id="bdi12609-cit-0186" publication-type="journal">
<string-name>
<surname>Mallinger</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Haskett</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>856</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">19594501</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0187">
<label>187</label>
<mixed-citation id="bdi12609-cit-0187" publication-type="journal">
<string-name>
<surname>Wisner</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Peindl</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Perel</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Hanusa</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Piontek</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Baab</surname>
<given-names>S</given-names>
</string-name>. <article-title>Verapamil treatment for women with bipolar disorder</article-title>. <source xml:lang="en"/>Biol Psychiatry. <year>2002</year>;<volume>51</volume>:<fpage>745</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">11983188</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0188">
<label>188</label>
<mixed-citation id="bdi12609-cit-0188" publication-type="journal">
<string-name>
<surname>Kusumakar</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Haslam</surname>
<given-names>DRS</given-names>
</string-name>, et al. <article-title>Treatment of mania, mixed state, and rapid cycling</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>1997</year>;<volume>42</volume>:<fpage>S79</fpage>‐<lpage>S86</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0189">
<label>189</label>
<mixed-citation id="bdi12609-cit-0189" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Key treatment studies of lithium in manic‐depressive illness: efficacy and side effects</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1998</year>;<volume>59</volume>:<fpage>13</fpage>‐<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0190">
<label>190</label>
<mixed-citation id="bdi12609-cit-0190" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Clinical correlates of therapeutic response in bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2001</year>;<volume>67</volume>:<fpage>257</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">11869775</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0191">
<label>191</label>
<mixed-citation id="bdi12609-cit-0191" publication-type="journal">
<string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Depression during mania – treatment response to lithium or divalproex</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1997</year>;<volume>54</volume>:<fpage>37</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">9006398</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0192">
<label>192</label>
<mixed-citation id="bdi12609-cit-0192" publication-type="journal">
<string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>. <article-title>Predicting therapeutic response in acute manic episodes: data from controlled studies with divalproex</article-title>. <source xml:lang="en"/>Encephale. <year>2001</year>;<volume>27</volume>:<fpage>277</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">11488258</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0193">
<label>193</label>
<mixed-citation id="bdi12609-cit-0193" publication-type="journal">
<string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Dilsaver</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>DD</given-names>
</string-name>. <article-title>Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania</article-title>. <source xml:lang="en"/>Neuropsychopharmacology. <year>2002</year>;<volume>26</volume>:<fpage>530</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">11927177</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0194">
<label>194</label>
<mixed-citation id="bdi12609-cit-0194" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Strakowski</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Anticonvulsants and antipsychotics in the treatment of bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1998</year>;<volume>59</volume>:<fpage>74</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">9674940</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0195">
<label>195</label>
<mixed-citation id="bdi12609-cit-0195" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficacy of antimanic treatments in mixed states</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>22</fpage>‐<lpage>36</lpage>.<pub-id pub-id-type="pmid">22510034</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0196">
<label>196</label>
<mixed-citation id="bdi12609-cit-0196" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>O'Donovan</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2005</year>;<volume>7</volume>:<fpage>5</fpage>‐<lpage>69</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0197">
<label>197</label>
<mixed-citation id="bdi12609-cit-0197" publication-type="journal">
<string-name>
<surname>Gonzalez‐Pinto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Galan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Martin‐Carrasco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ballesteros</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Maurino</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>. <article-title>Anxiety as a marker of severity in acute mania</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2012</year>;<volume>126</volume>:<fpage>351</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">22620488</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0198">
<label>198</label>
<mixed-citation id="bdi12609-cit-0198" publication-type="journal">
<string-name>
<surname>Feske</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mallinger</surname>
<given-names>AG</given-names>
</string-name>, et al. <article-title>Anxiety as a correlate of response to the acute treatment of bipolar I disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2000</year>;<volume>157</volume>:<fpage>956</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">10831476</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0199">
<label>199</label>
<mixed-citation id="bdi12609-cit-0199" publication-type="journal">
<string-name>
<surname>Rakofsky</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Dunlop</surname>
<given-names>BW</given-names>
</string-name>. <article-title>Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>81</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">21208580</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0200">
<label>200</label>
<mixed-citation id="bdi12609-cit-0200" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Morralla</surname>
<given-names>C</given-names>
</string-name>. <article-title>Prevalence of mixed mania using 3 definitions</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>125</volume>:<fpage>61</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">20627320</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0201">
<label>201</label>
<mixed-citation id="bdi12609-cit-0201" publication-type="journal">
<string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bonnin</surname>
<given-names>CDM</given-names>
</string-name>, <string-name>
<surname>Hidalgo‐Mazzei</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Making sense of DSM‐5 mania with depressive features</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2015</year>;<volume>49</volume>:<fpage>540</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">25943979</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0202">
<label>202</label>
<mixed-citation id="bdi12609-cit-0202" publication-type="journal">
<string-name>
<surname>Castle</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Bipolar mixed states: still mixed up?</article-title>
<source xml:lang="en"/>Curr Opin Psychiatry. <year>2014</year>;<volume>27</volume>:<fpage>38</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">24270474</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0203">
<label>203</label>
<mixed-citation id="bdi12609-cit-0203" publication-type="journal">
<string-name>
<surname>Fountoulakis</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Kontis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gonda</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Siamouli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Treatment of mixed bipolar states</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2012</year>;<volume>15</volume>:<fpage>1015</fpage>‐<lpage>26</lpage>.<pub-id pub-id-type="pmid">22217434</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0204">
<label>204</label>
<mixed-citation id="bdi12609-cit-0204" publication-type="journal">
<string-name>
<surname>Muralidharan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>
<given-names>LE</given-names>
</string-name>, et al. <article-title>Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta‐analysis of placebo‐controlled trials</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>150</volume>:<fpage>408</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">23735211</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0205">
<label>205</label>
<mixed-citation id="bdi12609-cit-0205" publication-type="journal">
<string-name>
<surname>Cuomo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nikolova</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Yalin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Arnone</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fagiolini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Pharmacological treatment of mixed states</article-title>. <source xml:lang="en"/>CNS Spectr. <year>2017</year>;<volume>22</volume>:<fpage>186</fpage>‐<lpage>95</lpage>.<pub-id pub-id-type="pmid">28416033</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0206">
<label>206</label>
<mixed-citation id="bdi12609-cit-0206" publication-type="journal">
<string-name>
<surname>Coryell</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Turvey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Mueller</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Endicott</surname>
<given-names>J</given-names>
</string-name>. <article-title>The significance of psychotic features in manic episodes: a report from the NIMH collaborative study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2001</year>;<volume>67</volume>:<fpage>79</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">11869754</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0207">
<label>207</label>
<mixed-citation id="bdi12609-cit-0207" publication-type="journal">
<string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Daniel</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Kochan</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Wozniak</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Psychosis in mania: specificity of its role in severity and treatment response</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2004</year>;<volume>65</volume>:<fpage>825</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15291660</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0208">
<label>208</label>
<mixed-citation id="bdi12609-cit-0208" publication-type="journal">
<string-name>
<surname>Toni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Perugi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mata</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Madaro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maremmani</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>. <article-title>Is mood‐incongruent manic psychosis a distinct subtype?</article-title>
<source xml:lang="en"/>Eur Arch Psychiatry Clin Neurosci. <year>2001</year>;<volume>251</volume>:<fpage>12</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">11315512</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0209">
<label>209</label>
<mixed-citation id="bdi12609-cit-0209" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsuang</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>DC</given-names>
</string-name>. <article-title>Prediction of outcome in mania by mood‐congruent or mood‐incongruent psychotic features</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1992</year>;<volume>149</volume>:<fpage>1580</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">1415828</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0210">
<label>210</label>
<mixed-citation id="bdi12609-cit-0210" publication-type="journal">
<string-name>
<surname>Strakowski</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sax</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Fleck</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Bourne</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Is impaired outcome following a first manic episode due to mood‐incongruent psychosis?</article-title>
<source xml:lang="en"/>J Affect Disord. <year>2000</year>;<volume>61</volume>:<fpage>87</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">11099745</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0211">
<label>211</label>
<mixed-citation id="bdi12609-cit-0211" publication-type="journal">
<string-name>
<surname>Fennig</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bromet</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Karant</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Ram</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jandorf</surname>
<given-names>L</given-names>
</string-name>. <article-title>Mood‐congruent versus mood‐incongruent psychotic symptoms in first‐admission patients with affective disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1996</year>;<volume>37</volume>:<fpage>23</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">8682975</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0212">
<label>212</label>
<mixed-citation id="bdi12609-cit-0212" publication-type="journal">
<string-name>
<surname>Carlson</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Kotov</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Ruggero</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bromet</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Early determinants of four‐year clinical outcomes in bipolar disorder with psychosis</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>19</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">22329469</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0213">
<label>213</label>
<mixed-citation id="bdi12609-cit-0213" publication-type="journal">
<string-name>
<surname>Smulevich</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Khanna</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eerdekens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Karcher</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>F</given-names>
</string-name>. <article-title>Acute and continuation risperidone monotherapy in bipolar mania: a 3‐week placebo‐controlled trial followed by a 9‐week double‐blind trial of risperidone and haloperidol</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2005</year>;<volume>15</volume>:<fpage>75</fpage>‐<lpage>84</lpage>.<pub-id pub-id-type="pmid">15572276</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0214">
<label>214</label>
<mixed-citation id="bdi12609-cit-0214" publication-type="journal">
<string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>, <string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Rapid antimanic effect of risperidone monotherapy: a 3‐week multicenter, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2004</year>;<volume>161</volume>:<fpage>1057</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">15169694</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0215">
<label>215</label>
<mixed-citation id="bdi12609-cit-0215" publication-type="journal">
<string-name>
<surname>Valenti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Undurraga</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Risk factors for rapid cycling in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>549</fpage>‐<lpage>59</lpage>.<pub-id pub-id-type="pmid">25682854</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0216">
<label>216</label>
<mixed-citation id="bdi12609-cit-0216" publication-type="journal">
<string-name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Angst</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS‐R)</article-title>. <source xml:lang="en"/>Mol Psychiatry. <year>2010</year>;<volume>15</volume>:<fpage>1075</fpage>‐<lpage>87</lpage>.<pub-id pub-id-type="pmid">19564874</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0217">
<label>217</label>
<mixed-citation id="bdi12609-cit-0217" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsang</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>RC</given-names>
</string-name>, et al. <article-title>Rapid‐cycling bipolar disorder: cross‐national community study</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2010</year>;<volume>196</volume>:<fpage>217</fpage>‐<lpage>25</lpage>.<pub-id pub-id-type="pmid">20194545</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0218">
<label>218</label>
<mixed-citation id="bdi12609-cit-0218" publication-type="journal">
<string-name>
<surname>Carvalho</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Dimellis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gonda</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Fountoulakis</surname>
<given-names>KN</given-names>
</string-name>. <article-title>Rapid cycling in bipolar disorder: a systematic review</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>E578</fpage>‐<lpage>E86</lpage>.<pub-id pub-id-type="pmid">25004199</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0219">
<label>219</label>
<mixed-citation id="bdi12609-cit-0219" publication-type="journal">
<string-name>
<surname>Fountoulakis</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Kontis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gonda</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>A systematic review of the evidence on the treatment of rapid cycling bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>115</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">23437958</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0220">
<label>220</label>
<mixed-citation id="bdi12609-cit-0220" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Shelton</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Rapport</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>A 20‐month, double‐blind, maintenance trial of lithium versus divalproex in rapid‐cycling bipolar disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2005</year>;<volume>162</volume>:<fpage>2152</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">16263857</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0221">
<label>221</label>
<mixed-citation id="bdi12609-cit-0221" publication-type="journal">
<string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Fein</surname>
<given-names>EB</given-names>
</string-name>, et al. <article-title>Lamotrigine as add‐on treatment to lithium and divalproex: lessons learned from a double‐blind, placebo‐controlled trial in rapid‐cycling bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>780</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23107222</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0222">
<label>222</label>
<mixed-citation id="bdi12609-cit-0222" publication-type="journal">
<string-name>
<surname>Murray</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Beaulieu</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation</article-title>
<source xml:lang="en"/>Bipolar Disord. <year>2011</year>;<volume>13</volume>:<fpage>687</fpage>‐<lpage>95</lpage>.<pub-id pub-id-type="pmid">22085482</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0223">
<label>223</label>
<mixed-citation id="bdi12609-cit-0223" publication-type="journal">
<string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Denicoff</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>, et al. <article-title>Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>680</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">12823083</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0224">
<label>224</label>
<mixed-citation id="bdi12609-cit-0224" publication-type="journal">
<string-name>
<surname>Forte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vazquez</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Pompili</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Girardi</surname>
<given-names>P</given-names>
</string-name>. <article-title>Long‐term morbidity in bipolar‐I, bipolar‐II, and unipolar major depressive disorders</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>178</volume>:<fpage>71</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">25797049</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0225">
<label>225</label>
<mixed-citation id="bdi12609-cit-0225" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Lecrubier</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fieve</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Krishnan</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Quality of life in patients with bipolar I depression: data from 920 patients</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>379</fpage>‐<lpage>85</lpage>.<pub-id pub-id-type="pmid">15383130</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0226">
<label>226</label>
<mixed-citation id="bdi12609-cit-0226" publication-type="journal">
<string-name>
<surname>Vojta</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kinosian</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Glick</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Altshuler</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Self‐reported quality of life across mood states in bipolar disorder</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2001</year>;<volume>42</volume>:<fpage>190</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">11349236</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0227">
<label>227</label>
<mixed-citation id="bdi12609-cit-0227" publication-type="journal">
<string-name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Gitlin</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Mintz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Leight</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Subsyndromal depression is associated with functional impairment in patients with bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>807</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">12363122</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0228">
<label>228</label>
<mixed-citation id="bdi12609-cit-0228" publication-type="journal">
<string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Dennehy</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Miyahara</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP‐BD</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>114</volume>:<fpage>58</fpage>‐<lpage>67</lpage>.<pub-id pub-id-type="pmid">18708263</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0229">
<label>229</label>
<mixed-citation id="bdi12609-cit-0229" publication-type="journal">
<string-name>
<surname>Gitlin</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Miklowitz</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>The difficult lives of individuals with bipolar disorder: a review of functional outcomes and their implications for treatment</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2017</year>;<volume>209</volume>:<fpage>147</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">27914248</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0230">
<label>230</label>
<mixed-citation id="bdi12609-cit-0230" publication-type="journal">
<string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hennen</surname>
<given-names>J</given-names>
</string-name>. <article-title>Lithium treatment and suicide risk in major affective disorders: update and new findings</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>44</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">12720484</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0231">
<label>231</label>
<mixed-citation id="bdi12609-cit-0231" publication-type="journal">
<string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pompili</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Suicide attempts in bipolar disorders: comprehensive review of 101 reports</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2016</year>;<volume>133</volume>:<fpage>174</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">26555604</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0232">
<label>232</label>
<mixed-citation id="bdi12609-cit-0232" publication-type="journal">
<string-name>
<surname>Holma</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Haukka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Suominen</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>652</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">24636453</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0233">
<label>233</label>
<mixed-citation id="bdi12609-cit-0233" publication-type="journal">
<string-name>
<surname>Bonnin</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Gonzalez‐Pinto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sole</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>160</volume>:<fpage>50</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">24709022</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0234">
<label>234</label>
<mixed-citation id="bdi12609-cit-0234" publication-type="journal">
<string-name>
<surname>Mora</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Portella</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Forcada</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mur</surname>
<given-names>M</given-names>
</string-name>. <article-title>Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium‐treated, euthymic bipolar patients: a 6‐year follow‐up study</article-title>. <source xml:lang="en"/>Psychol Med. <year>2013</year>;<volume>43</volume>:<fpage>1187</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">22935452</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0235">
<label>235</label>
<mixed-citation id="bdi12609-cit-0235" publication-type="journal">
<string-name>
<surname>Demant</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Vinberg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Messing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Miskowiak</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Assessment of subjective and objective cognitive function in bipolar disorder: correlations, predictors and the relation to psychosocial function</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2015</year>;<volume>229</volume>:<fpage>565</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">26073281</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0236">
<label>236</label>
<mixed-citation id="bdi12609-cit-0236" publication-type="journal">
<string-name>
<surname>Rock</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Roiser</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Riedel</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Blackwell</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Cognitive impairment in depression: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Psychol Med. <year>2014</year>;<volume>44</volume>:<fpage>2029</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">24168753</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0237">
<label>237</label>
<mixed-citation id="bdi12609-cit-0237" publication-type="journal">
<string-name>
<surname>Depp</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Mausbach</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Harmell</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>Meta‐analysis of the association between cognitive abilities and everyday functioning in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>217</fpage>‐<lpage>26</lpage>.<pub-id pub-id-type="pmid">22548895</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0238">
<label>238</label>
<mixed-citation id="bdi12609-cit-0238" publication-type="journal">
<string-name>
<surname>Kozicky</surname>
<given-names>J‐M</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2012</year>;<volume>27</volume>:<fpage>91</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">22124206</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0239">
<label>239</label>
<mixed-citation id="bdi12609-cit-0239" publication-type="journal">
<string-name>
<surname>Miskowiak</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Carvalho</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>. <article-title>Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2016</year>;<volume>26</volume>:<fpage>1541</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">27593623</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0240">
<label>240</label>
<mixed-citation id="bdi12609-cit-0240" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Mackala</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Basivireddy</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open‐label, pilot study</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2017</year>;<volume>4</volume>:<fpage>208</fpage>‐<lpage>17</lpage>.<pub-id pub-id-type="pmid">28185899</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0241">
<label>241</label>
<mixed-citation id="bdi12609-cit-0241" publication-type="journal">
<string-name>
<surname>Maneeton</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Maneeton</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Srisurapanont</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Quetiapine monotherapy in acute phase for major depressive disorder: a meta‐analysis of randomized, placebo‐controlled trials</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2012</year>;<volume>12</volume>:<fpage>160</fpage>.<pub-id pub-id-type="pmid">23017200</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0242">
<label>242</label>
<mixed-citation id="bdi12609-cit-0242" publication-type="journal">
<string-name>
<surname>Selle</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Schalkwijk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vazquez</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Treatments for acute bipolar depression: meta‐analyses of placebo‐controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2014</year>;<volume>47</volume>:<fpage>43</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">24549862</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0243">
<label>243</label>
<mixed-citation id="bdi12609-cit-0243" publication-type="journal">
<string-name>
<surname>Datto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pottorf</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Feeley</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>LaPorte</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liss</surname>
<given-names>C</given-names>
</string-name>. <article-title>Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo‐controlled clinical trials of acute bipolar depression</article-title>. <source xml:lang="en"/>Ann Gen Psychiatry. <year>2016</year>;<volume>15</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">26973704</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0244">
<label>244</label>
<mixed-citation id="bdi12609-cit-0244" publication-type="journal">
<string-name>
<surname>Srisurapanont</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Zis</surname>
<given-names>AP</given-names>
</string-name>. <article-title>Treatment of acute bipolar depression: a review of the literature</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>1995</year>;<volume>40</volume>:<fpage>533</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">8574989</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0245">
<label>245</label>
<mixed-citation id="bdi12609-cit-0245" publication-type="journal">
<string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>Effectiveness of adjunctive antidepressant treatment for bipolar depression</article-title>. <source xml:lang="en"/>N Engl J Med. <year>2007</year>;<volume>356</volume>:<fpage>1711</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">17392295</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0246">
<label>246</label>
<mixed-citation id="bdi12609-cit-0246" publication-type="journal">
<string-name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Gyulai</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Double‐blind, placebo‐controlled comparison of imipramine and paroxetine in the treatment of bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2001</year>;<volume>158</volume>:<fpage>906</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">11384898</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0247">
<label>247</label>
<mixed-citation id="bdi12609-cit-0247" publication-type="journal">
<string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Lamotrigine for treatment of bipolar depression: independent meta‐analysis and meta‐regression of individual patient data from five randomised trials</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2009</year>;<volume>194</volume>:<fpage>4</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19118318</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0248">
<label>248</label>
<mixed-citation id="bdi12609-cit-0248" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, et al. <article-title>A double‐blind placebo‐controlled study of lamotrigine monotherapy in outpatients with bipolar I depression</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1999</year>;<volume>60</volume>:<fpage>79</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">10084633</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0249">
<label>249</label>
<mixed-citation id="bdi12609-cit-0249" publication-type="journal">
<string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cucchiaro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2014</year>;<volume>171</volume>:<fpage>169</fpage>‐<lpage>77</lpage>.<pub-id pub-id-type="pmid">24170221</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0250">
<label>250</label>
<mixed-citation id="bdi12609-cit-0250" publication-type="journal">
<string-name>
<surname>Pikalov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>. <article-title>Efficacy of lurasidone in bipolar depression: pooled results of two adjunctive studies with lithium or valproate</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>178</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0251">
<label>251</label>
<mixed-citation id="bdi12609-cit-0251" publication-type="journal">
<string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Gardiner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rendell</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 x 2 factorial randomised trial</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2016</year>;<volume>3</volume>:<fpage>31</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">26687300</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0252">
<label>252</label>
<mixed-citation id="bdi12609-cit-0252" publication-type="journal">
<string-name>
<surname>van der Loos</surname>
<given-names>MLM</given-names>
</string-name>, <string-name>
<surname>Mulder</surname>
<given-names>PGH</given-names>
</string-name>, <string-name>
<surname>Hartong</surname>
<given-names>EGTM</given-names>
</string-name>, et al. <article-title>Efficacy and safety of lamotrigine as add‐on treatment to lithium in bipolar depression: a multicenter, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2009</year>;<volume>70</volume>:<fpage>223</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">19200421</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0253">
<label>253</label>
<mixed-citation id="bdi12609-cit-0253" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>A double‐blind, placebo‐controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>150</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">20122369</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0254">
<label>254</label>
<mixed-citation id="bdi12609-cit-0254" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Huffman</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>RL</given-names>
</string-name>, et al. <article-title>Lamotrigine in the acute treatment of bipolar depression: results of five double‐blind, placebo‐controlled clinical trials</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>323</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">18271912</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0255">
<label>255</label>
<mixed-citation id="bdi12609-cit-0255" publication-type="journal">
<string-name>
<surname>Unholzer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haen</surname>
<given-names>E</given-names>
</string-name>. <article-title>Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2015</year>;<volume>48</volume>:<fpage>211</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">26252722</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0256">
<label>256</label>
<mixed-citation id="bdi12609-cit-0256" publication-type="journal">
<string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Ganocy</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Brecher</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Clinical value of early partial symptomatic improvement in the prediction of response and remission during short‐term treatment trials in 3369 subjects with bipolar I or II depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>130</volume>:<fpage>171</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">21071096</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0257">
<label>257</label>
<mixed-citation id="bdi12609-cit-0257" publication-type="journal">
<string-name>
<surname>Grande</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bobes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Saiz‐Ruiz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alamo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>. <article-title>Antipsychotic switching in bipolar disorders: a systematic review</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2014</year>;<volume>17</volume>:<fpage>497</fpage>‐<lpage>507</lpage>.<pub-id pub-id-type="pmid">24139622</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0258">
<label>258</label>
<mixed-citation id="bdi12609-cit-0258" publication-type="journal">
<string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>124</volume>:<fpage>228</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">20044142</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0259">
<label>259</label>
<mixed-citation id="bdi12609-cit-0259" publication-type="journal">
<string-name>
<surname>McGirr</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vohringer</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Safety and efficacy of adjunctive second‐generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta‐analysis of randomised placebo‐controlled trials</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2016</year>;<volume>3</volume>:<fpage>1138</fpage>‐<lpage>46</lpage>.<pub-id pub-id-type="pmid">28100425</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0260">
<label>260</label>
<mixed-citation id="bdi12609-cit-0260" publication-type="journal">
<string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, et al. <article-title>The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2013</year>;<volume>170</volume>:<fpage>1249</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">24030475</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0261">
<label>261</label>
<mixed-citation id="bdi12609-cit-0261" publication-type="journal">
<string-name>
<surname>Schoeyen</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Kessler</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Andreassen</surname>
<given-names>OA</given-names>
</string-name>, et al. <article-title>Treatment‐resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm‐based pharmacological treatment</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2015</year>;<volume>172</volume>:<fpage>41</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">25219389</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0262">
<label>262</label>
<mixed-citation id="bdi12609-cit-0262" publication-type="journal">
<string-name>
<surname>Durgam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Earley</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lipschitz</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>An 8‐week randomized, double‐blind, placebo‐controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2016</year>;<volume>173</volume>:<fpage>271</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">26541814</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0263">
<label>263</label>
<mixed-citation id="bdi12609-cit-0263" publication-type="book">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Durgam</surname>
<given-names>S</given-names>
</string-name>, et al. <source xml:lang="en"/>Efficacy of Cariprazine in Bipolar Depression: Post Hoc Band‐Pass Analyses of 2 Randomized, Double‐Blind, Placebo‐Controlled Trials. <publisher-loc>Atlanta, Georga</publisher-loc>: <publisher-name>American Psychiatric Association Annual meeting</publisher-name>; <year>2016</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0264">
<label>264</label>
<mixed-citation id="bdi12609-cit-0264" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Efficacy of olanzapine and olanzapine‐fluoxetine combination in the treatment of bipolar I depression</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2003</year>;<volume>60</volume>:<fpage>1079</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">14609883</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0265">
<label>265</label>
<mixed-citation id="bdi12609-cit-0265" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
<suffix>Jr</suffix>
</string-name>, et al. <article-title>A 7‐week, randomized, double‐blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>1025</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">16889444</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0266">
<label>266</label>
<mixed-citation id="bdi12609-cit-0266" publication-type="journal">
<string-name>
<surname>Dunn</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Stan</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Chriki</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Filkowski</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>. <article-title>A prospective, open‐label study of Aripiprazole mono‐ and adjunctive treatment in acute bipolar depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2008</year>;<volume>110</volume>:<fpage>70</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">18272230</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0267">
<label>267</label>
<mixed-citation id="bdi12609-cit-0267" publication-type="journal">
<string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Open‐label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2007</year>;<volume>101</volume>:<fpage>275</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">17229469</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0268">
<label>268</label>
<mixed-citation id="bdi12609-cit-0268" publication-type="journal">
<string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Grunze</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>A placebo‐controlled evaluation of adjunctive modafinil in the treatment of bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2007</year>;<volume>164</volume>:<fpage>1242</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">17671288</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0269">
<label>269</label>
<mixed-citation id="bdi12609-cit-0269" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double‐blind, placebo‐controlled, multicenter trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>1054</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">25099397</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0270">
<label>270</label>
<mixed-citation id="bdi12609-cit-0270" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tiller</surname>
<given-names>JWG</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Weiller</surname>
<given-names>E</given-names>
</string-name>. <article-title>Effects of asenapine in bipolar I patients meeting proxy criteria for moderate‐to‐severe mixed major depressive episodes: a post hoc analysis</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2015</year>;<volume>76</volume>:<fpage>728</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">25612216</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0271">
<label>271</label>
<mixed-citation id="bdi12609-cit-0271" publication-type="journal">
<string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Berman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stamm</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo‐controlled positron emission tomography study</article-title>. <source xml:lang="en"/>Mol Psychiatry. <year>2016</year>;<volume>21</volume>:<fpage>229</fpage>‐<lpage>36</lpage>.<pub-id pub-id-type="pmid">25600111</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0272">
<label>272</label>
<mixed-citation id="bdi12609-cit-0272" publication-type="journal">
<string-name>
<surname>Stamm</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Lewitzka</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Sauer</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>162</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">24345793</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0273">
<label>273</label>
<mixed-citation id="bdi12609-cit-0273" publication-type="journal">
<string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Burdick</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Endick</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Preliminary randomized, double‐blind, placebo‐controlled trial of pramipexole added to mood stabilizers for treatment‐resistant bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2004</year>;<volume>161</volume>:<fpage>564</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">14992985</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0274">
<label>274</label>
<mixed-citation id="bdi12609-cit-0274" publication-type="journal">
<string-name>
<surname>Zarate</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Payne</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Pramipexole for bipolar II depression: a placebo‐controlled proof of concept study</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2004</year>;<volume>56</volume>:<fpage>54</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">15219473</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0275">
<label>275</label>
<mixed-citation id="bdi12609-cit-0275" publication-type="journal">
<string-name>
<surname>McGirr</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Karmani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Arsappa</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression</article-title>. <source xml:lang="en"/>World Psychiatry. <year>2016</year>;<volume>15</volume>:<fpage>85</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">26833619</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0276">
<label>276</label>
<mixed-citation id="bdi12609-cit-0276" publication-type="journal">
<string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>, et al. <article-title>Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2006</year>;<volume>189</volume>:<fpage>124</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">16880481</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0277">
<label>277</label>
<mixed-citation id="bdi12609-cit-0277" publication-type="journal">
<string-name>
<surname>Himmelhoch</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>
<given-names>CZ</given-names>
</string-name>, <string-name>
<surname>Symons</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>A double‐blind‐study of tranylcypromine treatment of major anergic depression</article-title>. <source xml:lang="en"/>J Nerv Ment Dis. <year>1982</year>;<volume>170</volume>:<fpage>628</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">7050302</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0278">
<label>278</label>
<mixed-citation id="bdi12609-cit-0278" publication-type="journal">
<string-name>
<surname>Himmelhoch</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Mallinger</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Houck</surname>
<given-names>P</given-names>
</string-name>. <article-title>Tranylcypromine versus imipramine in anergic bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1991</year>;<volume>148</volume>:<fpage>910</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">2053632</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0279">
<label>279</label>
<mixed-citation id="bdi12609-cit-0279" publication-type="journal">
<string-name>
<surname>Grosso</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pajak</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marventano</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Role of omega‐3 fatty acids in the treatment of depressive disorders: a comprehensive meta‐analysis of randomized clinical trials</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2014</year>;<volume>9</volume>:<fpage>e96905</fpage>.<pub-id pub-id-type="pmid">24805797</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0280">
<label>280</label>
<mixed-citation id="bdi12609-cit-0280" publication-type="journal">
<string-name>
<surname>Rosenblat</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Kakar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>89</fpage>‐<lpage>101</lpage>.<pub-id pub-id-type="pmid">26990051</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0281">
<label>281</label>
<mixed-citation id="bdi12609-cit-0281" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Copolov</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Dean</surname>
<given-names>O</given-names>
</string-name>, et al. <article-title>N‐acetyl cysteine for depressive symptoms in bipolar disorder – A double‐blind randomized placebo‐controlled trial</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2008</year>;<volume>64</volume>:<fpage>468</fpage>‐<lpage>75</lpage>.<pub-id pub-id-type="pmid">18534556</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0282">
<label>282</label>
<mixed-citation id="bdi12609-cit-0282" publication-type="journal">
<string-name>
<surname>Tseng</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YW</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>KY</given-names>
</string-name>, et al. <article-title>Light therapy in the treatment of patients with bipolar depression: a meta‐analytic study</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2016</year>;<volume>26</volume>:<fpage>1037</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">26993616</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0283">
<label>283</label>
<mixed-citation id="bdi12609-cit-0283" publication-type="journal">
<string-name>
<surname>Sit</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>McGowan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wiltrout</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Adjunctive bright light therapy for bipolar depression: a randomized double‐blind placebo‐controlled trial</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2017</year>; [e‐pub] appiajp201716101200.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0284">
<label>284</label>
<mixed-citation id="bdi12609-cit-0284" publication-type="journal">
<string-name>
<surname>Romeo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Choucha</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fossati</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rotge</surname>
<given-names>JY</given-names>
</string-name>. <article-title>Meta‐analysis of short‐ and mid‐term efficacy of ketamine in unipolar and bipolar depression</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2015</year>;<volume>230</volume>:<fpage>682</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">26548981</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0285">
<label>285</label>
<mixed-citation id="bdi12609-cit-0285" publication-type="journal">
<string-name>
<surname>Andrade</surname>
<given-names>C</given-names>
</string-name>. <article-title>Ketamine for depression, 5: potential pharmacokinetic and pharmacodynamic drug interactions</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2017</year>;<volume>78</volume>:<fpage>e858</fpage>‐<lpage>e61</lpage>.<pub-id pub-id-type="pmid">28858450</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0286">
<label>286</label>
<mixed-citation id="bdi12609-cit-0286" publication-type="journal">
<string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>181</volume>:<fpage>87</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">25933099</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0287">
<label>287</label>
<mixed-citation id="bdi12609-cit-0287" publication-type="journal">
<string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Amchin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Randomized, placebo‐controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2015</year>;<volume>3</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">26330288</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0288">
<label>288</label>
<mixed-citation id="bdi12609-cit-0288" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Youakim</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Tiller</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double‐blind, placebo‐controlled, proof‐of‐concept study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>1363</fpage>‐<lpage>70</lpage>.<pub-id pub-id-type="pmid">20673554</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0289">
<label>289</label>
<mixed-citation id="bdi12609-cit-0289" publication-type="journal">
<string-name>
<surname>Viktorin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2014</year>;<volume>171</volume>:<fpage>1067</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">24935197</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0290">
<label>290</label>
<mixed-citation id="bdi12609-cit-0290" publication-type="journal">
<string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A double‐blind, placebo‐controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>163</fpage>‐<lpage>74</lpage>.<pub-id pub-id-type="pmid">20122366</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0291">
<label>291</label>
<mixed-citation id="bdi12609-cit-0291" publication-type="journal">
<string-name>
<surname>Peet</surname>
<given-names>M</given-names>
</string-name>. <article-title>Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>1994</year>;<volume>164</volume>:<fpage>549</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">8038948</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0292">
<label>292</label>
<mixed-citation id="bdi12609-cit-0292" publication-type="journal">
<string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Jonas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Aripiprazole monotherapy in non‐psychotic bipolar I depression</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2008</year>;<volume>28</volume>:<fpage>13</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">18204335</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0293">
<label>293</label>
<mixed-citation id="bdi12609-cit-0293" publication-type="journal">
<string-name>
<surname>Fountoulakis</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</string-name>. <article-title>Aripiprazole monotherapy in the treatment of bipolar disorder: a meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>133</volume>:<fpage>361</fpage>‐<lpage>70</lpage>.<pub-id pub-id-type="pmid">21040979</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0294">
<label>294</label>
<mixed-citation id="bdi12609-cit-0294" publication-type="journal">
<string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Ice</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Chappell</surname>
<given-names>PB</given-names>
</string-name>, et al. <article-title>Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar i disorder: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>1413</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">21672493</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0295">
<label>295</label>
<mixed-citation id="bdi12609-cit-0295" publication-type="journal">
<string-name>
<surname>Watson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gallagher</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Porter</surname>
<given-names>RJ</given-names>
</string-name>, et al. <article-title>A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2012</year>;<volume>72</volume>:<fpage>943</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">22770649</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0296">
<label>296</label>
<mixed-citation id="bdi12609-cit-0296" publication-type="journal">
<string-name>
<surname>Saroukhani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Emami‐Parsa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Modabbernia</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Aspirin for treatment of lithium‐associated sexual dysfunction in men: randomized double‐blind placebo‐controlled study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>650</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">23924261</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0297">
<label>297</label>
<mixed-citation id="bdi12609-cit-0297" publication-type="journal">
<string-name>
<surname>Nery</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Monkul</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Hatch</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2008</year>;<volume>23</volume>:<fpage>87</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">18172906</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0298">
<label>298</label>
<mixed-citation id="bdi12609-cit-0298" publication-type="journal">
<string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Kimbrell</surname>
<given-names>TA</given-names>
</string-name>, et al. <article-title>A placebo‐controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2000</year>;<volume>20</volume>:<fpage>607</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">11106131</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0299">
<label>299</label>
<mixed-citation id="bdi12609-cit-0299" publication-type="journal">
<string-name>
<surname>Saricicek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maloney</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Muralidharan</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Levetiracetam in the management of bipolar depression: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>744</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">21034692</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0300">
<label>300</label>
<mixed-citation id="bdi12609-cit-0300" publication-type="journal">
<string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Martens</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2015</year>;<volume>30</volume>:<fpage>6</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">25340384</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0301">
<label>301</label>
<mixed-citation id="bdi12609-cit-0301" publication-type="journal">
<string-name>
<surname>Anand</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gunn</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Barkay</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>64</fpage>‐<lpage>70</lpage>.<pub-id pub-id-type="pmid">22329473</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0302">
<label>302</label>
<mixed-citation id="bdi12609-cit-0302" publication-type="journal">
<string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Schinagle</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>KM</given-names>
</string-name>, et al. <article-title>PPAR‐gamma agonism as a modulator of mood: proof‐of‐concept for pioglitazone in bipolar depression</article-title>. <source xml:lang="en"/>CNS Drugs. <year>2014</year>;<volume>28</volume>:<fpage>571</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">24715548</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0303">
<label>303</label>
<mixed-citation id="bdi12609-cit-0303" publication-type="journal">
<string-name>
<surname>Zeinoddini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sorayani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hassanzadeh</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Depress Anxiety. <year>2015</year>;<volume>32</volume>:<fpage>167</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">25620378</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0304">
<label>304</label>
<mixed-citation id="bdi12609-cit-0304" publication-type="journal">
<string-name>
<surname>Zarate</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Quiroz</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>An open‐label trial of the glutamate‐modulating agent riluzole in combination with lithium for the treatment of bipolar depression</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2005</year>;<volume>57</volume>:<fpage>430</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">15705360</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0305">
<label>305</label>
<mixed-citation id="bdi12609-cit-0305" publication-type="journal">
<string-name>
<surname>Shelton</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Stahl</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Risperidone and paroxetine given singly and in combination for bipolar depression</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2004</year>;<volume>65</volume>:<fpage>1715</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15641878</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0306">
<label>306</label>
<mixed-citation id="bdi12609-cit-0306" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marx</surname>
<given-names>CE</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled trial of pregnenolone for bipolar depression</article-title>. <source xml:lang="en"/>Neuropsychopharmacology. <year>2014</year>;<volume>39</volume>:<fpage>2867</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">24917198</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0307">
<label>307</label>
<mixed-citation id="bdi12609-cit-0307" publication-type="journal">
<string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Siu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rajagopalan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pikalov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cucchiaro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Recovery in bipolar depression: post‐hoc analysis of a placebo‐controlled lurasidone trial followed by a long‐term continuation study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>186</volume>:<fpage>376</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">26363720</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0308">
<label>308</label>
<mixed-citation id="bdi12609-cit-0308" publication-type="journal">
<string-name>
<surname>Chiesa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chierzi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>De Ronchi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Serretti</surname>
<given-names>A</given-names>
</string-name>. <article-title>Quetiapine for bipolar depression: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2012</year>;<volume>27</volume>:<fpage>76</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">22107783</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0309">
<label>309</label>
<mixed-citation id="bdi12609-cit-0309" publication-type="journal">
<string-name>
<surname>Mitchell</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Hadzi‐Pavlovic</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Evoniuk</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>. <article-title>A factor analytic study in bipolar depression, and response to lamotrigine</article-title>. <source xml:lang="en"/>CNS Spectr. <year>2013</year>;<volume>18</volume>:<fpage>214</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">23702258</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0310">
<label>310</label>
<mixed-citation id="bdi12609-cit-0310" publication-type="journal">
<string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Valenti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bonnin</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>Factors associated with initial treatment response with antidepressants in bipolar disorder</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2011</year>;<volume>21</volume>:<fpage>362</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">21056928</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0311">
<label>311</label>
<mixed-citation id="bdi12609-cit-0311" publication-type="journal">
<string-name>
<surname>Coryell</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fiedorowicz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Rice</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Effects of anxiety on the long‐term course of depressive disorders</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2012</year>;<volume>200</volume>:<fpage>210</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">21984801</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0312">
<label>312</label>
<mixed-citation id="bdi12609-cit-0312" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Cooke</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Levitt</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Joffe</surname>
<given-names>RT</given-names>
</string-name>. <article-title>Anxious and nonanxious bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1993</year>;<volume>29</volume>:<fpage>49</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">8254143</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0313">
<label>313</label>
<mixed-citation id="bdi12609-cit-0313" publication-type="journal">
<string-name>
<surname>Lydiard</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Culpepper</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Schioler</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gustafsson</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Paulsson</surname>
<given-names>B</given-names>
</string-name>. <article-title>Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double‐blind, randomized, placebo‐controlled studies</article-title>. <source xml:lang="en"/>Prim Care Companion J Clin Psychiatry. <year>2009</year>;<volume>11</volume>:<fpage>215</fpage>‐<lpage>25</lpage>.<pub-id pub-id-type="pmid">19956459</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0314">
<label>314</label>
<mixed-citation id="bdi12609-cit-0314" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Effect of comorbid anxiety on treatment response in bipolar depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2007</year>;<volume>104</volume>:<fpage>137</fpage>‐<lpage>46</lpage>.<pub-id pub-id-type="pmid">17512607</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0315">
<label>315</label>
<mixed-citation id="bdi12609-cit-0315" publication-type="journal">
<string-name>
<surname>Tsai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ng‐Mak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pikalov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>. <article-title>Lurasidone for major depressive disorder with mixed features and anxiety: a post‐hoc analysis of a randomized, placebo‐controlled study</article-title>. <source xml:lang="en"/>CNS Spectr. <year>2017</year>;<volume>22</volume>:<fpage>236</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">28357969</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0316">
<label>316</label>
<mixed-citation id="bdi12609-cit-0316" publication-type="journal">
<string-name>
<surname>Davis</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Bartolucci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Petty</surname>
<given-names>F</given-names>
</string-name>. <article-title>Divalproex in the treatment of bipolar depression: a placebo‐controlled study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2005</year>;<volume>85</volume>:<fpage>259</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">15780695</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0317">
<label>317</label>
<mixed-citation id="bdi12609-cit-0317" publication-type="journal">
<string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Perlis</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, et al. <article-title>Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP‐BD</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2009</year>;<volume>166</volume>:<fpage>173</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">19122008</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0318">
<label>318</label>
<mixed-citation id="bdi12609-cit-0318" publication-type="journal">
<string-name>
<surname>Montgomery</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Schatzberg</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Guelfi</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Pharmacotherapy of depression and mixed states in bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2000</year>;<volume>59</volume>:<fpage>S39</fpage>‐<lpage>S56</lpage>.<pub-id pub-id-type="pmid">11121826</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0319">
<label>319</label>
<mixed-citation id="bdi12609-cit-0319" publication-type="journal">
<string-name>
<surname>Fornaro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stubbs</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>De Berardis</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta‐analysis of placebo‐controlled clinical trials</article-title>. <source xml:lang="en"/>Int J Mol Sci. <year>2016</year>;<volume>17</volume>:<fpage>241</fpage>.<pub-id pub-id-type="pmid">26891297</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0320">
<label>320</label>
<mixed-citation id="bdi12609-cit-0320" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cucchiaro</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2016</year>;<volume>173</volume>:<fpage>400</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">26552942</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0321">
<label>321</label>
<mixed-citation id="bdi12609-cit-0321" publication-type="journal">
<string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Mallinger</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>McKnight</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Himmelhoch</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Treatment of imipramine‐resistant recurrent depression 4. A double‐blind crossover study of tranylcypromine for anergic bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1992</year>;<volume>149</volume>:<fpage>195</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">1734739</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0322">
<label>322</label>
<mixed-citation id="bdi12609-cit-0322" publication-type="journal">
<string-name>
<surname>Black</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Nasrallah</surname>
<given-names>A</given-names>
</string-name>. <article-title>Hallucinations and delusions in 1,715 patients with unipolar and bipolar affective‐disorders</article-title>. <source xml:lang="en"/>Psychopathology. <year>1989</year>;<volume>22</volume>:<fpage>28</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">2657835</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0323">
<label>323</label>
<mixed-citation id="bdi12609-cit-0323" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, et al. <article-title>A double‐blind, placebo‐controlled, prophylaxis study of lamotrigine in rapid‐cycling bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2000</year>;<volume>61</volume>:<fpage>841</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">11105737</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0324">
<label>324</label>
<mixed-citation id="bdi12609-cit-0324" publication-type="journal">
<string-name>
<surname>El‐Mallakh</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Vohringer</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Ostacher</surname>
<given-names>MM</given-names>
</string-name>, et al. <article-title>Antidepressants worsen rapid‐cycling course in bipolar depression: a STEP‐BD randomized clinical trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>184</volume>:<fpage>318</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">26142612</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0325">
<label>325</label>
<mixed-citation id="bdi12609-cit-0325" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Reinares</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosa</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Staging bipolar disorder</article-title>. <source xml:lang="en"/>Neurotox Res. <year>2011</year>;<volume>19</volume>:<fpage>279</fpage>‐<lpage>85</lpage>.<pub-id pub-id-type="pmid">20461491</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0326">
<label>326</label>
<mixed-citation id="bdi12609-cit-0326" publication-type="journal">
<string-name>
<surname>Kozicky</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>e587</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">25004200</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0327">
<label>327</label>
<mixed-citation id="bdi12609-cit-0327" publication-type="journal">
<string-name>
<surname>Kozicky</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>McGirr</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Neuroprogression and episode recurrence in bipolar I disorder: a study of gray matter volume changes in first‐episode mania and association with clinical outcome</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>511</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">27759214</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0328">
<label>328</label>
<mixed-citation id="bdi12609-cit-0328" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dodd</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Stage managing bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>471</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">23782499</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0329">
<label>329</label>
<mixed-citation id="bdi12609-cit-0329" publication-type="journal">
<string-name>
<surname>Daglas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cotton</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Allott</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>A single‐blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12‐month follow‐up study</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2016</year>;<volume>31</volume>:<fpage>20</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">26655594</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0330">
<label>330</label>
<mixed-citation id="bdi12609-cit-0330" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dandash</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Daglas</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume</article-title>. <source xml:lang="en"/>Transl Psychiatry. <year>2017</year>;<volume>7</volume>:<fpage>e1041</fpage>.<pub-id pub-id-type="pmid">28221364</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0331">
<label>331</label>
<mixed-citation id="bdi12609-cit-0331" publication-type="journal">
<string-name>
<surname>Vazquez</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Holtzman</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Lolich</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Recurrence rates in bipolar disorder: systematic comparison of long‐term prospective, naturalistic studies versus randomized controlled trials</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2015</year>;<volume>25</volume>:<fpage>1501</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">26238969</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0332">
<label>332</label>
<mixed-citation id="bdi12609-cit-0332" publication-type="journal">
<string-name>
<surname>Gignac</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McGirr</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Recovery and recurrence following a first episode of mania: a systematic review and meta‐analysis of prospectively characterized cohorts</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2015</year>;<volume>76</volume>:<fpage>1241</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">25845021</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0333">
<label>333</label>
<mixed-citation id="bdi12609-cit-0333" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Angst</surname>
<given-names>J</given-names>
</string-name>. <article-title>The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders – a life‐long perspective</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2004</year>;<volume>109</volume>:<fpage>339</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">15049770</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0334">
<label>334</label>
<mixed-citation id="bdi12609-cit-0334" publication-type="journal">
<string-name>
<surname>Perlis</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Ostacher</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>JK</given-names>
</string-name>, et al. <article-title>Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP‐BD)</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2006</year>;<volume>163</volume>:<fpage>217</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">16449474</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0335">
<label>335</label>
<mixed-citation id="bdi12609-cit-0335" publication-type="journal">
<string-name>
<surname>Yen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stout</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hower</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>The influence of comorbid disorders on the episodicity of bipolar disorder in youth</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2016</year>;<volume>133</volume>:<fpage>324</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">26475572</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0336">
<label>336</label>
<mixed-citation id="bdi12609-cit-0336" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2008</year>;<volume>65</volume>:<fpage>386</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">18391127</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0337">
<label>337</label>
<mixed-citation id="bdi12609-cit-0337" publication-type="journal">
<string-name>
<surname>De Dios</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ezquiaga</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Agud</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Soler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Garcia‐Lopez</surname>
<given-names>A</given-names>
</string-name>. <article-title>Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>143</volume>:<fpage>160</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">22925351</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0338">
<label>338</label>
<mixed-citation id="bdi12609-cit-0338" publication-type="journal">
<string-name>
<surname>Cohen</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Hammen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Daley</surname>
<given-names>SE</given-names>
</string-name>. <article-title>Effects of stress and social support on recurrence in bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2004</year>;<volume>82</volume>:<fpage>143</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">15465589</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0339">
<label>339</label>
<mixed-citation id="bdi12609-cit-0339" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hallam</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Enhancing medication adherence in patients with bipolar disorder</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2010</year>;<volume>25</volume>:<fpage>1</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">20041478</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0340">
<label>340</label>
<mixed-citation id="bdi12609-cit-0340" publication-type="journal">
<string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Castle</surname>
<given-names>D</given-names>
</string-name>. <article-title>A collaborative approach to the treatment alliance in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>504</fpage>‐<lpage>18</lpage>.<pub-id pub-id-type="pmid">15541066</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0341">
<label>341</label>
<mixed-citation id="bdi12609-cit-0341" publication-type="journal">
<string-name>
<surname>Velligan</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Weiden</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines</article-title>. <source xml:lang="en"/>J Psychiatr Pract. <year>2010</year>;<volume>16</volume>:<fpage>34</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">20098229</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0342">
<label>342</label>
<mixed-citation id="bdi12609-cit-0342" publication-type="journal">
<string-name>
<surname>Lingam</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>J</given-names>
</string-name>. <article-title>Treatment non‐adherence in affective disorders</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2002</year>;<volume>105</volume>:<fpage>164</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">11939969</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0343">
<label>343</label>
<mixed-citation id="bdi12609-cit-0343" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Valenstein</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blow</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ganoczy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ignacio</surname>
<given-names>R</given-names>
</string-name>. <article-title>Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2007</year>;<volume>58</volume>:<fpage>855</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">17535948</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0344">
<label>344</label>
<mixed-citation id="bdi12609-cit-0344" publication-type="journal">
<string-name>
<surname>Moon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>MY</given-names>
</string-name>, et al. <article-title>Dropout rate and associated factors in patients with bipolar disorders</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>141</volume>:<fpage>47</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">22410504</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0345">
<label>345</label>
<mixed-citation id="bdi12609-cit-0345" publication-type="journal">
<string-name>
<surname>Baker</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Outcomes of lithium discontinuation – a metaanalysis</article-title>. <source xml:lang="en"/>Lithium. <year>1994</year>;<volume>5</volume>:<fpage>187</fpage>‐<lpage>92</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0346">
<label>346</label>
<mixed-citation id="bdi12609-cit-0346" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Faedda</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Risk of recurrence following discontinuation of lithium treatment in bipolar disorder</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1991</year>;<volume>48</volume>:<fpage>1082</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">1845226</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0347">
<label>347</label>
<mixed-citation id="bdi12609-cit-0347" publication-type="journal">
<string-name>
<surname>Faedda</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1993</year>;<volume>50</volume>:<fpage>448</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">8498879</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0348">
<label>348</label>
<mixed-citation id="bdi12609-cit-0348" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kongasseri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Praharaj</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Outcome of mood stabilizer discontinuation in bipolar disorder after 5 years of euthymia</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2014</year>;<volume>34</volume>:<fpage>504</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">24943387</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0349">
<label>349</label>
<mixed-citation id="bdi12609-cit-0349" publication-type="journal">
<string-name>
<surname>Franks</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Macritchie</surname>
<given-names>KAN</given-names>
</string-name>, <string-name>
<surname>Mahmood</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study</article-title>. <source xml:lang="en"/>J Psychopharmacol. <year>2008</year>;<volume>22</volume>:<fpage>452</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">18635725</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0350">
<label>350</label>
<mixed-citation id="bdi12609-cit-0350" publication-type="journal">
<string-name>
<surname>Scott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pope</surname>
<given-names>M</given-names>
</string-name>. <article-title>Nonadherence with mood stabilizers: prevalence and predictors</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>384</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">12019661</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0351">
<label>351</label>
<mixed-citation id="bdi12609-cit-0351" publication-type="journal">
<string-name>
<surname>Hong</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reed</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Novick</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maria Haro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Windmeijer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Knapp</surname>
<given-names>M</given-names>
</string-name>. <article-title>The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study</article-title>. <source xml:lang="en"/>Pharmacoeconomics. <year>2010</year>;<volume>28</volume>:<fpage>555</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">20405969</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0352">
<label>352</label>
<mixed-citation id="bdi12609-cit-0352" publication-type="journal">
<string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pompili</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Hennen</surname>
<given-names>J</given-names>
</string-name>. <article-title>Decreased risk of suicides and attempts during long‐term lithium treatment: a meta‐analytic review</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2006</year>;<volume>8</volume>:<fpage>625</fpage>‐<lpage>39</lpage>.<pub-id pub-id-type="pmid">17042835</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0353">
<label>353</label>
<mixed-citation id="bdi12609-cit-0353" publication-type="journal">
<string-name>
<surname>Leclerc</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mansur</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Brietzke</surname>
<given-names>E</given-names>
</string-name>. <article-title>Determinants of adherence to treatment in bipolar disorder: a comprehensive review</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>149</volume>:<fpage>247</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">23489403</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0354">
<label>354</label>
<mixed-citation id="bdi12609-cit-0354" publication-type="journal">
<string-name>
<surname>MacDonald</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Syrett</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bowskill</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Horne</surname>
<given-names>R</given-names>
</string-name>. <article-title>Improving medication adherence in bipolar disorder: a systematic review and meta‐analysis of 30 years of intervention trials</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>194</volume>:<fpage>202</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">26851552</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0355">
<label>355</label>
<mixed-citation id="bdi12609-cit-0355" publication-type="journal">
<string-name>
<surname>Crowe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Inder</surname>
<given-names>M</given-names>
</string-name>. <article-title>Patients’ reports of the factors influencing medication adherence in bipolar disorder – An integrative review of the literature</article-title>. <source xml:lang="en"/>Int J Nurs Stud. <year>2011</year>;<volume>48</volume>:<fpage>894</fpage>‐<lpage>903</lpage>.<pub-id pub-id-type="pmid">21481391</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0356">
<label>356</label>
<mixed-citation id="bdi12609-cit-0356" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hrouda</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Enhancement of treatment adherence among patients with bipolar disorder</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2004</year>;<volume>55</volume>:<fpage>264</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15001726</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0357">
<label>357</label>
<mixed-citation id="bdi12609-cit-0357" publication-type="journal">
<string-name>
<surname>Velligan</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Weiden</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines</article-title>. <source xml:lang="en"/>J Psychiatr Pract. <year>2010</year>;<volume>16</volume>:<fpage>306</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">20859108</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0358">
<label>358</label>
<mixed-citation id="bdi12609-cit-0358" publication-type="journal">
<string-name>
<surname>Hayes</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Marston</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Walters</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>M</given-names>
</string-name>. <article-title>Osborn DPJ. lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records</article-title>. <source xml:lang="en"/>World Psychiatry. <year>2016</year>;<volume>15</volume>:<fpage>53</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">26833609</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0359">
<label>359</label>
<mixed-citation id="bdi12609-cit-0359" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Hellmund</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>. <article-title>Predictors of excellent response to lithium: results from a nationwide register‐based study</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2011</year>;<volume>26</volume>:<fpage>323</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">21876441</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0360">
<label>360</label>
<mixed-citation id="bdi12609-cit-0360" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Hellmund</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>. <article-title>Valproate V. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register‐based cohort study</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2011</year>;<volume>199</volume>:<fpage>57</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">21593515</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0361">
<label>361</label>
<mixed-citation id="bdi12609-cit-0361" publication-type="journal">
<string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Fireman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Hunkeler</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Revicki</surname>
<given-names>D</given-names>
</string-name>. <article-title>Suicide risk in bipolar disorder during treatment with lithium and divalproex</article-title>. <source xml:lang="en"/>JAMA J Am Med Assoc. <year>2003</year>;<volume>290</volume>:<fpage>1467</fpage>‐<lpage>73</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0362">
<label>362</label>
<mixed-citation id="bdi12609-cit-0362" publication-type="journal">
<string-name>
<surname>Hayes</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Pitman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marston</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Self‐harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population‐based electronic health records study</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2016</year>;<volume>73</volume>:<fpage>630</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">27167638</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0363">
<label>363</label>
<mixed-citation id="bdi12609-cit-0363" publication-type="journal">
<string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>. <article-title>Does lithium treatment still work? Evidence of stable responses over three decades</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2000</year>;<volume>57</volume>:<fpage>187</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">10665622</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0364">
<label>364</label>
<mixed-citation id="bdi12609-cit-0364" publication-type="journal">
<string-name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Chlopocka‐Wozniak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Suwalska</surname>
<given-names>A</given-names>
</string-name>. <article-title>The prophylactic effect of long‐term lithium administration in bipolar patients entering treatment in the 1970s and 1980s</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2001</year>;<volume>3</volume>:<fpage>63</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">11333064</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0365">
<label>365</label>
<mixed-citation id="bdi12609-cit-0365" publication-type="journal">
<string-name>
<surname>Peselow</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Clevenger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>IsHak</surname>
<given-names>WW</given-names>
</string-name>. <article-title>Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2016</year>;<volume>31</volume>:<fpage>218</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">26523730</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0366">
<label>366</label>
<mixed-citation id="bdi12609-cit-0366" publication-type="journal">
<string-name>
<surname>Altshuler</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1‐year follow‐up</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2003</year>;<volume>160</volume>:<fpage>1252</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">12832239</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0367">
<label>367</label>
<mixed-citation id="bdi12609-cit-0367" publication-type="journal">
<string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Beaulieu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double‐blind trial</article-title>. <source xml:lang="en"/>Mol Psychiatry. <year>2016</year>;<volume>21</volume>:<fpage>1050</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">26460229</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0368">
<label>368</label>
<mixed-citation id="bdi12609-cit-0368" publication-type="journal">
<string-name>
<surname>Severus</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sauer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pfennig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficacy of lithium in the long‐term treatment of bipolar disorders: a new meta‐analysis</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>96</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0369">
<label>369</label>
<mixed-citation id="bdi12609-cit-0369" publication-type="journal">
<string-name>
<surname>Miura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Noma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>TA</given-names>
</string-name>, et al. <article-title>Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta‐analysis</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2014</year>;<volume>1</volume>:<fpage>351</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">26360999</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0370">
<label>370</label>
<mixed-citation id="bdi12609-cit-0370" publication-type="journal">
<string-name>
<surname>Weisler</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Neijber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hellqvist</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Paulsson</surname>
<given-names>B</given-names>
</string-name>. <article-title>Trial 144 study I. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>1452</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">22054050</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0371">
<label>371</label>
<mixed-citation id="bdi12609-cit-0371" publication-type="journal">
<string-name>
<surname>Cipriani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reid</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Macritchie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>J</given-names>
</string-name>. <article-title>Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder</article-title>. <source xml:lang="en"/>Cochrane Database Syst Rev
<year>2013</year>;(<issue>10</issue>):<fpage>CD003196</fpage>.<pub-id pub-id-type="pmid">24132760</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0372">
<label>372</label>
<mixed-citation id="bdi12609-cit-0372" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>A randomized, placebo‐controlled 12‐month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2000</year>;<volume>57</volume>:<fpage>481</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">10807488</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0373">
<label>373</label>
<mixed-citation id="bdi12609-cit-0373" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, et al. <article-title>Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double‐blind maintenance studies</article-title>. <source xml:lang="en"/>Biol Psychiatry. <year>2006</year>;<volume>59</volume>:<fpage>1061</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">16769295</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0374">
<label>374</label>
<mixed-citation id="bdi12609-cit-0374" publication-type="journal">
<string-name>
<surname>Szegedi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Durgam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mackle</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Randomized, double‐blind, placebo‐controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2018</year>;<volume>175</volume>:<fpage>71</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">28946761</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0375">
<label>375</label>
<mixed-citation id="bdi12609-cit-0375" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>McQuade</surname>
<given-names>RD</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled 26‐week trial of aripiprazole in recently manic patients with bipolar I disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>626</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">16669728</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0376">
<label>376</label>
<mixed-citation id="bdi12609-cit-0376" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100‐week, double‐blind study versus placebo</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2007</year>;<volume>68</volume>:<fpage>1480</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">17960961</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0377">
<label>377</label>
<mixed-citation id="bdi12609-cit-0377" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sanchez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Efficacy and safety of aripiprazole once‐monthly in the maintenance treatment of bipolar I disorder: a double‐blind, placebo‐controlled, 52‐week randomized withdrawal study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2017</year>;<volume>78</volume>:<fpage>324</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">28146613</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0378">
<label>378</label>
<mixed-citation id="bdi12609-cit-0378" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brecher</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Paulsson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Trial</surname>
<given-names>I</given-names>
</string-name>. <article-title>Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127)</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2009</year>;<volume>166</volume>:<fpage>476</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">19289454</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0379">
<label>379</label>
<mixed-citation id="bdi12609-cit-0379" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Eggens</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2008</year>;<volume>109</volume>:<fpage>251</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">18579216</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0380">
<label>380</label>
<mixed-citation id="bdi12609-cit-0380" publication-type="journal">
<string-name>
<surname>Marcus</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rollin</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2011</year>;<volume>13</volume>:<fpage>133</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">21443567</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0381">
<label>381</label>
<mixed-citation id="bdi12609-cit-0381" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, et al. <article-title>Randomized, placebo‐controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2006</year>;<volume>163</volume>:<fpage>247</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">16449478</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0382">
<label>382</label>
<mixed-citation id="bdi12609-cit-0382" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Montgomery</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sulaiman</surname>
<given-names>AH</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled trial to assess prevention of mood episodes with risperidone long‐acting injectable in patients with bipolar I disorder</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2012</year>;<volume>22</volume>:<fpage>825</fpage>‐<lpage>35</lpage>.<pub-id pub-id-type="pmid">22503488</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0383">
<label>383</label>
<mixed-citation id="bdi12609-cit-0383" publication-type="journal">
<string-name>
<surname>Quiroz</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Palumbo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Karcher</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kushner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kusumakar</surname>
<given-names>V</given-names>
</string-name>. <article-title>Risperidone long‐acting injectable monotherapy in the maintenance treatment of bipolar I disorder</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2010</year>;<volume>68</volume>:<fpage>156</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">20227682</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0384">
<label>384</label>
<mixed-citation id="bdi12609-cit-0384" publication-type="journal">
<string-name>
<surname>Macfadden</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Alphs</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Haskins</surname>
<given-names>JT</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse frequently</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>827</fpage>‐<lpage>39</lpage>.<pub-id pub-id-type="pmid">19922552</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0385">
<label>385</label>
<mixed-citation id="bdi12609-cit-0385" publication-type="journal">
<string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Speer</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Obrocea</surname>
<given-names>GV</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>. <article-title>Acute and prophylactic effects of anticonvulsants in bipolar depression</article-title>. <source xml:lang="en"/>Clin Neurosci Res. <year>2002</year>;<volume>2</volume>:<fpage>228</fpage>‐<lpage>51</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0386">
<label>386</label>
<mixed-citation id="bdi12609-cit-0386" publication-type="journal">
<string-name>
<surname>Berwaerts</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Melkote</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nuamah</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>P</given-names>
</string-name>. <article-title>A randomized, placebo‐ and active‐controlled study of paliperidone extended‐release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>138</volume>:<fpage>247</fpage>‐<lpage>58</lpage>.<pub-id pub-id-type="pmid">22377512</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0387">
<label>387</label>
<mixed-citation id="bdi12609-cit-0387" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ice</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Versavel</surname>
<given-names>M</given-names>
</string-name>. <article-title>Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6‐month, randomized, placebo‐controlled, double‐blind trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>130</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">20122373</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0388">
<label>388</label>
<mixed-citation id="bdi12609-cit-0388" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Pikalov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Streicher</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cucchiaro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>. <article-title>Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2017</year>;<volume>27</volume>:<fpage>865</fpage>‐<lpage>876</lpage>.<pub-id pub-id-type="pmid">28689688</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0389">
<label>389</label>
<mixed-citation id="bdi12609-cit-0389" publication-type="journal">
<string-name>
<surname>Carlson</surname>
<given-names>BX</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Aripiprazole in combination with lamotrigine for the long‐term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double‐blind study (CN138‐392)</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>41</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">22329471</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0390">
<label>390</label>
<mixed-citation id="bdi12609-cit-0390" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Goikolea</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Martinez‐Aran</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A double‐blind, randomized, placebo‐controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>473</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">16649836</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0391">
<label>391</label>
<mixed-citation id="bdi12609-cit-0391" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dunner</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Olanzapine/fluoxetine combination vs. lamotrigine in the 6‐month treatment of bipolar I depression</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2009</year>;<volume>12</volume>:<fpage>773</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">19079815</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0392">
<label>392</label>
<mixed-citation id="bdi12609-cit-0392" publication-type="journal">
<string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Starace</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Cariprazine in the treatment of acute mania in bipolar I disorder: a double‐blind, placebo‐controlled, phase III trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>174</volume>:<fpage>296</fpage>‐<lpage>302</lpage>.<pub-id pub-id-type="pmid">25532076</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0393">
<label>393</label>
<mixed-citation id="bdi12609-cit-0393" publication-type="journal">
<string-name>
<surname>Ahlfors</surname>
<given-names>UG</given-names>
</string-name>, <string-name>
<surname>Baastrup</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Dencker</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>Flupenthixol decanoate in recurrent manic‐depressive illness. A comparison with lithium</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>1981</year>;<volume>64</volume>:<fpage>226</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">7324992</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0394">
<label>394</label>
<mixed-citation id="bdi12609-cit-0394" publication-type="journal">
<string-name>
<surname>Vasudev</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Macritchie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Oxcarbazepine in the maintenance treatment of bipolar disorder</article-title>. <source xml:lang="en"/>Cochrane Database Syst Rev
<year>2008</year>;(<issue>1</issue>):<fpage>CD005171</fpage>.<pub-id pub-id-type="pmid">18254071</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0395">
<label>395</label>
<mixed-citation id="bdi12609-cit-0395" publication-type="journal">
<string-name>
<surname>Mazza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Di Nicola</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martinotti</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Oxcarbazepine in bipolar disorder: a critical review of the literature</article-title>. <source xml:lang="en"/>Expert Opin Pharmacother. <year>2007</year>;<volume>8</volume>:<fpage>649</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">17376019</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0396">
<label>396</label>
<mixed-citation id="bdi12609-cit-0396" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cruz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Garcia‐Campayo</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>A double‐blind, randomized, placebo‐controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long‐term treatment of bipolar I and II disorder</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2008</year>;<volume>11</volume>:<fpage>445</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">18346292</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0397">
<label>397</label>
<mixed-citation id="bdi12609-cit-0397" publication-type="journal">
<string-name>
<surname>Zarate</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Double‐blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2004</year>;<volume>161</volume>:<fpage>169</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">14702269</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0398">
<label>398</label>
<mixed-citation id="bdi12609-cit-0398" publication-type="journal">
<string-name>
<surname>Prien</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Klett</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Caffey</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Lithium‐carbonate and imipramine in prevention of affective episodes – comparison in recurrent affective illness</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1973</year>;<volume>29</volume>:<fpage>420</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">4579507</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0399">
<label>399</label>
<mixed-citation id="bdi12609-cit-0399" publication-type="journal">
<string-name>
<surname>Kane</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Quitkin</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Rifkin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ramoslorenzi</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Nayak</surname>
<given-names>DD</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>A</given-names>
</string-name>. <article-title>Lithium‐carbonate and imipramine in the prophylaxis of unipolar and bipolar‐II illness – a prospective, placebo‐controlled comparison</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1982</year>;<volume>39</volume>:<fpage>1065</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">6810839</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0400">
<label>400</label>
<mixed-citation id="bdi12609-cit-0400" publication-type="journal">
<string-name>
<surname>Prien</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Kupfer</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Mansky</surname>
<given-names>PA</given-names>
</string-name>, et al. <article-title>Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate‐imipramine combination</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1984</year>;<volume>41</volume>:<fpage>1096</fpage>‐<lpage>104</lpage>.<pub-id pub-id-type="pmid">6437366</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0401">
<label>401</label>
<mixed-citation id="bdi12609-cit-0401" publication-type="journal">
<string-name>
<surname>Solomon</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Keitner</surname>
<given-names>GI</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>IW</given-names>
</string-name>, <string-name>
<surname>Shea</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Course of illness and maintenance treatments for patients with bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1995</year>;<volume>56</volume>:<fpage>5</fpage>‐<lpage>13</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0402">
<label>402</label>
<mixed-citation id="bdi12609-cit-0402" publication-type="journal">
<string-name>
<surname>MacQueen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Marriott</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cooke</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Joffe</surname>
<given-names>RT</given-names>
</string-name>. <article-title>Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2000</year>;<volume>101</volume>:<fpage>374</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">10823297</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0403">
<label>403</label>
<mixed-citation id="bdi12609-cit-0403" publication-type="journal">
<string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baethge</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Lepri</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bratti</surname>
<given-names>IM</given-names>
</string-name>. <article-title>Effects of treatment latency on response to maintenance treatment in manic‐depressive disorders</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2007</year>;<volume>9</volume>:<fpage>386</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">17547585</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0404">
<label>404</label>
<mixed-citation id="bdi12609-cit-0404" publication-type="journal">
<string-name>
<surname>Berghofer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Alda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Adli</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Long‐term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>1860</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">19026269</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0405">
<label>405</label>
<mixed-citation id="bdi12609-cit-0405" publication-type="journal">
<string-name>
<surname>Kleindienst</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Greil</surname>
<given-names>W</given-names>
</string-name>. <article-title>Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study</article-title>. <source xml:lang="en"/>Neuropsychobiology. <year>2000</year>;<volume>42</volume>:<fpage>2</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">11093063</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0406">
<label>406</label>
<mixed-citation id="bdi12609-cit-0406" publication-type="journal">
<string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>RH</given-names>
</string-name>. <article-title>The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double‐blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144)</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>100</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23228201</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0407">
<label>407</label>
<mixed-citation id="bdi12609-cit-0407" publication-type="journal">
<string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Garno</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Leon</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Kocsis</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Portera</surname>
<given-names>L</given-names>
</string-name>. <article-title>A history of substance abuse complicates remission from acute mania in bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1999</year>;<volume>60</volume>:<fpage>733</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">10584760</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0408">
<label>408</label>
<mixed-citation id="bdi12609-cit-0408" publication-type="journal">
<string-name>
<surname>Riemann</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Weisscher</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, et al. <article-title>The relationship between self‐reported borderline personality features and prospective illness course in bipolar disorder</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2017</year>;<volume>5</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">28944443</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0409">
<label>409</label>
<mixed-citation id="bdi12609-cit-0409" publication-type="journal">
<string-name>
<surname>Coppen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Standishbarry</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Houston</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Silcocks</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hermon</surname>
<given-names>C</given-names>
</string-name>. <article-title>Does lithium reduce the mortality of recurrent mood disorders</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1991</year>;<volume>23</volume>:<fpage>1</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">1774419</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0410">
<label>410</label>
<mixed-citation id="bdi12609-cit-0410" publication-type="journal">
<string-name>
<surname>Coppen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Farmer</surname>
<given-names>R</given-names>
</string-name>. <article-title>Suicide mortality in patients on lithium maintenance therapy</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1998</year>;<volume>50</volume>:<fpage>261</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">9858085</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0411">
<label>411</label>
<mixed-citation id="bdi12609-cit-0411" publication-type="journal">
<string-name>
<surname>Ahrens</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Grof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Moller</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Mulleroerlinghausen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>T</given-names>
</string-name>. <article-title>Extended survival of patients on long‐term lithium treatment</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>1995</year>;<volume>40</volume>:<fpage>241</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">7553542</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0412">
<label>412</label>
<mixed-citation id="bdi12609-cit-0412" publication-type="journal">
<string-name>
<surname>Ahrens</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Muller‐Oerlinghausen</surname>
<given-names>B</given-names>
</string-name>. <article-title>Does lithium exert an independent antisuicidal effect?</article-title>
<source xml:lang="en"/>Pharmacopsychiatry. <year>2001</year>;<volume>34</volume>:<fpage>132</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">11518473</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0413">
<label>413</label>
<mixed-citation id="bdi12609-cit-0413" publication-type="journal">
<string-name>
<surname>Cipriani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hawton</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stockton</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Lithium in the prevention of suicide in mood disorders: updated systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>BMJ. <year>2013</year>;<volume>346</volume>:<fpage>f3646</fpage>.<pub-id pub-id-type="pmid">23814104</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0414">
<label>414</label>
<mixed-citation id="bdi12609-cit-0414" publication-type="journal">
<string-name>
<surname>Grof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Alda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Grof</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>P</given-names>
</string-name>. <article-title>The challenge of predicting response to stabilizing lithium treatment – the importance of patient selection</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>1993</year>;<volume>163</volume>:<fpage>16</fpage>‐<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0415">
<label>415</label>
<mixed-citation id="bdi12609-cit-0415" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Fatemi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kujawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Woyshville</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Predictors of response to mood stabilizers</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>1996</year>;<volume>16</volume>:<fpage>S24</fpage>‐<lpage>S31</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0416">
<label>416</label>
<mixed-citation id="bdi12609-cit-0416" publication-type="journal">
<string-name>
<surname>Rohayem</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bayle</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Richa</surname>
<given-names>S</given-names>
</string-name>. <article-title>Predictors of prophylactic response to lithium</article-title>. <source xml:lang="en"/>Encephale. <year>2008</year>;<volume>34</volume>:<fpage>394</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">18922242</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0417">
<label>417</label>
<mixed-citation id="bdi12609-cit-0417" publication-type="journal">
<string-name>
<surname>Grof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Duffy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cavazzoni</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Is response to prophylactic lithium a familial trait?</article-title>
<source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>942</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12416605</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0418">
<label>418</label>
<mixed-citation id="bdi12609-cit-0418" publication-type="journal">
<string-name>
<surname>Ikeda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>T</given-names>
</string-name>. <article-title>Biological predictors of lithium response in bipolar disorder</article-title>. <source xml:lang="en"/>Psychiatry Clin Neurosci. <year>2003</year>;<volume>57</volume>:<fpage>243</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">12753562</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0419">
<label>419</label>
<mixed-citation id="bdi12609-cit-0419" publication-type="journal">
<string-name>
<surname>Mertens</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>QW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder</article-title>. <source xml:lang="en"/>Nature. <year>2015</year>;<volume>527</volume>:<fpage>95</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">26524527</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0420">
<label>420</label>
<mixed-citation id="bdi12609-cit-0420" publication-type="journal">
<string-name>
<surname>Passmore</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Garnham</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Duffy</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2003</year>;<volume>5</volume>:<fpage>110</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">12680900</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0421">
<label>421</label>
<mixed-citation id="bdi12609-cit-0421" publication-type="journal">
<string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>146</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">11874216</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0422">
<label>422</label>
<mixed-citation id="bdi12609-cit-0422" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ekholm</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Udd</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gustafsson</surname>
<given-names>U</given-names>
</string-name>. <article-title>Long‐term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>142</volume>:<fpage>36</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">23062763</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0423">
<label>423</label>
<mixed-citation id="bdi12609-cit-0423" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>. <article-title>Bipolar II disorder: arguments for and against a distinct diagnostic entity</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>163</fpage>‐<lpage>78</lpage>.<pub-id pub-id-type="pmid">18199235</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0424">
<label>424</label>
<mixed-citation id="bdi12609-cit-0424" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, et al. <article-title>Psychosocial disability in the course of bipolar I and II disorders – A prospective, comparative, longitudinal study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2005</year>;<volume>62</volume>:<fpage>1322</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">16330720</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0425">
<label>425</label>
<mixed-citation id="bdi12609-cit-0425" publication-type="journal">
<string-name>
<surname>Dilsaver</surname>
<given-names>SC</given-names>
</string-name>. <article-title>An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>129</volume>:<fpage>79</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">20888048</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0426">
<label>426</label>
<mixed-citation id="bdi12609-cit-0426" publication-type="journal">
<string-name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Sugar</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double‐blind comparison</article-title>. <source xml:lang="en"/>Am J Psychiatry
<year>2017</year>;<volume>173</volume>:<fpage>266</fpage>‐<lpage>76</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0427">
<label>427</label>
<mixed-citation id="bdi12609-cit-0427" publication-type="journal">
<string-name>
<surname>Judd</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Akiskal</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Schettler</surname>
<given-names>PJ</given-names>
</string-name>, et al. <article-title>A prospective investigation of the natural history of the long‐term weekly symptomatic status of bipolar II disorder</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2003</year>;<volume>60</volume>:<fpage>261</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">12622659</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0428">
<label>428</label>
<mixed-citation id="bdi12609-cit-0428" publication-type="journal">
<string-name>
<surname>Kupka</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>, et al. <article-title>Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2007</year>;<volume>9</volume>:<fpage>531</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">17680925</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0429">
<label>429</label>
<mixed-citation id="bdi12609-cit-0429" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Isometsa</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>International Society for Bipolar Disorders Task Force on Suicide: meta‐analyses and meta‐regression of correlates of suicide attempts and suicide deaths in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>1</fpage>‐<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0430">
<label>430</label>
<mixed-citation id="bdi12609-cit-0430" publication-type="journal">
<string-name>
<surname>Sani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Koukopoulos</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Suicide in a large population of former psychiatric inpatients</article-title>. <source xml:lang="en"/>Psychiatry Clin Neurosci. <year>2011</year>;<volume>65</volume>:<fpage>286</fpage>‐<lpage>95</lpage>.<pub-id pub-id-type="pmid">21507136</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0431">
<label>431</label>
<mixed-citation id="bdi12609-cit-0431" publication-type="journal">
<string-name>
<surname>Greil</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kleindienst</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Erazo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Muller‐Oerlinghausen</surname>
<given-names>B</given-names>
</string-name>. <article-title>Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>1998</year>;<volume>18</volume>:<fpage>455</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">9864077</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0432">
<label>432</label>
<mixed-citation id="bdi12609-cit-0432" publication-type="journal">
<string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Martens</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Creech</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Randomized, double‐blind, placebo‐controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate‐to‐severe hypomania or mild mania</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>557</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">20361901</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0433">
<label>433</label>
<mixed-citation id="bdi12609-cit-0433" publication-type="journal">
<string-name>
<surname>Magalhaes</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dean</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Bush</surname>
<given-names>AI</given-names>
</string-name>, et al. <article-title>A preliminary investigation on the efficacy of N‐acetyl cysteine for mania or hypomania</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2013</year>;<volume>47</volume>:<fpage>564</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">23493756</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0434">
<label>434</label>
<mixed-citation id="bdi12609-cit-0434" publication-type="journal">
<string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Martens</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Winstanley</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Creech</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Malhotra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Placebo‐controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate‐to‐severe hypomania or mild mania</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>124</volume>:<fpage>157</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">19963274</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0435">
<label>435</label>
<mixed-citation id="bdi12609-cit-0435" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Gwizdowski</surname>
<given-names>IS</given-names>
</string-name>, et al. <article-title>First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>150</volume>:<fpage>37</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">23521871</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0436">
<label>436</label>
<mixed-citation id="bdi12609-cit-0436" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gasto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Role of risperidone in bipolar II: an open 6‐month study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2001</year>;<volume>67</volume>:<fpage>213</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">11869771</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0437">
<label>437</label>
<mixed-citation id="bdi12609-cit-0437" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Gustafsson</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2013</year>;<volume>1</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">25505677</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0438">
<label>438</label>
<mixed-citation id="bdi12609-cit-0438" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Macfadden</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled trial of quetiapine in the treatment of bipolar I or II depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2005</year>;<volume>162</volume>:<fpage>1351</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">15994719</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0439">
<label>439</label>
<mixed-citation id="bdi12609-cit-0439" publication-type="journal">
<string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Macfadden</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>RH</given-names>
</string-name>, et al. <article-title>Efficacy of quetiapine monotherapy in bipolar I and II depression – A double‐blind, placebo‐controlled study (The BOLDER II study)</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2006</year>;<volume>26</volume>:<fpage>600</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">17110817</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0440">
<label>440</label>
<mixed-citation id="bdi12609-cit-0440" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Datto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Minkwitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nordenhem</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Darko</surname>
<given-names>D</given-names>
</string-name>. <article-title>Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>121</volume>:<fpage>106</fpage>‐<lpage>15</lpage>.<pub-id pub-id-type="pmid">19903574</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0441">
<label>441</label>
<mixed-citation id="bdi12609-cit-0441" publication-type="journal">
<string-name>
<surname>Jeong</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Bahk</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>YS</given-names>
</string-name>, et al. <article-title>Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open‐label, observational study</article-title>. <source xml:lang="en"/>Neuropsychiatr Dis Treat. <year>2013</year>;<volume>9</volume>:<fpage>197</fpage>‐<lpage>204</lpage>.<pub-id pub-id-type="pmid">23431086</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0442">
<label>442</label>
<mixed-citation id="bdi12609-cit-0442" publication-type="journal">
<string-name>
<surname>Ahn</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Nam</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Culver</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Bonner</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Lamotrigine plus quetiapine combination therapy in treatment‐resistant bipolar depression</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2011</year>;<volume>23</volume>:<fpage>17</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">21318192</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0443">
<label>443</label>
<mixed-citation id="bdi12609-cit-0443" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>1998</year>;<volume>18</volume>:<fpage>414</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">9790160</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0444">
<label>444</label>
<mixed-citation id="bdi12609-cit-0444" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Garcia‐Espana</surname>
<given-names>F</given-names>
</string-name>. <article-title>Venlafaxine monotherapy in women with bipolar II and unipolar major depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2000</year>;<volume>59</volume>:<fpage>225</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">10854639</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0445">
<label>445</label>
<mixed-citation id="bdi12609-cit-0445" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Bernstein</surname>
<given-names>IH</given-names>
</string-name>, et al. <article-title>A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2008</year>;<volume>111</volume>:<fpage>334</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">18358540</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0446">
<label>446</label>
<mixed-citation id="bdi12609-cit-0446" publication-type="journal">
<string-name>
<surname>Donnelly</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Waldman</surname>
<given-names>IN</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Prediction of antidepressant responses to lithium</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1978</year>;<volume>135</volume>:<fpage>552</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">645948</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0447">
<label>447</label>
<mixed-citation id="bdi12609-cit-0447" publication-type="journal">
<string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Bunney</surname>
<given-names>WE</given-names>
</string-name>. <article-title>Lithium‐carbonate treatment in depression and mania – a longitudinal double‐blind study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1969</year>;<volume>21</volume>:<fpage>486</fpage>‐<lpage>496</lpage>.<pub-id pub-id-type="pmid">4896983</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0448">
<label>448</label>
<mixed-citation id="bdi12609-cit-0448" publication-type="journal">
<string-name>
<surname>Goodwin</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Bunney</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Dunner</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Lithium Response in unipolar versus bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1972</year>;<volume>129</volume>:<fpage>44</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">4556087</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0449">
<label>449</label>
<mixed-citation id="bdi12609-cit-0449" publication-type="journal">
<string-name>
<surname>Baron</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gershon</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Rudy</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jonas</surname>
<given-names>WZ</given-names>
</string-name>, <string-name>
<surname>Buchsbaum</surname>
<given-names>M</given-names>
</string-name>. <article-title>Lithium‐carbonate response in depression – prediction by unipolar bipolar illness, average‐evoked response, catechol‐o‐methyl transferase, and family history</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1975</year>;<volume>32</volume>:<fpage>1107</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">1101845</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0450">
<label>450</label>
<mixed-citation id="bdi12609-cit-0450" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Lorenzo‐Luaces</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Soeller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>SQ</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>DeRubeis</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Short‐term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2016</year>;<volume>208</volume>:<fpage>359</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">26892848</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0451">
<label>451</label>
<mixed-citation id="bdi12609-cit-0451" publication-type="journal">
<string-name>
<surname>Fieve</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Kumbaraci</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dunner</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Lithium prophylaxis of depression in bipolar‐1, bipolar‐2, and unipolar patients</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1976</year>;<volume>133</volume>:<fpage>925</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">782261</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0452">
<label>452</label>
<mixed-citation id="bdi12609-cit-0452" publication-type="journal">
<string-name>
<surname>Dunner</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Fieve</surname>
<given-names>RR</given-names>
</string-name>. <article-title>Clinical factors in lithium‐carbonate prophylaxis failure</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1974</year>;<volume>30</volume>:<fpage>229</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">4589148</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0453">
<label>453</label>
<mixed-citation id="bdi12609-cit-0453" publication-type="journal">
<string-name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Friedman</surname>
<given-names>ES</given-names>
</string-name>, et al. <article-title>Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): a pragmatic 6‐month trial of lithium versus quetiapine for bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2016</year>;<volume>77</volume>:<fpage>90</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">26845264</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0454">
<label>454</label>
<mixed-citation id="bdi12609-cit-0454" publication-type="journal">
<string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Noronha</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Kauer‐Sant'Anna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Antidepressant‐associated mood elevations in bipolar II disorder compared with bipolar i disorder and major depressive disorder: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>1589</fpage>‐<lpage>601</lpage>.<pub-id pub-id-type="pmid">19192442</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0455">
<label>455</label>
<mixed-citation id="bdi12609-cit-0455" publication-type="journal">
<string-name>
<surname>Vohringer</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Ostacher</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>El‐Mallakh</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Antidepressants in type II versus type I bipolar depression a randomized discontinuation trial</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2015</year>;<volume>35</volume>:<fpage>605</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">26267418</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0456">
<label>456</label>
<mixed-citation id="bdi12609-cit-0456" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C‐H</given-names>
</string-name>, <string-name>
<surname>Shwarz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>. <article-title>Venlafaxine versus lithium monotherapy of rapid and non‐rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open‐label trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>112</volume>:<fpage>219</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">18486235</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0457">
<label>457</label>
<mixed-citation id="bdi12609-cit-0457" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>. <article-title>Effectiveness and mood conversion rate of short‐term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2013</year>;<volume>33</volume>:<fpage>420</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">23609385</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0458">
<label>458</label>
<mixed-citation id="bdi12609-cit-0458" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficacy and mood conversion rate during long‐term fluoxetine v. lithium monotherapy in rapid‐ and non‐rapid‐cycling bipolar II disorder</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2013</year>;<volume>202</volume>:<fpage>301</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">23099447</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0459">
<label>459</label>
<mixed-citation id="bdi12609-cit-0459" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>A placebo‐controlled 18‐month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>1013</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">14628976</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0460">
<label>460</label>
<mixed-citation id="bdi12609-cit-0460" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Cornelius</surname>
<given-names>VR</given-names>
</string-name>, <string-name>
<surname>Azorin</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Valproate for the treatment of acute bipolar depression: systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>122</volume>:<fpage>1</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19926140</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0461">
<label>461</label>
<mixed-citation id="bdi12609-cit-0461" publication-type="journal">
<string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>. <article-title>A 25‐year‐old woman with bipolar disorder</article-title>. <source xml:lang="en"/>JAMA. <year>2001</year>;<volume>285</volume>:<fpage>454</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">11242431</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0462">
<label>462</label>
<mixed-citation id="bdi12609-cit-0462" publication-type="journal">
<string-name>
<surname>Muzina</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, et al. <article-title>Acute efficacy of divalproex sodium versus placebo in mood stabilizer‐naive bipolar I or II depression: a double‐blind, randomized, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>813</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">20816041</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0463">
<label>463</label>
<mixed-citation id="bdi12609-cit-0463" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Joffe</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>MacQueen</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Marriott</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Patelis‐Siotis</surname>
<given-names>I</given-names>
</string-name>. <article-title>Double‐blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2000</year>;<volume>157</volume>:<fpage>124</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">10618026</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0464">
<label>464</label>
<mixed-citation id="bdi12609-cit-0464" publication-type="journal">
<string-name>
<surname>Winsberg</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>DeGolia</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Strong</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Divalproex therapy in medication‐naive and mood‐stabilizer‐naive bipolar II depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2001</year>;<volume>67</volume>:<fpage>207</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">11869770</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0465">
<label>465</label>
<mixed-citation id="bdi12609-cit-0465" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Nowakowska</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chandler</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Divalproex extended‐release in acute bipolar II depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>124</volume>:<fpage>170</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">19923006</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0466">
<label>466</label>
<mixed-citation id="bdi12609-cit-0466" publication-type="journal">
<string-name>
<surname>Frankenburg</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>Zanarini</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double‐blind placebo‐controlled pilot study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>442</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">12019669</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0467">
<label>467</label>
<mixed-citation id="bdi12609-cit-0467" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brunswick</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hundert</surname>
<given-names>M</given-names>
</string-name>. <article-title>Short‐term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>75</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">14996144</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0468">
<label>468</label>
<mixed-citation id="bdi12609-cit-0468" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Garcia‐Espana</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fawcett</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Efficacy and safety of fluoxetine in treating bipolar II major depressive episode</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>1998</year>;<volume>18</volume>:<fpage>435</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">9864074</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0469">
<label>469</label>
<mixed-citation id="bdi12609-cit-0469" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficacy and safety of long‐term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double‐blind, placebo‐substitution study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2010</year>;<volume>167</volume>:<fpage>792</fpage>‐<lpage>800</lpage>.<pub-id pub-id-type="pmid">20360317</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0470">
<label>470</label>
<mixed-citation id="bdi12609-cit-0470" publication-type="journal">
<string-name>
<surname>Patkar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gilmer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Pae</surname>
<given-names>CU</given-names>
</string-name>, et al. <article-title>A 6 week randomized double‐blind placebo‐controlled trial of ziprasidone for the acute depressive mixed state</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2012</year>;<volume>7</volume>:<fpage>e34757</fpage>.<pub-id pub-id-type="pmid">22545088</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0471">
<label>471</label>
<mixed-citation id="bdi12609-cit-0471" publication-type="journal">
<string-name>
<surname>Liebowitz</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Salman</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mech</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Ziprasidone monotherapy in bipolar II depression: an open trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>118</volume>:<fpage>205</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">19264363</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0472">
<label>472</label>
<mixed-citation id="bdi12609-cit-0472" publication-type="journal">
<string-name>
<surname>Fornaro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>De Berardis</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study</article-title>. <source xml:lang="en"/>Neuropsychiatr Dis Treat. <year>2013</year>;<volume>9</volume>:<fpage>243</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">23430979</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0473">
<label>473</label>
<mixed-citation id="bdi12609-cit-0473" publication-type="journal">
<string-name>
<surname>Stoll</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Severus</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>MP</given-names>
</string-name>, et al. <article-title>Omega 3 fatty acids in bipolar disorder – A preliminary double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1999</year>;<volume>56</volume>:<fpage>407</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">10232294</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0474">
<label>474</label>
<mixed-citation id="bdi12609-cit-0474" publication-type="journal">
<string-name>
<surname>Frangou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McCrone</surname>
<given-names>P</given-names>
</string-name>. <article-title>Efficacy of ethyl‐eicosapentaenoic acid in bipolar depression: randomised double‐blind placebo‐controlled study</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2006</year>;<volume>188</volume>:<fpage>46</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">16388069</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0475">
<label>475</label>
<mixed-citation id="bdi12609-cit-0475" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Mintz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Double‐blind, randomized, placebo‐controlled trials of ethyl‐eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2006</year>;<volume>60</volume>:<fpage>1020</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">16814257</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0476">
<label>476</label>
<mixed-citation id="bdi12609-cit-0476" publication-type="journal">
<string-name>
<surname>Magalhaes</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Dean</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Bush</surname>
<given-names>AI</given-names>
</string-name>, et al. <article-title>N‐acetyl cysteine add‐on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>129</volume>:<fpage>317</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">20800897</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0477">
<label>477</label>
<mixed-citation id="bdi12609-cit-0477" publication-type="journal">
<string-name>
<surname>Diazgranados</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Brutsche</surname>
<given-names>NE</given-names>
</string-name>, et al. <article-title>A randomized add‐on trial of an <italic>N</italic>‐methyl‐<sc>d</sc>‐aspartate antagonist in treatment‐resistant bipolar depression</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2010</year>;<volume>67</volume>:<fpage>793</fpage>‐<lpage>802</lpage>.<pub-id pub-id-type="pmid">20679587</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0478">
<label>478</label>
<mixed-citation id="bdi12609-cit-0478" publication-type="journal">
<string-name>
<surname>Zarate</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Brutsche</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add‐on trial</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2012</year>;<volume>71</volume>:<fpage>939</fpage>‐<lpage>46</lpage>.<pub-id pub-id-type="pmid">22297150</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0479">
<label>479</label>
<mixed-citation id="bdi12609-cit-0479" publication-type="journal">
<string-name>
<surname>McClure</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Greenman</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Koppolu</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Varvara</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yaseen</surname>
<given-names>ZS</given-names>
</string-name>, <string-name>
<surname>Galynker</surname>
<given-names>II</given-names>
</string-name>. <article-title>A pilot study of safety and efficacy of cranial electrotherapy stimulation in treatment of bipolar II depression</article-title>. <source xml:lang="en"/>J Nerv Ment Dis. <year>2015</year>;<volume>203</volume>:<fpage>827</fpage>‐<lpage>35</lpage>.<pub-id pub-id-type="pmid">26414234</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0480">
<label>480</label>
<mixed-citation id="bdi12609-cit-0480" publication-type="journal">
<string-name>
<surname>Kelly</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Lieberman</surname>
<given-names>DZ</given-names>
</string-name>. <article-title>The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>167</volume>:<fpage>333</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">25016490</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0481">
<label>481</label>
<mixed-citation id="bdi12609-cit-0481" publication-type="journal">
<string-name>
<surname>Dauphinais</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>JZ</given-names>
</string-name>, <string-name>
<surname>Terman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DiFebo</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Tuggle</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2012</year>;<volume>196</volume>:<fpage>57</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">22424890</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0482">
<label>482</label>
<mixed-citation id="bdi12609-cit-0482" publication-type="journal">
<string-name>
<surname>Sit</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wisner</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Hanusa</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Stull</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Terman</surname>
<given-names>M</given-names>
</string-name>. <article-title>Light therapy for bipolar disorder: a case series in women</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2007</year>;<volume>9</volume>:<fpage>918</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">18076544</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0483">
<label>483</label>
<mixed-citation id="bdi12609-cit-0483" publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Kelsoe</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Schachat</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2009</year>;<volume>66</volume>:<fpage>298</fpage>‐<lpage>301</lpage>.<pub-id pub-id-type="pmid">19358978</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0484">
<label>484</label>
<mixed-citation id="bdi12609-cit-0484" publication-type="journal">
<string-name>
<surname>Colombo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lucca</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Barbini</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Campori</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</string-name>. <article-title>Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2000</year>;<volume>95</volume>:<fpage>43</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">10904122</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0485">
<label>485</label>
<mixed-citation id="bdi12609-cit-0485" publication-type="journal">
<string-name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pontiggia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bernasconi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Florita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</string-name>. <article-title>Morning light treatment hastens the antidepressant effect of citalopram: a placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>648</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">12823078</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0486">
<label>486</label>
<mixed-citation id="bdi12609-cit-0486" publication-type="journal">
<string-name>
<surname>Kirino</surname>
<given-names>E</given-names>
</string-name>. <article-title>Efficacy of olanzapine for treating depressive episodes in bipolar disorder</article-title>. <source xml:lang="en"/>Clin Neuropsychopharmacol Ther. <year>2014</year>;<volume>5</volume>:<fpage>11</fpage>‐<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0487">
<label>487</label>
<mixed-citation id="bdi12609-cit-0487" publication-type="journal">
<string-name>
<surname>Daryani</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Bokade</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Raichandani</surname>
<given-names>OP</given-names>
</string-name>. <article-title>A comparative study of efficacy of lamotrigine and levetiracetam in the continuous maintenance phase of patients with bipolar depressive disorder</article-title>. <source xml:lang="en"/>Int J Bioassay. <year>2014</year>;<volume>3</volume>:<fpage>3062</fpage>‐<lpage>3065</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0488">
<label>488</label>
<mixed-citation id="bdi12609-cit-0488" publication-type="journal">
<string-name>
<surname>Lipinski</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Frankenburg</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Open trial of S‐adenosylmethionine for treatment of depression</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1984</year>;<volume>141</volume>:<fpage>448</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">6367496</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0489">
<label>489</label>
<mixed-citation id="bdi12609-cit-0489" publication-type="journal">
<string-name>
<surname>Carney</surname>
<given-names>MWP</given-names>
</string-name>, <string-name>
<surname>Chary</surname>
<given-names>TKN</given-names>
</string-name>, <string-name>
<surname>Bottiglieri</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>EH</given-names>
</string-name>. <article-title>The switch mechanism and the bipolar unipolar dichotomy</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>1989</year>;<volume>154</volume>:<fpage>48</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">2673478</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0490">
<label>490</label>
<mixed-citation id="bdi12609-cit-0490" publication-type="journal">
<string-name>
<surname>Murphy</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Babb</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Ravichandran</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</string-name>. <article-title>Oral SAMe in persistent treatment‐refractory bipolar depression a double‐blind, randomized clinical trial</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2014</year>;<volume>34</volume>:<fpage>413</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">24699040</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0491">
<label>491</label>
<mixed-citation id="bdi12609-cit-0491" publication-type="journal">
<string-name>
<surname>Brennan</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Hudson</surname>
<given-names>JI</given-names>
</string-name>, et al. <article-title>A placebo‐controlled trial of acetyl‐<sc>l</sc>‐carnitine and alpha‐lipoic acid in the treatment of bipolar depression</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2013</year>;<volume>33</volume>:<fpage>627</fpage>‐<lpage>35</lpage>.<pub-id pub-id-type="pmid">23948785</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0492">
<label>492</label>
<mixed-citation id="bdi12609-cit-0492" publication-type="journal">
<string-name>
<surname>Hu</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>DR</given-names>
</string-name>, et al. <article-title>Efficacy of repetitive transcranial magnetic stimulation with quetiapine in treating bipolar II depression: a randomized, double‐blinded, control study</article-title>. <source xml:lang="en"/>Sci Rep. <year>2016</year>;<volume>6</volume>:<fpage>30537</fpage>.<pub-id pub-id-type="pmid">27460201</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0493">
<label>493</label>
<mixed-citation id="bdi12609-cit-0493" publication-type="journal">
<string-name>
<surname>Gilmer</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Lorenzen</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Zarnicki</surname>
<given-names>J</given-names>
</string-name>. <article-title>Transcranial magnetic stimulation (TMS) for treatment resistant bipolar depression: a naturalistic case series with clinical outcomes and observations</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>80</fpage>‐<lpage>1</lpage>.<pub-id pub-id-type="pmid">23301947</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0494">
<label>494</label>
<mixed-citation id="bdi12609-cit-0494" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>YH</given-names>
</string-name>, et al. <article-title>The effects of add‐on low‐dose memantine on cytokine levels in bipolar II depression: a 12‐week double‐ blind, randomized controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2014</year>;<volume>34</volume>:<fpage>337</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">24717258</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0495">
<label>495</label>
<mixed-citation id="bdi12609-cit-0495" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Olausson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Paulsson</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Embolden</surname>
<given-names>IDCI</given-names>
</string-name>. <article-title>Embolden IIDCI. A randomised, placebo‐controlled 52‐week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder</article-title>. <source xml:lang="en"/>World J Biol Psychiatry. <year>2014</year>;<volume>15</volume>:<fpage>96</fpage>‐<lpage>112</lpage>.<pub-id pub-id-type="pmid">22404704</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0496">
<label>496</label>
<mixed-citation id="bdi12609-cit-0496" publication-type="journal">
<string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Rapport</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bilali</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>. <article-title>New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2005</year>;<volume>20</volume>:<fpage>92</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">15797691</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0497">
<label>497</label>
<mixed-citation id="bdi12609-cit-0497" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Lorenzo‐Luaces</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Soeller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>SQ</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>DeRubeis</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse‐prevention of bipolar II depression: a randomized, double‐blind, parallel‐group, prospective study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>185</volume>:<fpage>31</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">26143402</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0498">
<label>498</label>
<mixed-citation id="bdi12609-cit-0498" publication-type="journal">
<string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Floris</surname>
<given-names>G</given-names>
</string-name>. <article-title>Long‐term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2001</year>;<volume>178</volume>:<fpage>S184</fpage>‐<lpage>S90</lpage>.<pub-id pub-id-type="pmid">11388960</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0499">
<label>499</label>
<mixed-citation id="bdi12609-cit-0499" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Lamotrigine for the treatment of bipolar disorder: a clinical case series</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1999</year>;<volume>53</volume>:<fpage>95</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">10363672</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0500">
<label>500</label>
<mixed-citation id="bdi12609-cit-0500" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Moon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cha</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ha</surname>
<given-names>K</given-names>
</string-name>. <article-title>Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers</article-title>. <source xml:lang="en"/>Prog Neuropsychopharmacol Biol Psychiatry. <year>2010</year>;<volume>34</volume>:<fpage>1322</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">20673782</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0501">
<label>501</label>
<mixed-citation id="bdi12609-cit-0501" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Corpse</surname>
<given-names>C</given-names>
</string-name>. <article-title>Role of lamotrigine in the management of treatment‐resistant bipolar II depression: a chart review</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2008</year>;<volume>111</volume>:<fpage>100</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">18314200</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0502">
<label>502</label>
<mixed-citation id="bdi12609-cit-0502" publication-type="journal">
<string-name>
<surname>Jung</surname>
<given-names>IK</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Lamotrigine treatment for patients with bipolar ii disorder: retrospective report of 30 cases</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>45</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">18199241</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0503">
<label>503</label>
<mixed-citation id="bdi12609-cit-0503" publication-type="journal">
<string-name>
<surname>Amsterdam</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Shults</surname>
<given-names>J</given-names>
</string-name>. <article-title>Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double‐blind, placebo‐substitution, continuation study</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2005</year>;<volume>20</volume>:<fpage>257</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">16096516</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0504">
<label>504</label>
<mixed-citation id="bdi12609-cit-0504" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo‐controlled maintenance treatment for bipolar depression</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2012</year>;<volume>126</volume>:<fpage>342</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">22708645</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0505">
<label>505</label>
<mixed-citation id="bdi12609-cit-0505" publication-type="journal">
<string-name>
<surname>Parker</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tully</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Olley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hadzi‐Pavlovic</surname>
<given-names>D</given-names>
</string-name>. <article-title>SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2006</year>;<volume>92</volume>:<fpage>205</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">16516304</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0506">
<label>506</label>
<mixed-citation id="bdi12609-cit-0506" publication-type="journal">
<string-name>
<surname>Pan</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Yeh</surname>
<given-names>CB</given-names>
</string-name>. <article-title>Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2014</year>;<volume>14</volume>:<fpage>145</fpage>.<pub-id pub-id-type="pmid">24885966</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0507">
<label>507</label>
<mixed-citation id="bdi12609-cit-0507" publication-type="journal">
<string-name>
<surname>Viguera</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Bouffard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Whitfield</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2002</year>;<volume>159</volume>:<fpage>2102</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">12450965</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0508">
<label>508</label>
<mixed-citation id="bdi12609-cit-0508" publication-type="journal">
<string-name>
<surname>Rusner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Berg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Begley</surname>
<given-names>C</given-names>
</string-name>. <article-title>Bipolar disorder in pregnancy and childbirth: a systematic review of outcomes</article-title>. <source xml:lang="en"/>BMC Pregnancy Childbirth. <year>2016</year>;<volume>16</volume>:<fpage>331</fpage>.<pub-id pub-id-type="pmid">27793111</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0509">
<label>509</label>
<mixed-citation id="bdi12609-cit-0509" publication-type="journal">
<string-name>
<surname>Boden</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lundgren</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Reutfors</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kieler</surname>
<given-names>H</given-names>
</string-name>. <article-title>Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study</article-title>. <source xml:lang="en"/>BMJ. <year>2012</year>;<volume>345</volume>:<fpage>e7085</fpage>.<pub-id pub-id-type="pmid">23137820</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0510">
<label>510</label>
<mixed-citation id="bdi12609-cit-0510" publication-type="journal">
<string-name>
<surname>Joffe</surname>
<given-names>H</given-names>
</string-name>. <article-title>Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2007</year>;<volume>68</volume>:<fpage>10</fpage>‐<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0511">
<label>511</label>
<mixed-citation id="bdi12609-cit-0511" publication-type="journal">
<string-name>
<surname>Viguera</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Whitfield</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, et al. <article-title>Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2007</year>;<volume>164</volume>:<fpage>1817</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">18056236</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0512">
<label>512</label>
<mixed-citation id="bdi12609-cit-0512" publication-type="journal">
<string-name>
<surname>Freeman</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>SA</given-names>
</string-name>, et al. <article-title>The impact of reproductive events on the course of bipolar disorder in women</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>284</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12004800</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0513">
<label>513</label>
<mixed-citation id="bdi12609-cit-0513" publication-type="journal">
<string-name>
<surname>Viguera</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Nonacs</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2000</year>;<volume>157</volume>:<fpage>179</fpage>‐<lpage>84</lpage>.<pub-id pub-id-type="pmid">10671384</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0514">
<label>514</label>
<mixed-citation id="bdi12609-cit-0514" publication-type="journal">
<string-name>
<surname>Iqbal</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Gundlapalli</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Ryals</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Passman</surname>
<given-names>TE</given-names>
</string-name>. <article-title>Effects of antimanic mood‐stabilizing drugs on fetuses, neonates, and nursing infants</article-title>. <source xml:lang="en"/>South Med J. <year>2001</year>;<volume>94</volume>:<fpage>304</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">11284518</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0515">
<label>515</label>
<mixed-citation id="bdi12609-cit-0515" publication-type="journal">
<string-name>
<surname>Yonkers</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Wisner</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Stowe</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Management of bipolar disorder during pregnancy and the postpartum period</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2004</year>;<volume>161</volume>:<fpage>608</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">15056503</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0516">
<label>516</label>
<mixed-citation id="bdi12609-cit-0516" publication-type="journal">
<string-name>
<surname>Sabers</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Buchholt</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Uldall</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>EL</given-names>
</string-name>. <article-title>Lamotrigine plasma levels reduced by oral contraceptives</article-title>. <source xml:lang="en"/>Epilepsy Res. <year>2001</year>;<volume>47</volume>:<fpage>151</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">11673029</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0517">
<label>517</label>
<mixed-citation id="bdi12609-cit-0517" publication-type="journal">
<string-name>
<surname>Crawford</surname>
<given-names>P</given-names>
</string-name>. <article-title>Interactions between antiepileptic drugs and hormonal contraception</article-title>. <source xml:lang="en"/>CNS Drugs. <year>2002</year>;<volume>16</volume>:<fpage>263</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">11945109</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0518">
<label>518</label>
<mixed-citation id="bdi12609-cit-0518" publication-type="journal">
<string-name>
<surname>Patel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Viguera</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Mood‐stabilising anticonvulsants, spina bifida, and folate supplementation: commentary</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2018</year>;<volume>38</volume>:<fpage>7</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">29215383</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0519">
<label>519</label>
<mixed-citation id="bdi12609-cit-0519" publication-type="miscellaneous">
<collab collab-type="authors">Health Product InfoWatch</collab>
. <ext-link ext-link-type="uri" xlink:href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/health-product-infowatch-april-2017-page-2.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/health-product-infowatch-april-2017-page-2.html</ext-link>. Accessed January 30, 2018.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0520">
<label>520</label>
<mixed-citation id="bdi12609-cit-0520" publication-type="journal">
<string-name>
<surname>Kuehn</surname>
<given-names>BM</given-names>
</string-name>. <article-title>No easy answers for physicians caring for pregnant women with depression</article-title>. <source xml:lang="en"/>JAMA. <year>2009</year>;<volume>302</volume>(<issue>2413–4</issue>):<fpage>2420</fpage>.<pub-id pub-id-type="pmid">19996393</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0521">
<label>521</label>
<mixed-citation id="bdi12609-cit-0521" publication-type="journal">
<string-name>
<surname>Frey</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>M</given-names>
</string-name>. <article-title>Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2012</year>;<volume>73</volume>:<fpage>1456</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">23146292</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0522">
<label>522</label>
<mixed-citation id="bdi12609-cit-0522" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>B</given-names>
</string-name>. <article-title>Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>131</volume>:<fpage>408</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">21185082</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0523">
<label>523</label>
<mixed-citation id="bdi12609-cit-0523" publication-type="journal">
<string-name>
<surname>Clark</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Sit</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Driscoll</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Does screening with the MDQ and EPDS improve identification of bipolar disorder in an obstetrical sample?</article-title>
<source xml:lang="en"/>Depress Anxiety. <year>2015</year>;<volume>32</volume>:<fpage>518</fpage>‐<lpage>26</lpage>.<pub-id pub-id-type="pmid">26059839</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0524">
<label>524</label>
<mixed-citation id="bdi12609-cit-0524" publication-type="journal">
<string-name>
<surname>Merrill</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Mittal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nicoloro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Caiozzo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Maciejewski</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>LJ</given-names>
</string-name>. <article-title>Screening for bipolar disorder during pregnancy</article-title>. <source xml:lang="en"/>Arch Womens Ment Health. <year>2015</year>;<volume>18</volume>:<fpage>579</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">25968603</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0525">
<label>525</label>
<mixed-citation id="bdi12609-cit-0525" publication-type="journal">
<string-name>
<surname>Wisner</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Sit</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>McShea</surname>
<given-names>MC</given-names>
</string-name>, et al. <article-title>Onset timing, thoughts of self‐harm, and diagnoses in postpartum women with screen‐positive depression findings</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2013</year>;<volume>70</volume>:<fpage>490</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">23487258</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0526">
<label>526</label>
<mixed-citation id="bdi12609-cit-0526" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pope</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Pregnancy and bipolar disorder: a systematic review</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2012</year>;<volume>73</volume>:<fpage>1447</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">22938889</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0527">
<label>527</label>
<mixed-citation id="bdi12609-cit-0527" publication-type="journal">
<string-name>
<surname>Patorno</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Huybrechts</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Bateman</surname>
<given-names>BT</given-names>
</string-name>, et al. <article-title>Lithium use in pregnancy and the risk of cardiac malformations</article-title>. <source xml:lang="en"/>N Engl J Med. <year>2017</year>;<volume>376</volume>:<fpage>2245</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">28591541</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0528">
<label>528</label>
<mixed-citation id="bdi12609-cit-0528" publication-type="journal">
<string-name>
<surname>Ernst</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>. <article-title>The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad‐spectrum psychotropics</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>42</fpage>‐<lpage>55</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0529">
<label>529</label>
<mixed-citation id="bdi12609-cit-0529" publication-type="journal">
<string-name>
<surname>Jentink</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Loane</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Dolk</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Valproic acid monotherapy in pregnancy and major congenital malformations</article-title>. <source xml:lang="en"/>N Engl J Med. <year>2010</year>;<volume>362</volume>:<fpage>2185</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">20558369</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0530">
<label>530</label>
<mixed-citation id="bdi12609-cit-0530" publication-type="journal">
<string-name>
<surname>Meador</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Browning</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs</article-title>. <source xml:lang="en"/>N Engl J Med. <year>2009</year>;<volume>360</volume>:<fpage>1597</fpage>‐<lpage>605</lpage>.<pub-id pub-id-type="pmid">19369666</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0531">
<label>531</label>
<mixed-citation id="bdi12609-cit-0531" publication-type="miscellaneous">
<article-title>Information for healthcare professionals: risk of neural tube birth defects following prenatal exposure to valproate</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm">https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm</ext-link>. Accessed December 4, 2017.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0532">
<label>532</label>
<mixed-citation id="bdi12609-cit-0532" publication-type="journal">
<string-name>
<surname>Freedman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>RG</given-names>
</string-name>. <article-title>Prenatal choline and the development of schizophrenia</article-title>. <source xml:lang="en"/>Shanghai Arch Psychiatry. <year>2015</year>;<volume>27</volume>:<fpage>90</fpage>‐<lpage>102</lpage>.<pub-id pub-id-type="pmid">26120259</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0533">
<label>533</label>
<mixed-citation id="bdi12609-cit-0533" publication-type="journal">
<string-name>
<surname>Raghavan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Riley</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Volk</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Maternal multivitamin intake, plasma folate and vitamin b12 levels and autism spectrum disorder risk in offspring</article-title>. <source xml:lang="en"/>Paediatr Perinat Epidemiol. <year>2017</year>;<volume>32</volume>:<fpage>100</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">28984369</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0534">
<label>534</label>
<mixed-citation id="bdi12609-cit-0534" publication-type="journal">
<string-name>
<surname>Wesseloo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kamperman</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Munk‐Olsen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pop</surname>
<given-names>VJM</given-names>
</string-name>, <string-name>
<surname>Kushner</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Bergink</surname>
<given-names>V</given-names>
</string-name>. <article-title>Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2016</year>;<volume>173</volume>:<fpage>117</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">26514657</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0535">
<label>535</label>
<mixed-citation id="bdi12609-cit-0535" publication-type="journal">
<string-name>
<surname>Bergink</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Burgerhout</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Koorengevel</surname>
<given-names>KM</given-names>
</string-name>, et al. <article-title>Treatment of psychosis and mania in the postpartum period</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2015</year>;<volume>172</volume>:<fpage>115</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">25640930</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0536">
<label>536</label>
<mixed-citation id="bdi12609-cit-0536" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sommerdyk</surname>
<given-names>C</given-names>
</string-name>. <article-title>Quetiapine in the acute treatment of bipolar postpartum depression a chart review</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2015</year>;<volume>35</volume>:<fpage>733</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">26444950</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0537">
<label>537</label>
<mixed-citation id="bdi12609-cit-0537" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Doobay</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baczynski</surname>
<given-names>C</given-names>
</string-name>. <article-title>Bipolar postpartum depression: an update and recommendations</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2017</year>;<volume>219</volume>:<fpage>105</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">28535448</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0538">
<label>538</label>
<mixed-citation id="bdi12609-cit-0538" publication-type="journal">
<string-name>
<surname>Heron</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McGuinness</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blackmore</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>I</given-names>
</string-name>. <article-title>Early postpartum symptoms in puerperal psychosis</article-title>. <source xml:lang="en"/>BJOG. <year>2008</year>;<volume>115</volume>:<fpage>348</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">18190371</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0539">
<label>539</label>
<mixed-citation id="bdi12609-cit-0539" publication-type="journal">
<string-name>
<surname>Menon</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Psychotropic medication during pregnancy and lactation</article-title>. <source xml:lang="en"/>Arch Gynecol Obstet. <year>2008</year>;<volume>277</volume>:<fpage>1</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">17710428</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0540">
<label>540</label>
<mixed-citation id="bdi12609-cit-0540" publication-type="journal">
<string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Leon‐Caballero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Murru</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Mood stabilizers and antipsychotics during breastfeeding: focus on bipolar disorder</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2016</year>;<volume>26</volume>:<fpage>1562</fpage>‐<lpage>78</lpage>.<pub-id pub-id-type="pmid">27568278</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0541">
<label>541</label>
<mixed-citation id="bdi12609-cit-0541" publication-type="journal">
<string-name>
<surname>Ward</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Bates</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Benitz</surname>
<given-names>WE</given-names>
</string-name>, et al. <article-title>The transfer of drugs and other chemicals into human milk</article-title>. <source xml:lang="en"/>Pediatrics. <year>2001</year>;<volume>108</volume>:<fpage>776</fpage>‐<lpage>89</lpage>.<pub-id pub-id-type="pmid">11533352</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0542">
<label>542</label>
<mixed-citation id="bdi12609-cit-0542" publication-type="journal">
<string-name>
<surname>Thomson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>. <article-title>Between a rock‐a‐bye and a hard place: mood disorders during the perinatal period</article-title>. <source xml:lang="en"/>CNS Spectr. <year>2000</year>;<volume>22</volume>:<fpage>49</fpage>‐<lpage>64</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0543">
<label>543</label>
<mixed-citation id="bdi12609-cit-0543" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>MK</given-names>
</string-name>, et al. <article-title>A prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in pregnancy and postpartum</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>16</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">24127853</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0544">
<label>544</label>
<mixed-citation id="bdi12609-cit-0544" publication-type="journal">
<string-name>
<surname>Dias</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Lafer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Longitudinal follow‐up of bipolar disorder in women with premenstrual exacerbation: findings from STEP‐BD</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2011</year>;<volume>168</volume>:<fpage>386</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">21324951</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0545">
<label>545</label>
<mixed-citation id="bdi12609-cit-0545" publication-type="journal">
<string-name>
<surname>Frey</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Minuzzi</surname>
<given-names>L</given-names>
</string-name>. <article-title>Comorbid bipolar disorder and premenstrual dysphoric disorder: real patients, unanswered questions</article-title>. <source xml:lang="en"/>Arch Womens Ment Health. <year>2013</year>;<volume>16</volume>:<fpage>79</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">23135309</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0546">
<label>546</label>
<mixed-citation id="bdi12609-cit-0546" publication-type="journal">
<string-name>
<surname>Slyepchenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Frey</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Lafer</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Dias</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEP‐BD study</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2017</year>;<volume>136</volume>:<fpage>473</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">28846801</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0547">
<label>547</label>
<mixed-citation id="bdi12609-cit-0547" publication-type="journal">
<string-name>
<surname>Teatero</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Mazmanian</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>. <article-title>Effects of the menstrual cycle on bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>22</fpage>‐<lpage>36</lpage>.<pub-id pub-id-type="pmid">24467469</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0548">
<label>548</label>
<mixed-citation id="bdi12609-cit-0548" publication-type="journal">
<string-name>
<surname>Wittchen</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lieb</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Krause</surname>
<given-names>P</given-names>
</string-name>. <article-title>Prevalence, incidence and stability of premenstrual dysphoric disorder in the community</article-title>. <source xml:lang="en"/>Psychol Med. <year>2002</year>;<volume>32</volume>:<fpage>119</fpage>‐<lpage>32</lpage>.<pub-id pub-id-type="pmid">11883723</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0549">
<label>549</label>
<mixed-citation id="bdi12609-cit-0549" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Frey</surname>
<given-names>BN</given-names>
</string-name>. <article-title>Treating comorbid premenstrual dysphoric disorder in women with bipolar disorder</article-title>. <source xml:lang="en"/>J Psychiatry Neurosci. <year>2016</year>;<volume>41</volume>:<fpage>E22</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">26898728</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0550">
<label>550</label>
<mixed-citation id="bdi12609-cit-0550" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Friedman</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Schuermeyer</surname>
<given-names>IN</given-names>
</string-name>, et al. <article-title>Menopause knowledge and subjective experience among peri‐ and postmenopausal women with bipolar disorder, schizophrenia and major depression</article-title>. <source xml:lang="en"/>J Nerv Ment Dis. <year>2006</year>;<volume>194</volume>:<fpage>173</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">16534434</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0551">
<label>551</label>
<mixed-citation id="bdi12609-cit-0551" publication-type="journal">
<string-name>
<surname>Blackmore</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Craddock</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Walters</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>I</given-names>
</string-name>. <article-title>Is the perimenopause a time of increased risk of recurrence in women with a history of bipolar affective postpartum psychosis? A case series</article-title>. <source xml:lang="en"/>Arch Womens Ment Health. <year>2008</year>;<volume>11</volume>:<fpage>75</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">18278429</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0552">
<label>552</label>
<mixed-citation id="bdi12609-cit-0552" publication-type="journal">
<string-name>
<surname>Marsh</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Kroll‐Desrosiers</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Rothschild</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Progression of female reproductive stages associated with bipolar illness exacerbation</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>515</fpage>‐<lpage>26</lpage>.<pub-id pub-id-type="pmid">22650986</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0553">
<label>553</label>
<mixed-citation id="bdi12609-cit-0553" publication-type="journal">
<string-name>
<surname>Marsh</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Templeton</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Rasgon</surname>
<given-names>NL</given-names>
</string-name>. <article-title>Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: preliminary report</article-title>. <source xml:lang="en"/>J Psychiatr Res. <year>2008</year>;<volume>42</volume>:<fpage>247</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">17266987</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0554">
<label>554</label>
<mixed-citation id="bdi12609-cit-0554" publication-type="journal">
<string-name>
<surname>Soares</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>V</given-names>
</string-name>. <article-title>Effects and management of the menopausal transition in women with depression and bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2007</year>;<volume>68</volume>:<fpage>16</fpage>‐<lpage>21</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0555">
<label>555</label>
<mixed-citation id="bdi12609-cit-0555" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>. <article-title>Prevalence, clinical presentation and differential diagnosis of pediatric bipolar disorder</article-title>. <source xml:lang="en"/>Isr J Psychiatry Relat Sci. <year>2012</year>;<volume>49</volume>:<fpage>3</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">22652925</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0556">
<label>556</label>
<mixed-citation id="bdi12609-cit-0556" publication-type="journal">
<string-name>
<surname>Van Meter</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Meta‐analysis of epidemiologic studies of pediatric bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>1250</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">21672501</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0557">
<label>557</label>
<mixed-citation id="bdi12609-cit-0557" publication-type="journal">
<string-name>
<surname>Van Meter</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kowatch</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Ten‐year updated meta‐analysis of the clinical characteristics of pediatric mania and hypomania</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>19</fpage>‐<lpage>32</lpage>.<pub-id pub-id-type="pmid">26748678</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0558">
<label>558</label>
<mixed-citation id="bdi12609-cit-0558" publication-type="journal">
<string-name>
<surname>Leibenluft</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rich</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Pediatric bipolar disorder</article-title>. <source xml:lang="en"/>Annu Rev Clin Psychol. <year>2008</year>;<volume>4</volume>:<fpage>163</fpage>‐<lpage>87</lpage>.<pub-id pub-id-type="pmid">17716034</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0559">
<label>559</label>
<mixed-citation id="bdi12609-cit-0559" publication-type="journal">
<string-name>
<surname>Leibenluft</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Charney</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Towbin</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Bhangoo</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Pine</surname>
<given-names>DS</given-names>
</string-name>. <article-title>Defining clinical phenotypes of juvenile mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2003</year>;<volume>160</volume>:<fpage>430</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12611821</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0560">
<label>560</label>
<mixed-citation id="bdi12609-cit-0560" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>GA</given-names>
</string-name>, et al. <article-title>The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2017</year>;<volume>19</volume>:<fpage>524</fpage>‐<lpage>543</lpage>.<pub-id pub-id-type="pmid">28944987</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0561">
<label>561</label>
<mixed-citation id="bdi12609-cit-0561" publication-type="journal">
<string-name>
<surname>Perlis</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Miyahara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, et al. <article-title>Long‐term implications of early onset in bipolar disorder: Data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD)</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2004</year>;<volume>55</volume>:<fpage>875</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">15110730</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0562">
<label>562</label>
<mixed-citation id="bdi12609-cit-0562" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Levitt</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Further evidence for a developmental subtype of bipolar disorder defined by age at onset: results from the national epidemiologic survey on alcohol and related conditions</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2006</year>;<volume>163</volume>:<fpage>1633</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">16946191</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0563">
<label>563</label>
<mixed-citation id="bdi12609-cit-0563" publication-type="journal">
<string-name>
<surname>Axelson</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, et al. <article-title>Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the diagnostic and statistical manual of mental disorders, fifth edition</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2011</year>;<volume>72</volume>:<fpage>1257</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">21672494</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0564">
<label>564</label>
<mixed-citation id="bdi12609-cit-0564" publication-type="journal">
<string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Axelson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Four‐year longitudinal course of children and adolescents with bipolar spectrum disorders: the course and outcome of bipolar youth (COBY) study</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2009</year>;<volume>166</volume>:<fpage>795</fpage>‐<lpage>804</lpage>.<pub-id pub-id-type="pmid">19448190</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0565">
<label>565</label>
<mixed-citation id="bdi12609-cit-0565" publication-type="journal">
<string-name>
<surname>Parens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>J</given-names>
</string-name>. <article-title>Controversies concerning the diagnosis and treatment of bipolar disorder in children</article-title>. <source xml:lang="en"/>Child Adolesc Psychiatry Ment Health. <year>2010</year>;<volume>4</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">20219111</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0566">
<label>566</label>
<mixed-citation id="bdi12609-cit-0566" publication-type="journal">
<string-name>
<surname>Kozloff</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Bipolar disorder among adolescents and young adults: results from an epidemiological sample</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2010</year>;<volume>125</volume>:<fpage>350</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">20226535</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0567">
<label>567</label>
<mixed-citation id="bdi12609-cit-0567" publication-type="journal">
<string-name>
<surname>Khazanov</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Merikangas</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Angst</surname>
<given-names>J</given-names>
</string-name>. <article-title>Treatment patterns of youth with bipolar disorder: results from the National Comorbidity Survey‐Adolescent Supplement (NCS‐A)</article-title>. <source xml:lang="en"/>J Abnorm Child Psychol. <year>2015</year>;<volume>43</volume>:<fpage>391</fpage>‐<lpage>400</lpage>.<pub-id pub-id-type="pmid">24958307</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0568">
<label>568</label>
<mixed-citation id="bdi12609-cit-0568" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>. <article-title>Recent progress in understanding pediatric bipolar disorder</article-title>. <source xml:lang="en"/>Arch Pediatr Adolesc Med. <year>2012</year>;<volume>166</volume>:<fpage>362</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">22213607</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0569">
<label>569</label>
<mixed-citation id="bdi12609-cit-0569" publication-type="journal">
<string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Kupka</surname>
<given-names>RW</given-names>
</string-name>, et al. <article-title>Early‐onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2010</year>;<volume>71</volume>:<fpage>864</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">20667291</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0570">
<label>570</label>
<mixed-citation id="bdi12609-cit-0570" publication-type="journal">
<string-name>
<surname>Miller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Bipolar disorder and attention‐deficit/hyperactivity disorder comorbidity in children and adolescents: evidence‐based approach to diagnosis and treatment</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2013</year>;<volume>74</volume>:<fpage>628</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23842014</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0571">
<label>571</label>
<mixed-citation id="bdi12609-cit-0571" publication-type="journal">
<string-name>
<surname>Fonseka</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Swampillai</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Timmins</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Significance of borderline personality‐spectrum symptoms among adolescents with bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>170</volume>:<fpage>39</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">25233237</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0572">
<label>572</label>
<mixed-citation id="bdi12609-cit-0572" publication-type="journal">
<string-name>
<surname>Uchida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Serra</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zayas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kenworthy</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Biederman</surname>
<given-names>J</given-names>
</string-name>. <article-title>Can unipolar and bipolar pediatric major depression be differentiated from each other? A systematic review of cross‐sectional studies examining differences in unipolar and bipolar depression</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>176</volume>:<fpage>1</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">25682377</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0573">
<label>573</label>
<mixed-citation id="bdi12609-cit-0573" publication-type="journal">
<string-name>
<surname>Uchida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Serra</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zayas</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Can manic switches be predicted in pediatric major depression? A systematic literature review</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>172</volume>:<fpage>300</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">25451429</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0574">
<label>574</label>
<mixed-citation id="bdi12609-cit-0574" publication-type="journal">
<string-name>
<surname>Ratheesh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Davey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hetrick</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A systematic review and meta‐analysis of prospective transition from major depression to bipolar disorder</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2017</year>;<volume>135</volume>:<fpage>273</fpage>‐<lpage>84</lpage>.<pub-id pub-id-type="pmid">28097648</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0575">
<label>575</label>
<mixed-citation id="bdi12609-cit-0575" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dienes</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Adleman</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ketter</surname>
<given-names>T</given-names>
</string-name>. <article-title>Bipolar offspring: a window into bipolar disorder evolution</article-title>. <source xml:lang="en"/>Biol Psychiatry. <year>2003</year>;<volume>53</volume>:<fpage>945</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">12788239</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0576">
<label>576</label>
<mixed-citation id="bdi12609-cit-0576" publication-type="journal">
<string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Axelson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Monk</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Lifetime psychiatric disorders in school‐aged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2009</year>;<volume>66</volume>:<fpage>287</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">19255378</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0577">
<label>577</label>
<mixed-citation id="bdi12609-cit-0577" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Shamseddeen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Axelson</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2010</year>;<volume>49</volume>:<fpage>388</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">20410731</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0578">
<label>578</label>
<mixed-citation id="bdi12609-cit-0578" publication-type="journal">
<string-name>
<surname>Goldsmith</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>. <article-title>Antidepressants and psychostimulants in pediatric populations: is there an association with mania?</article-title>
<source xml:lang="en"/>Paediatr Drugs. <year>2011</year>;<volume>13</volume>:<fpage>225</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">21692547</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0579">
<label>579</label>
<mixed-citation id="bdi12609-cit-0579" publication-type="journal">
<string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Frazier</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Demeter</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>. <article-title>Developing a ten item mania scale from the parent general behavior inventory for children and adolescents</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>831</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">18452343</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0580">
<label>580</label>
<mixed-citation id="bdi12609-cit-0580" publication-type="journal">
<string-name>
<surname>Diler</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Axelson</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>The child behavior checklist (CBCL) and the cbcl‐bipolar phenotype are not useful in diagnosing pediatric bipolar disorder</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2009</year>;<volume>19</volume>:<fpage>23</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">19232020</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0581">
<label>581</label>
<mixed-citation id="bdi12609-cit-0581" publication-type="journal">
<string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>R</given-names>
</string-name>. <article-title>The child network for parents to track their child's mood and behavior</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2017</year>;<volume>27</volume>:<fpage>840</fpage>‐<lpage>843</lpage>.<pub-id pub-id-type="pmid">28441041</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0582">
<label>582</label>
<mixed-citation id="bdi12609-cit-0582" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Carnethon</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>KA</given-names>
</string-name>, et al. <article-title>Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease a scientific statement from the American Heart Association</article-title>. <source xml:lang="en"/>Circulation. <year>2015</year>;<volume>132</volume>:<fpage>965</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">26260736</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0583">
<label>583</label>
<mixed-citation id="bdi12609-cit-0583" publication-type="journal">
<string-name>
<surname>Correll</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Sheridan</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo‐controlled trials</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2010</year>;<volume>12</volume>:<fpage>116</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">20402706</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0584">
<label>584</label>
<mixed-citation id="bdi12609-cit-0584" publication-type="journal">
<string-name>
<surname>Geller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Luby</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Joshi</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A Randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2012</year>;<volume>69</volume>:<fpage>515</fpage>‐<lpage>28</lpage>.<pub-id pub-id-type="pmid">22213771</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0585">
<label>585</label>
<mixed-citation id="bdi12609-cit-0585" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>
<given-names>NK</given-names>
</string-name>, et al. <article-title>Lithium in the Acute treatment of bipolar I disorder: a double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>Pediatrics. <year>2015</year>;<volume>136</volume>:<fpage>885</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">26459650</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0586">
<label>586</label>
<mixed-citation id="bdi12609-cit-0586" publication-type="journal">
<string-name>
<surname>Haas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Pandina</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>687</fpage>‐<lpage>700</lpage>.<pub-id pub-id-type="pmid">19839994</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0587">
<label>587</label>
<mixed-citation id="bdi12609-cit-0587" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Nyilas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forbes</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Acute treatment of pediatric bipolar i disorder, manic or mixed episode, with aripiprazole: a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2009</year>;<volume>70</volume>:<fpage>1441</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">19906348</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0588">
<label>588</label>
<mixed-citation id="bdi12609-cit-0588" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Landbloom</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Szegedi</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Asena pine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2015</year>;<volume>54</volume>:<fpage>1032</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">26598478</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0589">
<label>589</label>
<mixed-citation id="bdi12609-cit-0589" publication-type="journal">
<string-name>
<surname>Pathak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Earley</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Acevedo</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Stankowski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3‐week, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2013</year>;<volume>74</volume>:<fpage>E100</fpage>‐<lpage>U47</lpage>.<pub-id pub-id-type="pmid">23419231</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0590">
<label>590</label>
<mixed-citation id="bdi12609-cit-0590" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kryzhanovskaya</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Olanzapine versus placebo in the treatment of adolescents with bipolar mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2007</year>;<volume>164</volume>:<fpage>1547</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">17898346</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0591">
<label>591</label>
<mixed-citation id="bdi12609-cit-0591" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Cavus</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Pappadopulos</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Efficacy, long‐term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2013</year>;<volume>23</volume>:<fpage>545</fpage>‐<lpage>57</lpage>.<pub-id pub-id-type="pmid">24111980</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0592">
<label>592</label>
<mixed-citation id="bdi12609-cit-0592" publication-type="journal">
<string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Schwiers</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Rosenberg</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Strakowski</surname>
<given-names>SM</given-names>
</string-name>. <article-title>A double‐blind, randomized, placebo‐controlled study of quetiapine as adjunctive treatment for adolescent mania</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2002</year>;<volume>41</volume>:<fpage>1216</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">12364843</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0593">
<label>593</label>
<mixed-citation id="bdi12609-cit-0593" publication-type="book">
<string-name>
<surname>Kowatch</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Scheffer</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Stanford</surname>
<given-names>K</given-names>
</string-name>. <article-title>Pediatric bipolar collaborative mood stabilizer trial</article-title>. Annual meeting of the American Academy of Child and Adolescent Psychiatry. <publisher-loc>Boston MA</publisher-loc>, <year>2007</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0594">
<label>594</label>
<mixed-citation id="bdi12609-cit-0594" publication-type="journal">
<string-name>
<surname>Wagner</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Kowatch</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Emslie</surname>
<given-names>GJ</given-names>
</string-name>, et al. <article-title>A double‐blind, randomized, placebo‐controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2006</year>;<volume>163</volume>:<fpage>1179</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">16816222</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0595">
<label>595</label>
<mixed-citation id="bdi12609-cit-0595" publication-type="journal">
<string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cucchiaro</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Loebel</surname>
<given-names>A</given-names>
</string-name>. <article-title>Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2017</year>;<volume>56</volume>:<fpage>1015</fpage>‐<lpage>1025</lpage>.<pub-id pub-id-type="pmid">29173735</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0596">
<label>596</label>
<mixed-citation id="bdi12609-cit-0596" publication-type="journal">
<string-name>
<surname>Patel</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Delbello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Bryan</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Open‐label lithium for the treatment of adolescents with bipolar depression</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2006</year>;<volume>45</volume>:<fpage>289</fpage>‐<lpage>97</lpage>.<pub-id pub-id-type="pmid">16540813</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0597">
<label>597</label>
<mixed-citation id="bdi12609-cit-0597" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saxena</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Howe</surname>
<given-names>M</given-names>
</string-name>. <article-title>An open‐label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2006</year>;<volume>45</volume>:<fpage>298</fpage>‐<lpage>304</lpage>.<pub-id pub-id-type="pmid">16540814</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0598">
<label>598</label>
<mixed-citation id="bdi12609-cit-0598" publication-type="journal">
<string-name>
<surname>Detke</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Landry</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Usher</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2015</year>;<volume>54</volume>:<fpage>217</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">25721187</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0599">
<label>599</label>
<mixed-citation id="bdi12609-cit-0599" publication-type="journal">
<string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Welge</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>A double‐blind, placebo‐controlled pilot study of quetiapine for depressed adolescents with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>483</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">19624387</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0600">
<label>600</label>
<mixed-citation id="bdi12609-cit-0600" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Pathak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Earley</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Efficacy and safety of extended‐release quetiapine fumarate in youth with bipolar depression: an 8 week, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2014</year>;<volume>24</volume>:<fpage>325</fpage>‐<lpage>35</lpage>.<pub-id pub-id-type="pmid">24956042</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0601">
<label>601</label>
<mixed-citation id="bdi12609-cit-0601" publication-type="journal">
<string-name>
<surname>Bhowmik</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Aparasu</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Rajan</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Sherer</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Ochoa‐Perez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>. <article-title>Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2014</year>;<volume>24</volume>:<fpage>551</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">25470655</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0602">
<label>602</label>
<mixed-citation id="bdi12609-cit-0602" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Correll</surname>
<given-names>CU</given-names>
</string-name>, <string-name>
<surname>Nyilas</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Aripiprazole for the treatment of pediatric bipolar I disorder: a 30‐week, randomized, placebo‐controlled study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2013</year>;<volume>15</volume>:<fpage>138</fpage>‐<lpage>49</lpage>.<pub-id pub-id-type="pmid">23437959</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0603">
<label>603</label>
<mixed-citation id="bdi12609-cit-0603" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>
<given-names>NK</given-names>
</string-name>, et al. <article-title>Double‐blind, randomized, placebo‐controlled long‐term maintenance study of aripiprazole in children with bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2012</year>;<volume>73</volume>:<fpage>57</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">22152402</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0604">
<label>604</label>
<mixed-citation id="bdi12609-cit-0604" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Youngstrom</surname>
<given-names>EA</given-names>
</string-name>, et al. <article-title>Double‐blind 18‐month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2005</year>;<volume>44</volume>:<fpage>409</fpage>‐<lpage>17</lpage>.<pub-id pub-id-type="pmid">15843762</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0605">
<label>605</label>
<mixed-citation id="bdi12609-cit-0605" publication-type="journal">
<string-name>
<surname>Pavuluri</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Carbray</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Naylor</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Janicak</surname>
<given-names>PG</given-names>
</string-name>. <article-title>Divalproex sodium for pediatric mixed mania: a 6‐month prospective trial</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2005</year>;<volume>7</volume>:<fpage>266</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">15898964</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0606">
<label>606</label>
<mixed-citation id="bdi12609-cit-0606" publication-type="journal">
<string-name>
<surname>Kowatch</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>TJ</given-names>
</string-name>, et al. <article-title>Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2000</year>;<volume>39</volume>:<fpage>713</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">10846305</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0607">
<label>607</label>
<mixed-citation id="bdi12609-cit-0607" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: A Placebo‐Controlled, Randomized Withdrawal Study</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2015</year>;<volume>54</volume>:<fpage>1020</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">26598477</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0608">
<label>608</label>
<mixed-citation id="bdi12609-cit-0608" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Landbloom</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Mackle</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Long‐term safety of asenapine in pediatric patients diagnosed with bipolar I disorder: A 50‐Week Open‐Label, flexible‐dose trial</article-title>. <source xml:lang="en"/>Paediatr Drugs. <year>2016</year>;<volume>18</volume>:<fpage>367</fpage>‐<lpage>78</lpage>.<pub-id pub-id-type="pmid">27461426</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0609">
<label>609</label>
<mixed-citation id="bdi12609-cit-0609" publication-type="journal">
<string-name>
<surname>Duffy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Milin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Grof</surname>
<given-names>P</given-names>
</string-name>. <article-title>Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine</article-title>. <source xml:lang="en"/>BMC Psychiatry. <year>2009</year>;<volume>9</volume>:<fpage>4</fpage>.<pub-id pub-id-type="pmid">19200370</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0610">
<label>610</label>
<mixed-citation id="bdi12609-cit-0610" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Pathak</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Earley</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>M</given-names>
</string-name>. <article-title>Safety, Tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26‐week, open‐label, continuation study</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2013</year>;<volume>23</volume>:<fpage>490</fpage>‐<lpage>501</lpage>.<pub-id pub-id-type="pmid">24024534</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0611">
<label>611</label>
<mixed-citation id="bdi12609-cit-0611" publication-type="journal">
<string-name>
<surname>Scheffer</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Kowatch</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Randomized, placebo‐controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2005</year>;<volume>162</volume>:<fpage>58</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">15625202</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0612">
<label>612</label>
<mixed-citation id="bdi12609-cit-0612" publication-type="journal">
<string-name>
<surname>Findling</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Short</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>
<given-names>NK</given-names>
</string-name>, et al. <article-title>Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention‐deficit/hyperactivity disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2007</year>;<volume>46</volume>:<fpage>1445</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">18049294</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0613">
<label>613</label>
<mixed-citation id="bdi12609-cit-0613" publication-type="journal">
<string-name>
<surname>Viktorin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ryden</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>The risk of treatment‐emergent mania with methylphenidate in bipolar disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2017</year>;<volume>174</volume>:<fpage>341</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">27690517</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0614">
<label>614</label>
<mixed-citation id="bdi12609-cit-0614" publication-type="journal">
<string-name>
<surname>Hah</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>KK</given-names>
</string-name>. <article-title>Atomoxetine for the treatment of attention‐deficit/hyperactivity disorder in children and adolescents with bipolar disorders</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2005</year>;<volume>15</volume>:<fpage>996</fpage>‐<lpage>1004</lpage>.<pub-id pub-id-type="pmid">16379520</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0615">
<label>615</label>
<mixed-citation id="bdi12609-cit-0615" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Nayar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Howe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rana</surname>
<given-names>M</given-names>
</string-name>. <article-title>Atomoxetine as an adjunct therapy in the treatment of co‐morbid attention‐deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder</article-title>. <source xml:lang="en"/>J Child Adolesc Psychopharmacol. <year>2009</year>;<volume>19</volume>:<fpage>547</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">19877979</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0616">
<label>616</label>
<mixed-citation id="bdi12609-cit-0616" publication-type="journal">
<string-name>
<surname>Peruzzolo</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Tramontina</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rodrigues</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Rohde</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Zeni</surname>
<given-names>CP</given-names>
</string-name>. <article-title>Avoiding stimulants may not prevent manic switch: a case report with atomoxetine</article-title>. <source xml:lang="en"/>J Neuropsychiatry Clin Neurosci. <year>2014</year>;<volume>26</volume>:<fpage>E30</fpage>‐<lpage>1</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0617">
<label>617</label>
<mixed-citation id="bdi12609-cit-0617" publication-type="journal">
<string-name>
<surname>Geller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Double‐blind and placebo‐controlled study of lithium for adolescent bipolar disorders with secondary substance dependency</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>1998</year>;<volume>37</volume>:<fpage>171</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">9473913</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0618">
<label>618</label>
<mixed-citation id="bdi12609-cit-0618" publication-type="journal">
<string-name>
<surname>Gray</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Carpenter</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>NL</given-names>
</string-name>, et al. <article-title>A double‐blind randomized controlled trial of <italic>N</italic>‐acetylcysteine in cannabis‐dependent adolescents</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2012</year>;<volume>169</volume>:<fpage>805</fpage>‐<lpage>12</lpage>.<pub-id pub-id-type="pmid">22706327</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0619">
<label>619</label>
<mixed-citation id="bdi12609-cit-0619" publication-type="journal">
<string-name>
<surname>Prado</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Maes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Piccoli</surname>
<given-names>LG</given-names>
</string-name>, et al. <article-title>N‐acetylcysteine for therapy‐resistant tobacco use disorder: a pilot study</article-title>. <source xml:lang="en"/>Redox Rep. <year>2015</year>;<volume>20</volume>:<fpage>215</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">25729878</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0620">
<label>620</label>
<mixed-citation id="bdi12609-cit-0620" publication-type="journal">
<string-name>
<surname>Depp</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</string-name>. <article-title>Bipolar disorder in older adults: a critical review</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>343</fpage>‐<lpage>67</lpage>.<pub-id pub-id-type="pmid">15383127</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0621">
<label>621</label>
<mixed-citation id="bdi12609-cit-0621" publication-type="journal">
<string-name>
<surname>Yu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sylvestre</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Looper</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Rej</surname>
<given-names>S</given-names>
</string-name>. <article-title>Predictors of psychiatric re‐hospitalization in older adults with severe mental illness</article-title>. <source xml:lang="en"/>Int J Geriatr Psychiatry. <year>2015</year>;<volume>30</volume>:<fpage>1114</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">26388437</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0622">
<label>622</label>
<mixed-citation id="bdi12609-cit-0622" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bingham</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>DF</given-names>
</string-name>. <article-title>Bipolar disorder in older adult inpatients</article-title>. <source xml:lang="en"/>J Nerv Ment Dis. <year>2005</year>;<volume>193</volume>:<fpage>417</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15920383</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0623">
<label>623</label>
<mixed-citation id="bdi12609-cit-0623" publication-type="journal">
<string-name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Alexopoulos</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Bartels</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>Consensus statement on the upcoming crisis in geriatric mental health – Research agenda for the next 2 decades</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1999</year>;<volume>56</volume>:<fpage>848</fpage>‐<lpage>53</lpage>.<pub-id pub-id-type="pmid">12884891</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0624">
<label>624</label>
<mixed-citation id="bdi12609-cit-0624" publication-type="journal">
<string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Weissman</surname>
<given-names>MM</given-names>
</string-name>, et al. <article-title>Screening for bipolar disorder in the community</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>53</fpage>‐<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0625">
<label>625</label>
<mixed-citation id="bdi12609-cit-0625" publication-type="journal">
<string-name>
<surname>Yassa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>NPV</given-names>
</string-name>, <string-name>
<surname>Iskandar</surname>
<given-names>H</given-names>
</string-name>. <article-title>Late‐onset bipolar disorder</article-title>. <source xml:lang="en"/>Psychiatr Clin North Am. <year>1988</year>;<volume>11</volume>:<fpage>117</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">3288976</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0626">
<label>626</label>
<mixed-citation id="bdi12609-cit-0626" publication-type="journal">
<string-name>
<surname>Subramaniam</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Dennis</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Byrne</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>The role of vascular risk factors in late onset bipolar disorder</article-title>. <source xml:lang="en"/>Int J Geriatr Psychiatry. <year>2007</year>;<volume>22</volume>:<fpage>733</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">17146839</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0627">
<label>627</label>
<mixed-citation id="bdi12609-cit-0627" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blow</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Ignacio</surname>
<given-names>RV</given-names>
</string-name>, <string-name>
<surname>Kales</surname>
<given-names>HC</given-names>
</string-name>. <article-title>New‐onset bipolar disorder in later life</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2005</year>;<volume>13</volume>:<fpage>282</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15845753</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0628">
<label>628</label>
<mixed-citation id="bdi12609-cit-0628" publication-type="journal">
<string-name>
<surname>Depp</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mohamed</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaskow</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Jeste</surname>
<given-names>DV</given-names>
</string-name>. <article-title>Bipolar disorder in middle‐aged and elderly adults: Is age of onset important?</article-title>
<source xml:lang="en"/>J Nerv Ment Dis. <year>2004</year>;<volume>192</volume>:<fpage>796</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">15505527</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0629">
<label>629</label>
<mixed-citation id="bdi12609-cit-0629" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Kiosses</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Heo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Age and ratings of manic psychopathology</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2007</year>;<volume>9</volume>:<fpage>301</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">17430306</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0630">
<label>630</label>
<mixed-citation id="bdi12609-cit-0630" publication-type="journal">
<string-name>
<surname>Oostervink</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Boomsma</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Board</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Bipolar disorder in the elderly; different effects of age and of age of onset</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>116</volume>:<fpage>176</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">19087895</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0631">
<label>631</label>
<mixed-citation id="bdi12609-cit-0631" publication-type="journal">
<string-name>
<surname>Lala</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>. <article-title>Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review</article-title>. <source xml:lang="en"/>J Geriatr Psychiatry Neurol. <year>2012</year>;<volume>25</volume>:<fpage>20</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">22467842</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0632">
<label>632</label>
<mixed-citation id="bdi12609-cit-0632" publication-type="journal">
<string-name>
<surname>Depp</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Lindamer</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Folsom</surname>
<given-names>DP</given-names>
</string-name>, et al. <article-title>Differences in clinical features and mental health service use in bipolar disorder across the lifespan</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2005</year>;<volume>13</volume>:<fpage>290</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">15845754</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0633">
<label>633</label>
<mixed-citation id="bdi12609-cit-0633" publication-type="journal">
<string-name>
<surname>Tsai</surname>
<given-names>S‐Y</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H‐C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C‐C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y‐L</given-names>
</string-name>. <article-title>Cognitive impairment in later life in patients with early‐onset bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2007</year>;<volume>9</volume>:<fpage>868</fpage>‐<lpage>75</lpage>.<pub-id pub-id-type="pmid">18076536</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0634">
<label>634</label>
<mixed-citation id="bdi12609-cit-0634" publication-type="journal">
<string-name>
<surname>Gildengers</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Chisholm</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Butters</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Two‐year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression?</article-title>
<source xml:lang="en"/>Psychol Med. <year>2013</year>;<volume>43</volume>:<fpage>801</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">22846332</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0635">
<label>635</label>
<mixed-citation id="bdi12609-cit-0635" publication-type="journal">
<string-name>
<surname>Schouws</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Comijs</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Dols</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beekman</surname>
<given-names>ATF</given-names>
</string-name>, <string-name>
<surname>Stek</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Five‐year follow‐up of cognitive impairment in older adults with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>148</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">26961121</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0636">
<label>636</label>
<mixed-citation id="bdi12609-cit-0636" publication-type="journal">
<string-name>
<surname>Santos</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Aparicio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bagney</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A five‐year follow‐up study of neurocognitive functioning in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2014</year>;<volume>16</volume>:<fpage>722</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">24909395</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0637">
<label>637</label>
<mixed-citation id="bdi12609-cit-0637" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Sondergard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>. <article-title>Lithium treatment and risk of dementia</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2008</year>;<volume>65</volume>:<fpage>1331</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">18981345</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0638">
<label>638</label>
<mixed-citation id="bdi12609-cit-0638" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Gerds</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Knudsen</surname>
<given-names>NN</given-names>
</string-name>, et al. <article-title>Association of lithium in drinking water with the incidence of dementia</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2017</year>;<volume>74</volume>:<fpage>1005</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="pmid">28832877</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0639">
<label>639</label>
<mixed-citation id="bdi12609-cit-0639" publication-type="journal">
<string-name>
<surname>Morris</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>. <article-title>The putative use of lithium in Alzheimer's disease</article-title>. <source xml:lang="en"/>Curr Alzheimer Res. <year>2016</year>;<volume>13</volume>:<fpage>853</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">26892287</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0640">
<label>640</label>
<mixed-citation id="bdi12609-cit-0640" publication-type="journal">
<string-name>
<surname>Andreou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bozikas</surname>
<given-names>VP</given-names>
</string-name>. <article-title>The predictive significance of neurocognitive factors for functional outcome in bipolar disorder</article-title>. <source xml:lang="en"/>Curr Opin Psychiatry. <year>2013</year>;<volume>26</volume>:<fpage>54</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23154642</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0641">
<label>641</label>
<mixed-citation id="bdi12609-cit-0641" publication-type="journal">
<string-name>
<surname>Tsai</surname>
<given-names>S‐Y</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>C‐J</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>K‐H</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y‐L</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H‐C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C‐C</given-names>
</string-name>. <article-title>Cognitive dysfunction and medical morbidity in elderly outpatients with bipolar disorder</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2009</year>;<volume>17</volume>:<fpage>1004</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">20104057</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0642">
<label>642</label>
<mixed-citation id="bdi12609-cit-0642" publication-type="journal">
<string-name>
<surname>Westman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hallgren</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wahlbeck</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Erlinge</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Alfredsson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Osby</surname>
<given-names>U</given-names>
</string-name>. <article-title>Cardiovascular mortality in bipolar disorder: a population‐based cohort study in Sweden</article-title>. <source xml:lang="en"/>BMJ Open. <year>2013</year>;<volume>3</volume>:<fpage>e002373</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0643">
<label>643</label>
<mixed-citation id="bdi12609-cit-0643" publication-type="journal">
<string-name>
<surname>Kilbourne</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Goodrich</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>ZS</given-names>
</string-name>, et al. <article-title>Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the self‐management addressing heart risk trial (SMAHRT)</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2013</year>;<volume>74</volume>:<fpage>E655</fpage>‐<lpage>E62</lpage>.<pub-id pub-id-type="pmid">23945460</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0644">
<label>644</label>
<mixed-citation id="bdi12609-cit-0644" publication-type="journal">
<string-name>
<surname>Young</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Mulsant</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>GERI‐BD: a randomized double‐blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2017</year>;<volume>174</volume>:<fpage>1086</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">29088928</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0645">
<label>645</label>
<mixed-citation id="bdi12609-cit-0645" publication-type="journal">
<string-name>
<surname>Marras</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>HD</given-names>
</string-name>, et al. <article-title>Lithium use in older adults is associated with increased prescribing of parkinson medications</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2016</year>;<volume>24</volume>:<fpage>301</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">27037047</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0646">
<label>646</label>
<mixed-citation id="bdi12609-cit-0646" publication-type="journal">
<string-name>
<surname>Rej</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Elie</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mucsi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Looper</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>M</given-names>
</string-name>. <article-title>Chronic kidney disease in lithium‐treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late‐life mood disorders</article-title>. <source xml:lang="en"/>Drugs Aging. <year>2015</year>;<volume>32</volume>:<fpage>31</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">25519823</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0647">
<label>647</label>
<mixed-citation id="bdi12609-cit-0647" publication-type="journal">
<string-name>
<surname>Svendal</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fasmer</surname>
<given-names>OB</given-names>
</string-name>, <string-name>
<surname>Engeland</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lund</surname>
<given-names>A</given-names>
</string-name>. <article-title>Co‐prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population‐based study with focus on gender differences</article-title>. <source xml:lang="en"/>BMC Med. <year>2012</year>;<volume>10</volume>:<fpage>148</fpage>.<pub-id pub-id-type="pmid">23186328</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0648">
<label>648</label>
<mixed-citation id="bdi12609-cit-0648" publication-type="journal">
<string-name>
<surname>Dols</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sienaert</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>van Gerven</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2013</year>;<volume>28</volume>:<fpage>287</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">23873292</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0649">
<label>649</label>
<mixed-citation id="bdi12609-cit-0649" publication-type="journal">
<string-name>
<surname>Graff‐Guerrero</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rajji</surname>
<given-names>TK</given-names>
</string-name>, <string-name>
<surname>Mulsant</surname>
<given-names>BH</given-names>
</string-name>, et al. <article-title>Evaluation of antipsychotic dose reduction in late‐life schizophrenia: a prospective dopamine D2/3 receptor occupancy study</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2015</year>;<volume>72</volume>:<fpage>927</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">26131622</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0650">
<label>650</label>
<mixed-citation id="bdi12609-cit-0650" publication-type="journal">
<string-name>
<surname>Maust</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Seyfried</surname>
<given-names>LS</given-names>
</string-name>, et al. <article-title>Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2015</year>;<volume>72</volume>:<fpage>438</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">25786075</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0651">
<label>651</label>
<mixed-citation id="bdi12609-cit-0651" publication-type="journal">
<string-name>
<surname>Hwang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Dixon</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Reiss</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population‐based cohort study</article-title>. <source xml:lang="en"/>Ann Intern Med. <year>2014</year>;<volume>161</volume>:<fpage>242</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">25133360</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0652">
<label>652</label>
<mixed-citation id="bdi12609-cit-0652" publication-type="journal">
<string-name>
<surname>Ng</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mammen</surname>
<given-names>OK</given-names>
</string-name>, <string-name>
<surname>Wilting</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2009</year>;<volume>11</volume>:<fpage>559</fpage>‐<lpage>95</lpage>.<pub-id pub-id-type="pmid">19689501</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0653">
<label>653</label>
<mixed-citation id="bdi12609-cit-0653" publication-type="journal">
<string-name>
<surname>Al Jurdi</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gyulai</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>. <article-title>Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a “recovered” status in the systematic treatment enhancement program for bipolar disorder</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2008</year>;<volume>16</volume>:<fpage>922</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">18978253</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0654">
<label>654</label>
<mixed-citation id="bdi12609-cit-0654" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Strejilevich</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Gildengers</surname>
<given-names>AG</given-names>
</string-name>, et al. <article-title>A report on older‐age bipolar disorder from the International Society for Bipolar Disorders Task Force</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>689</fpage>‐<lpage>704</lpage>.<pub-id pub-id-type="pmid">26384588</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0655">
<label>655</label>
<mixed-citation id="bdi12609-cit-0655" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Mullen</surname>
<given-names>J</given-names>
</string-name>. <article-title>Quetiapine for the treatment of bipolar mania in older adults</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2008</year>;<volume>10</volume>:<fpage>662</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">18837860</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0656">
<label>656</label>
<mixed-citation id="bdi12609-cit-0656" publication-type="journal">
<string-name>
<surname>Baruch</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tadger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Plopski</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Barak</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Asenapine for elderly bipolar manic patients</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>145</volume>:<fpage>130</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">22877962</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0657">
<label>657</label>
<mixed-citation id="bdi12609-cit-0657" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dines</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Casiano</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Asenapine in the treatment of older adults with bipolar disorder</article-title>. <source xml:lang="en"/>Int J Geriatr Psychiatry. <year>2015</year>;<volume>30</volume>:<fpage>710</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">25335125</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0658">
<label>658</label>
<mixed-citation id="bdi12609-cit-0658" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coconcea</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ignacio</surname>
<given-names>RV</given-names>
</string-name>, et al. <article-title>Aripiprazole therapy in 20 older adults with bipolar disorder: A 12‐week, open‐label trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>41</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">18312036</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0659">
<label>659</label>
<mixed-citation id="bdi12609-cit-0659" publication-type="journal">
<string-name>
<surname>Madhusoodanan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brenner</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Araujo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Abaza</surname>
<given-names>A</given-names>
</string-name>. <article-title>Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1995</year>;<volume>56</volume>:<fpage>514</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">7592504</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0660">
<label>660</label>
<mixed-citation id="bdi12609-cit-0660" publication-type="journal">
<string-name>
<surname>Shulman</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>
<given-names>KI</given-names>
</string-name>. <article-title>Treatment of elderly institutionalized bipolar patients with clozapine</article-title>. <source xml:lang="en"/>Psychopharmacol Bull. <year>1997</year>;<volume>33</volume>:<fpage>113</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">9133761</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0661">
<label>661</label>
<mixed-citation id="bdi12609-cit-0661" publication-type="book">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Paulsson</surname>
<given-names>B</given-names>
</string-name>. <article-title>Quetiapine for the treatment of depressive episodes in adults aged 55 to 65 years with bipolar disorder</article-title>. AAGP Annual Meeting. <publisher-loc>New Orleans, LA</publisher-loc>, <year>2007</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0662">
<label>662</label>
<mixed-citation id="bdi12609-cit-0662" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forester</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double‐blind, placebo‐controlled studies</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2016</year>;<volume>77</volume>:<fpage>e1324</fpage>‐<lpage>e31</lpage>.<pub-id pub-id-type="pmid">27529375</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0663">
<label>663</label>
<mixed-citation id="bdi12609-cit-0663" publication-type="journal">
<string-name>
<surname>Robillard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Conn</surname>
<given-names>DK</given-names>
</string-name>. <article-title>Lamotrigine use in geriatric patients with bipolar depression</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>2002</year>;<volume>47</volume>:<fpage>767</fpage>‐<lpage>70</lpage>.<pub-id pub-id-type="pmid">12420655</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0664">
<label>664</label>
<mixed-citation id="bdi12609-cit-0664" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gildengers</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Al Jurdi</surname>
<given-names>RK</given-names>
</string-name>, et al. <article-title>Multisite, open‐label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2011</year>;<volume>13</volume>:<fpage>294</fpage>‐<lpage>302</lpage>.<pub-id pub-id-type="pmid">21676132</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0665">
<label>665</label>
<mixed-citation id="bdi12609-cit-0665" publication-type="journal">
<string-name>
<surname>Cullen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Brodaty</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Carbamazepine for treatment‐resistant melancholia</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1991</year>;<volume>52</volume>:<fpage>472</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">1744065</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0666">
<label>666</label>
<mixed-citation id="bdi12609-cit-0666" publication-type="journal">
<string-name>
<surname>Rej</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Fung</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gruneir</surname>
<given-names>A</given-names>
</string-name>. <article-title>Current psychotropic medication prescribing patterns in late‐life bipolar disorder</article-title>. <source xml:lang="en"/>Int J Geriatr Psychiatry. <year>2017</year>;<volume>32</volume>:<fpage>1459</fpage>‐<lpage>1465</lpage>.<pub-id pub-id-type="pmid">27911003</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0667">
<label>667</label>
<mixed-citation id="bdi12609-cit-0667" publication-type="journal">
<string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Rendell</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open‐label trial</article-title>. <source xml:lang="en"/>Lancet. <year>2010</year>;<volume>375</volume>:<fpage>385</fpage>‐<lpage>95</lpage>.<pub-id pub-id-type="pmid">20092882</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0668">
<label>668</label>
<mixed-citation id="bdi12609-cit-0668" publication-type="journal">
<string-name>
<surname>Sajatovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gyulai</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>Maintenance treatment outcomes in older patients with bipolar I disorder</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2005</year>;<volume>13</volume>:<fpage>305</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">15845756</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0669">
<label>669</label>
<mixed-citation id="bdi12609-cit-0669" publication-type="journal">
<string-name>
<surname>Lish</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Dimemeenan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Whybrow</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>. <article-title>The National Depressive and Manic‐Depressive Association (DMDA) survey of bipolar members</article-title>. <source xml:lang="en"/>J Affect Disord. <year>1994</year>;<volume>31</volume>:<fpage>281</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">7989643</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0670">
<label>670</label>
<mixed-citation id="bdi12609-cit-0670" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Konarski</surname>
<given-names>JZ</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Comorbidity in bipolar disorder: a framework for rational treatment selection</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2004</year>;<volume>19</volume>:<fpage>369</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">15303241</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0671">
<label>671</label>
<mixed-citation id="bdi12609-cit-0671" publication-type="journal">
<string-name>
<surname>Stratford</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Di Simplicio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blackwell</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Psychological therapy for anxiety in bipolar spectrum disorders: a systematic review</article-title>. <source xml:lang="en"/>Clin Psychol Rev. <year>2015</year>;<volume>35</volume>:<fpage>19</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">25462111</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0672">
<label>672</label>
<mixed-citation id="bdi12609-cit-0672" publication-type="journal">
<string-name>
<surname>Provencher</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Hawke</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Thienot</surname>
<given-names>E</given-names>
</string-name>. <article-title>Psychotherapies for comorbid anxiety in bipolar spectrum disorders</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>133</volume>:<fpage>371</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">21093062</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0673">
<label>673</label>
<mixed-citation id="bdi12609-cit-0673" publication-type="journal">
<string-name>
<surname>Secades‐Alvarez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fernandez‐Rodriguez</surname>
<given-names>C</given-names>
</string-name>. <article-title>Review of the efficacy of treatments for bipolar disorder and substance abuse</article-title>. <source xml:lang="en"/>Rev Psiquiatr Salud Ment. <year>2017</year>;<volume>10</volume>:<fpage>113</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">26778814</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0674">
<label>674</label>
<mixed-citation id="bdi12609-cit-0674" publication-type="journal">
<string-name>
<surname>Hunt</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Cleary</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Sitharthan</surname>
<given-names>T</given-names>
</string-name>. <article-title>Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990‐2015: Systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>206</volume>:<fpage>321</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">27426694</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0675">
<label>675</label>
<mixed-citation id="bdi12609-cit-0675" publication-type="journal">
<string-name>
<surname>Hunt</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Cleary</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Sitharthan</surname>
<given-names>T</given-names>
</string-name>. <article-title>Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990‐2015: systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>206</volume>:<fpage>331</fpage>‐<lpage>49</lpage>.<pub-id pub-id-type="pmid">27476137</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0676">
<label>676</label>
<mixed-citation id="bdi12609-cit-0676" publication-type="journal">
<string-name>
<surname>Sonne</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Morton</surname>
<given-names>WA</given-names>
</string-name>. <article-title>Substance‐abuse and bipolar affective‐disorder</article-title>. <source xml:lang="en"/>J Nerv Ment Dis. <year>1994</year>;<volume>182</volume>:<fpage>349</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">8201307</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0677">
<label>677</label>
<mixed-citation id="bdi12609-cit-0677" publication-type="journal">
<string-name>
<surname>Cassidy</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ahearn</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Substance abuse in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2001</year>;<volume>3</volume>:<fpage>181</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">11552957</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0678">
<label>678</label>
<mixed-citation id="bdi12609-cit-0678" publication-type="journal">
<string-name>
<surname>Dalton</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Cate‐Carter</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Mundo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Suicide risk in bipolar patients: the role of co‐morbid substance use disorders</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2003</year>;<volume>5</volume>:<fpage>58</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">12656940</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0679">
<label>679</label>
<mixed-citation id="bdi12609-cit-0679" publication-type="journal">
<string-name>
<surname>Beaulieu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Saury</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sareen</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2012</year>;<volume>24</volume>:<fpage>38</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">22303521</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0680">
<label>680</label>
<mixed-citation id="bdi12609-cit-0680" publication-type="journal">
<string-name>
<surname>Messer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lammers</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Muller‐Siecheneder</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Latifi</surname>
<given-names>S</given-names>
</string-name>. <article-title>Substance abuse in patients with bipolar disorder: A systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Psychiatry Res. <year>2017</year>;<volume>253</volume>:<fpage>338</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">28419959</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0681">
<label>681</label>
<mixed-citation id="bdi12609-cit-0681" publication-type="journal">
<string-name>
<surname>Soyka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kranzler</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Hesselbrock</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kasper</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mutschler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Moller</surname>
<given-names>HJ</given-names>
</string-name>. <article-title>Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision</article-title>. <source xml:lang="en"/>World J Biol Psychiatry. <year>2017</year>;<volume>18</volume>:<fpage>86</fpage>‐<lpage>119</lpage>.<pub-id pub-id-type="pmid">28006997</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0682">
<label>682</label>
<mixed-citation id="bdi12609-cit-0682" publication-type="journal">
<string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ganocy</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>A 6‐month, double‐blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid‐cycling bipolar disorder and co‐occurring substance abuse or dependence</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2009</year>;<volume>70</volume>:<fpage>113</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">19192457</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0683">
<label>683</label>
<mixed-citation id="bdi12609-cit-0683" publication-type="journal">
<string-name>
<surname>Salloum</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Cornelius</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Daley</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Kirisci</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Himmelhoch</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism – A double‐blind placebo‐controlled study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2005</year>;<volume>62</volume>:<fpage>37</fpage>‐<lpage>45</lpage>.<pub-id pub-id-type="pmid">15630071</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0684">
<label>684</label>
<mixed-citation id="bdi12609-cit-0684" publication-type="journal">
<string-name>
<surname>Rubio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lopez‐Munoz</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Alamo</surname>
<given-names>C</given-names>
</string-name>. <article-title>Effects of lamotrigine in patients with bipolar disorder and alcohol dependence</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2006</year>;<volume>8</volume>:<fpage>289</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">16696832</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0685">
<label>685</label>
<mixed-citation id="bdi12609-cit-0685" publication-type="journal">
<string-name>
<surname>Brady</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Sonne</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Anton</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ballenger</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1995</year>;<volume>56</volume>:<fpage>118</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">7883730</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0686">
<label>686</label>
<mixed-citation id="bdi12609-cit-0686" publication-type="journal">
<string-name>
<surname>Albanese</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Clodfelter</surname>
<given-names>RC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Khantzian</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Divalproex sodium in substance abusers with mood disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2000</year>;<volume>61</volume>:<fpage>916</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">11206596</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0687">
<label>687</label>
<mixed-citation id="bdi12609-cit-0687" publication-type="journal">
<string-name>
<surname>Hertzman</surname>
<given-names>M</given-names>
</string-name>. <article-title>Divalproex sodium to treat concomitant substance abuse and mood disorders</article-title>. <source xml:lang="en"/>J Subst Abuse Treat. <year>2000</year>;<volume>18</volume>:<fpage>371</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">10812311</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0688">
<label>688</label>
<mixed-citation id="bdi12609-cit-0688" publication-type="journal">
<string-name>
<surname>Mueser</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Noordsy</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wolfe</surname>
<given-names>R</given-names>
</string-name>. <article-title>Disulfiram treatment for alcoholism in severe mental illness</article-title>. <source xml:lang="en"/>Am J Addictions. <year>2003</year>;<volume>12</volume>:<fpage>242</fpage>‐<lpage>52</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0689">
<label>689</label>
<mixed-citation id="bdi12609-cit-0689" publication-type="journal">
<string-name>
<surname>Larson</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Olincy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rummans</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Morse</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review</article-title>. <source xml:lang="en"/>Alcohol Clin Exp Res. <year>1992</year>;<volume>16</volume>:<fpage>125</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">1558293</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0690">
<label>690</label>
<mixed-citation id="bdi12609-cit-0690" publication-type="journal">
<string-name>
<surname>Kofoed</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kania</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Atkinson</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1986</year>;<volume>143</volume>:<fpage>867</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">3087222</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0691">
<label>691</label>
<mixed-citation id="bdi12609-cit-0691" publication-type="journal">
<string-name>
<surname>Petrakis</surname>
<given-names>IL</given-names>
</string-name>, <string-name>
<surname>Nich</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ralevski</surname>
<given-names>E</given-names>
</string-name>. <article-title>Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram</article-title>. <source xml:lang="en"/>Schizophr Bull. <year>2006</year>;<volume>32</volume>:<fpage>644</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">16887890</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0692">
<label>692</label>
<mixed-citation id="bdi12609-cit-0692" publication-type="journal">
<string-name>
<surname>Petrakis</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ralevski</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nich</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Naltrexone and disulfiram in patients with alcohol dependence and current depression</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2007</year>;<volume>27</volume>:<fpage>160</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">17414239</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0693">
<label>693</label>
<mixed-citation id="bdi12609-cit-0693" publication-type="journal">
<string-name>
<surname>Sonne</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>K</given-names>
</string-name>. <article-title>Naltrexone for individuals with comorbid bipolar disorder and alcohol dependence</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2000</year>;<volume>20</volume>:<fpage>114</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">10653225</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0694">
<label>694</label>
<mixed-citation id="bdi12609-cit-0694" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Beard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dobbs</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Naltrexone in patients with bipolar disorder and alcohol dependence</article-title>. <source xml:lang="en"/>Depress Anxiety. <year>2006</year>;<volume>23</volume>:<fpage>492</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">16841344</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0695">
<label>695</label>
<mixed-citation id="bdi12609-cit-0695" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Schmitz</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence</article-title>. <source xml:lang="en"/>Alcohol Clin Exp Res. <year>2009</year>;<volume>33</volume>:<fpage>1863</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19673746</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0696">
<label>696</label>
<mixed-citation id="bdi12609-cit-0696" publication-type="journal">
<string-name>
<surname>Perugi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Toni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Frare</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Effectiveness of adjunctive gabapentin in resistant bipolar disorder: Is it due to anxious‐alcohol abuse comorbidity?</article-title>
<source xml:lang="en"/>J Clin Psychopharmacol. <year>2002</year>;<volume>22</volume>:<fpage>584</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">12454558</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0697">
<label>697</label>
<mixed-citation id="bdi12609-cit-0697" publication-type="journal">
<string-name>
<surname>Azorin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Garay</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Perugi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism</article-title>. <source xml:lang="en"/>Neuropsychiatr Dis Treat. <year>2010</year>;<volume>6</volume>:<fpage>37</fpage>‐<lpage>46</lpage>.<pub-id pub-id-type="pmid">20361060</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0698">
<label>698</label>
<mixed-citation id="bdi12609-cit-0698" publication-type="journal">
<string-name>
<surname>Jonas</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Amick</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Feltner</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>JAMA. <year>2014</year>;<volume>311</volume>:<fpage>1889</fpage>‐<lpage>900</lpage>.<pub-id pub-id-type="pmid">24825644</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0699">
<label>699</label>
<mixed-citation id="bdi12609-cit-0699" publication-type="journal">
<string-name>
<surname>Stedman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pettinati</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Kotz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Raines</surname>
<given-names>S</given-names>
</string-name>. <article-title>A double‐blind, placebo‐controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar i patients with coexisting alcohol dependence</article-title>. <source xml:lang="en"/>Alcohol Clin Exp Res. <year>2010</year>;<volume>34</volume>:<fpage>1822</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">20626727</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0700">
<label>700</label>
<mixed-citation id="bdi12609-cit-0700" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Davila</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence</article-title>. <source xml:lang="en"/>Alcohol Clin Exp Res. <year>2014</year>;<volume>38</volume>:<fpage>2113</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">24976394</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0701">
<label>701</label>
<mixed-citation id="bdi12609-cit-0701" publication-type="journal">
<string-name>
<surname>Gao</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, et al. <article-title>Efficacy and safety of quetiapine‐xr as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo‐controlled trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>1062</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">25007003</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0702">
<label>702</label>
<mixed-citation id="bdi12609-cit-0702" publication-type="journal">
<string-name>
<surname>Tolliver</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>DeSantis</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Prisciandaro</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Brady</surname>
<given-names>KT</given-names>
</string-name>. <article-title>A randomized, double‐blind, placebo‐controlled clinical trial of acamprosate in alcohol‐dependent individuals with bipolar disorder: a preliminary report</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2012</year>;<volume>14</volume>:<fpage>54</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">22329472</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0703">
<label>703</label>
<mixed-citation id="bdi12609-cit-0703" publication-type="journal">
<string-name>
<surname>Weinstock</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Gaudiano</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Wenze</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Epstein‐Lubow</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>IW</given-names>
</string-name>. <article-title>Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2016</year>;<volume>65</volume>:<fpage>57</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">26773991</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0704">
<label>704</label>
<mixed-citation id="bdi12609-cit-0704" publication-type="journal">
<string-name>
<surname>Strakowski</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>DelBello</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Fleck</surname>
<given-names>DE</given-names>
</string-name>, et al. <article-title>Effects of co‐occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2007</year>;<volume>64</volume>:<fpage>57</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">17199055</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0705">
<label>705</label>
<mixed-citation id="bdi12609-cit-0705" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Gorman</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Hynan</surname>
<given-names>LS</given-names>
</string-name>. <article-title>A randomized, placebo‐controlled trial of citicoline add‐on therapy in outpatients with bipolar disorder and cocaine dependence</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2007</year>;<volume>27</volume>:<fpage>498</fpage>‐<lpage>502</lpage>.<pub-id pub-id-type="pmid">17873684</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0706">
<label>706</label>
<mixed-citation id="bdi12609-cit-0706" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Todd</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>LT</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled trial of citicoline for cocaine dependence in bipolar I disorder</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2015</year>;<volume>172</volume>:<fpage>1014</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">25998279</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0707">
<label>707</label>
<mixed-citation id="bdi12609-cit-0707" publication-type="journal">
<string-name>
<surname>Salloum</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Douaihy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cornelius</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Kirisci</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Hayes</surname>
<given-names>J</given-names>
</string-name>. <article-title>Divalproex utility in bipolar disorder with co‐occurring cocaine dependence: a pilot study</article-title>. <source xml:lang="en"/>Addict Behav. <year>2007</year>;<volume>32</volume>:<fpage>410</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">16814474</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0708">
<label>708</label>
<mixed-citation id="bdi12609-cit-0708" publication-type="journal">
<string-name>
<surname>Nunes</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>McGrath</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Wager</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Quitkin</surname>
<given-names>FM</given-names>
</string-name>. <article-title>Lithium treatment for cocaine abusers with bipolar spectrum disorders</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1990</year>;<volume>147</volume>:<fpage>655</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">2109540</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0709">
<label>709</label>
<mixed-citation id="bdi12609-cit-0709" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Nejtek</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Perantie</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Bobadilla</surname>
<given-names>L</given-names>
</string-name>. <article-title>Quetiapine in bipolar disorder and cocaine dependence</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2002</year>;<volume>4</volume>:<fpage>406</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">12519101</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0710">
<label>710</label>
<mixed-citation id="bdi12609-cit-0710" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Nejtek</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Perantie</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Rajan Thomas</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2003</year>;<volume>23</volume>:<fpage>384</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">12920415</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0711">
<label>711</label>
<mixed-citation id="bdi12609-cit-0711" publication-type="journal">
<string-name>
<surname>Nejtek</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Avila</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>L‐A</given-names>
</string-name>, et al. <article-title>Do atypical antipsychotics effectively treat co‐occurring bipolar disorder and stimulant dependence? A randomized, double‐blind trial</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>1257</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">18681757</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0712">
<label>712</label>
<mixed-citation id="bdi12609-cit-0712" publication-type="journal">
<string-name>
<surname>Albanese</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Suh</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Risperidone in cocaine‐dependent patients with comorbid psychiatric disorders</article-title>. <source xml:lang="en"/>J Psychiatr Pract. <year>2006</year>;<volume>12</volume>:<fpage>306</fpage>‐<lpage>11</lpage>.<pub-id pub-id-type="pmid">16998418</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0713">
<label>713</label>
<mixed-citation id="bdi12609-cit-0713" publication-type="journal">
<string-name>
<surname>Sepede</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Di Lorio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lupi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Bupropion as an add‐on therapy in depressed bipolar disorder type I patients with comorbid cocaine dependence</article-title>. <source xml:lang="en"/>Clin Neuropharmacol. <year>2014</year>;<volume>37</volume>:<fpage>17</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">24434527</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0714">
<label>714</label>
<mixed-citation id="bdi12609-cit-0714" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Gabrielson</surname>
<given-names>B</given-names>
</string-name>. <article-title>A randomized, double‐blind, placebo‐controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2012</year>;<volume>143</volume>:<fpage>257</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">22974472</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0715">
<label>715</label>
<mixed-citation id="bdi12609-cit-0715" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Sunderajan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Sowell</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>TJ</given-names>
</string-name>. <article-title>A randomized, double‐blind, placebo‐controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence</article-title>. <source xml:lang="en"/>Neuropsychopharmacology. <year>2012</year>;<volume>37</volume>:<fpage>2347</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">22669171</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0716">
<label>716</label>
<mixed-citation id="bdi12609-cit-0716" publication-type="journal">
<string-name>
<surname>Maremmani</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Zolesi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Aglietti</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity</article-title>. <source xml:lang="en"/>J Addict Dis. <year>2000</year>;<volume>19</volume>:<fpage>29</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">10809518</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0717">
<label>717</label>
<mixed-citation id="bdi12609-cit-0717" publication-type="journal">
<string-name>
<surname>Maremmani</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Rovai</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bacciardi</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The long‐term outcomes of heroin dependent‐treatment‐resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>151</volume>:<fpage>582</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23931828</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0718">
<label>718</label>
<mixed-citation id="bdi12609-cit-0718" publication-type="journal">
<string-name>
<surname>Sani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kotzalidis</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Vohringer</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Effectiveness of short‐term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2013</year>;<volume>33</volume>:<fpage>231</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">23422396</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0719">
<label>719</label>
<mixed-citation id="bdi12609-cit-0719" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Jeffress</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liggin</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Garza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beard</surname>
<given-names>L</given-names>
</string-name>. <article-title>Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2005</year>;<volume>66</volume>:<fpage>756</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">15960570</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0720">
<label>720</label>
<mixed-citation id="bdi12609-cit-0720" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McIntosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, et al. <article-title>The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2012</year>;<volume>24</volume>:<fpage>6</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">22303519</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0721">
<label>721</label>
<mixed-citation id="bdi12609-cit-0721" publication-type="journal">
<string-name>
<surname>Hawke</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>Provencher</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Zagorski</surname>
<given-names>B</given-names>
</string-name>. <article-title>Comorbid anxiety disorders in canadians with bipolar disorder: clinical characteristics and service use</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>2013</year>;<volume>58</volume>:<fpage>393</fpage>‐<lpage>401</lpage>.<pub-id pub-id-type="pmid">23870721</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0722">
<label>722</label>
<mixed-citation id="bdi12609-cit-0722" publication-type="journal">
<string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cairney</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Veldhuizen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cheung</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levitt</surname>
<given-names>A</given-names>
</string-name>. <article-title>Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2007</year>;<volume>68</volume>:<fpage>1785</fpage>‐<lpage>92</lpage>.<pub-id pub-id-type="pmid">18052573</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0723">
<label>723</label>
<mixed-citation id="bdi12609-cit-0723" publication-type="journal">
<string-name>
<surname>Baldwin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lawson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>D</given-names>
</string-name>. <article-title>Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>BMJ. <year>2011</year>;<volume>342</volume>:<fpage>d1199</fpage>.<pub-id pub-id-type="pmid">21398351</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0724">
<label>724</label>
<mixed-citation id="bdi12609-cit-0724" publication-type="journal">
<string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Harnett‐Sheehan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hidalgo</surname>
<given-names>RB</given-names>
</string-name>, et al. <article-title>Randomized, placebo‐controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>145</volume>:<fpage>83</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">22920718</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0725">
<label>725</label>
<mixed-citation id="bdi12609-cit-0725" publication-type="journal">
<string-name>
<surname>Hirschfeld</surname>
<given-names>RMA</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Raines</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Macfadden</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Grp</surname>
<given-names>BS</given-names>
</string-name>. <article-title>Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>355</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">16649820</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0726">
<label>726</label>
<mixed-citation id="bdi12609-cit-0726" publication-type="journal">
<string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Harnett‐Sheehan</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Randomized, placebo‐controlled trial of risperidone for acute treatment of bipolar anxiety</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2009</year>;<volume>115</volume>:<fpage>376</fpage>‐<lpage>85</lpage>.<pub-id pub-id-type="pmid">19042026</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0727">
<label>727</label>
<mixed-citation id="bdi12609-cit-0727" publication-type="journal">
<string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, et al. <article-title>A randomized, double‐blind, placebo‐controlled study of ziprasidone monotherapy in bipolar disorder with co‐occurring lifetime panic or generalized anxiety disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2014</year>;<volume>75</volume>:<fpage>77</fpage>‐<lpage>84</lpage>.<pub-id pub-id-type="pmid">24345758</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0728">
<label>728</label>
<mixed-citation id="bdi12609-cit-0728" publication-type="journal">
<string-name>
<surname>Maina</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Rosso</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bogetto</surname>
<given-names>F</given-names>
</string-name>. <article-title>Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single‐blind, pilot study</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2008</year>;<volume>69</volume>:<fpage>609</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">18294024</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0729">
<label>729</label>
<mixed-citation id="bdi12609-cit-0729" publication-type="journal">
<string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Martinez‐Aran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nieto</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Adjunctive gabapentin treatment of bipolar disorder</article-title>. <source xml:lang="en"/>Eur Psychiatry. <year>2000</year>;<volume>15</volume>:<fpage>433</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">11112936</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0730">
<label>730</label>
<mixed-citation id="bdi12609-cit-0730" publication-type="journal">
<string-name>
<surname>Amerio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Odone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marchesi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>. <article-title>Treatment of comorbid bipolar disorder and obsessive‐compulsive disorder: a systematic review</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>166</volume>:<fpage>258</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">25012439</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0731">
<label>731</label>
<mixed-citation id="bdi12609-cit-0731" publication-type="journal">
<string-name>
<surname>Amerio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stubbs</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Odone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tonna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marchesi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>. <article-title>The prevalence and predictors of comorbid bipolar disorder and obsessive‐compulsive disorder: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>186</volume>:<fpage>99</fpage>‐<lpage>109</lpage>.<pub-id pub-id-type="pmid">26233320</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0732">
<label>732</label>
<mixed-citation id="bdi12609-cit-0732" publication-type="journal">
<string-name>
<surname>Jeon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baek</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>SY</given-names>
</string-name>, et al. <article-title>Exploration of comorbid obsessive‐compulsive disorder in patients with bipolar disorder: the clinic‐based prevalence rate, symptoms nature and clinical correlates</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2018</year>;<volume>225</volume>:<fpage>227</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">28841485</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0733">
<label>733</label>
<mixed-citation id="bdi12609-cit-0733" publication-type="journal">
<string-name>
<surname>Nabavi</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Nutt</surname>
<given-names>D</given-names>
</string-name>. <article-title>A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta‐analysis of 52 interview‐based studies of psychiatric population</article-title>. <source xml:lang="en"/>EBioMedicine. <year>2015</year>;<volume>2</volume>:<fpage>1405</fpage>‐<lpage>19</lpage>.<pub-id pub-id-type="pmid">26629535</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0734">
<label>734</label>
<mixed-citation id="bdi12609-cit-0734" publication-type="book">
<string-name>
<surname>Sadock</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Sadock</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Ruiz</surname>
<given-names>P</given-names>
</string-name>. <source xml:lang="en"/>Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. <publisher-loc>New York</publisher-loc>: <publisher-name>Wolters Kluwer</publisher-name>; <year>2014</year>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0735">
<label>735</label>
<mixed-citation id="bdi12609-cit-0735" publication-type="journal">
<string-name>
<surname>Baek</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Cha</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Moon</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The effects of ethnic, social and cultural factors on axis I comorbidity of bipolar disorder: results from the clinical setting in Korea</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>166</volume>:<fpage>264</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">25012440</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0736">
<label>736</label>
<mixed-citation id="bdi12609-cit-0736" publication-type="journal">
<string-name>
<surname>Amerio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stubbs</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Odone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tonna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marchesi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nassir Ghaemi</surname>
<given-names>S</given-names>
</string-name>. <article-title>Bipolar I and II disorders: a systematic review and meta‐analysis on differences in comorbid obsessive‐compulsive disorder</article-title>. <source xml:lang="en"/>Iran J Psychiatry Behav Sci. <year>2016</year>;<volume>10</volume>:<fpage>e3604</fpage>.<pub-id pub-id-type="pmid">27826323</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0737">
<label>737</label>
<mixed-citation id="bdi12609-cit-0737" publication-type="journal">
<string-name>
<surname>Kruger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Braunig</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cooke</surname>
<given-names>RG</given-names>
</string-name>. <article-title>Comorbidity of obsessive‐compulsive disorder in recovered inpatients with bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2000</year>;<volume>2</volume>:<fpage>71</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">11254024</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0738">
<label>738</label>
<mixed-citation id="bdi12609-cit-0738" publication-type="journal">
<string-name>
<surname>Goes</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>McCusker</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Bienvenu</surname>
<given-names>OJ</given-names>
</string-name>, et al. <article-title>Co‐morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co‐morbid panic disorder, social phobia, specific phobia and obsessive‐compulsive disorder</article-title>. <source xml:lang="en"/>Psychol Med. <year>2012</year>;<volume>42</volume>:<fpage>1449</fpage>‐<lpage>59</lpage>.<pub-id pub-id-type="pmid">22099954</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0739">
<label>739</label>
<mixed-citation id="bdi12609-cit-0739" publication-type="journal">
<string-name>
<surname>Issler</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Monkul</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Amaral</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>Bipolar disorder and comorbid obsessive‐compulsive disorder is associated with higher rates of anxiety and impulse control disorders</article-title>. <source xml:lang="en"/>Acta Neuropsychiatr. <year>2010</year>;<volume>22</volume>:<fpage>81</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">25385033</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0740">
<label>740</label>
<mixed-citation id="bdi12609-cit-0740" publication-type="journal">
<string-name>
<surname>Magalhaes</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Kapczinski</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>. <article-title>Correlates and impact of obsessive‐compulsive comorbidity in bipolar disorder</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2010</year>;<volume>51</volume>:<fpage>353</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">20579506</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0741">
<label>741</label>
<mixed-citation id="bdi12609-cit-0741" publication-type="journal">
<string-name>
<surname>Ozdemiroglu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sevincok</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sen</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Comorbid obsessive‐compulsive disorder with bipolar disorder: A distinct form?</article-title>
<source xml:lang="en"/>Psychiatry Res. <year>2015</year>;<volume>230</volume>:<fpage>800</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">26561371</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0742">
<label>742</label>
<mixed-citation id="bdi12609-cit-0742" publication-type="journal">
<string-name>
<surname>Shashidhara</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sushma</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Viswanath</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Math</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Janardhan Reddy</surname>
<given-names>YC</given-names>
</string-name>. <article-title>Comorbid obsessive compulsive disorder in patients with bipolar‐I disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2015</year>;<volume>174</volume>:<fpage>367</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">25545603</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0743">
<label>743</label>
<mixed-citation id="bdi12609-cit-0743" publication-type="journal">
<string-name>
<surname>Raja</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Azzoni</surname>
<given-names>A</given-names>
</string-name>. <article-title>Clinical management of obsessive‐compulsive‐bipolar comorbidity: a case series</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>264</fpage>‐<lpage>70</lpage>.<pub-id pub-id-type="pmid">15117406</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0744">
<label>744</label>
<mixed-citation id="bdi12609-cit-0744" publication-type="journal">
<string-name>
<surname>Tonna</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Amerio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Odone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stubbs</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ghaemi</surname>
<given-names>SN</given-names>
</string-name>. <article-title>Comorbid bipolar disorder and obsessive‐compulsive disorder: which came first?</article-title>
<source xml:lang="en"/>Aust N Z J Psychiatry. <year>2016</year>;<volume>50</volume>:<fpage>695</fpage>‐<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0745">
<label>745</label>
<mixed-citation id="bdi12609-cit-0745" publication-type="journal">
<string-name>
<surname>Vazquez</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>. <article-title>Co‐occurrence of anxiety and bipolar disorders: clinical and therapeutic overview</article-title>. <source xml:lang="en"/>Depress Anxiety. <year>2014</year>;<volume>31</volume>:<fpage>196</fpage>‐<lpage>206</lpage>.<pub-id pub-id-type="pmid">24610817</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0746">
<label>746</label>
<mixed-citation id="bdi12609-cit-0746" publication-type="journal">
<string-name>
<surname>Bisol</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>Lara</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Improvement of obsessive‐compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2009</year>;<volume>42</volume>:<fpage>37</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">19153947</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0747">
<label>747</label>
<mixed-citation id="bdi12609-cit-0747" publication-type="journal">
<string-name>
<surname>Marazziti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pfanner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dell'Osso</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long‐term open‐label study</article-title>. <source xml:lang="en"/>J Psychopharmacol. <year>2005</year>;<volume>19</volume>:<fpage>392</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">15982994</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0748">
<label>748</label>
<mixed-citation id="bdi12609-cit-0748" publication-type="journal">
<string-name>
<surname>Petrikis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andreou</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bozikas</surname>
<given-names>VP</given-names>
</string-name>, <string-name>
<surname>Karavatos</surname>
<given-names>A</given-names>
</string-name>. <article-title>Effective use of olanzapine for obsessive‐compulsive symptoms in a patient with bipolar disorder</article-title>. <source xml:lang="en"/>Can J Psychiatry. <year>2004</year>;<volume>49</volume>:<fpage>572</fpage>‐<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0749">
<label>749</label>
<mixed-citation id="bdi12609-cit-0749" publication-type="journal">
<string-name>
<surname>Jacobsen</surname>
<given-names>FM</given-names>
</string-name>. <article-title>Risperidone in the treatment of affective‐illness and obsessive‐compulsive disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1995</year>;<volume>56</volume>:<fpage>423</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">7545159</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0750">
<label>750</label>
<mixed-citation id="bdi12609-cit-0750" publication-type="journal">
<string-name>
<surname>Pfanner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Marazziti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dell'Osso</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Risperidone augmentation in refractory obsessive‐compulsive disorder: an open‐label study</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2000</year>;<volume>15</volume>:<fpage>297</fpage>‐<lpage>301</lpage>.<pub-id pub-id-type="pmid">10993132</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0751">
<label>751</label>
<mixed-citation id="bdi12609-cit-0751" publication-type="journal">
<string-name>
<surname>Gao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Muzina</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gajwani</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>1327</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">17017818</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0752">
<label>752</label>
<mixed-citation id="bdi12609-cit-0752" publication-type="journal">
<string-name>
<surname>Uguz</surname>
<given-names>F</given-names>
</string-name>. <article-title>Successful treatment of comorbid obsessive‐compulsive disorder with aripiprazole in three patients with bipolar disorder</article-title>. <source xml:lang="en"/>Gen Hosp Psychiatry. <year>2010</year>;<volume>32</volume>:<fpage>556</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">20851277</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0753">
<label>753</label>
<mixed-citation id="bdi12609-cit-0753" publication-type="journal">
<string-name>
<surname>Lai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>S</given-names>
</string-name>. <article-title>Aripiprazole augmentation in managing comorbid obsessive‐compulsive disorder and bipolar disorder: a case with suicidal attempts</article-title>. <source xml:lang="en"/>Neuropsychiatr Dis Treat. <year>2017</year>;<volume>13</volume>:<fpage>87</fpage>‐<lpage>90</lpage>.<pub-id pub-id-type="pmid">28096676</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0754">
<label>754</label>
<mixed-citation id="bdi12609-cit-0754" publication-type="journal">
<string-name>
<surname>Patra</surname>
<given-names>S</given-names>
</string-name>. <article-title>Treat the disease not the symptoms: successful management of obsessive compulsive disorder in bipolar disorder with aripiprazole augmentation</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2016</year>;<volume>50</volume>:<fpage>809</fpage>‐<lpage>10</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0755">
<label>755</label>
<mixed-citation id="bdi12609-cit-0755" publication-type="journal">
<string-name>
<surname>Bulbul</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Copoglu</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Alpak</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Unal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tastan</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Savas</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Maintenance therapy with electroconvulsive therapy in a patient with a codiagnosis of bipolar disorder and obsessive‐compulsive disorder</article-title>. <source xml:lang="en"/>J ECT. <year>2013</year>;<volume>29</volume>:<fpage>e21</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">23519221</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0756">
<label>756</label>
<mixed-citation id="bdi12609-cit-0756" publication-type="journal">
<string-name>
<surname>Sahraian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bigdeli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</string-name>. <article-title>Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: A randomized double blind placebo controlled clinical trial</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>166</volume>:<fpage>201</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">25012432</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0757">
<label>757</label>
<mixed-citation id="bdi12609-cit-0757" publication-type="journal">
<string-name>
<surname>Friborg</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Martinsen</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Martinussen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaiser</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Overgard</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>Rosenvinge</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Comorbidity of personality disorders in mood disorders: a meta‐analytic review of 122 studies from 1988 to 2010</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2014</year>;<volume>152–154</volume>:<fpage>1</fpage>‐<lpage>11</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0758">
<label>758</label>
<mixed-citation id="bdi12609-cit-0758" publication-type="journal">
<string-name>
<surname>Rosenbluth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>MacQueen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Beaulieu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schaffer</surname>
<given-names>A</given-names>
</string-name>. <article-title>The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2012</year>;<volume>24</volume>:<fpage>56</fpage>‐<lpage>68</lpage>.<pub-id pub-id-type="pmid">22303522</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0759">
<label>759</label>
<mixed-citation id="bdi12609-cit-0759" publication-type="journal">
<string-name>
<surname>Preston</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Marchant</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Reimherr</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Strong</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Hedges</surname>
<given-names>DW</given-names>
</string-name>. <article-title>Borderline personality disorder in patients with bipolar disorder and response to lamotrigine</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2004</year>;<volume>79</volume>:<fpage>297</fpage>‐<lpage>303</lpage>.<pub-id pub-id-type="pmid">15023511</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0760">
<label>760</label>
<mixed-citation id="bdi12609-cit-0760" publication-type="journal">
<string-name>
<surname>Colom</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Moreno</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Psychoeducation in bipolar patients with comorbid personality disorders</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2004</year>;<volume>6</volume>:<fpage>294</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">15225146</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0761">
<label>761</label>
<mixed-citation id="bdi12609-cit-0761" publication-type="journal">
<string-name>
<surname>Alesiani</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Boccalon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Giarolli</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Blum</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fossati</surname>
<given-names>A</given-names>
</string-name>. <article-title>Systems Training for Emotional Predictability and Problem Solving (STEPPS): program efficacy and personality features as predictors of drop‐out – an Italian study</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2014</year>;<volume>55</volume>:<fpage>920</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">24556518</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0762">
<label>762</label>
<mixed-citation id="bdi12609-cit-0762" publication-type="journal">
<string-name>
<surname>Goldstein</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Axelson</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Birmaher</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Brent</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Dialectical behavior therapy for adolescents with bipolar disorder: A 1‐year open trial</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2007</year>;<volume>46</volume>:<fpage>820</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">17581446</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0763">
<label>763</label>
<mixed-citation id="bdi12609-cit-0763" publication-type="journal">
<string-name>
<surname>Van Dijk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jeffrey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>MR</given-names>
</string-name>. <article-title>A randomized, controlled, pilot study of dialectical behavior therapy skills in a psychoeducational group for individuals with bipolar disorder</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2013</year>;<volume>145</volume>:<fpage>386</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">22858264</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0764">
<label>764</label>
<mixed-citation id="bdi12609-cit-0764" publication-type="journal">
<string-name>
<surname>Brus</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Solanto</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Adult ADHD vs. bipolar disorder in the DSM‐5 Era: a challenging differentiation for clinicians</article-title>. <source xml:lang="en"/>J Psychiatr Pract. <year>2014</year>;<volume>20</volume>:<fpage>428</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">25406047</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0765">
<label>765</label>
<mixed-citation id="bdi12609-cit-0765" publication-type="journal">
<string-name>
<surname>Bond</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hadjipavlou</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>, et al. <article-title>The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention‐deficit/hyperactivity disorder</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2012</year>;<volume>24</volume>:<fpage>23</fpage>‐<lpage>37</lpage>.<pub-id pub-id-type="pmid">22303520</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0766">
<label>766</label>
<mixed-citation id="bdi12609-cit-0766" publication-type="journal">
<string-name>
<surname>Wilens</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Prince</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>An open trial of bupropion for the treatment of adults with attention‐deficit/hyperactivity disorder and bipolar disorder</article-title>. <source xml:lang="en"/>Biol Psychiatry. <year>2003</year>;<volume>54</volume>:<fpage>9</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">12842303</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0767">
<label>767</label>
<mixed-citation id="bdi12609-cit-0767" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Alsuwaidan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soczynska</surname>
<given-names>JK</given-names>
</string-name>, et al. <article-title>The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2013</year>;<volume>28</volume>:<fpage>421</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">24014142</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0768">
<label>768</label>
<mixed-citation id="bdi12609-cit-0768" publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>FHC</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>KY</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>TC</given-names>
</string-name>. <article-title>The incidence and relative risk of stroke among patients with bipolar disorder: a seven‐year follow‐up study</article-title>. <source xml:lang="en"/>PLoS ONE. <year>2013</year>;<volume>8</volume>:<fpage>e73037</fpage>.<pub-id pub-id-type="pmid">24023667</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0769">
<label>769</label>
<mixed-citation id="bdi12609-cit-0769" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Langan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guthrie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mercer</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study</article-title>. <source xml:lang="en"/>BMC Med. <year>2013</year>;<volume>11</volume>:<fpage>263</fpage>.<pub-id pub-id-type="pmid">24359325</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0770">
<label>770</label>
<mixed-citation id="bdi12609-cit-0770" publication-type="journal">
<string-name>
<surname>Forty</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ulanova</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Comorbid medical illness in bipolar disorder</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2014</year>;<volume>205</volume>:<fpage>465</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">25359927</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0771">
<label>771</label>
<mixed-citation id="bdi12609-cit-0771" publication-type="journal">
<string-name>
<surname>Weber</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Cowan</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Niebuhr</surname>
<given-names>DW</given-names>
</string-name>. <article-title>Psychiatric and general medical conditions comorbid with bipolar disorder in the national hospital discharge survey</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2011</year>;<volume>62</volume>:<fpage>1152</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">21969641</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0772">
<label>772</label>
<mixed-citation id="bdi12609-cit-0772" publication-type="journal">
<string-name>
<surname>Gomes</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Almeida</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Magalhaes</surname>
<given-names>PV</given-names>
</string-name>, et al. <article-title>Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in bipolar disorder</article-title>. <source xml:lang="en"/>Revista Brasileira De Psiquiatria. <year>2013</year>;<volume>35</volume>:<fpage>126</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">23904016</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0773">
<label>773</label>
<mixed-citation id="bdi12609-cit-0773" publication-type="journal">
<string-name>
<surname>Sylvia</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Shelton</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, et al. <article-title>Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE)</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>212</fpage>‐<lpage>23</lpage>.<pub-id pub-id-type="pmid">25130321</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0774">
<label>774</label>
<mixed-citation id="bdi12609-cit-0774" publication-type="journal">
<string-name>
<surname>Kemp</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Sylvia</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2014</year>;<volume>129</volume>:<fpage>24</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">23465084</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0775">
<label>775</label>
<mixed-citation id="bdi12609-cit-0775" publication-type="journal">
<string-name>
<surname>Chesney</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Fazel</surname>
<given-names>S</given-names>
</string-name>. <article-title>Risks of all‐cause and suicide mortality in mental disorders: a meta‐review</article-title>. <source xml:lang="en"/>World Psychiatry. <year>2014</year>;<volume>13</volume>:<fpage>153</fpage>‐<lpage>60</lpage>.<pub-id pub-id-type="pmid">24890068</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0776">
<label>776</label>
<mixed-citation id="bdi12609-cit-0776" publication-type="journal">
<string-name>
<surname>Crump</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sundquist</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Winkleby</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Sundquist</surname>
<given-names>J</given-names>
</string-name>. <article-title>Comorbidities and mortality in bipolar disorder a Swedish national cohort study</article-title>. <source xml:lang="en"/>JAMA Psychiatry. <year>2013</year>;<volume>70</volume>:<fpage>931</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">23863861</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0777">
<label>777</label>
<mixed-citation id="bdi12609-cit-0777" publication-type="journal">
<string-name>
<surname>de Almeida</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Lafer</surname>
<given-names>B</given-names>
</string-name>. <article-title>Metabolic syndrome and bipolar disorder: what should psychiatrists know?</article-title>
<source xml:lang="en"/>CNS Neurosci Ther. <year>2012</year>;<volume>18</volume>:<fpage>160</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">22070636</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0778">
<label>778</label>
<mixed-citation id="bdi12609-cit-0778" publication-type="journal">
<collab collab-type="authors">Third Report of the National Cholesterol Education Program</collab>
. <article-title>(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report</article-title>. <source xml:lang="en"/>Circulation. <year>2002</year>;<volume>106</volume>:<fpage>3143</fpage>‐<lpage>421</lpage>.<pub-id pub-id-type="pmid">12485966</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0779">
<label>779</label>
<mixed-citation id="bdi12609-cit-0779" publication-type="journal">
<string-name>
<surname>Gans</surname>
<given-names>RO</given-names>
</string-name>. <article-title>The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms</article-title>. <source xml:lang="en"/>Med Clin North Am. <year>2006</year>;<volume>90</volume>:<fpage>573</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">16843763</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0780">
<label>780</label>
<mixed-citation id="bdi12609-cit-0780" publication-type="journal">
<string-name>
<surname>Taylor</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>MacQueen</surname>
<given-names>G</given-names>
</string-name>. <article-title>Associations between bipolar disorder and metabolic syndrome: A review</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2006</year>;<volume>67</volume>:<fpage>1034</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">16889445</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0781">
<label>781</label>
<mixed-citation id="bdi12609-cit-0781" publication-type="journal">
<string-name>
<surname>Krishnan</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Psychiatric and medical comorbidities of bipolar disorder</article-title>. <source xml:lang="en"/>Psychosom Med. <year>2005</year>;<volume>67</volume>:<fpage>1</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">15673617</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0782">
<label>782</label>
<mixed-citation id="bdi12609-cit-0782" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Soczynska</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Konarski</surname>
<given-names>JZ</given-names>
</string-name>, et al. <article-title>Should depressive syndromes be reclassified as “metabolic syndrome type II”?</article-title>
<source xml:lang="en"/>Ann Clin Psychiatry. <year>2007</year>;<volume>19</volume>:<fpage>257</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">18058283</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0783">
<label>783</label>
<mixed-citation id="bdi12609-cit-0783" publication-type="journal">
<string-name>
<surname>Kapczinski</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vieta</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</string-name>, et al. <article-title>Allostatic load in bipolar disorder: implications for pathophysiology and treatment</article-title>. <source xml:lang="en"/>Neurosci Biobehav Rev. <year>2008</year>;<volume>32</volume>:<fpage>675</fpage>‐<lpage>92</lpage>.<pub-id pub-id-type="pmid">18199480</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0784">
<label>784</label>
<mixed-citation id="bdi12609-cit-0784" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Kenna</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>HT</given-names>
</string-name>, et al. <article-title>Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders?</article-title>
<source xml:lang="en"/>Adv Ther. <year>2010</year>;<volume>27</volume>:<fpage>63</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">20390390</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0785">
<label>785</label>
<mixed-citation id="bdi12609-cit-0785" publication-type="journal">
<string-name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Alsuwaidan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>BI</given-names>
</string-name>, et al. <article-title>The Canadian Network for Mood and Anxiety Treatments (CANWAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders</article-title>. <source xml:lang="en"/>Ann Clin Psychiatry. <year>2012</year>;<volume>24</volume>:<fpage>69</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">22303523</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0786">
<label>786</label>
<mixed-citation id="bdi12609-cit-0786" publication-type="journal">
<string-name>
<surname>Domino</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Wells</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Morrissey</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Serving persons with severe mental illness in primary care‐based medical homes</article-title>. <source xml:lang="en"/>Psychiatr Serv. <year>2015</year>;<volume>66</volume>:<fpage>477</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">25686809</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0787">
<label>787</label>
<mixed-citation id="bdi12609-cit-0787" publication-type="journal">
<string-name>
<surname>Steele</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Durbin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sibley</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Glazier</surname>
<given-names>R</given-names>
</string-name>. <article-title>Inclusion of persons with mental illness in patient‐centred medical homes: cross‐sectional findings from Ontario, Canada</article-title>. <source xml:lang="en"/>Open Med. <year>2013</year>;<volume>7</volume>:<fpage>e9</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">23687535</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0788">
<label>788</label>
<mixed-citation id="bdi12609-cit-0788" publication-type="journal">
<string-name>
<surname>Kohler‐Forsberg</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Gasse</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ostergaard</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Do statins have antidepressant effects?</article-title>
<source xml:lang="en"/>CNS Drugs. <year>2017</year>;<volume>31</volume>:<fpage>335</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">28303466</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0789">
<label>789</label>
<mixed-citation id="bdi12609-cit-0789" publication-type="journal">
<string-name>
<surname>Salagre</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Dodd</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brownstein</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>. <article-title>Statins for the treatment of depression: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>200</volume>:<fpage>235</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">27148902</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0790">
<label>790</label>
<mixed-citation id="bdi12609-cit-0790" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Mohebbi</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Statin and aspirin use and the risk of mood disorders among men</article-title>. <source xml:lang="en"/>Int J Neuropsychopharmacol. <year>2016</year>;<volume>19</volume>:<fpage>pyw008</fpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0791">
<label>791</label>
<mixed-citation id="bdi12609-cit-0791" publication-type="journal">
<string-name>
<surname>Brownstein</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Salagre</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kohler</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Blockade of the angiotensin system improves mental health domain of quality of life: a meta‐analysis of randomized clinical trials</article-title>. <source xml:lang="en"/>Aust N Z J Psychiatry. <year>2018</year>;<volume>52</volume>:<fpage>24</fpage>‐<lpage>38</lpage>.<pub-id pub-id-type="pmid">28754072</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0792">
<label>792</label>
<mixed-citation id="bdi12609-cit-0792" publication-type="journal">
<string-name>
<surname>Vian</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chavarria</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>The renin‐angiotensin system: a possible new target for depression</article-title>. <source xml:lang="en"/>BMC Med. <year>2017</year>;<volume>15</volume>:<fpage>144</fpage>.<pub-id pub-id-type="pmid">28760142</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0793">
<label>793</label>
<mixed-citation id="bdi12609-cit-0793" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Quirk</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Fernandes</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>. <article-title>Angiotensin converting enzyme inhibitors and risk of mood disorders</article-title>. <source xml:lang="en"/>Psychother Psychosom. <year>2016</year>;<volume>85</volume>:<fpage>250</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">27230871</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0794">
<label>794</label>
<mixed-citation id="bdi12609-cit-0794" publication-type="journal">
<string-name>
<surname>Lan</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>CH</given-names>
</string-name>, et al. <article-title>A reduced risk of stroke with lithium exposure in bipolar disorder: a population‐based retrospective cohort study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>705</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">26394555</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0795">
<label>795</label>
<mixed-citation id="bdi12609-cit-0795" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>RY</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>YH</given-names>
</string-name>. <article-title>Use of lithium and cancer risk in patients with bipolar disorder: population‐based cohort study</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2016</year>;<volume>209</volume>:<fpage>395</fpage>‐<lpage>401</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0796">
<label>796</label>
<mixed-citation id="bdi12609-cit-0796" publication-type="journal">
<string-name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Gerds</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Feldt‐Rasmussen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Licht</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Lithium and renal and upper urinary tract tumors – results from a nationwide population‐based study</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2015</year>;<volume>17</volume>:<fpage>805</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">26534877</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0797">
<label>797</label>
<mixed-citation id="bdi12609-cit-0797" publication-type="journal">
<string-name>
<surname>Diniz</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Teixeira</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>History of bipolar disorder and the risk of dementia: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2017</year>;<volume>25</volume>:<fpage>357</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">28161155</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0798">
<label>798</label>
<mixed-citation id="bdi12609-cit-0798" publication-type="journal">
<string-name>
<surname>Gerhard</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Devanand</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Crystal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Olfson</surname>
<given-names>M</given-names>
</string-name>. <article-title>Lithium treatment and risk for dementia in adults with bipolar disorder: population‐based cohort study</article-title>. <source xml:lang="en"/>Br J Psychiatry. <year>2015</year>;<volume>207</volume>:<fpage>46</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">25614530</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0799">
<label>799</label>
<mixed-citation id="bdi12609-cit-0799" publication-type="journal">
<string-name>
<surname>McKnight</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Adida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Budge</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stockton</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Lithium toxicity profile: a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Lancet. <year>2012</year>;<volume>379</volume>:<fpage>721</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">22265699</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0800">
<label>800</label>
<mixed-citation id="bdi12609-cit-0800" publication-type="journal">
<string-name>
<surname>Locharernkul</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shotelersuk</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hirankarn</surname>
<given-names>N</given-names>
</string-name>. <article-title>Pharmacogenetic screening of carbamazepine‐induced severe cutaneous allergic reactions</article-title>. <source xml:lang="en"/>J Clin Neurosci. <year>2011</year>;<volume>18</volume>:<fpage>1289</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">21802305</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0801">
<label>801</label>
<mixed-citation id="bdi12609-cit-0801" publication-type="journal">
<string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Gessler</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Outhred</surname>
<given-names>T</given-names>
</string-name>. <article-title>The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2017</year>;<volume>217</volume>:<fpage>266</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">28437764</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0802">
<label>802</label>
<mixed-citation id="bdi12609-cit-0802" publication-type="journal">
<string-name>
<surname>Gelenberg</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Kane</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>MB</given-names>
</string-name>, et al. <article-title>Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder</article-title>. <source xml:lang="en"/>N Engl J Med. <year>1989</year>;<volume>321</volume>:<fpage>1489</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">2811970</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0803">
<label>803</label>
<mixed-citation id="bdi12609-cit-0803" publication-type="journal">
<string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Gershon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Outhred</surname>
<given-names>T</given-names>
</string-name>. <article-title>Lithiumeter: version 2.0</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>631</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">28063207</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0804">
<label>804</label>
<mixed-citation id="bdi12609-cit-0804" publication-type="journal">
<string-name>
<surname>Gitlin</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cochran</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Jamison</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Maintenance lithium treatment – side‐effects and compliance</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>1989</year>;<volume>50</volume>:<fpage>127</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">2925600</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0805">
<label>805</label>
<mixed-citation id="bdi12609-cit-0805" publication-type="journal">
<string-name>
<surname>Allen</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Hirschfeld</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Wozniak</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2006</year>;<volume>163</volume>:<fpage>272</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">16449481</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0806">
<label>806</label>
<mixed-citation id="bdi12609-cit-0806" publication-type="journal">
<string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Trajectories of body mass index change in first episode of mania: 3‐year data from the Systematic Treatment Optimization Program for Early Mania (STOP‐EM)</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2017</year>;<volume>208</volume>:<fpage>291</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">27794253</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0807">
<label>807</label>
<mixed-citation id="bdi12609-cit-0807" publication-type="journal">
<string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Perry</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pike</surname>
<given-names>J</given-names>
</string-name>. <article-title>Factors associated with treatment nonadherence among US bipolar disorder patients</article-title>. <source xml:lang="en"/>Hum Psychopharmacol. <year>2008</year>;<volume>23</volume>:<fpage>95</fpage>‐<lpage>105</lpage>.<pub-id pub-id-type="pmid">18058849</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0808">
<label>808</label>
<mixed-citation id="bdi12609-cit-0808" publication-type="journal">
<string-name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</string-name>. <article-title>Safety of available agents used to treat bipolar disorder: focus on weight gain</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>532</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">12755655</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0809">
<label>809</label>
<mixed-citation id="bdi12609-cit-0809" publication-type="journal">
<string-name>
<surname>Fang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>K</given-names>
</string-name>. <article-title>Is there a ‘weight neutral’ second‐generation antipsychotic for bipolar disorder?</article-title>
<source xml:lang="en"/>Expert Rev Neurother. <year>2017</year>;<volume>17</volume>:<fpage>407</fpage>‐<lpage>18</lpage>.<pub-id pub-id-type="pmid">28005435</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0810">
<label>810</label>
<mixed-citation id="bdi12609-cit-0810" publication-type="journal">
<string-name>
<surname>Orsolini</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tomasetti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Valchera</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>An update of safety of clinically used atypical antipsychotics</article-title>. <source xml:lang="en"/>Expert Opin Drug Saf. <year>2016</year>;<volume>15</volume>:<fpage>1329</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">27347638</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0811">
<label>811</label>
<mixed-citation id="bdi12609-cit-0811" publication-type="journal">
<string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Brugger</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, et al. <article-title>Efficacy of divalproex vs lithium and placebo in the treatment of mania</article-title>. <source xml:lang="en"/>JAMA. <year>1994</year>;<volume>271</volume>:<fpage>918</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">8120960</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0812">
<label>812</label>
<mixed-citation id="bdi12609-cit-0812" publication-type="journal">
<string-name>
<surname>Persson</surname>
<given-names>G</given-names>
</string-name>. <article-title>Lithium side‐effects in relation to dose and to levels and gradients of lithium in plasma</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>1977</year>;<volume>55</volume>:<fpage>208</fpage>‐<lpage>13</lpage>.<pub-id pub-id-type="pmid">848339</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0813">
<label>813</label>
<mixed-citation id="bdi12609-cit-0813" publication-type="journal">
<string-name>
<surname>Persson</surname>
<given-names>G</given-names>
</string-name>. <article-title>Plasma lithium levels and side‐effects during administration of a slow release lithium sulfate preparation (Lithium‐lipett‐C) and lithium‐carbonate tablets</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>1974</year>;<volume>50</volume>:<fpage>174</fpage>‐<lpage>82</lpage>.<pub-id pub-id-type="pmid">4853671</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0814">
<label>814</label>
<mixed-citation id="bdi12609-cit-0814" publication-type="journal">
<string-name>
<surname>Stone</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Lithium‐induced nephrogenic diabetes insipidus</article-title>. <source xml:lang="en"/>J Am Board Fam Pract. <year>1999</year>;<volume>12</volume>:<fpage>43</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">10050642</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0815">
<label>815</label>
<mixed-citation id="bdi12609-cit-0815" publication-type="journal">
<string-name>
<surname>Bosquet</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Descombes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gauthier</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fellay</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Regamey</surname>
<given-names>C</given-names>
</string-name>. <article-title>Nephrotic syndrome during lithium therapy</article-title>. <source xml:lang="en"/>Nephrol Dial Transplant. <year>1997</year>;<volume>12</volume>:<fpage>2728</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">9430882</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0816">
<label>816</label>
<mixed-citation id="bdi12609-cit-0816" publication-type="journal">
<string-name>
<surname>Tandon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zaltzman</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Lithium‐induced minimal change disease and acute kidney injury</article-title>. <source xml:lang="en"/>N Am J Med Sci. <year>2015</year>;<volume>7</volume>:<fpage>328</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">26258081</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0817">
<label>817</label>
<mixed-citation id="bdi12609-cit-0817" publication-type="journal">
<string-name>
<surname>Pradhan</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Chakrabarti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Irpati</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Bhardwaj</surname>
<given-names>R</given-names>
</string-name>. <article-title>Distress due to lithium‐induced polyuria: exploratory study</article-title>. <source xml:lang="en"/>Psychiatry Clin Neurosci. <year>2011</year>;<volume>65</volume>:<fpage>386</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">21569176</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0818">
<label>818</label>
<mixed-citation id="bdi12609-cit-0818" publication-type="journal">
<string-name>
<surname>Presne</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fakhouri</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Noel</surname>
<given-names>LH</given-names>
</string-name>, et al. <article-title>Lithium‐induced nephropathy: rate of progression and prognostic factors</article-title>. <source xml:lang="en"/>Kidney Int. <year>2003</year>;<volume>64</volume>:<fpage>585</fpage>‐<lpage>92</lpage>.<pub-id pub-id-type="pmid">12846754</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0819">
<label>819</label>
<mixed-citation id="bdi12609-cit-0819" publication-type="journal">
<string-name>
<surname>Johnson</surname>
<given-names>G</given-names>
</string-name>. <article-title>Lithium – early development, toxicity, and renal function</article-title>. <source xml:lang="en"/>Neuropsychopharmacology. <year>1998</year>;<volume>19</volume>:<fpage>200</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">9653708</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0820">
<label>820</label>
<mixed-citation id="bdi12609-cit-0820" publication-type="journal">
<string-name>
<surname>Castro</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Roberson</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>McCoy</surname>
<given-names>TH</given-names>
</string-name>, et al. <article-title>Stratifying risk for renal insufficiency among lithium‐treated patients: an electronic health record study</article-title>. <source xml:lang="en"/>Neuropsychopharmacology. <year>2016</year>;<volume>41</volume>:<fpage>1138</fpage>‐<lpage>43</lpage>.<pub-id pub-id-type="pmid">26294109</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0821">
<label>821</label>
<mixed-citation id="bdi12609-cit-0821" publication-type="journal">
<string-name>
<surname>Bocchetta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ardau</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fanni</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Renal function during long‐term lithium treatment: a cross‐sectional and longitudinal study</article-title>. <source xml:lang="en"/>BMC Med. <year>2015</year>;<volume>13</volume>:<fpage>12</fpage>.<pub-id pub-id-type="pmid">25604586</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0822">
<label>822</label>
<mixed-citation id="bdi12609-cit-0822" publication-type="journal">
<string-name>
<surname>Rej</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Lithium use, but not valproate use, is associated with a higher risk of chronic kidney disease in older adults with mental illness</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2017</year>;<volume>78</volume>:<fpage>e980</fpage>‐<lpage>e985</lpage>.<pub-id pub-id-type="pmid">28767208</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0823">
<label>823</label>
<mixed-citation id="bdi12609-cit-0823" publication-type="journal">
<string-name>
<surname>Coresh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Selvin</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>LA</given-names>
</string-name>, et al. <article-title>Prevalence of chronic kidney disease in the United States</article-title>. <source xml:lang="en"/>JAMA. <year>2007</year>;<volume>298</volume>:<fpage>2038</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">17986697</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0824">
<label>824</label>
<mixed-citation id="bdi12609-cit-0824" publication-type="journal">
<string-name>
<surname>Crowe</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Halpin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>P</given-names>
</string-name>. <article-title>Early identification and management of chronic kidney disease: summary of NICE guidance</article-title>. <source xml:lang="en"/>BMJ. <year>2008</year>;<volume>337</volume>:<fpage>a1530</fpage>.<pub-id pub-id-type="pmid">18824486</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0825">
<label>825</label>
<mixed-citation id="bdi12609-cit-0825" publication-type="journal">
<string-name>
<surname>Okusa</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Crystal</surname>
<given-names>LJT</given-names>
</string-name>. <article-title>Clinical manifestations and management of acute lithium intoxication</article-title>. <source xml:lang="en"/>Am J Med. <year>1994</year>;<volume>97</volume>:<fpage>383</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">7942943</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0826">
<label>826</label>
<mixed-citation id="bdi12609-cit-0826" publication-type="journal">
<string-name>
<surname>Tondo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Abramowicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Alda</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Long‐term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2017</year>;<volume>5</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">28480485</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0827">
<label>827</label>
<mixed-citation id="bdi12609-cit-0827" publication-type="journal">
<string-name>
<surname>Haussmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>von Bonin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lewitzka</surname>
<given-names>U</given-names>
</string-name>. <article-title>Treatment of lithium intoxication: facing the need for evidence</article-title>. <source xml:lang="en"/>Int J Bipolar Disord. <year>2015</year>;<volume>3</volume>:<fpage>23</fpage>.<pub-id pub-id-type="pmid">26493348</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0828">
<label>828</label>
<mixed-citation id="bdi12609-cit-0828" publication-type="journal">
<string-name>
<surname>Stubner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grohmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Engel</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Blood dyscrasias induced by psychotropic drugs</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2004</year>;<volume>37</volume>:<fpage>S70</fpage>‐<lpage>S8</lpage>.<pub-id pub-id-type="pmid">15052517</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0829">
<label>829</label>
<mixed-citation id="bdi12609-cit-0829" publication-type="journal">
<string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>. <article-title>Major system toxicities and side effects of anticonvulsants</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2001</year>;<volume>62</volume>:<fpage>16</fpage>‐<lpage>21</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0830">
<label>830</label>
<mixed-citation id="bdi12609-cit-0830" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Castillo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Zarate</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kando</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Blood dyscrasias with carbamazepine and valproate – a pharmacoepidemiologic study of 2,228 patients at risk</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1995</year>;<volume>152</volume>:<fpage>413</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">7864268</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0831">
<label>831</label>
<mixed-citation id="bdi12609-cit-0831" publication-type="journal">
<string-name>
<surname>Blackburn</surname>
<given-names>SCF</given-names>
</string-name>, <string-name>
<surname>Oliart</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>LAG</given-names>
</string-name>, <string-name>
<surname>Gutthann</surname>
<given-names>SP</given-names>
</string-name>. <article-title>Antiepileptics and blood dyscrasias: a cohort study</article-title>. <source xml:lang="en"/>Pharmacotherapy. <year>1998</year>;<volume>18</volume>:<fpage>1277</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">9855327</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0832">
<label>832</label>
<mixed-citation id="bdi12609-cit-0832" publication-type="journal">
<string-name>
<surname>Trannel</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Goebert</surname>
<given-names>D</given-names>
</string-name>. <article-title>Occurrence of thrombocytopenia in psychiatric patients taking valproate</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2001</year>;<volume>158</volume>:<fpage>128</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">11136646</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0833">
<label>833</label>
<mixed-citation id="bdi12609-cit-0833" publication-type="journal">
<string-name>
<surname>King</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Wager</surname>
<given-names>E</given-names>
</string-name>. <article-title>Haematological safety of antipsychotic drugs</article-title>. <source xml:lang="en"/>J Psychopharmacol. <year>1998</year>;<volume>12</volume>:<fpage>283</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">10958256</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0834">
<label>834</label>
<mixed-citation id="bdi12609-cit-0834" publication-type="journal">
<string-name>
<surname>Reilly</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Ayis</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Ferrier</surname>
<given-names>IN</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>SHL</given-names>
</string-name>. <article-title>QTc‐interval abnormalities and psychotropic drug therapy in psychiatric patients</article-title>. <source xml:lang="en"/>Lancet. <year>2000</year>;<volume>355</volume>:<fpage>1048</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">10744090</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0835">
<label>835</label>
<mixed-citation id="bdi12609-cit-0835" publication-type="journal">
<string-name>
<surname>Roose</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Bone</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haidorfer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dunner</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Fieve</surname>
<given-names>RR</given-names>
</string-name>. <article-title>Lithium treatment in older patients</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1979</year>;<volume>136</volume>:<fpage>843</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">443475</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0836">
<label>836</label>
<mixed-citation id="bdi12609-cit-0836" publication-type="journal">
<string-name>
<surname>Frye</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Denicoff</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Bryan</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>Association between lower serum free T‐4 and greater mood instability and depression in lithium‐maintained bipolar patients</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1999</year>;<volume>156</volume>:<fpage>1909</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="pmid">10588404</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0837">
<label>837</label>
<mixed-citation id="bdi12609-cit-0837" publication-type="journal">
<string-name>
<surname>Kupka</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Luckenbaugh</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Leverich</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>. <article-title>Rapid and non‐rapid cycling bipolar disorder: a meta‐analysis of clinical studies</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2003</year>;<volume>64</volume>:<fpage>1483</fpage>‐<lpage>94</lpage>.<pub-id pub-id-type="pmid">14728111</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0838">
<label>838</label>
<mixed-citation id="bdi12609-cit-0838" publication-type="journal">
<string-name>
<surname>Bendz</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sjodin</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Toss</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Berglund</surname>
<given-names>K</given-names>
</string-name>. <article-title>Hyperparathyroidism and long‐term lithium therapy–a cross‐sectional study and the effect of lithium withdrawal</article-title>. <source xml:lang="en"/>J Intern Med. <year>1996</year>;<volume>240</volume>:<fpage>357</fpage>‐<lpage>65</lpage>.<pub-id pub-id-type="pmid">9010382</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0839">
<label>839</label>
<mixed-citation id="bdi12609-cit-0839" publication-type="journal">
<string-name>
<surname>Joffe</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Valproate is associated with new‐onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder</article-title>. <source xml:lang="en"/>Biol Psychiat. <year>2006</year>;<volume>59</volume>:<fpage>1078</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">16448626</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0840">
<label>840</label>
<mixed-citation id="bdi12609-cit-0840" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>X</given-names>
</string-name>. <article-title>Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta‐analysis</article-title>. <source xml:lang="en"/>Eur J Obstet Gynecol Reprod Biol. <year>2016</year>;<volume>202</volume>:<fpage>26</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">27160812</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0841">
<label>841</label>
<mixed-citation id="bdi12609-cit-0841" publication-type="journal">
<string-name>
<surname>Joffe</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Suppes</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Longitudinal follow‐up of reproductive and metabolic features of valproate‐associated polycystic ovarian syndrome features: a preliminary report</article-title>. <source xml:lang="en"/>Biol Psychiatry. <year>2006</year>;<volume>60</volume>:<fpage>1378</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">16950230</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0842">
<label>842</label>
<mixed-citation id="bdi12609-cit-0842" publication-type="journal">
<string-name>
<surname>Montejo</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Arango</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics</article-title>. <source xml:lang="en"/>Front Neuroendocrinol. <year>2017</year>;<volume>45</volume>:<fpage>25</fpage>‐<lpage>34</lpage>.<pub-id pub-id-type="pmid">28235557</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0843">
<label>843</label>
<mixed-citation id="bdi12609-cit-0843" publication-type="journal">
<string-name>
<surname>Montejo</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Arango</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Spanish consensus on the risks and detection of antipsychotic drug‐related hyperprolactinaemia</article-title>. <source xml:lang="en"/>Rev Psiquiatr Salud Ment. <year>2016</year>;<volume>9</volume>:<fpage>158</fpage>‐<lpage>73</lpage>.<pub-id pub-id-type="pmid">26927534</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0844">
<label>844</label>
<mixed-citation id="bdi12609-cit-0844" publication-type="journal">
<string-name>
<surname>Pacchiarotti</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Murru</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kotzalidis</surname>
<given-names>GD</given-names>
</string-name>, et al. <article-title>Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2015</year>;<volume>25</volume>:<fpage>1045</fpage>‐<lpage>59</lpage>.<pub-id pub-id-type="pmid">25937241</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0845">
<label>845</label>
<mixed-citation id="bdi12609-cit-0845" publication-type="journal">
<string-name>
<surname>Cullen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ward</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>NA</given-names>
</string-name>, et al. <article-title>Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: a systematic review</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>205</volume>:<fpage>165</fpage>‐<lpage>81</lpage>.<pub-id pub-id-type="pmid">27449549</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0846">
<label>846</label>
<mixed-citation id="bdi12609-cit-0846" publication-type="journal">
<string-name>
<surname>Goswami</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Varma</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>The neurocognitive performance of drug‐free and medicated euthymic bipolar patients do not differ</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2009</year>;<volume>120</volume>:<fpage>456</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">19416126</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0847">
<label>847</label>
<mixed-citation id="bdi12609-cit-0847" publication-type="journal">
<string-name>
<surname>Dias</surname>
<given-names>VV</given-names>
</string-name>, <string-name>
<surname>Balanza‐Martinez</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Soeiro‐de‐Souza</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>2012</year>;<volume>126</volume>:<fpage>315</fpage>‐<lpage>31</lpage>.<pub-id pub-id-type="pmid">22881296</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0848">
<label>848</label>
<mixed-citation id="bdi12609-cit-0848" publication-type="journal">
<string-name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>McAulay</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gershon</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The lithium battery: assessing the neurocognitive profile of lithium in bipolar disorder</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2016</year>;<volume>18</volume>:<fpage>102</fpage>‐<lpage>15</lpage>.<pub-id pub-id-type="pmid">27004564</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0849">
<label>849</label>
<mixed-citation id="bdi12609-cit-0849" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sanger</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>McElroy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Olanzapine versus placebo in the treatment of acute mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>1999</year>;<volume>156</volume>:<fpage>702</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">10327902</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0850">
<label>850</label>
<mixed-citation id="bdi12609-cit-0850" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jacobs</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Grundy</surname>
<given-names>SL</given-names>
</string-name>, et al. <article-title>Efficacy of olanzapine in acute bipolar mania – a double‐blind, placebo‐controlled study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>2000</year>;<volume>57</volume>:<fpage>841</fpage>‐<lpage>9</lpage>.<pub-id pub-id-type="pmid">10986547</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0851">
<label>851</label>
<mixed-citation id="bdi12609-cit-0851" publication-type="journal">
<string-name>
<surname>Keck</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Versiani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Potkin</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Ziprasidone in the treatment of acute bipolar mania: a three‐week, placebo‐controlled, double‐blind, randomized trial</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2003</year>;<volume>160</volume>:<fpage>741</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">12668364</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0852">
<label>852</label>
<mixed-citation id="bdi12609-cit-0852" publication-type="journal">
<string-name>
<surname>Tohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Altshuler</surname>
<given-names>LL</given-names>
</string-name>, et al. <article-title>Olanzapine versus divalproex in the treatment of acute mania</article-title>. <source xml:lang="en"/>Am J Psychiatry. <year>2002</year>;<volume>159</volume>:<fpage>1011</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">12042191</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0853">
<label>853</label>
<mixed-citation id="bdi12609-cit-0853" publication-type="journal">
<string-name>
<surname>Zajecka</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Weisler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Swann</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Wozniak</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sommerville</surname>
<given-names>KW</given-names>
</string-name>. <article-title>A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2002</year>;<volume>63</volume>:<fpage>1148</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">12523875</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0854">
<label>854</label>
<mixed-citation id="bdi12609-cit-0854" publication-type="journal">
<string-name>
<surname>Ketter</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Theodore</surname>
<given-names>WH</given-names>
</string-name>. <article-title>Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders</article-title>. <source xml:lang="en"/>Neurology. <year>1999</year>;<volume>53</volume>:<fpage>S53</fpage>‐<lpage>67</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0855">
<label>855</label>
<mixed-citation id="bdi12609-cit-0855" publication-type="journal">
<string-name>
<surname>Macritchie</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Geddes</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Haslam</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder</article-title>. <source xml:lang="en"/>Cochrane Database Syst Rev. <year>2001</year>;(<issue>3</issue>):<fpage>Cd003196</fpage>.<pub-id pub-id-type="pmid">11687047</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0856">
<label>856</label>
<mixed-citation id="bdi12609-cit-0856" publication-type="journal">
<string-name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Bowden</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Calabrese</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>A pooled analysis of 2 placebo‐controlled 18‐month trials of lamotrigine and lithium maintenance in bipolar I disorder</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2004</year>;<volume>65</volume>:<fpage>432</fpage>‐<lpage>41</lpage>.<pub-id pub-id-type="pmid">15096085</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0857">
<label>857</label>
<mixed-citation id="bdi12609-cit-0857" publication-type="journal">
<string-name>
<surname>Karas</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Wilder</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Hammond</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Bauman</surname>
<given-names>AW</given-names>
</string-name>. <article-title>Treatment of valproate tremors</article-title>. <source xml:lang="en"/>Neurology. <year>1983</year>;<volume>33</volume>:<fpage>1380</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">6412157</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0858">
<label>858</label>
<mixed-citation id="bdi12609-cit-0858" publication-type="journal">
<string-name>
<surname>Cheng</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>. <article-title>Valproate (VPA)‐associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012</article-title>. <source xml:lang="en"/>Compr Psychiatry. <year>2013</year>;<volume>54</volume>:<fpage>562</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">23246073</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0859">
<label>859</label>
<mixed-citation id="bdi12609-cit-0859" publication-type="journal">
<string-name>
<surname>Maj</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Starace</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nolfe</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kemali</surname>
<given-names>D</given-names>
</string-name>. <article-title>Minimum plasma lithium levels required for effective prophylaxis in DSM‐III bipolar disorder – a prospective‐study</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>1986</year>;<volume>19</volume>:<fpage>420</fpage>‐<lpage>3</lpage>.<pub-id pub-id-type="pmid">3797469</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0860">
<label>860</label>
<mixed-citation id="bdi12609-cit-0860" publication-type="journal">
<string-name>
<surname>Vestergaard</surname>
<given-names>P</given-names>
</string-name>. <article-title>How does the patient prefer his lithium treatment</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>1985</year>;<volume>18</volume>:<fpage>223</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">4011670</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0861">
<label>861</label>
<mixed-citation id="bdi12609-cit-0861" publication-type="journal">
<string-name>
<surname>Wirshing</surname>
<given-names>WC</given-names>
</string-name>. <article-title>Movement disorders associated with neuroleptic treatment</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2001</year>;<volume>62</volume>:<fpage>15</fpage>‐<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0862">
<label>862</label>
<mixed-citation id="bdi12609-cit-0862" publication-type="journal">
<string-name>
<surname>Chue</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kovacs</surname>
<given-names>CS</given-names>
</string-name>. <article-title>Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management</article-title>. <source xml:lang="en"/>Bipolar Disord. <year>2003</year>;<volume>5</volume>:<fpage>62</fpage>‐<lpage>79</lpage>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0863">
<label>863</label>
<mixed-citation id="bdi12609-cit-0863" publication-type="journal">
<string-name>
<surname>Miller</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Comparative efficacy of typical and atypical antipsychotics as add‐on therapy to mood stabilizers in the treatment of acute mania</article-title>. <source xml:lang="en"/>J Clin Psychiatry. <year>2001</year>;<volume>62</volume>:<fpage>975</fpage>‐<lpage>80</lpage>.<pub-id pub-id-type="pmid">11780879</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0864">
<label>864</label>
<mixed-citation id="bdi12609-cit-0864" publication-type="journal">
<string-name>
<surname>Rudolph</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Gardner</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Gramigna</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>McGlinchey</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Antipsychotics and oropharyngeal dysphagia in hospitalized older patients</article-title>. <source xml:lang="en"/>J Clin Psychopharmacol. <year>2008</year>;<volume>28</volume>:<fpage>532</fpage>‐<lpage>5</lpage>.<pub-id pub-id-type="pmid">18794648</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0865">
<label>865</label>
<mixed-citation id="bdi12609-cit-0865" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Takeshita</surname>
<given-names>J</given-names>
</string-name>. <article-title>Antipsychotic‐induced dysphagia: a case report</article-title>. <source xml:lang="en"/>Prim Care Companion CNS Disord. <year>2015</year>;<volume>17</volume>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4088/PCC.15l01792">https://doi.org/10.4088/PCC.15l01792</ext-link>.</mixed-citation>
</ref>
<ref id="bdi12609-bib-0866">
<label>866</label>
<mixed-citation id="bdi12609-cit-0866" publication-type="journal">
<string-name>
<surname>Sarkar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>N</given-names>
</string-name>. <article-title>Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association</article-title>. <source xml:lang="en"/>BJPsych Bull. <year>2017</year>;<volume>41</volume>:<fpage>211</fpage>‐<lpage>6</lpage>.<pub-id pub-id-type="pmid">28811916</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0867">
<label>867</label>
<mixed-citation id="bdi12609-cit-0867" publication-type="journal">
<string-name>
<surname>Tse</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Barr</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Scarapicchia</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vila‐Rodriguez</surname>
<given-names>F</given-names>
</string-name>. <article-title>Neuroleptic malignant syndrome: a review from a clinically oriented perspective</article-title>. <source xml:lang="en"/>Curr Neuropharmacol. <year>2015</year>;<volume>13</volume>:<fpage>395</fpage>‐<lpage>406</lpage>.<pub-id pub-id-type="pmid">26411967</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0868">
<label>868</label>
<mixed-citation id="bdi12609-cit-0868" publication-type="journal">
<string-name>
<surname>Kwok</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>TY</given-names>
</string-name>. <article-title>Recurrent heat‐related illnesses during antipsychotic treatment</article-title>. <source xml:lang="en"/>Ann Pharmacother. <year>2005</year>;<volume>39</volume>:<fpage>1940</fpage>‐<lpage>2</lpage>.<pub-id pub-id-type="pmid">16174785</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0869">
<label>869</label>
<mixed-citation id="bdi12609-cit-0869" publication-type="journal">
<string-name>
<surname>Kreuzer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Landgrebe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wittmann</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature</article-title>. <source xml:lang="en"/>J Clin Pharmacol. <year>2012</year>;<volume>52</volume>:<fpage>1090</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">21956608</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0870">
<label>870</label>
<mixed-citation id="bdi12609-cit-0870" publication-type="journal">
<string-name>
<surname>Guberman</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Besag</surname>
<given-names>FMC</given-names>
</string-name>, <string-name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Lamotrigine‐associated rash: risk benefit considerations in adults and children</article-title>. <source xml:lang="en"/>Epilepsia. <year>1999</year>;<volume>40</volume>:<fpage>985</fpage>‐<lpage>91</lpage>.<pub-id pub-id-type="pmid">10403224</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0871">
<label>871</label>
<mixed-citation id="bdi12609-cit-0871" publication-type="journal">
<string-name>
<surname>Messenheimer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mullens</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Giorgi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>F</given-names>
</string-name>. <article-title>Safety review of adult clinical trial experience with lamotrigine</article-title>. <source xml:lang="en"/>Drug Saf. <year>1998</year>;<volume>18</volume>:<fpage>281</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">9565739</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0872">
<label>872</label>
<mixed-citation id="bdi12609-cit-0872" publication-type="journal">
<string-name>
<surname>Rzany</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Correia</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case‐control study</article-title>. <source xml:lang="en"/>Lancet. <year>1999</year>;<volume>353</volume>:<fpage>2190</fpage>‐<lpage>4</lpage>.<pub-id pub-id-type="pmid">10392983</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0873">
<label>873</label>
<mixed-citation id="bdi12609-cit-0873" publication-type="journal">
<string-name>
<surname>Yeung</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>HH</given-names>
</string-name>. <article-title>Cutaneous adverse effects of lithium: epidemiology and management</article-title>. <source xml:lang="en"/>Am J Clin Dermatol. <year>2004</year>;<volume>5</volume>:<fpage>3</fpage>‐<lpage>8</lpage>.<pub-id pub-id-type="pmid">14979738</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0874">
<label>874</label>
<mixed-citation id="bdi12609-cit-0874" publication-type="journal">
<string-name>
<surname>Mezuk</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Morden</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Ganoczy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Post</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Kilbourne</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration</article-title>. <source xml:lang="en"/>Am J Geriatr Psychiatry. <year>2010</year>;<volume>18</volume>:<fpage>245</fpage>‐<lpage>55</lpage>.<pub-id pub-id-type="pmid">20224520</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0875">
<label>875</label>
<mixed-citation id="bdi12609-cit-0875" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Berk</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression</article-title>. <source xml:lang="en"/>Int Clin Psychopharmacol. <year>2008</year>;<volume>23</volume>:<fpage>84</fpage>‐<lpage>7</lpage>.<pub-id pub-id-type="pmid">18301122</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0876">
<label>876</label>
<mixed-citation id="bdi12609-cit-0876" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Pasco</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Depression as a risk factor for fracture in women: a 10 year longitudinal study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2016</year>;<volume>192</volume>:<fpage>34</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">26706830</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0877">
<label>877</label>
<mixed-citation id="bdi12609-cit-0877" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Bjerkeset</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Langhammer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study</article-title>. <source xml:lang="en"/>J Affect Disord. <year>2011</year>;<volume>131</volume>:<fpage>164</fpage>‐<lpage>71</lpage>.<pub-id pub-id-type="pmid">21211851</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0878">
<label>878</label>
<mixed-citation id="bdi12609-cit-0878" publication-type="journal">
<collab collab-type="authors">ACOG Committee on Practice Bulletins–Obstetrics</collab>
. <article-title>ACOG Practice Bulletin. Clinical Management Guidelines for Obstetricians‐Gynecologists. Use of psychiatric medications during pregnancy and lactation</article-title>. <source xml:lang="en"/>Obstet Gynecol. <year>2008</year>;<volume>111</volume>:<fpage>1001</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">18378767</pub-id></mixed-citation>
</ref>
<ref id="bdi12609-bib-0879">
<label>879</label>
<mixed-citation id="bdi12609-cit-0879" publication-type="book">
<string-name>
<surname>Hale</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>HE</given-names>
</string-name>. <source xml:lang="en"/>Medications and Mother's Milk. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer Publishing Company, LLC</publisher-name>;<year>2017</year>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>